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Abstract 
Regulatory T cells have recently become the focus of intense interest 
due to their apparent ability to control the development of autoimmune 
disease and transplant rejection. They may also play a critical role in 
controlling the development of allergy and asthma. One such regulatory T cell 
is the naturally occurring CD4+CD25+ regulatory T cell. Originally described in 
the mouse, this population has now also been shown to be present in humans 
where they comprise approximately 10 % of peripheral blood CD4+ T cells. 
This thesis describes the chemokine receptor expression profile of 
human CD4+CD25+ and CD4+CD25- T cells from both atopic and non-atopic 
donors during regulation, using a CFSE-based, allergen-driven cell culture 
protocol and flow cytometry. Furthermore, the chemotactic responses of both 
populations to a number of different chemokines were also investigated. 
Results describe the unique chemokine receptor expression of CD4+CD25+ T 
cells isolated from human peripheral blood. These cells express increased 
CCR4, CCR5, CCR6, and CCR8 and decreased CCR7 compared to their 
CD4+CD25- T cell counterparts. In addition, the modulation of this chemokine 
receptor expression in response to allergen stimulation is also described. 
Although the mechanism of action of CD4+CD25+ T cells has been 
shown to be cell contact dependent, the specific molecules involved have yet 
to be discovered. A lack of a definitive cell surface marker has also hampered 
investigation into this regulatory T cell population. This thesis also describes 
the results of micro-array analysis of CD4+CD25+ and CD4+CD25- T cells to 
determine differentially expressed genes from the two T cell populations. 
Duplicate microarray experiments were undertaken comparing gene 
expression profiles of both stimulated and non-stimulated CD4+CD25+ and 
CD4+CD25- T cells. A number of differentially expressed genes were 
subsequently validated using RT-PCR techniques. 
In addition, micro-array and flow cytometry analysis was performed on 
peripheral blood leukocytes isolated from both asthmatic and non-asthmatic 
patients to identify a gene signature associated with patients who present with 
clinical asthma. These experiments revealed the differential expression of 65 
gene targets in peripheral blood leukocytes isolated from asthmatic and non-
asthmatic individuals. These differentially expressed gene targets may 
represent a gene signature with a potential use as a diagnostic tool for 
asthma, as well as identifying potential future targets for research into this 
disease. 
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Chapter 1: Introduction 
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1.1 Allergy and Atopy 
The term allergy was originally defined by Clemens Von Pirquet as "an 
altered capacity of the body to react to a foreign substance" (Von Pirquet, 
1906). This broad definition can be more accurately restricted to "disease 
following a response by the immune system to an otherwise innocuous 
antigen". Allergic reactions occur when an individual who has produced IgE 
antibody in response to an innocuous antigen or allergen, subsequently 
encounters the same allergen, triggering the activation of IgE-binding mast 
cells in the exposed tissue. Allergic reactions are an example of one type of 
undesirable reaction produced by the normal immune systems that are 
referred to as hypersensitivity reactions, discussed in more detail below. 
Allergic diseases such as rhinitis, asthma and atopic eczema are 
increasing in prevalence in developed countries (Holgate, 2004). Recent 
studies put the rise in the UK as approximately threefold in the last twenty 
years, giving the UK one of the highest rates of allergic disease in the world 
(The International Study of Asthma and Allergies in Childhood (ISAAC) 
Steering Committee, 1998). Current estimates suggest that one-third of the 
total UK population - approximately 18 million people - will develop allergy at 
some point in their lives (Royal College of Physicians, 2004). The cost to the 
NHS of combating this "allergy epidemic" in primary care alone (excluding 
hospital services) is estimated to be as high as £900 million per year (Royal 
College of Physicians, 2004). 
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A number of proposals have been put forward to explain the recent rise 
in the incidence of allergic disease. The strongest predisposing factor in 
developing allergic disease is atopy, the genetic disposition to mount an IgE-
mediated response to certain allergens after inhalation, digestion or skin 
contact. While genetic or heredity traits can explain part of the reason behind 
this trend, a critical role for environmental factors is evident. This was 
illustrated by studies including those done on the populations of East and 
West Germany after unification. These studies showed that children who grew 
up in East Germany had a substantially lower prevalence of allergic 
symptoms and atopic sensitisation than children from West Germany (von 
Mutius et al., 1992; Nowak et al., 1996). However, the question remains as to 
why the incidence of atopy in the population of developed countries is 
increasing. 
The "hygiene hypothesis" suggests that better public access health 
care, together with the increased use of vaccines and antibiotics has resulted 
in a decreased incidence of Thi-mediated immune responses to infectious 
agents in childhood. It was proposed that the loss of these infections in the 
developing immune system might tip the balance in favour of more Th2-
mediated allergic responses (Strachan, 2000). However, the increased 
incidence of Thi-mediated autoimmune diseases in parallel with allergic 
diseases over the last number of decades suggests that this is not the case 
(Black, 2001). Recently, the hygiene hypothesis has been refined to suggest 
that the increase in allergic disease in the developed world is due to a 
reduction in infections with microbes or parasites that, if present, might 
21 
stimulate regulatory cells and cytokines to suppress allergic Th2 or 
autoimmune Th1 responses (Rook and Brunet, 2005). 
A number of studies support the premise of protection from allergic 
disease by mycobacteria and helminth infection. Studies of children in a 
number of developing countries who have chronic intestinal helminth 
infections have been shown to have reduced prevalence of allergic disorders 
(Lynch et al., 1987; Scrivener et al., 2001; Nyan et al., 2001; Huang et al., 
2002; Cooper et al., 2003). In addition, studies using anthelminthic therapies 
have shown that atopic reactivity is increased after therapy (Lynch et al., 
1993; van den Biggelaar et al., 2004). Treatment of mice with heat-killed 
Mycobacterium vaccae during allergen immunisation reduced airway 
hyperresponsiveness, eosinophilia, IgE and production of Th2 cytokines. This 
down-regulation was dependent on production of IL-10 and TGF-(3 by 
regulatory T cells (Zuany-Amorim et al., 2002). The above studies support the 
hypothesis that childhood infections with non-harmful pathogens may tolerise 
an individual and decrease the possibility of developing atopy and allergy. 
1.1.1 Hypersensitivity reactions 
Coombs and Gell classified hypersensitivity reactions into four types. 
Type I reactions are mediated by IgE, whereas types II and III are mediated 
by IgG (Gell and Coombs, 1963). Type I reactions are driven by the 
engagment of IgE bound to mast cells by its appropriate antigen (Rajan, 
2003). This results in mast cell degranulation and subsequent release of 
histamine, leukotrienes and other mediators. Allergic disorders such as 
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allergic rhinitis and allergic asthma are examples of Type I hypersensitivity 
and allergy is often equated with IgE-mediated Type I hypersensitivity. 
Type II hypersensitivity reactions are directed against cell-surface or 
matrix antigens and are characterised by antigen-antibody interactions, 
resulting in the activation of the complement pathway and elimination of the 
cell by phagocytosis (Rajan, 2003). Tissue damage can occur due to the 
recruitment of polymorphonuclear lymphocytes and subsequent release of 
neutrophil enzymes after their autolysis. An example of type II hypersensitivity 
is the allergic reaction produced by some individuals to a drug such as 
penicillin. Penicillin can bind to the cell surface and serve as a target for anti-
drug IgG antibodies that cause the destruction of the cell. Type III 
hypersensitivity reactions are driven by the formation of soluble antigen-
antibody complexes in the blood that are subsequently deposited in various 
tissues where they may trigger an immune response (Rajan, 2003). 
Type IV hypersensitivity reactions are sometimes referred to as 
delayed-type hypersensitivity as the reaction takes two to three days to 
develop unlike Types I, II and III, which can develop within minutes or hours. 
Also unlike other hypersensitivity reactions. Type IV reactions are not 
antibody mediated but rather a type of cell-mediated response. Type IV 
reactions can be subdivided into three groups (Rajan, 2003). In the first group, 
tissue damage is caused by the activation of macrophages by Th1 cells, 
which results in an inflammatory response. In the second, tissue damage is 
caused by the activation by Th2 cells of inflammatory responses in which 
eosinophils predominate. In the third subgroup, tissue damage is caused 
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directly by the cytotoxicity activity of cytotoxic T lymphocytes (CTLs). 
Examples of Type IV hypersensitivity reactions are chronic asthma, chronic 
allergic rhinitis and contact dermatitis. 
1.1.2 Cellular basis of allergic reations 
An individual with atopy will generate IgE-specific antibodies to 
otherwise innocuous allergens, leading to sensitisation towards that allergen 
after repeated exposure. Upon subsequent encounter with the allergen, the 
sensitised atopic individual will immediately mount an immune reaction which, 
depending on the site of exposure, will result in either a cutaneous wheal and 
flare reaction, sneezing, runny nose or wheezing. This initial, immediate 
response to allergen exposure is known as the early phase reaction and can 
occur in a matter of minutes or even seconds. 
The early phase reaction is initiated by allergen binding to membrane-
bound high affinity IgE receptors (FceRI receptors) on the surface of mast 
cells and basophils leading to degranulation and release of histamine, 
leukotrienes, prostaglandins and cytokines (Broide, 2001). While contributing 
to the characteristic wheel and flare reaction of the early phase reaction, 
these mast cell products may also contribute to a later, secondary reaction 
known as the late phase reaction. The late phase reaction is associated with 
the recruitment of other leukocytes including neutrophils, eosinophils, 
lymphocytes and macrophages to the initial site. Many of the mediators 
released by activated mast cells and basophils act as chemoattractants 
(discussed later) that result in the recruitment of these leukocyte subsets and 
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subsequent activation of these cells can in turn promote further leukocyte 
recruitment. Recruited eosinophils degranulate and release a number of 
cytotoxic proteins, as well as producing cytokines such as IL-5 that plays a 
role in eosinophil recruitment, release from the bone marrow and enhanced 
survival. Recruited T cells are typically Th2 cells that produce the cytokines 
IL-4, IL-5, IL-9 and IL-13 that lead to the further recruitment of mast cells and 
eosinophils, as well as promoting B cell isotype switching to IgE which will 
bind to the mast cell FceRI receptors and prime the individual for further 
allergic responses. The late phase reaction occurs 3-9 hours after the initial 
allergen exposure and can last for 1-2 days. 
1.2 Asthma 
Asthma affects approximately 5 % of the population of the western 
world and, as with other allergic diseases, its prevalence is rising. Asthma has 
been defined as "a chronic inflammatory disorder of the airways in which 
many cells and cellular elements play a role, in particular mast cells, 
eosinophils, T lymphocytes, neutrophils and epithelial cells" (Lemanske, Jr. 
and Busse, 2003). The cell types and cellular components contributing to 
asthma are discussed in detail below. 
As with other allergic reactions outlined above, the allergic asthmatic 
reaction in the lung can be divided into two phases. The early asthmatic 
reaction (EAR) occurs within 15-30 minutes of allergen exposure. It is 
characterised by a decrease in lung function, and is mediated by the cross-
linking of high affinity IgE receptors on the surface of mast cells, leading to 
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degranulation and release of mediators such as histamine, leukotrienes, 
prostaglandins and cytokines (Bousquet et al., 2000). These mediators 
released by activated mast cells and basophils induce contraction of airways 
smooth muscle, mucous secretion, and vasodilation, together contributing to 
airflow obstruction (Bousquet et al., 2000). The late asthmatic reaction (LAR) 
occurs between 3 and 9 hours following the initial allergen exposure, and is 
characterised by a slow decrease in lung function, and the migration of 
neutrophils, eosinophils and lymphocytes into the lung tissue (Bentley et al., 
1997). In particular, this late asthmatic reaction is driven by the recruitment of 
Th2 cells and the release of Th2 cytokines such as IL-4, IL-5, IL-9 and IL-13, 
leading to lung eosinophilia. The late asthmatic reaction leads to the induction 
of pathophysiological changes in the airways such as the development of 
airway hyperreactivity (AHR) and mucus overproduction. 
Recent evidence has demonstrated that some patients with asthma 
have irreversible airway obstruction due to the occurrence of structural 
changes in the lung over time. This process has been termed airway 
remodelling and represents an injury-repair process of the airway tissue. 
These structural changes include epithelial damage and goblet cell 
hyperplasia (Ordonez et al., 2001), increased airway smooth muscle (Johnson 
et al., 2001), and recruitment and activation of myofibroblasts (Brewster et al., 
1990). In addition, increased deposition of collagens and other extracellular 
matrix proteins such as tenascin and fibronectin occurs (Roche et al., 1989). 
The cumulative effect of these structural changes is that the airways become 
narrowed, which is suggested to lead to an accelerated decrease in lung 
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function in asthmatic patients over time, compared with healthy controls. It is 
unclear if current asthma therapies are effective in reversing airway 
remodelling. 
1.3 Effector cells in asthma 
A number of different cell types contribute to the pathophysiology of 
asthma, and these are discussed in detail below. The pathways leading to 
allergic airway inflammation, showing important effector cells and mediators 
as well as potential points of therapeutic intervention are illustrated in Figure 
1.1. 
1.3.1 T cells 
T cells are produced in the bone marrow and subsequently migrate to 
the thymus to undergo maturation. After maturation in the thymus, T cells are 
released into the circulation where they migrate into lymphoid tissue, and 
return to the bloodstream unless they encounter antigen (Petrie, 2003). T cells 
express T cell receptors (TCRs) on their cell surface, with which they can 
recognise specific antigens on the surface of antigen presenting cells (APCs). 
The TCR is only capable of recognising antigen that is bound to major 
histocompatability molecules (MHC) displayed on the surface of ARC. There 
are two main functionally distinct classes of T lymphocyte, defined by the 
expression of co-receptors that interact with MHC molecules: CDS cytotoxic T 
cells and CD4 helper T cells. CDS T cells recognise antigen presented by 
MHC class I molecules and are involved in the elimination of virally infected 
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cells. Conversely, CD4 T cells recognise antigen presented by MHC class II 
molecules and are involved in pathogen defence. 
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Figure 1.1 Effector pathways in the pathogenesis of asthma, and 
potential points of therapeutic intervention. 
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1.3.1.1 Development and function of Thi and Th2 cells 
CD4 effector T cells have been subdivided into two functionally distinct 
subsets based upon their cytokine secretion profiles (Mosmann et al., 1986; 
Mosmann and Coffman, 1989). T helper 1 (Th1) cells produce IFN-y and are 
involved in pathogen defence, while T helper 2 cells (Th2) produce IL-4, IL-5, 
IL-9 and IL-13 and mediate immunity to helminth infection. The development 
of one or the other Th subset is dependent on different cytokines, signalling 
pathways and transcription factors. Thi cell development involves the 
cytokines IL-12 and IL-18, signalling through STAT4, and requires the 
transcription factor T-bet (Szabo et al., 2000). Th2 cell development is driven 
by IL-4 signalling through STAT6 (Shimoda et al., 1996; Takeda et al., 1996), 
and requires the transcription factor GATA-3 (Zheng and Flavell, 1997). In 
addition, both Th cell subsets display differing chemokine receptor expression 
profiles. Thi cells have been shown to express CCR2, CCR5 and CXCR3 
(Bonecchi et al., 1998), while Th2 cells express CCR3, CCR4 and CCR8 
(Sallusto et al., 1997; Bonecchi et al., 1998; Zingoni et al., 1998). 
Recently, the classical division of CD4 effector T cells into Thi and Th2 
cells has been expanded with the discovery of a third distinct lineage of helper 
T cell referred to as Th i7 cells. These cells require TGF-p for initiation of 
Thi 7 cell differentiation. This T cell lineage is discussed with induced 
regulatory T cells later in this introduction, as TGF-p seems to play a crucial 
role in the development of both cell types. 
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1.3.1.2 T cell activation 
The recognition of antigen by the TCR alone is insufficient to stimulate 
maximal T cell activation. In addition to this specific primary interaction of TCR 
with it's antigen/MHC complex on the surface of APC, a second co-stimulatory 
signal is also required to activate the T cell. This second signal is provided by 
the interaction between CD28 expressed on the T cell surface, with its ligand 
CD80 or CD86 expressed on the surface of the APC. This second signal acts 
as verification that the T cell is interacting with its antigen presented by an 
activated APC, and is a protective measure to ensure the T cell is responding 
to a foreign antigen. In the absence of this co-stimulatory signal, ligation of the 
TCR results in T cell anergy (Riley and June, 2005). 
T cell interactions with CD80 and CD86 on the surface of APC are also 
responsible for downregulating T cell activation. CTLA-4 is another member of 
the CD28 family but, in contrast to CD28, it provides an inhibitory signal to the 
T cell (Walunas et al., 1994). While CD28 is expressed on both naive and 
activated T cells, CTLA-4 expression is absent on non-activated T cells and 
upregulated upon activation. CTLA-4 has a higher affinity for CD80 and CD86 
and so its' expression on the T cell surface during interaction with APC will 
downregulate T cell activation. The critical role of CTLA-4 as a negative 
regulator of T cell activation and a key molecule in the prevention of excessive 
immune responses is highlighted in CTLA-4 deficient mice, which die within 3-
4 weeks of birth from massive lymphoproliferative disease (Waterhouse et al., 
1995;Tivol etal., 1995). 
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1.3.1.3 Th2 cells in asthma 
Considerable evidence supports a role for T cells, particularly Th2 
cells, in asthma. T cell numbers expressing IL-4 or IL-5 are increased in the 
lungs of asthmatics compared to healthy controls (Robinson et al., 1992). In 
addition, T cells play a critical role in murine models of allergic lung 
inflammation as lung eosinophilia and AHR are abrogated in CD4 T cell 
deficient mice (Gavett et al., 1994). The importance of Th2 cells in asthma 
pathology likely revolves around their production of the cytokines IL-4, IL-5, 
IL-9 and IL-13 and the effects of these cytokines on other cell types in the 
lung. In support of this, the expression of Th2 cytokines IL-4, IL-5, IL-9 and IL-
13 are increased in the lungs of asthmatic individuals compared to healthy 
controls (Robinson et al., 1992; Naseer et al., 1997; Shimbara et al., 2000). In 
addition the numbers of T cells expressing both IL-4 and IL-5 mRNA correlate 
with measures of disease severity (Robinson et al., 1993c). Adoptive transfer 
of Th2 cells induces airway inflammation in naive mice after allergen 
challenge, an effect not seen upon transfer of Th1 cells (Cohn et al., 1998). 
T1/ST2 is preferentially expressed on both mouse and human Th2 
cells compared to Th1 cells and plays a role in Th2 cell function (Lohning et 
al., 1998; Xu et al., 1998; Chan et al., 2001). Blockade of T1/ST2 in a mouse 
model of allergic lung inflammation inhibited allergen-induced lung 
eosinophilic inflammation and IL-5 production. Moreover, this effect was 
mediated by blockade of T1/ST2 on Th2 cells (Coyle et al., 1999). Taken 
together, these studies provide evidence supporting a critical role for Th2 cells 
in the pathology of asthma. As outlined elsewhere in this introduction, the 
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cytokines IL-4, IL-5, IL-9 and IL-13 produced by Th2 cells have dramatic 
effects on numerous cell types in the lung and drive the effector pathways 
responsible for asthma pathology (Figure 1.1). 
1.3.1.4 Th1 cells in asthma 
A potential role for Thi cells in the asthmatic process is controversial. 
Certainly, Th1 cells are present in the lungs of asthmatic patients (Krug et al., 
2001), however data from murine models as to whether they have a beneficial 
effect on allergic inflammation, or contribute towards it has been conflicting. 
Hansen et al demonstrated that co-transfer of Thi cells worsened the 
inflammation induced by transfer of Th2 cells (Hansen et al., 1999), an 
outcome also demonstrated in other studies (Randolph et al., 1999). However 
a number of conflicting reports have proposed that adopted transfer of Thi 
cells can inhibit allergen-induced inflammation (Cohn et al., 1999; Huang et 
al., 2001; Irifune et al., 2005). In addition, administration of IL-12 (Gavett et 
al., 1995) or IFN-y (Lack et al., 1994) has been shown to inhibit allergen-
induced airway inflammation. Furthermore, T-bet deficient mice, in which Thi 
cell development is impaired, exhibit spontaneous eosinophilia, AHR and 
collagen deposition, suggesting that Thi cells may protect against allergen-
induced airway inflammation and remodelling (Finotto et al., 2002). In 
addition, agents that enhance a Thi response, such as Thi attracting 
chemokines (Wiley et al., 2001) or TLR agonists (Pate! et al., 2005) inhibit 
Th2-mediated inflammation. These studies suggest that Thi cells may have a 
protective effect in asthma by crossregulation of Th2 cells, possibly via the 
production of IFN-y. 
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1.3.1.5 CD8 cells in asthma 
CDS T cells are also increased in the lungs of asthmatic patients 
(Bentley et al., 1992; Ying et al., 1997b). Depletion of CDS T cells protected 
sensitised mice from developing eosinophilia and AHR upon allergen 
challenge but had no effect on the IgE response to allergen (Hamelmann et 
al., 1996). This result suggested that CDS cells may be critical for the effector 
stage of the allergic response, possibly through production of lL-5, which the 
authors showed was produced by CDS cells. In addition, transfer of CDS T 
cells producing IL-4 and lL-5 can induce eosinophilic inflammation in the lung 
following allergen challenge (Sawicka et al., 2004). However, it was also 
found that CDS depletion prior to the sensitisation phase only, actually 
enhanced Th2 responses in the lung suggesting that CDS T cells may have a 
protective role during allergen sensitisation (Stock et al., 2004b). Taken 
together, these studies suggest that CDS T cells may be able to modulate the 
asthmatic response. 
1.3.2 Eosinophils 
Eosinophils are bone marrow derived leukocytes that share a common 
CD34+ progenitor cell type with neutrophils and basophils. Eosinophils are 
granular leukocytes that contain toxic granule proteins such as major basic 
protein (MBP) and eosinophil cationic protein (ECP), which they release upon 
activation (Robinson et al., 2002). These released granule contents can kill 
microorganisms and parasites but can also cause significant tissue damage in 
allergic reactions. Eosinophils also synthesise and release a number of 
chemical mediators such as leukotrienes, prostaglandins and cytokines upon 
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activation, which can amplify an inflammatory response by activating epithelial 
cells and promoting the recruitment of eosinophils and other leukocytes. 
Eosinophil numbers in the blood are generally very low in healthy 
individuals making up less than 4 % of circulating leukocytes (Robinson et al., 
2002). They are principally tissue dwelling cells, found especially in the 
connective tissue immediately under the respiratory and gut epithelium, where 
they are ideally placed to play an important role in defence against invading 
pathogens. Eosinophils also have a very short life span, estimated to be as 
low as 13 days from development to death. Therefore, in the absence of 
infection, eosinophil production by the bone marrow is minimal. However, 
during inflammation and in particular allergic inflammation, cytokines are key 
mediators of increased eosinophil recruitment, activation and survival. In 
particular, IL-5 produced by activated Th2 cells, has chemokinetic actions on 
eosinophils and is critical for their release from the bone marrow (Palframan 
et al., 1998). In addition, IL-5 has been shown to enhance eosinophil survival 
(Yamaguchi et al., 1988). 
The role of eosinohils in the pathogenesis of asthma is controversial. 
Certainly, eosinophil numbers are increased in bronchial biopsies from 
asthmatic individuals and correlate with disease severity (Wardlaw et al., 
1988; Bentley et al., 1992). In addition, the release of toxic granule proteins 
and other mediators by activated eosinophils can cause extensive tissue 
damage and amplification of the allergic response. There are a number of 
conflicting reports on the importance of eosinophils in the asthmatic response. 
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Transgenic mice in which the eosinophil lineage had been ablated showed no 
differences in AHR or mucus secretion compared to wild type mice (Humbles 
et al., 2004). Confusingly, a similar study of eosinophil deficient mice 
concluded that eosinophils were required for pulmonary mucus accumulation 
and AHR (Lee et al., 2004) suggesting that the importance of the eosinophil in 
animal models of allergic airways disease may be strain dependant. 
Administration of anti-IL-5 antibodies in a mouse model of allergic lung 
Inflammation suppressed eosinophils to < 1% of recruited cells but had no 
effect on the subsequent airway responses (Corry et al., 1996). However In 
lL-5-deficient mice, the eosinophilia, lung damage, and airways 
hyperreactivity normally resulting from aeroallergen challenge were abolished 
(Foster et al., 1996). With respect to asthma in human subjects, the 
administration of anti-IL-5 antibody significantly decreased the numbers of 
eosinophils in the blood and sputum of asthmatic patients, but the treatment 
had no effect on the clinical outcome of these patients (Leckie et al., 2000; 
Kips et al., 2003). In light of the conflicting results reported with respect to the 
involvement of eosinophils in the asthmatic response, the issue is still strongly 
debated. 
Evidence for the importance of the eosinophil in airway remodelling in 
asthma appears more conclusive. Humbles et al demonstrated that eosinophil 
deficient mice were protected against peribronchiolar collagen deposition and 
ASM proliferation in a model of chronic allergen-induced inflammation 
(Humbles et al., 2004). In agreement, peribronchial fibrosis was abrogated in 
IL-5 or IL-5R deficient mice (Cho et al., 2004; Tanaka et al., 2004), and 
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increased in transgenic mice that overexpress IL-5 in the lung (Lee et al., 
1997). Also, anti-IL-5 therapy in human asthmatic subjects resulted in reduced 
deposition of ECM proteins (Flood-Page etal., 2003). 
1.3.3 Antigen presenting cells 
APCs are cells that are capable of displaying foreign antigen 
complexed with MHC class II on its surface, and presenting this antigen/MHC 
complex to T cells. While many cell types can present antigen, including 
macrophages (Kovacsovics-Bankowski et al., 1993), B cells (Ke and Kapp, 
1996), endothelial cells (Limmer et al., 2000) and eosinophils (Shi et al., 
2000), it is the dendritic cell (DC) that is the strongest activator of naive T 
cells, and plays a pivotal role both the initiation and maintenance of an allergic 
response. 
Immature DCs (iDCs) form a network in the airway epithelium and 
capture antigen by a variety of mechanisms including receptor-mediated 
endocytosis, macropinocytosis and phagocytosis (de Heer et al., 2005). 
Antigen is then processed in intracellular compartments to generate short 
immunogenic peptides that are bound to MHC Class II molecules. The 
antigen-MHC complex is then exported to the cell surface to allow antigen 
presentation. Upon antigen uptake, iDCs undergo a development programme 
called maturation, whereby they lose their capacity to take up antigen, migrate 
to secondary lymph node organs, and acquire a phenotype of mature DCs 
expressing all the costimulatory molecules and chemokines to attract and 
stimulate naive T cells. Two main subsets of DC have been described in 
humans, myeloid DC (mDC) and plasmacytoid DC (pDC). Although these DC 
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subsets were initially referred to as DC1 and DC2, referring to their capacity to 
preferentially induce the differentiation of naive T cells into Th1 and Th2 
effector cells respectively, it is now believed that not only the lineage of the 
DC but also the microenvironment of cytokines and/or inflammatory mediators 
and maturation status that influences the outcome of the immune response 
(de Heer et al., 2005) . In addition to the cytokine and signalling environment 
of the DC:T cell interaction determining the type of immune response initiated, 
it can also overcome the suppression induced by regulatory T cells. Dendritic 
cells activated in the presence of certain microbial products results in the 
secretion of IL-6 which can block the suppressor activity of regulatory T cells 
(Rasare and Medzhitov, 2003). 
The importance of DCs in the mediation of pulmonary inflammation has 
been demonstrated in a mouse model of allergic ainA/ays disease, where 
instillation of allergen-pulsed dendritic cells in the airways and subsequent 
antigen challenge resulted in lung eosinophilia and increased IL-4 levels 
(Lambrecht et al., 2000). DCs are not only responsible for initial priming of 
naive T cells at the onset of inflammation but are also implicated in the 
maintenance of ongoing inflammation. Depletion of mDCs from the airways, 
lung and mediastinal lymph nodes prior to allergen challenge completely 
abrogated the development of allergic inflammation in sensitised mice (van 
Rijt et al., 2005). Moreover, depletion of mDCs during ongoing inflammation 
suppressed established inflammation. This study implies that DCs are not 
only involved in initial priming of T cell-mediated responses, and suggests that 
manipulation of DC function may also be relevant for the reversal of existing 
inflammatory responses. 
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While DCs play an important role in initiating immune responses to 
pathogens infiltrating the lung, the usual functional outcome of harmless 
antigen exposure is ignorance or tolerance. When an antigen, such as 
ovalbumin, is administered to the lungs of mice via aerosalisation, aspiration 
or intratrachael injection, it renders mice tolerant to a subsequent 
immunisation with the same antigen (Akbari et al., 2001; de Heer et al., 2004). 
In addition this induction of tolerance appears to rely on pDCs, as depletion of 
this subset resulted in the abrogation of tolerance to ovalbumin and the 
induction of many of the hallmark symptoms of airway inflammation (de Heer 
et al., 2004). Moreover, transfer of ovalbumin-loaded pDCs suppressed 
inflammation in ovalbumin-sensitised and challenged mice. Recent studies 
suggest that induction of tolerance in this way by DCs may be due to the 
generation of regulatory T cells (Akbari et al., 2002a; Stock et al., 2004a). In 
addition co-stimulatory molecules such as ICOS-L may be required for this 
pathway of tolerance induction (Akbari et al., 2002a). 
1.3.4 B cells and IgE synthesis 
B cells have a contributory role in asthma pathogenesis through their 
synthesis of IgE antibodies. IgE binds to high affinity IgE receptors on mast 
cells and basophils and can cause the degranulation of these cells when the 
IgE is crosslinked by allergen. B cell isotype switching to IgE synthesis 
requires two signals. The first signal is provided by lL-4 or lL-13, cytokines 
produced by Th2 cells (Del Prete et al., 1988). The second signal required is a 
costimulatory signal between CD40 expressed on the B cell surface and 
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CD40L expressed on the surface of Th2 cells (Kawabe et al., 1994). 
Therefore, Th2 cells play an important role in the production of IgE by B cells. 
1.3.5 Mast cells 
Mast cells are resident in all normal tissues, where they are believed to 
play an important role in tissue homeostasis, wound healing and host 
defence. Two types of mast cell have been described in human tissue. MCtc 
mast cells contain tryptase, chymase, carboxy peptidase and cathespin G, 
and predominate in normal skin and the respiratory and intestinal submucosa. 
MCT mast cells contain tryptase only, and predominate in the normal intestinal 
mucosa and lung alveolar wall (Irani et al., 1986). Mast cells also play an 
important role in the pathogenesis of asthma. They express high affinity IgE 
receptors that upon crosslinking with allergen stimulate the mast cell to 
degranulate and release a range of inflammatory mediators including 
histamine, leukotrienes and cytokines. Mast cell degranulation is thought to 
play a major role in the initial bronchoconstriction response to allergen in 
asthmatic patients (Williams and Galli, 2000). In addition, the release of 
chemoattratants by mast cells upon degranulation promotes the recruitment of 
other immune cells into the lung tissue that amplify the inflammatory 
response. They can also express CD40L, and thus potentiate IgE synthesis 
from B cells (Gauchat et al., 1993). Mast cell numbers are increased in the 
airway smooth muscle of asthmatic patients (Brightling et al., 2002). These 
mast cells within the ASM have been demonstrated to be of the MCtc 
phenotype, and express IL-4 and IL-13 (Brightling et al., 2003). The 
recruitment of mast cells to the ASM in asthmatic patients appears to rely on 
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CXCR3 expression on the mast cell and CXCL11 expression by the ASM 
(Brightling et a!., 2005). Mast cells are also capable of activating fibroblasts 
and so inducing collagen production (Gruber et al., 1997). Therefore mast 
cells, as well as playing a role in the initiation of the asthmatic response, may 
also be involved in remodelling of the airway. 
1.3.6 Epithelial cells 
Bronchial epithelial cells not only act as a barrier between the external 
environment and the inner tissues of the lung but also play a role in 
modulating many ainway functions. In the asthmatic ainA/ay, epithelial cells are 
in an activated state compared with healthy controls and are an important 
source of inflammatory mediators, prostaglandins, cytokines and chemokines 
(Bousquet et al., 2000). They also express increased levels of adhesion 
molecules, enhancing leukocyte recruitment (Bousquet et al., 2000). In the 
remodelled airways of asthmatics patients, the epithelium is damaged, leading 
to epithelial shedding (Montefort et al., 1993) and an increase in mucus 
producing cells (Ordonez et al., 2001). Epithelial damage also causes the 
release of growth factors such as TGF-p, which promotes the induction of 
myofibroblasts and so increased collagen production (Morishima et al., 2001). 
1.3.7 Fibroblasts and myofibroblasts 
Fibroblasts are lung resident cells found in connective tissue, and are 
involved in the maintenance of tissue integrity. Fibroblasts are also involved in 
the repair process In response to inflammation by the release of a variety of 
extracellular matrix proteins. They are also capable of producing a large array 
of inflammatory cytokines and chemokines. Myofibroblasts are thought to be 
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the main source of collagen deposition in the asthmatic lung (Zhang et al., 
1994). Numbers of myofibroblasts are elevated in asthmatic patients after 
allergen provocation, and there is a correlation between myofibroblast 
numbers and the thickness of the basement membrane (Brewster et al., 
1990). The differentiation of fibroblasts into myofibroblasts has also been 
demonstrated in a number of studies (Sun et al., 1997; Hashimoto et al., 
2001). In addition, circulating fibrocytes have been demonstrated to acquire 
the myofibroblast phenotype in response to stimulation with cytokines present 
in the asthmatic lung, suggesting fibrocytes may function as myofibrpblast 
precursors and contribute to the subepithelial fibrosis present in asthma 
(Schmidt et al., 2003). 
1.3.8 Airway smooth muscle cells 
Thickening of the airway smooth muscle (ASM) layer is one of the 
changes observed during airway remodelling in asthma. Possible causes of 
ASM layer thickening are increased proliferation or reduced apoptosis of ASM 
cells in response to the changes in levels of cytokines and growth factors 
present in the asthmatic lung. In vitro, it has been shown that ASM cells from 
asthmatics proliferate excessively (Johnson et al., 2001), and proliferation of 
ASM cells has also been demonstrated in vivo in a murine model of chronic 
inflammation and ain/vay remodelling (McMillan and Lloyd, 2004). ASM cells 
can also produce cytokines and growth factors, and thus may contribute to the 
ongoing inflammation in the lung (John et al., 1997). Increased smooth 
muscle mass may also contribute to AHR by increasing the force in response 
to bronchoconstricting agents, and by reducing diameter of the airway lumen. 
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1.4 Mediators in asthma 
A network of interacting cytokines and chemokines, secreted by both 
inflammatory cells and structural tissue components, regulates the airway 
inflammation underlying asthma. Of particular importance are the roles played 
by the Th2 cytokines IL4, IL-5, IL9 and IL-13 and these are discussed below. 
Chemokines that have been implicated in the pathogenesis of asthma are 
discussed later in this introduction. 
1.4.1 Th2 cytokines 
1.4.1.1 IL-4 
IL-4 is an important Th2 cytokine in the pathogenesis of asthma, with 
effects on a number of cell types involved in the disease. In bronchial biopsies 
of asthmatic patients, CD4+ and CD8+ T cells, eosinophils and mast cells 
express IL-4 (Ying et al., 1997b), and increased numbers of T cells 
expressing IL-4 are observed in BAL cells following allergen challenge 
(Robinson et al., 1993a). IL-4 plays a role in T helper cell differentiation by 
promoting Th2 cell development, as well as blocking Thi cell development 
(Swain et al., 1990). In addition, IL-4 is crucial in stimulating the production of 
IgE by B cells (Del Prete et al., 1988) and can stimulate the release of 
chemokines by airway epethilial cells (Li et al., 1999). 
Studies with wild type and IL-4 transgenic mice have provided 
evidence for the key role played by IL-4 in the pathogenesis of asthma. IL-4 
deficient mice fail to develop eosinophilia and AHR after sensitisation and 
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allergen exposure (Brusselle et al., 1994; Coyle et al., 1995; Brusselle et al., 
1995). T cells recovered from the airways of IL-4 knockout mice do not display 
a Th2 cytokine pattern, correlating with the absence of inflammatory airway 
changes such as eosinophilia and IL-5 secretion (Coyle et al., 1995). 
Overexpression of IL-4 in the lung induces lymphocytic and eosinophilic 
inflammation without resulting in an alteration in AHR (Rankin et al., 1996). 
This observation suggests that AHR develops independently of IL-4, a 
conclusion supported by Cohn et al, who demonstrated that transfer of Th2 
cells derived from IL-4 deficient mice could induce AHR after allergen 
exposure (Cohn et al., 1998). Treatment of wild type mice with anti-IL-4 
antibody during the allergen challenge phase had little effect on eosinophilia 
or AHR (Coyle et al., 1995; Corry et al., 1996; Hessel et al., 1997), while 
treatment during the initial sensitisation phase resulted in a marked reduction 
in eosinophil infiltration (Coyle et al., 1995). Taken together, these studies 
suggested that IL-4 is important for the initial sensitisation phase of the 
allergic response, but is less critical during the effector phase. However, in 
contrast to these findings, blockade of the IL-4 receptor suppressed AHR, 
mucus production and lung eosinophilia (Gavett et al., 1997). This 
discrepancy can be explained by the observation that IL-13 shares some 
receptor components with the IL-4 receptor and blocking IL-4 receptor may 
have the additional effect of blocking some IL-13 signalling (Zurawski et al., 
1995). IL-4 has also been implicated in mucus production, as transgenic mice 
overexpressing IL-4 in the airways have increased goblet cell numbers in the 
airways due to increased expression of the MLIC5 gene (Temann et al., 
1997). However, transfer of Th2 clones derived from IL-4 deficient mice could 
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still increase mucus production to the same extent as those derived from wild 
type, suggesting that it is Th2 cells, but not IL-4 itself that drives mucus 
hypersecretion (Cohn et al., 1997) 
1.4.1.2 IL-5 
IL-5 plays a key role in the pathogenesis of asthma through its 
influence on the production, maturation and activation of eosinophils. It has 
chemokinetic actions on eosinophils and is critical for their release from the 
bone marrow (Palframan et al., 1998), while also enhancing eosinophil 
survival (Yamaguchi et al., 1988). Increased IL-5 mRNA expression has been 
demonstrated for CD4+ T cells in asthmatic airway (Hamid et al., 1991). 
Furthermore, expression of IL-5 protein by CD4+ and CD8+ BAL cells was 
confirmed to be increased in cells from asthatic patients compared to healthy 
controls (Till et al., 1995). In addition, eosinophils themselves have been 
demonstrated to produce IL-5 (Dubucquoi et al., 1994). 
IL-5 deficient mice do not develop eosinophilia and AHR after 
sensitisation and challenge with ovalbumin, confirming the importance of IL-5 
in the development of eosinophilia (Foster et al., 1996). Transgenic mice 
overexpressing IL-5 in the lung develop many of the pathophysiological 
changes associated with allergic lung disease such as lung eosinophilia, and 
AHR (Lee et al., 1997). Treatment with an anti-IL-5 antibody prior to allergen 
challenge has been reported both to have no effect (Corry et al., 1996) and to 
abrogate eosinophilia and AHR (Hamelmann et al., 1999). This contradiction 
may be due to different experimental protocols or differences in genetic 
strains of mouse used. However, antil-IL-5 therapy in asthmatic patients had 
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no beneficial effects on airway inflammation (Leckie et al., 2000). A role for IL-
5 in airway remodelling has also been suggested when it was found that 
overexpression of IL-5 in the lung induced peribronchial collagen deposition 
(Lee et a!., 1997), and that IL-5 deficient and IL-5R deficient mice were 
protected from peribronchial fibrosis (Cho et al., 2004; Tanaka et al., 2004). In 
addition, anti-IL-5 therapy in human asthmatic patients reduced markers of 
airway remodelling such as deposition of ECM proteins (Flood-Page et al., 
2003) 
1.4.1.3 IL-9 
IL-9 is another cytokine produced mainly by Th2 cells, but also from 
eosinophils. It has been shown to synergise with IL-4 to potentiate IgE 
synthesis from B cells (Dugas et al., 1993), and to promote the proliferation 
and differentiation of mast cells (Hultner et al., 1990; Ekiund et al., 1993). 
Elevated expression of IL-9 has been demonstrated in the bronchial mucosa 
of atopic asthmatics (Ying et al., 2002). Transgenic mice overexpressing IL-9 
in the lung show massive infiltration of eosinophils and lymphocytes, 
increased numbers of mast cells within the airway epithelium and increased 
AHR (Temann et al., 1998). In another study, transgenic mice overexpressing 
IL-9 displayed significant eosinophilic airway inflammation, elevated IgE levels 
and increased AHR, following allergen challenge (McLane et al., 1998). In 
further support of a role for IL-9 in asthma pathogenesis, antibody blockade of 
IL-9 reduced inflammation and AHR after allergen challenge (Kung et al., 
2001; Cheng et al., 2002). However, IL-9 deficient mice develop AHR, 
eosinophilia, and mucus secretion in response to allergen challenge to a 
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similar extent as their wild type counterparts, suggesting that IL-9 is not 
essential for the development of the asthmatic phenotype, and that other Th2 
cytokines can act in a compensatory fashion (McMillan et al., 2002). 
1.4.1.4 IL-13 
IL-13 is produced by T cells (Minty et al., 1993), eosinophils (Schmid-
Grendelmeier et al., 2002) and NKT cells (Akbari et al., 2003). Elevated 
expression of IL-13 has been demonstrated in the bronchial mucosa of 
asthmatics (Humbert et al., 1997), with increased expression of the cytokine 
following segmental allergen challenge of patients with asthma (Huang et al., 
1995; Kroegel et al., 1996). IL-13 has been shown to induce CD23 expression 
and IgE production from B cells in vitro (Punnonen et al., 1993), and 
transgenic mice overexpressing IL-13 have elevated IgE levels (Emson et al., 
1998). These actions, among others, are similar to IL-4, and receptors for 
both cytokines have been shown to have receptor components in common 
(Zurawski et al., 1995). 
The functional importance of IL-13 in mediating allergic responses has 
been demonstrated using animal models. Direct instillation of IL-13 in the 
mouse trachea induced eosinophilia, AHR, mucus secretion and increased 
IgE levels (Wills-Karp et al., 1998). In addition, transgenic mice 
overexpressing IL-13 in the lung induced the same effects (Zhu et al., 1999). 
Blocking the activity of IL-13 using an antibody or a soluble IL-13R fusion 
protein suppressed the increase in mucus secretion, eosinophilia, and AHR 
following allergen challenge in sensitised mice (Wills-Karp et al., 1998; Grunig 
et al., 1998). Taken together these studies strongly suggest that IL-13 is both 
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necessary and sufficient to induce all aspects of allergen-induced airways 
disease. However, two recent studies with IL-13 deficient mice have reported 
opposing findings in allergen challenge models. Walter et al reported that IL-
13 deficient mice failed to develop allergen-induced AHR, despite the 
presence of vigorous Th2-biased, eosinophilic pulmonary inflammation 
(Walter et al., 2001). In contrast, Kumar ef a/reported that IL-13 deficient mice 
displayed diminished accumulation of eosinophils and chronic inflammatory 
cells while AHR was still demonstratable (Kumar et al., 2002). 
1.4.2 IL-10 
IL-10 is an anti-inflammatory cytokine produced by T cells, 
macrophages, dendritic cells, and mast cells. IL-10 has multiple effects on a 
variety of different cell types. It is a potent inhibitor of monocyte/macrophage 
function, suppressing the production of a number of pro-inflammatory 
cytokines (Fiorentino et al., 1991; de Waal et al., 1991a). IL-10 can also 
diminish the antigen-presenting capacity of monocytes by down-regulating 
MHC class II expression (de Waal et al., 1991b), as well as inhibiting the 
production of cytokines and chemokines from different cell types, including IL-
5 production by Th2 cells (Schandene et al., 1994). 
Both alveolar macrophages and BAL fluid from non-asthmatic 
individuals display increased expression of IL-10 compared to asthmatic 
subjects (Borish et al., 1996; John et al., 1998). However other studies have 
reported increased numbers of macrophages and T cells expressing IL-10 
mRNA in the BAL fluid of patients with asthma (Robinson et al., 1996). In 
keeping with its anti-inflammatory properties, transfer of cells engineered to 
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produce IL-10 can prevent the development of AHR and airway inflammation 
in animal models (Oh et al., 2002). In addition neutralisation of IL-10 in 
allergen-challenged mice exacerbated airway inflammation and AHR (Oh et 
al., 2002). Moreover, IL-10 deficient mice have exaggerated pulmonary 
inflammation after allergen challenge compared with their wild type 
counterparts (Grunig et al., 1997). There is increasing evidence that many 
types of regulatory cell suppress inflammation via IL-10 dependent 
mechanisms and these cells may play a role in controlling allergic and 
asthmatic responses (Hawrylowicz and O'Garra, 2005). 
1.4.3 TGF-p 
TGF-p is a pleiotropic cytokine, which has been shown to have both 
anti-inflammatory and pro-fibrotic effects. Three isoforms of TGF-|3 have been 
identified in mammals, TGF-|31, TGF-p2 and TGF-ps. While TGF-|32 and 
TGF-P3 knockout mice are embryonic lethal, TGF-(31 knockout mice die 
rapidly postnatally from extensive lymphoproliferative disease, illustrating the 
critical role played by TGF-(3 in the regulation of lymphocyte responses (Shull 
et al., 1992). Many cell types involved in the pathogenesis of asthma can 
produce TGF-p including eosinophils, neutrophils, macrophages, and lung 
resident cells such as epithelial cells and fibroblasts (Vignola et al., 1997). 
TGF-(3 is abundantly expressed in human lungs but expression was originally 
reported to be similar in lungs from asthmatic and normal individuals (Aubert 
et al., 1994). However, a number of subsequent studies have reported 
increased TGF-|3 expression in bronchial biopsies from asthmatic patients, 
particularly in inflammatory cells beneath the basement membrane, especially 
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in eosinophils (Ohno et al., 1996; Vignola et a!., 1997; Magnan et a!., 1997; 
Minshall et al., 1997). In addition, increased levels of TGF-(3 has been 
reported in the BAL fluid of asthmatic individuals compared to healthy controls 
(Redington et al., 1997). 
Currently it is unclear if the role played by TGF-p is pro- or anti-
inflammatory. Heterozygous knockout mice that express around 30% of the 
wild type TGF-|31 levels, have increased lung eosinophilia, mucus production, 
Th2 cytokine expression and IgE after allergen challenge (Scherf et al., 2005). 
Moreover, transfer of TGF-(3 producing cells can inhibit airway inflammation 
induced by transfer of Th2 cells (Hansen et al., 2000). These studies would 
suggest that TGF-p has an anti-inflammatory role in asthma, and that 
upregulation in the allergic airway is the result of compensatory mechanisms 
during inflammation. However, there is increasing evidence as to the critical 
role played by TGF-(3 in fibrosis, which implies that its increased expression in 
the asthmatic lung is a result of the remodelling process. Indeed, TGF-(3 has 
been shown to induce fibroblasts to synthesise and secrete ECM proteins 
including collagen (Fine and Goldstein, 1987). Transient overexpression of 
TGF-(3 in the lung induces prolonged severe fibrosis (Sime et al., 1997). In 
addition, in a mouse model of prolonged allergen challenge, therapeutic 
administration of anti-TGF-p antibody after the onset of established 
eosinophilic airway inflammation reduced peribronchiolar extracellular matrix 
deposition, airway smooth muscle cell proliferation, and mucus production in 
the lung (McMillan et al., 2005). In human asthmatics, TGF-(3 mRNA 
expression correlates well with basement membrane thickness, and more 
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importantly with disease severity, again implying TGF-(3 may play an 
important role in remodelling (Vignola et al., 1997; Minshall et al., 1997). 
1.5 Regulatory T cells 
1.5.1 The discovery of regulatory T cells 
The main role of the immune system is to protect the individual from 
pathogens, and one of its fundamental qualities is the ability to distinguish 
between self and non-self and between antigens encountered in harmful and 
non-harmful contexts. The classical mechanisms controlling discrimination 
between self and non-self include clonal deletion of auto reactive T cells in the 
thymus resulting in the generation of a peripheral T cell repertoire that is 
largely self-tolerant (Sebzda et al., 1999). Despite this, it is known that some 
self-reactive T cells are present in the periphery of normal individuals. These 
autoreactive T cells are controlled in the periphery by mechanisms such as 
deletion, anergy, and ignorance (Hammerling et al., 1991). In addition, certain 
populations of lymphocytes - either naturally occurring or induced - are now 
known to play a major part in maintaining peripheral tolerance by actively 
suppressing autoagressive T cells. These important T cell populations are 
termed regulatory T cells. 
It was hypothesised in the late 1960s that a specialised population of T 
cells may exist that could suppress immune responses (Gershon and Kondo, 
1970; Gershon and Kondo, 1971). These T cells were assumed to function via 
the secretion of antigen specific soluble factors that would act on responding 
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T cells. The subsequent failure to isolate these factors resulted in the belief 
that a suppressor population existed being largely abandoned. Despite this, 
experiments on animal models of autoimmune disease done at this time did 
provide evidence for the existence of a regulatory population of T cells. 
Nishizuka and Sakakura showed that thymetomy of mice on day 3 of life 
caused a wide range of organ specific autoimmune disease including 
oophritis, thyroiditis and gastritis, depending on the strain of mouse (Nishizuka 
and Sakakura, 1969). The effect was shown to be mediated by CD4+ T cells 
and that thymectomy after day 7 did not cause autoimmunity. The 
development of autoimmune disease could also be inhibited by transfer of 
CD4+ T cells from adult mice or by thymus transplant before day 14 (Kojima 
et al., 1976; Kojima et al., 1980). The conclusion from these experiments was 
that a population of CD4+ T cells developed within the thymus between days 
3 and 7 of life that could suppress the induction of autoimmunity by self-
reactive T cells. 
Later, Sakaguchi et al showed that the regulatory population was Lyt-
1 '^^ ^ and capable of preventing autoimmune disease development induced by 
Lyt-l'°^ cells when transferred to nu/nu recipient mice (Sakaguchi et al., 
1985). In other experiments using animal models of autoimmune disease, 
Powrie and Mason showed that transfer of CD4+CD45RB'^'^'^ T cells into 
athymic mice induced a severe autoimmune wasting disease and that transfer 
of CD4+CD45RB'°^ or unseparated T cells had no effect (Powrie and Mason, 
1990). Subsequently they showed that the CD4+CD45RB'°^ population was 
capable of preventing a variety of autoimmune diseases in animal models 
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(Powrie et al., 1993; Powell and Mason, 1993; Powrie et al., 1994a: Powrie et 
al., 1994b). In 1995, Sakaguchi and co-workers further characterised the 
regulatory T cell population as a subset (10%) of CD4+ T cells, which co-
expressed the interleukin-2 receptor alpha chain (CD25) (Sakaguchi et al., 
1995; Asano et al., 1996). This T cell population has become known as the 
naturally occurring CD4+CD25+ regulatory T cell (Bluestone and Abbas, 
2003). This Treg population has subsequently been identified in mouse, rat 
and human and isolated from a number of different sources - peripheral 
blood, cord blood, spleen and thymus. The phenotype and mechanism of 
action of this regulatory T cell population has become the focus of intense 
research and their role in a variety of different diseases, including asthma, is 
currently being investigated. 
1.5.2 Isolation and characterisation of naturally occurring CD4+CD25+ 
regulatory T cells. 
Naturally occurring CD4+CD25+ regulatory T cells are produced by the 
thymus as a functionally mature and distinct T cell population (Itoh et al., 
1999). They can be isolated from human peripheral blood using either 
immunomagnetic bead separation or FACS sorting on CD25 expression. 
Although termed CD4+CD25+ regulatory T cells, not all T cells expressing 
CD25 are in fact regulatory T cells. Indeed, CD25 is also expressed on 
activated effector T cells, hindering its use as a specific marker for regulatory 
T cells. Isolating regulatory T cells from mice based on CD25 expression 
results in a largely homogenous regulatory population. However, using the 
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same approach, regulatory T cells isolated from humans contain a sizeable 
population of activated effector T cells expressing CD25. Isolating human 
regulatory T cells using the above approaches merely results in the 
purification of a population of T cells within which the naturally occurring 
regulatory population is massively enriched. In the absence of a more specific 
marker for this T cell population recent studies have used FACS sorting to 
isolate only CD25-high expressing CD4+ T cells which are reported to be the 
regulatory T cell population (Baecher-Allan et al., 2001). However, as no 
consensus exists as to where the boundary between CD25-high and CD25-
medium expressing T cells occurs, this method of isolation is not ideal. In fact, 
under inflammatory conditions, significantly more activated effector T cells 
expressing CD25 are present, hindering comparisons between studies in 
relation to absolute regulatory T cell numbers and function. 
A number of additional molecules have been described as expressed 
by CD4+CD25+ regulatory T cells, including intracellular CTLA-4 (Takahashi 
et al., 2000), CD45RO (Taams et al., 2001), GDI22 (Stephens et al., 2001), 
HLA-DR (Baecher-Allan et al., 2006), glucocorticoid-induced tumor necrosis 
factor receptor (GITR) (McHugh et al., 2002), Nrpi (Bruder et al., 2004), 
CD103 (Banz et al., 2003), CD27 (Ruprecht et al., 2005), lymphocyte 
activation gene 3 (LAG-3/CD223) (Huang et al., 2004), granzyme A 
(Grossman et al., 2004) and G protein-coupled receptor 83 (GPR83) 
(Sugimoto et al., 2006; Hansen et al., 2006). However, none of these 
molecules have been useful in the isolation of pure populations of regulatory T 
cells. Some are up-regulated during T cell activation and are thus also present 
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on effector T cell populations. Others are expressed intracellularly and are 
therefore of no use in isolating viable regulatory T cell populations. Some 
however, have been implicated in the function of CD4+CD25+ regulatory T 
cells and these are discussed in more detail below. 
Among one of the most important recent developments in regulatory T 
cell biology was the discovery of a key transcription factor, F0XP3 (fork-head 
box P3), specifically expressed by CD4+CD25+ regulatory T cells (Hori et al., 
2003; Fontenot et al., 2003; Khattri et al., 2003). The discovery of this 
transcription factor has significantly helped the characterisation of regulatory T 
cells in vitro. F0XP3-expressing regulatory T cells appear to reside within the 
CD25-high expressing T cell population, in agreement with using this as a 
method for isolating regulatory T cells. However, as by its nature as a 
transcription factor, F0XP3 is expressed within the nucleus of a cell and is of 
no use, as yet, in the isolation of viable regulatory T cells. 
Recently, isolation of pure populations of human CD4+CD25+ 
regulatory T cells based on the expression of CD127 (a-chain of the IL-7 
receptor) using flow cytometry has been demonstrated (Seddiki et al., 2006; 
Liu et al., 2006). Expression of CD127 can discriminate between regulatory T 
cells and activated effector cells expressing CD25. While most CD4+ T cells 
express CD127, regulatory T cells are CD127-negative or CD127-low. In fact, 
CD127 was a better marker for regulatory T cells than CD25. A combination 
of CD25+ and CD127-low identifies a regulatory T cell population of 6-8 % of 
CD4+ T cells. F0XP3 expression inversely correlates with CD127 expression. 
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suggesting that F0XP3 may directly repress the expression of CD127 (Liu et 
al., 2006). Isolation of CD4+CD25+ regulatory T cells in the future is highly 
likely to be increasingly achieved using FACS sorting based on both CD25 
and CD127 expression. In addition, this method has also been shown to be 
relevant in isolating CD4+CD25+ regulatory T cells from both lymph node and 
cord blood (Seddiki et al., 2006) as well as purification from peripheral blood 
of mice and rhesus macaques (Hartigan-O'connor et al., 2007). 
Many of the cell surface molecules identified as being expressed to a 
higher degree on CD4+CD25+ Treg compared to their CD4+CD25-
counterparts are also expressed by memory CD4+ T cells and may be an 
indication of a memory T cell-like surface phenotype on CD4+CD25+ Treg. In 
addition, CD4+CD25+ Treg display a short telomere length comparable to 
CD4+ memory T cells (Taams et al., 2002) suggesting much of the phenotype 
of Tregs may be due to repeated exposure to antigen in the periphery. 
1.5.3. The role of F0XP3 
F0XP3 is a transcription factor expressed by CD4+CD25+ regulatory T 
cells and essential for their development and regulatory function. A number of 
groups reported on the specific expression of F0XP3, a member of the 
forkhead/winged-helix family, by CD4+CD25+ Tregs (Hori et al., 2003; 
Fontenot et al., 2003; Khattri et al., 2003). Transduced expression of F0XP3 
in non-regulatory T cells was sufficient to induce a regulatory phenotype in 
these cells. These transduced cells displayed all the hallmarks of regulatory T 
cells, including cell surface expression of GITR and CTLA-4, cell-contact 
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dependant suppressive activity and low levels of cytokine expression (Hori et 
al., 2003; Fontenot et al., 2003). These observations suggested that the 
transcription factor F0XP3 acts as a "master regulator" of CD4+CD25+ 
regulatory T cells. 
Mutations in the F0XP3 gene give rise to the multi-organ autoimmune 
disease IPEX (immune dysregulation, polyendocrinopathy, enteropathy, X-
linked) in humans (Bennett et al., 2001; Wildin et al., 2001). IPEX syndrome 
presents with a range of organ-specific immune diseases, IBD, allergic 
dermatitis, food allergy and haematological disorders. In addition, the X-linked 
recessive mouse mutant strain Scurfy, that results in a fatal 
lymphoproliferative disorder, has been demonstrated to arise as a 
consequence of mutation within the F0XP3 gene (Brunkow et al., 2001). 
Studies by Fontenot et al using a GFP-Foxp3 fusion-protein reporter 
knockin allele and immunophenotyping of single F0XP3+ cells by Roncador 
et al revealed expression of F0XP3 was exclusive to T cells (Roncador et al., 
2005; Fontenot et al., 2005b). In addition, ablation of F0XP3 expression in the 
T cell lineage is sufficient to induce a phenotype indistinguishable from that in 
scurfy mice. As well as being expressed by CD4+CD25+ T cells, both studies 
also reported that F0XP3 expression is also detectable in a small population 
of CD8+ and CD4+CD25- T cells in both mice and human. However, as noted 
above, CD25 expression is not an exact marker for regulatory T cells and the 
expression of F0XP3 by some CD4+CD25- T cells is a highlight of this fact. 
Fontenot et al, demonstrated that regulatory activity associates with F0XP3 
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expression more than with CD25 expression, with both FOXP3+CD25+ and 
FOXP3+CD25- T cells displaying similar gene expression profiles and equal 
potency in in vitro suppression assays (Fontenot et al., 2005b). Furthermore, 
this expression of F0XP3 on CD4+CD25- T cells has been suggested to 
distinguish a sub-population of naive regulatory T cells that are more resistant 
to apoptosis than their FOXP3+CD25+ counterparts (Fritzsching et al., 2006). 
Studies to date have substantiated the claims that F0XP3 is an 
important transcription factor in the function and development of CD4+CD25+ 
regulatory T cells. However, controversy does exist as to whether expression 
of F0XP3 is specific to this regulatory T cell population or can be induced 
upon activation in non-regulatory T cells. A number of studies have reported 
the expression of F0XP3 mRNA by in vitro activated human non-regulatory T 
cells and even the generation of regulatory activity by these cells (Walker et 
al., 2003; Walker et al., 2005; Morgan et al., 2005b). However a subsequent 
study by Gavin et al revealed that while activation can induce F0XP3 protein 
expression in human T cells, this expression is transient and insufficient to 
induce regulatory function on these cells (Gavin et al., 2006). The available 
data suggests that human non-regulatory T cells may transiently up-regulate 
F0XP3 expression upon activation, while activation of mouse non-regulatory 
T cells does not result in any up-regulation of F0XP3. However, there are 
now several reports of induction of regulatory T cells expressing F0XP3 from 
by stimulation of non-regulatory cells with TGF-p (Chen et al., 2003; Fantini et 
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al., 2004; Rao et al., 2005). The generation of FoxP3+ regulatory T cells in the 
periphery by stimulation with TGF-p is discussed later in this introduction. 
Initial experiments on transduced expression of F0XP3 in non-
regulatory T cells suggested that expression of F0XP3 by T cells was 
sufficient to impart a regulatory phenotype upon T cells. It was assumed that 
F0XP3 worked in a binary fashion and hence many researchers have sought 
to associate decreased numbers of F0XP3-expressing T cells with various 
autoimmune diseases (Meignin et al., 2005). However, recent reports from a 
number of groups suggest that a decreased expression of F0XP3 by Tregs 
might be associated with the development of autoimmune disease (Miura et 
al., 2004; Balandina et al., 2005; Huan et al., 2005). This question was 
recently addressed by Wan and Flavell using a targeted gene "knock-in" 
approach to generate mice with a 5-10 fold lower expression of F0XP3 (Wan 
and Flavell, 2007). The authors discovered that attenuated F0XP3 expression 
had no effect on the homeostatic expansion and maintenance of Tregs. 
Decreased expression of F0XP3 in Tregs also had no effect on their anergic 
phenotype. However, the immune-suppressive ability of these FOXP3-low 
Tregs was abolished in T cell transfer experiments. In addition to the defective 
suppressive function of these Treg, the authors also suggested decreased 
F0XP3 expression may result in the conversion of Treg into effector cells. 
These conclusions suggest that autoimmune disease may be caused by the 
aberrant expression of F0XP3 by Treg, and Treg may in addition contribute to 
the development of autoimmune disease. 
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1.5.4 Mechanism of action of CD4+CD25+ regulatory T cells. 
Among the earliest observations made with regard to CD4+CD25+ 
regulatory T cells was their dependence on cell-cell contact to exert their 
suppressive function in in vitro assays. In addition, Treg cells require 
activation through their TCR to be suppressive (Thornton and Shevach, 
1998). A number of the cell surface markers mentioned above that are 
preferentially expressed on CD4+CD25+ regulatory T cells have been 
investigated in an attempt to identify a role for these molecules in the contact-
dependant mechanism of suppression employed by regulatory T cells. These 
include CTLA-4, GITR, LAG-3 and granzyme A. 
1.5.4.1 The role of CTLA-4 
CTLA-4 is a member of the CD28-family and its expression is up-
regulated on T cells following activation. Like CD28 it is a receptor for CD80 
and CD86 expressed on the surface of B cells and antigen presenting cells, 
which it binds with greater affinity compared to CD28. Unlike CD28, which 
delivers a co-stimulatory signal to T cells required for T cell activation, CTLA-4 
ligation delivers an inhibitory signal to the T cell, attenuating T cell activation 
(Walunas et al., 1994). CTLA-4 gene deficient animals develop profound 
lymphoproliferative disease, resulting in immune-mediated damage to multiple 
organs (Waterhouse et al., 1995; Tivol et al., 1995). Constitutive expression of 
CTLA-4 has been reported on CD4+CD25+ Tregs (Takahashi et al., 2000) 
and many groups have attempted to identify a role for this receptor in their 
mechanism of action, with mixed results (Sansom and Walker, 2006). 
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Neutralising CTLA-4 in in vitro co-cultures of CD4+CD25+ and 
CD4+CD25- T cells using monoclonal antibodies failed to block suppression 
by regulatory T cells for cells isolated from both mouse (Chai et al., 2002) and 
human (Levings et al., 2001; Jonuleit et al., 2001; Chai et al., 2002; Thornton 
et al., 2004). In contrast, other groups have reported that blocking CTLA-4 in 
vitro does impact on the suppression mediated by CD4+CD25+ regulatory T 
cells (Takahashi et al., 2000; Annunziato et al., 2002; Tang et a!., 2004). 
These conflicting data may be explained by the use of antibodies to neutralise 
CTLA-4. Different antibodies may exhibit different efficacies in blocking CTLA-
4 function in vitro. Access to the immunological synapse to interact with and 
block CTLA-4 may differ for antibodies of different sizes and as CTLA-4 
expression by CD4+CD25+ regulatory T cells is mainly intracellular blocking 
its function in vitro using antibodies may be incomplete. Kataoka et al 
attempted to address this discrepancy by comparing the suppression of 
CD4+CD25+ regulatory T cells isolated from transgenic mice both deficient in 
and over-expressing CTLA-4. They noted that Treg from both groups 
displayed a similar suppressive ability in vitro (Kataoka et al., 2005). 
Data from in vivo experiments generally supports a role for CTLA-4 
during regulation by CD4+CD25+ regulatory T cells. In a number of adoptive 
transfer experiments CD4+CD25+ regulatory T cells were capable of 
suppressing onset of autoimmune disease and this effect was inhibited by 
administration of CTLA-4-neutralising antibody (Read et al., 2000; Liu et al., 
2003; Read etal., 2006). 
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Another observation that lends evidence to the absence of a role for 
CTLA-4 in the mechanism of action of Tregs comes from CTLA-4 gene-
deficient animals. Regulatory T cells isolated from these animals appear to 
have a normal population of CD4+CD25+FOXP3+ regulatory T cells capable 
of suppressive activity in vitro (Tang et al., 2004). However, even this 
observation does not provide a definitive answer as the authors noted that 
CTLA-4-deficient Treg produced increased levels of both IL-10 and TGF-(3. In 
addition, neutralising TGF-(3 inhibited the in vitro suppression mediated by 
CTLA-4-deficient Treg, suggesting that in the absence of CTLA-4, Treg 
develop a compensatory mechanism of suppression utilising suppressive 
cytokines. 
To date the data regarding a direct role for CTLA-4 in CD4+CD25+ 
regulatory T cell function is inconclusive. The fact may be that CTLA-4 does 
have an important function in the mechanism of suppression by Treg, and the 
conflicting results reported might be due to the fact that Treg can employ 
multiple methods for suppressing effector T cell proliferation in vivo, including 
one mechanism that relies on CTLA-4 expression on Treg cells. 
1.5.4.2 The role ofGITR 
GITR, also known as TNFRSF18, is a member of the TNF receptor 
superfamily. In non-activated T cells this receptor is preferentially expressed 
on CD4+CD25+ Tregs (Shimizu et al., 2002; McHugh et al., 2002). Activation 
through the TCR up-regulates GITR expression in non-regulatory T cells as 
well as a further induction of expression by CD4+CD25+ Tregs. In early 
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studies, stimulation through GITR on CD4+CD25+ Tregs with an agonistic 
anti-GITR Ab abrogated their suppressive functions in vitro, and furthermore, 
administration of anti-GITR Abs to normal mice or removal of GITR-
expressing T cells resulted in the induction of organ specific autoimmunity 
(Shimizu et al., 2002). These observations led to the conclusion that GITR 
played an important role in the suppressive function of CD4+CD25+ Tregs 
and activation of GITR on the surface of Tregs using agonistic antibodies 
abrogated their suppression function. However, subsequent experiments also 
demonstrated a role for GITR as a costimulatory molecule for non-regulatory 
T cells (Kanamaru et al., 2004; Stephens et al., 2004; Ronchetti et al., 2004; 
Kohm et al., 2004). This raised the possibility that earlier observations of 
antagonistic GITR antibodies abrogating CD4+CD25+ Treg suppression may 
in fact have been incorrectly interpreted and this effect may have been 
mediated by interaction with GITR on non-regulatory T cells in these co-
culture experiments. This question was addressed by Stephens et al using 
regulatory and non-regulatory T cells from normal and GITR-deficient mice in 
co-culture experiments (Stephens et al., 2004). This study revealed that 
ligation of GITR on the responder T cells was required to abrogate the 
suppression mediated by regulatory T cells. Therefore, signalling through 
GITR promotes resistance of responder T cells to Treg-mediated suppression 
rather than abrogating suppression by signalling through GITR on regulatory 
T cells. 
1.5.4.3 The role of LAGS 
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LAG-3 is a CD4 homologue that binds to iVlHC class II. Huang et al 
reported the preferential expression of LAG-3 mRNA by CD4+CD25+ 
regulatory T cells compared to CD4+CD25- T cells (Huang et al., 2004). 
However, no cell surface expression of LAG-3 on Tregs was observed, 
excluding its use a selection marker for Tregs. In addition LAG-3 mRNA is 
also up-regulated by CD4+CD25- T cells upon activation, in a dose dependant 
manner. The discrepancy between expression of LAG-3 mRNA by 
CD4+CD25+ Tregs and the absence of cell surface expression of the protein 
can be explained by cleavage of LAG-3 on the surface of T cells by the 
metalloproteinases ADAM10 and ADAM17 (Li et al., 2004; Li et al., 2007). A 
potential role for LAG-3 in the mechanism of suppression by CD4+CD25+ 
regulatory T cells is suggested by experiments where antibodies to LAG-3 
blocked the suppression mediated by CD4+CD25+ regulatory T cells in vitro 
(Huang et al., 2004). In addition, ectopic expression of LAG-3 in naive T cells 
conferred regulatory activity on these cells to a comparable degree as that 
seen when F0XP3 was ectopically expressed. 
One argument against a pivotal role for LAG-3 in the function of 
CD4+CD25+ regulatory T cells is the absence of multi-organ autoimmunity in 
LAG-3 deficient mice, similar to that seen in scurfy mice in the absence of 
F0XP3. However, older LAG-3 deficient mice have been shown to have twice 
the number of T cells compared to normal mice, suggesting a role for LAG-3 
in regulating T cell homeostasis, possibly via regulatory T cells (Workman and 
Vignali, 2005). 
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1.5.4.4 The role of perforin/granzyme 
Cytotoxic T lymphocytes (CTLs) and natural killer (NK) cells are 
capable of recognising and killing cells infected with intracellular pathogens, 
principally via the perforin/granzyme pathway. CTLs and NK cells contain lytic 
granules that are released upon recognition of antigen on the surface of the 
target cell. The lytic granules contain two types of effector protein, perforin 
and granzyme. Perforin polymerises to form transmembrane pores in the 
target cell membrane, allowing salts and water to pass into the cell. In doing 
so perforin destroys the integrity of the cell membrane causing rapid cell 
death. Two types of granzyme, A and B, are also released along with perforin. 
Both are serine proteases that can enter the target cell via the perforin pore 
and trigger apoptosis by initiating enzyme cascades that result in DNA 
degradation. 
Grossman et al suggested a role for the perforin/granzyme pathway in 
the mechanism of action of CD4+CD25+ regulatory T cells (Grossman et al., 
2004). The authors observed that CD4+CD25+ T cells expressed granzyme A 
(but not granzyme B) upon activation with platebound anti-CD3/CD28 or 
CD3/CD46. Furthermore, CD4+CD25+ T cells activated for four days under 
these conditions were capable of killing purified autologous CD4+, CD8+ and 
CD14+ target cells in a porforin-dependant manner. In addition, blocking 
antibodies to CD18, which is a critical component of the immune synapse of 
CD4+ T cells, inhibited the cytotoxicity of the CD4+CD25+ Tregs. Although 
these studies outline a possible role for the perforin/granzyme pathway in the 
mechanism of action of CD4+CD25+ regulatory T cells it cannot account for 
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the contact-dependant suppression of proliferation seen in in vitro co-culture 
experiments of CD4+CD25+ and CD4+CD25- T cells. In addition, original 
experiments on CD4+CD25+ Tregs showed no evidence of cell death in co-
culture experiments and identical numbers of viable cells were recovered in 
the presence or absence of the CD4+CD25+ cells after twenty-four hours of 
culture (Thornton and Shevach, 1998). 
1.5.4.5 The role of cytoldnes 
As noted earlier, the dependence on cell-cell contact to exert their 
suppressive function in vitro was among one of the earliest observations 
regarding CD4+CD25+ regulatory T cells. Separating CD4+CD25+ Tregs 
from CD4+CD25- effector T cells in co-culture experiments by use of a 
permeable membrane abrogated suppression (Thornton and Shevach, 1998). 
In addition, supernatants from cultured CD4+CD25+ T cells are incapable of 
suppressing the proliferation of CD4+CD25- T cells indicating that 
suppression is not mediated by a soluble factor, at least in vitro. Furthermore, 
a role for the suppressive cytokines IL-10 and TGF-p was initially ruled out by 
the addition of neutralising antibodies to co-cultures of human CD4+CD25+ 
and CD4+CD25- T cells, and by use of CD4+CD25+ Tregs isolated from IL-10 
and TGF-p deficient mice. Neutralising antibodies to these cytokines had no 
effect on the suppression of proliferation mediated by human CD4+CD25+ T 
cells in vitro (Levings et al., 2001; Jonuleit et al., 2001; Taams et al., 2001; 
Dieckmann et al., 2001), and CD4+CD25+ T cells isolated from both gene 
deficient animals are equally capable of suppressing proliferation (Thornton 
and Shevach, 1998; Piccirillo et al., 2002; Nakamura et al., 2004). 
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Despite suggestions from the above studies that IL-10 and TGF-p are 
not required for suppression mediated by CD4+CD25+ T cells in vitro, it has 
been noted that both mouse and human CD4+CD25+ Tregs produce both 
cytokines upon TCR activation (Thornton and Shevach, 1998; Levings et al., 
2001; Nakamura et al., 2001). Some studies have also reported at least a 
partial reversal of human CD4+CD25+ Treg suppression using neutralising 
antibodies to TGF-p in vitro (Annunziato et al., 2002) or with the use of high 
concentration of antibodies (Nakamura et al., 2004). These conflicting reports 
can possibly be explained by the observation that activated human and 
mouse CD4+CD25+ regulatory T cells express cell-surface bound TGF-|3 
which may be involved in suppression via a cell-contact dependent 
mechanism (Nakamura et al., 2001). Furthermore, CD4+CD25+ Tregs from 
TGF-P deficient mice exhibit suppressor activity in vitro yet failed to prevent 
induction of colitis in a SCID transfer model of colitis, suggesting in vivo, 
CD4+CD25+ Tregs from TGF-(3 deficient mice do have impaired suppressor 
function (Nakamura et al., 2004). Blockade of TGF-|3 signalling, by addition of 
recombinant latency-associated peptide of TGF-|3 (rLAP) to co-cultures of 
murine or human CD4+CD25- T cells and CD4+CD25+ Tregs, blocked the 
suppressive function of CD4+CD25+ T cells, implying addition of anti-TGF-(3 
Abs to in vitro co-cultures may not efficiently blockade TGF-p signalling 
between CD4+CD25+ and CD4+CD25- T cells (Nakamura et al., 2004). The 
in vitro studies regarding the role of IL-10 and TGF-p in the suppression 
mediated by CD4+CD25+ regulatory T cells suggest that these cells may 
exert their suppressive function via more than one mechanism. This 
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conclusion is supported by observations made in vivo that demonstrate a role 
for one or both cytokines in the mechanism of action of CD4+CD25+ 
regulatory T cells. 
It has been demonstrated that CD4+CD25+ regulatory T cells isolated 
from IL-10 deficient mice fail to suppress experimental autoimmune 
encephalomyelitis (EAE) and colitis in adoptive transfer models, yet wild type 
CD4+CD25+ regulatory T cells could suppress disease (Asseman et al., 
1999; Suri-Payer and Cantor, 2001; Zhang et al., 2004). Resolution of airway 
inflammation by adoptive transfer of CD4+CD25+ regulatory T cells in an 
animal model of airway inflammation was dependant on IL-10. However 
CD4+CD25+ cells from IL-10 deficient animals were equally capable of 
suppressing disease, suggesting production of IL-10 by the regulatory T cells 
themselves is not required for this effect (Kearley et al., 2005). In addition, as 
noted above, CD4+CD25+ regulatory T cells isolated from TGF-p deficient 
mice fail to prevent induction of colitis in a SCID transfer model of colitis, while 
at the same time exhibiting potent suppressor activity in vitro (Nakamura et 
al., 2004). 
The conclusions from both in vitro and in vivo experiments investigating 
the mechanism of action of CD4+CD25+ regulatory T cells suggest that these 
cells may have several modes of action that may depend on the 
microenvironment in which the cell is activated. These different modes of 
suppressive action may also be differentially used to suppress different forms 
of immunopathology (von Boehmer, 2005). 
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1.5.4.6 Modulation of APC function 
Recent evidence has suggested a role for modulation of APC function 
in the mechanism of action of regulatory T cells. Murine CD4+CD25+ 
reguiatory T cells have been shown to decrease the expression of the co-
stimulatory molecules CD80 and CD86 on APCs (both bone marrow-derived 
DC and B cells) in a dose-dependent manner when both cell types are co-
cultured (Cederbom et al., 2000). Subsequently, human regulatory T cells 
were shown to exert similar effects on the expression of co-stimulatory 
molecules on monocyte-derived DC when co-cultured, as well as rendering 
the DC inefficient as APCs (IVlisra et al., 2004). In a further study, co-culture of 
monocytes/macrophages with CD4+CD25+ regulatory T cells in the presence 
of anti-CD3 antibody failed to upregulate CD40, HLA II and CD80 on 
monocytes, as seen when co-cultured with CD4+CD25- T cells (Taams et al., 
2005). Furthermore, the antigen presenting function of these cells was 
impaired after co-culture with CD4+CD25+ regulatory T cells as seen by their 
decreased ability to induce antigen-specific or allo-specific T cell proliferation. 
Co-culture of monocytes with CD4+CD25+ regulatory T cells prior to 
stimulation with LPS also decreased their ability to produce the pro-
inflammatory cytokines TNF-a and IL-6 (Taams et al., 2005). These studies 
combined suggest that regulatory T cells inhibit activation and function of 
APC. 
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1.5.5 Cytokines in the generation and maintenance of Tregs 
T cell development occurs In the thymus where steps involving both 
positive and negative selection determine the peripheral T cell repertoire (von 
Boehmer et al., 2003). Developing T cells initially undergo a positive selection 
step where only T cells that can interact with the MHC survive. Subsequently 
T cells with a high avidity for self-MHC undergo a negative selection process 
and are deleted. These positive and negative selection steps in the thymus 
result in a peripheral T cell repertoire capable of interacting with MHC with 
relatively low avidity. Despite this, and other mechanisms such as T cell 
anergy, autoreactive T cells are also found in the periphery of humans and 
are actively controlled by the action of regulatory T cells. 
Naturally occuring CD4+CD25+ regulatory T cells also develop 
intrathymically. Their development appears to be similar to that of 
conventional T cells but develop due to different avidity interactions. Selection 
of CD4+CD25+ thymocytes appears to require a TCR with intermediate 
affinity for self-peptide because thymocytes expressing TCRs with low affinity 
do not undergo selection by this pathway (Jordan et al., 2001). It has been 
suggested that this alternative positive selection of regulatory T cells triggers 
a development programme that protects the developing thymocytes from 
subsequent deletion via the negative selection step. The site where positive 
selection of regulatory T cells occurs is suggested to be cortical medullary 
epithelial cells (Bensinger et al., 2001). 
Recent studies have highlighted the importance of a number of 
molecules and cytokines in the maintenance of regulatory T cells in the 
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periphery once they have migrated from the thymus. A critical role for IL-2 in 
the peripheral maintenance of Tregs is suggested by studies using anti-IL-2 
antibody to neutralise circulating levels of the cytokine. This treatment results 
in autoimmune diseases associated with reduced numbers of F0XP3 
expressing Tregs in the periphery (Setoguchi et al., 2005). The importance of 
IL-2 signalling in the peripheral maintenance of Tregs is further supported by 
transgenic mice in which components of the IL-2 signalling pathway have 
been deleted, including IL-2 (Sadlack et al., 1993), CD25 (Willerford et al., 
1995), IL-2RP (Suzuki et al., 1995) and STAT5 (Antov et al., 2003; Snow et 
al., 2003). However, while some of these studies concluded that IL-2 was 
critical for both the development and maintenace of Tregs, a recent study by 
Fontenot et al has concluded that IL-2 signalling is critical for maintenance of 
peripheral Tregs only and not for their development. The authors found that 
normal F0XP3+ regulatory T cells were present in the thymus and periphery 
of both IL-2 and CD25 knock-out mice (Fontenot et al., 2005a). Interestingly, 
transgenic mice deficient in the third subunit of the IL-2R, the yc subunit, did 
display an abolishment of Treg development, indicating the importance of one 
or some of the jc cytokines such as IL-4, IL-9, IL-15, and IL-21 in Treg 
development. 
A role for TGF-p in the induction of regulatory T cells in the periphery 
has recently been described and this is discussed in the section below. 
However, the role of TGF-p in the development and peripheral maintenance 
of naturally occurring CD4+CD25+ regulatory T cells is controversial. One 
study on TGF-|3-knock-out mice has reported reduced numbers of peripheral 
70 
but not thymic CD4+CD25+ Treg suggesting a role for TGF-p in the peripheral 
maintenance of Tregs (Marie et al., 2005). However, other studies have 
reported normal development and numbers of CD4+CD25+ Tregs in TGF-p-
knock-out mice (Mamura et al., 2004) and so a role for TGF-p is not 
conclusive. 
1.5.6 TGF-p and the extrathymic development of Tregs 
In addition to the widely studied naturally occurring CD4+CD25+ 
regulatory T cells that develop intrathymically, a number of other types of 
regulatory cell have been reported, referred to as adaptive or induced Tregs. 
In particular, a number of recent studies have reported the development of 
FoxP3+ regulatory T cells in the periphery by stimulation of naive T cells with 
TGF-p. This pathway of regulatory T cell induction has obvious links with the 
generation of a recently described new lineage of effector T cells known as 
Th17 cells and these pathways are discussed below. 
1.5.6.1 Generation of FoxP3+ Treg in the periphery 
A role for TGF-p in the generation of regulatory T cells from naive 
CD45RA+ T cells was originally described by Horwitz and colleagues 
(Yamagiwa et al., 2001; Zheng et al., 2002). Recently, independent studies 
have confirmed this observation with both mouse and human naive CD4 T 
cells (Chen et al., 2003; Fantini et al., 2004; Rao et al., 2005). Stimulation of 
naive T cells throught TCR in the presence of TGF-p induced a population of 
regulatory T cells. These induced regulatory T cells express FoxPS and 
display suppressive activities indistinguishable from naturally occurring 
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CD4+CD25+ Treg. In addition these cells display many of the hallmarks of 
naturally occurring Tregs, including their anergic phenotype and expression of 
specific cell surface markers. The existence of an autoregulatory loop 
controlling this development has also been suggested as TGF-p-induced 
FoxP3 inhibited the expression of Smad7, an inhibitor of TGF-p signalling, 
thereby augmenting TGF-p signalling (Fantini et al., 2004). Through the use of 
a transgenic mouse in which a bicistronic fluorescent reporter had been 
knocked-in to the endogenous FoxP3 locus, it was shown that the 
development of FoxP3+ T cells from FoxPS- naive cells in response to TGF-p 
stimulation was the result of de novo FoxPS synthesis (Wan and Flavell, 
2005). This study also provided evidence that the induction of these FoxP3+ 
Tregs was not due to outgrowth of contaminating FoxP3+ cells in the starting 
T cell fraction. The existence of FoxP3+ Treg induced by TGF-p has also 
been reported in a number of in vivo mouse models of transplant tolerance 
and oral tolerance induction (Cobbold et al., 2004; Curotto de Lafaille et al., 
2004). These recent studies have clearly highlighted a mechanism by which 
TGF-p stimulation of naive T cells can induce a regulatory T cell phenotype 
similar to that of naturally occurring CD4+CD25+ Tregs. This pathway of 
regulatory T cell induction shares some parallels with the induction of the 
recently described Th17 lineage of effector T cells. 
1.5.6.2 The Th17 lineage of effector T cells 
Recently, the classical division of CD4 effector T cells into Th1 and Th2 
cells has been expanded with the discovery of a third distinct lineage of helper 
T cell referred to as Th17 cells. The discovery of the Th17 lineage came from 
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observations made with two autoimmune mouse models, experimental 
autoimmune encephalitis (EAE) and collagen-induced arthritis (CIA). Both 
have traditionally been associated with abnormal Th1 responses mainly 
because disease development was inhibited by neutralising antibodies to a 
subunit of IL-12 (the p40 subunit) or in transgenic mice where the p40 subunit 
had been deleted. The subsequent discovery of IL-23, a member of the IL-12 
family that also has the p40 subunit, questioned the association of EAE and 
CIA with unchecked Thi responses (Oppmann et al., 2000). Indeed, disease 
development is ablated only in mice deficient in IL-23 or in both IL-23 and IL-
12, while mice deficient in IL-12 only remain susceptible (Cua et al., 2003; 
Murphy et al., 2003; Zhang et al., 2003). Resistence to disease correlated 
with an absence of IL-17 producing CD4+ T cells (Murphy et al., 2003). 
Langrish et al subsequently showed that passive transfer of CD4+ T cells 
producing IL-17, enriched by culture in IL-23, induced severe EAE in recipient 
mice, while Thi cells enriched by culture in IL-12 did not (Langrish et al., 
2005). In addition, both T cell populations had unique gene expression 
profiles (Langrish et al., 2005). 
Further evidence that Thi 7 cells represented a unique lineage came 
from two studies on the differentiation of Th17 cells. Taken together both 
studies showed that the differentiation of naive precursors into Thi 7 cells was 
independent of the cytokines and transcription factors required for Thi and 
Th2 differentiation. Furthermore, both IL-4 and IFN-y actively suppressed 
Thi7 development (Harrington et al., 2005; Park et al., 2005). Recently, the 
orphan nuclear receptor RORyt has been demonstrated as the key 
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transcription factor that orchestrates the differentiation of Th17 cells (Ivanov et 
al., 2006). Surprisingly, three independent studies reported that IL-23 is not 
required for the initiation of Th17 lineage commitment as the development of 
Th17 effector cells was undiminished under conditions of IL-23 deficiency and 
addition of exogenous IL-23 did not enhance Th17 development (Bettelli et 
a!., 2006; Mangan et al., 2006; Veldhoen et al., 2006). All three reports 
concluded that TGF-p was necessary for initiation of Th17 differentiation. In 
addition, IL-6 was identified as a critical co-factor in their differentiation, and 
IL-1 p and TNF-a were found to amplify the response. 
Since the initial description of Th17 cells a number of important 
observations with regard to Th17 biology have been published. As outlined 
above, the orphan receptor RORyt has been identified as the key lineage 
defining trancription factor for Th17 cells (Ivanov et al., 2006). In addition 
downstream signalling for Th17 differentiation has been shown to be 
dependant on activation of STAT3. A number of research groups have 
demonstrated that the gp130-Stat3 pathway is essential for Th17 
differentiation and expression of RORyt (Yang et al., 2007; Mathur et al., 
2007; Nishihara et al., 2007). A role for Socs3, a negative regulator of IL-6 
and IL-23 signalling has also been demonstrated for the differentiation of 
Th17 cells, with inhibition of Socs3 constraining the generation of Th17 
differentiation (Chen et al., 2006). A role for IL-21, acting downstream of IL-6 
signalling, in amplifying Th17 generation by activating IL-23R expression has 
also been described (Korn et al., 2007; Nurieva et al., 2007; Zhou et al., 
2007). Recenty, IRF4, a transcription factor previously shown to be important 
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for Th2 cell differentiation, has also been described a role in Th17 cell 
differentiation (Brustle et al., 2007). IRF4-deficient mice were protected from 
EAE and T cells from these mice failed to differentiate into Th17 cells. In 
addition, T cells from these IRF4-deficient mice displayed decreased 
expression of RORyt. 
The majority of the studies mentioned above were conducted on 
mouse T cells and recently the study of Th17 cells has moved into the field of 
human T cells. A number of differences have been described in the Th17 
differentiation pathway between the two species. However, it must be noted 
that interpreting these differences is complicated by the fact that while murine 
studies have been conducted on naive T cells, the human cells analysed are 
generally antigen-experienced cells. In addition, contamination of naive T 
cells isolated in human studies with even small number of pre-activated T 
cells or pre-activated APCs may have strong effects on in vitro Th17 
differentiation due to the strong inhibitory effects of cytokines such as IL-4, IL-
12 and IFNy on this pathway (Harrington et al., 2005; Veldhoen et al., 2006). 
With this complication in mind, it has been described that in contrast to murine 
T cells, TGPp and IL-6 failed to induce Th17 differentiation in TCR-stimulated 
CD45+ human T cells. Instead, IL-1|3 was found to induce Th17 production 
and this was enhanced when IL-6 was also included (Acosta-Rodriguez et al., 
2007a). In contrast, while IL-1|3 has been shown to enhance murine Th17 cell 
differentiation in vitro, it cannot induce the differentiation of naive mouse T 
cells into Th17 cells in the absence of TGFp (Veldhoen et al., 2006). In 
common with murine Th17 cells, human Th17 cells express RORyt (Acosta-
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Rodriguez et al., 2007a) and upregulate IL-23R expression (Annunziato et al., 
2007). A number of recent reports have demonstrated that human Th17 cells 
express CCR6 and CCR4, and purification of activated T cells on the basis of 
co-expression of these receptors enriches for IL-17 producing T cells 
expressing RORyt (Annunziato et al., 2007; Acosta-Rodriguez et al., 2007b). 
CCR6 expression on murine Th17 cells has also recently been reported 
(Hirota et al., 2007). 
1.5.6.3 TGF/3, regulatory T cells and the Th17 lineage 
As outlined above, recent evidence suggests that TGF-p stimulation is 
important in the induction of two distinct T cell populations, Th17 cells and 
extrathymically induced FoxP3+ Tregs. The generation of both these T cell 
populations appears to have many parallels and may represent a pathway for 
the induction of effector or regulatory T cells from naive T cells in the 
periphery. In the studies of Th17 development in response to TGF-p 
stimulation it was noted that TGF-p signalling induced two distinct T cell 
populations, principally Th17 cells and also a minor population of FoxP3+ 
Tregs (Mangan et al., 2006). In addition, expression of IL-17 and FoxPS was 
restricted to separate T cell subsets. Moreover, addition of exogenous IL-6 
eliminated the development of the FoxP3+ Treg subset, while blockade of IL-6 
enhanced their development (Bettelli et al., 2006; Mangan et al., 2006). 
Therefore, TGF-p stimulation in the presence of IL-6 appears to divert the 
development of FoxP3+ Tregs towards the Th17 lineage. The presence of IL-
6 within the cytokine environment during activation of naive T cells may 
prevent the induction of FoxP3+ Tregs capable of suppressing the immune 
76 
response. Indeed, microbial induction of the toll pathway has been shown to 
block the suppressive effect of CD4+CD25+ Tregs and this effect is 
dependent on IL-6 (Pasare and Medzhitov, 2003). It is possible that these 
observations are due to IL-6 blocking natural Treg function, as well as 
blocking the induction of adaptive Tregs in response to TGF-(3 signalling. 
1.5.7 Other types of regulatory T cell 
A number of additional regulatory T cell populations have recently been 
described. These Treg populations produce the cytokines IL-10 or TGF-p and 
are induced by a number of different experimental models. The relationship 
between each of these induced Treg populations is currently unknown. 
1.5.7.1 Induced IL-10 producing regulatory T cells 
One type of regulatory T cell, termed Tr1 cells, can be induced in 
culture through repeated antigen stimulation in the presence of IL-10 (Groux 
et al., 1997). Tr1 cells are characterised by their unique pattern of cytokine 
secretion. They produce high levels of IL-10 but not TGF-(3, and their 
regulatory function has been demonstrated in vivo, as transfer of Tr i cells 
prevents colitis (Groux et al., 1997). In addition, administration of Tr i cells 
was also found to inhibit Th2 mediated responses in mice immunised with 
ovalbumin (Cottrez et al., 2000). This effect was mediated in part through IL-
10 secretion as anti-IL-10 receptor antibody abrogated their inhibitory effect. 
Splenocytes cultured in vitamin D3 and dexamethasone with repeated 
antigen stimulation induces a regulatory, IL-10-producing phenotype, and 
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moreover these cells do not produce IL-4, IL-5 or IFN-y (Barrat et al., 2002). 
Adoptive transfer of these cells abrogated disease in a model of experimental 
autoimmune encephalomyelitis (EAE) via an IL-10 dependent mechanism 
(Barrat et al., 2002). A recent study has now shown that induction of IL-10 
producing cells by vitamin D3 and dexamethasone may also be relevant in 
human asthma in vivo (Xystrakis et al., 2006). Vitamin D3 treatment of 
asthmatic patients was shown to enhance IL-10 production from CD4+ T cells 
induced by stimulation in the presence of dexamethasone. Importantly, 
vitamin D3 restored responsiveness to dexamethasone in the CD4+ T cells of 
steroid resistant asthmatics, indicating that vitamin D3 may enhance patient 
response to steroid treatment. 
Regulatory cells can also be generated by repeated intranasal 
exposure to allergen via an APC dependent mechanism. After OVA exposure, 
pulmonary DCs produced IL-10, and could induce IL-10 production from CD4 
T cells in vitro and in vivo (Akbari et al., 2001). Moreover, transfer of these IL-
10 producing Treg cells could inhibit airway inflammation (Akbari et al., 
2002b). In addition the development and the inhibitory function of these cells 
was shown to be dependent on the presence of IL-10 and required T-cell 
costimulation via the inducible costimulator (ICOS)-ICOS-ligand pathway. 
Administration of heat killed Mycobacterium vaccae was shown to 
inhibit airway inflammation in allergen sensitised and challenged mice (Wang 
and Rook, 1998). This effect was subsequently shown to be due to the 
induction of a T cell population with regulatory activity, since transfer of 
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splenocytes from mice treated with Mycobacteria vaccae could suppress AHR 
and eosinophilia in recipient mice via a mechanism that was IL-10 and TGF-(3 
dependent (Zuany-Amorim et al., 2002). Interestingly, this group has also 
investigated the effects of an intradermal injection of heat killed 
Mycobacterium vaccae in an asthma clinical trial, where it was found that 
treatment decreased serum IgE and IL-5 levels, and reduced the fall in lung 
function during the LAR (Camporota et al., 2003). 
Peptide immunotherapy has been found to be effective in the treatment 
of allergic patients, and is associated with an increase in IL-10 expression 
(Oldfield et al., 2002). PMBCs isolated from allergic patients after 
immunotherapy showed a decreased proliferative response compared with 
before treatment (Verhoef et al., 2005). This decreased proliferative response 
was associated with an increased production of IL-10 and a decreased 
production of IL-5. In addition, CD4+ cells isolated after immunotherapy were 
able to actively suppress allergen-specific proliferative responses of 
pretreatment CD4- cells in co-culture experiments, suggesting peptide 
immunotherapy induced a population of CD4+ regulatory T cells (Verhoef et 
al., 2005). 
1.5.8 Regulatory T cells and allergic disease. 
Upon exposure to allergens some individuals produce an exaggerated 
Th2-driven immune response resulting in the development of allergic disease 
and asthma, while others display a tolerance to these same allergens and a 
lack of clinical symptoms. Recent evidence suggests that regulatory T cells 
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play an important role in suppressing the proliferation and Th2 cytokine 
production in non-allergic individuals and raises the possibility that a defect in 
this regulatory T cell population contributes to the development of allergic 
disease and asthma. 
Ling et al demonstrated that CD4+CD25+ regulatory T cells isolated 
from non-atopic individuals suppressed the proliferation and cytokine 
production by allergen-activated CD4+CD25- T cells (Ling et al., 2004). This 
inhibition of proliferation and cytokine production was significantly reduced for 
CD4+CD25+ Tregs isolated from atopic individuals. Furthermore, 
CD4+CD25+ Tregs isolated from hayfever patients during the height of the 
pollen season demonstrated a further diminished ability to inhibit the 
proliferation and cytokine production by allergen-activated CD4+CD25- T 
cells. CD4+CD25+ Tregs isolated from the same group of hayfever patients 
outside the pollen season displayed increased suppressive ability compared 
to those isolated during the pollen season but were still less suppressive 
compared to those CD4+CD25+ Treg isolated from non-atopic individuals 
(Ling et al., 2004). Similarly, Grindebacke et al reported that CD4+CD25+ 
Treg isolated from both allergic and non-allergic individuals were capable of 
suppressing proliferation of birch allergen-activated T cells both in and out of 
the birch pollen season (Grindebacke et al., 2004). However, during the birch 
pollen season, CD4+CD25+ Treg isolated from allergic individuals were 
incapable of suppressing the production of IL-5 and IL-13 by allergen-
activated T cells. This was in contrast to findings outside of the pollen season 
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when CD4+CD25+ Treg from both allergies and non-allergics were equally 
capable of suppressing cytokine production. 
A recent study has attempted to determine whether numbers of 
CD4+CD25+ regulatory T cells are related to allergic rhinitis and asthma in 
paediatric patients. Numbers of both CD4+CD25+ and CD4+CD25'^'^'^ T cells 
were found to be decreased in the peripheral blood of patients with allergic 
airways disease (Lee et al., 2007). However, patients with more severe 
asthma had increased numbers of Treg cells compared to patients with less 
severe disease. This increase in Treg numbers in severe asthmatics is 
consistent with the finding of increased peripheral blood Treg numbers in 
asthmatics during acute exacerbation (Zhong et al., 2003). However, as noted 
earlier, determining absolute numbers of Treg based on CD25 expression is 
not an ideal method for quantifying this T cell population. 
Taken together, the above studies confirm that CD4+CD25+ regulatory 
T cells can be isolated from the peripheral blood of patients with asthma or 
allergic disease (Ling et al., 2004; Grindebacke et al., 2004; Karagiannidis et 
al., 2004; Shi et al., 2004; Lee et al., 2007). However, reports on the numbers 
of Treg present in the peripheral blood are inconsistent, although most reports 
conclude that Treg numbers in patients with asthma or allergic disease are 
not altered compared to healthy individuals. Some studies have highlighted a 
defect in the suppressive ability of CD4+CD25+ regulatory T cells in atopic 
patients, especially during the pollen season. 
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The ability of CD4+CD25+ T cells to regulate airway inflammation was 
demonstrated in a mouse model of allergen-induced airways disease. 
Transfer of ovalbumin (OVA) peptide-specific CD4+CD25+ T cells to OVA-
sensitized mice reduced AHR, recruitment of eosinophils, and Th2 cytokine 
expression in the lung after allergen challenge (Kearley et al., 2005). 
Moreover, this effect was mediated by IL-10 as increased levels of IL-10 was 
detected after transfer of CD4+CD25+ T cells and regulation was reversed 
using anti-IL-IOR antibody. In addition these effects were still mediated by 
transfer of CD4+CD25+ T cells from IL-10 deficient mice, indicating that IL-10 
production by CD4+CD25+ T cells themselves is not required (Kearley et al., 
2005). 
As noted earlier, mutations in the gene encoding F0XP3 result in the 
disease IPEX in humans, which is associated with a lack of CD4+CD25+ 
regulatory T cells. Patients with IPEX also present with eczema, eosinophilia, 
increased serum IgE levels, and enhanced Th2 responses, providing further 
evidence that CD4+CD25+ regulatory T cells play a role in the suppression of 
allergic responses in normal individuals (Chatila et al., 2000). In addition, 
glucocorticoid treatment has recently been demonstrated to increase F0XP3 
mRNA expression in CD4+ T cells (Karagiannidis et al., 2004). 
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1.6 Chemotaxis and leukocyte extravasation. 
1.6.1 Leukocyte extravasation 
Leukocytes are released from the bone marrow and enter the 
peripheral blood circulation system. From here, leukocytes must populate the 
tissues and secondary lymphoid organs and traffic to sites of inflammation 
and infection. The migration of leukocytes from the blood is controlled by 
chemoattractant gradients emanating from specific tissues or sites of 
inflammation. Release of chemoattractants is tightly controlled to prevent 
inappropriate trafficking of immune cells. Once a chemoattractant gradient is 
encountered, leukocytes in the blood must cross the endothelium in order to 
reach tissues in a process known as extravasation. Leukocyte extravasation 
has been demonstrated to occur via a multi-step process involving rolling, 
tethering, adhesion, diapedesis and migration (Butcher, 1992; Springer, 
1994). 
The first step involves the rolling of leukocytes along the endothelium. 
This is mediated by the low-affinity interactions of selectins and their 
glycoprotein ligands expressed by endothelial cells and leukocytes. E-selectin 
and P-selectin are constitutively expressed at low levels on vascular 
endothelium (Eppihimer et al., 1997). However, exposure to inflammatory 
cytokines such as IL-ip and TNF-a, chemoattractants and bacterial products 
can up-regulate expression on endothelial cells (Collins et al., 1995). L-
selectin is constitutively expressed on leukocytes and mediates lymphocyte 
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homing to the lymph nodes, which does not require E- or P-selectin 
expression. Once selectin-mediated tethering of the lymphocyte to the 
endothelium has occurred, the next step involves the upregulation of integrins 
that result in firm adhesion of the leukocyte to the endothelium and the 
prevention of further rolling (Butcher, 1992). 
The third step of leul^ocyte extravasation is the crossing of the 
endothelium in a process termed 'diapedesis'. Controversy exists as to the 
exact mechanism by which leukocytes cross the endothelium barrier. The 
prevalent view is that leukocytes cross the endothelium paracellularly, 
migrating through the junctions between individual endothelial cells 
(Engelhardt and Wolburg, 2004). However, emerging evidence suggests that 
leukocytes may also cross the endothelium transcellularly, passing through 
the endothelial cell, possibly through trancellular pores or caveolae (Feng et 
al., 1998). 
Finally, after leukocytes have passed through the endothelium, 
leukocytes migrate through the tissue to the site of infection. Chemoattractant 
gradients guide the leukocyte through the tissue to its final destination. 
Leukocytes localise to specific microenvironments by sequential integration of 
signals from multiple chemoattractant sources. Chemoattractant receptors 
clustered on the leading edge of the leukocyte sense these chemoattractant 
gradients and transmit signals to the cell. 
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1.6.2 Organ-specific lymphocyte homing 
The migration of subsets of lymphocytes to specific organs, tissues and 
microenvironments is controlled by the combined expression of adhesion 
molecules and chemokine receptors on the surface of cells. Trafficking of 
lymphocytes to two specific sites in particular - skin and intestinal mucosal 
tissues - has recently been described in detail and these are discussed 
below. Naive T cells circulate continuously through secondary lymphoid 
organs including spleen, peripheral lymph nodes and mucosal-associated 
lymphoid tissue. Lymphocyte migration to these secondary lymphoid organs is 
controlled at post capillary high endothelial venules (HEV) by specific 
interactions between receptors and their ligands. As outlined earlier, leukocyte 
migration is a multi-step process involving tethering, rolling, firm adhesion, 
and finally transmigration (Butcher, 1992; Springer, 1994). Firstly, initial 
adhesion occurs due to the interaction of L-selectin expressed on the cell 
surface of naive lymphocytes with its ligands expressed on the cell surface of 
HEV. As outlined earlier, this weak interaction results in the rolling of the cell 
on the vessel surface. The binding of chemokines (attached to extracellular 
matrix componenents) to their chemokine receptors expressed on the surface 
of the rolling lymphocytes activates the expression of adhesion receptors on 
the surface of the lymphocyte. The interaction of these adhesion receptors 
with their ligands expressed on HEV results in firm adhesion of the 
lymphocyte, followed by entry into secondary lymphoid organs. In lymphoid 
tissue, lymphocytes may encounter their cognate antigen in the form of MHC-
peptide on the surface of DCs and hence become activated, differentiate into 
effector cells, proliferate and acquire a restricted set of new tissue homing 
85 
receptors before exiting via efferent lymphatics. Upon returning to the 
circulation these activated effector lymphocytes will migrate to the site of 
antigen entry due to the expression of the ligands to their newly acquired 
homing receptors at these sites. Lymphocytes that do not encounter their 
cognate antigen will exit the lymphoid tissue without becoming activated or 
acquiring a set of new tissue homing receptors. 
The migration of naive lymphocytes to secondary lymphoid tissue is 
controlled by the expression of addressins on HEVs and a chemokine 
gradient. Naive lymphocytes can migrate to both non-mucosal lymph nodes 
as well as mucosal sites such as Peyer's patches. L-selectin expressed on 
the T cell surface can interact with peripheral node addressin (PNAd) 
expressed on peripheral lymph nodes and mucosal addressin cell-adhesion 
molecule-1 (MAdCAM-1) expressed on small intestine HEVs (Berlin et al., 
1993; Berlin et al., 1995; Bargatze et al., 1995). Chemokines such as CCL19 
and CCL21 secreted by cells in HEV interact with CCR7 expressed on the T 
cell surface to activate integrins and promote strong adhesion of rolling 
lymphocytes (Gunn et al., 1998; Baekkevold et al., 2001). Entry into 
peripheral lymph nodes is dependent on the activation of lymphocyte function-
associated molecule-1 (LFA-1) and integrin a4(31 in response to chemokine 
binding which bind to ICAM-1 and 2 and VCAM-1 respectively present on 
peripheral lymph node endothelium. Entry into mucosal sites is dependent on 
the additional activation of a4(37, which interacts with MAdCAM-1. Antigen-
presenting DCs also express CCR7 and migrate to secondary lymphoid 
tissue, locating to the T cell areas where they scan entering CCR7+ naive T 
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cells, activating antigen-specific T cells that they encounter (Yanagihara et al., 
1998; Sozzani et al., 1998; Sallusto et al., 1998b). 
Effector T cells generated in different lymphoid organs display a distinct 
imprinting of adhesion molecules and chemokine receptors. Activation of T 
cells in skin-draining peripheral lymph nodes by DCs results in a decrease in 
L-selectin expression and an upregulation of ligands for P- and E-selectin 
(Tietz et al., 1998) and an upregulation of CCR4 and CCR10 (Campbell et al., 
1999; Reiss et al., 2001; Homey et al., 2002). In addition, the homing receptor 
cutaneous lymphocyte antigen (CLA) is highly expressed on skin-homing T 
cells (Berg et al., 1991). In contrast, activation of T cells in mucosal lymph 
nodes and Peyer's patches draining the gut also results in a decrease in L-
selectin expression but increased expression of integrin a4(37 (Hamann et al., 
1994) and CCR9 (Zabel et al., 1999; Kunkel et al., 2000; Papadakis et al., 
2000). 
After activation and acquisition of a new set of homing and chemokine 
receptors in secondary lymphoid organs, T cells return to the circulation. T 
cells activated by peripheral lymph node DCs are subsequently attracted to 
inflamed skin, which produces the chemokines CCL17 and CCL27 - ligands 
for their newly acquired CCR4 and CCR10. T cells activated by Peyer's patch 
or mucosal DCs are attracted to the epithelium and lamina propria of the small 
intestine in response to production of CCL25 - ligand for CCR9. 
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In addition to chemokines, other molecules may play a role in organ-
specific lymphocyte homing. Indeed a recent report has described a role for 
retinoic acid in imprinting gut-homing specificity on T cells (Iwata et al., 2004). 
Retinoic acid, a metabolite of vitamin A, induced high expression of a4(37 on T 
cells and vitamin A deficient animals exhibited decreased numbers of a4(37+ T 
cells in the small intestine compared to wild type animals. In addition, this 
study demonstrated that mucosal lymph node and Peyer's patches DC, but 
not peripheral lymph node or spleen DC, expressed the enzymes that are 
involved in the synthesis of retinoic acid. Inhibition of these enzymes also 
abrogated the DC-induced increase of a4|37 on T cells. 
A recent report has examined the induction of organ-selective homing 
on regulatory T cells (Siewert et al., 2007). Similar to their conventional naive 
T cell counterparts, the migratory properties of regulatory T cells are shaped 
by the tissue microenvironment and organ-specific dendritic cells during 
priming. The authors showed that priming of regulatory T cells within 
peripheral lymph nodes led to the imprinting of the set of homing receptors 
required for migration to inflamed. Priming within mesenteric lymph nodes led 
to the imprinting of the set of homing receptors required for migration into 
mucosal tissues. In this study, stimulation in the presence of retinoic acid also 
induced increased a4(37 expression on regulatory T cells, similar to their 
conventional T cell counterparts. 
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1.6.3 Chemoattractants 
Chemoattractants are a diverse set of molecules, which can be 
proteins, peptides or lipids. The classically identified chemoattractants include 
complement components and leukotrienes. In addition, the large family of 
chemokines {chemotacWc cytokines) that mediate the recruitment of specific 
cell subsets has been identified. 
1.6.3.1 Classical chemoattractants 
Fragments of the complement cascade such as C5a, C3a and C4a 
have been demonstrated to act as chemoattractants for neutrophils, 
eosinophils, basophils, monocytes, macrophages, activated T and B cells 
(WARD et al., 1965). The cysteinyl leukotrienes (LT), LTC4, LTD4, LTE4 and 
the dihydroxy leukotriene, LTB4, are generated by oxidative metabolism of 
arachidonic acid liberated from membrane phospholipids. LTB4 is a potent 
chemoattractant for neutrophils, eosinophils, monocytes and macrophages 
(Ford-Hutchinson et al., 1980; Morita et al., 1989). Bacterial products such as 
the formyl peptide N-formyl-L-methionyl-L-leucyl-L-phenyalanine (fMLF) has 
been shown to be a chemoattractant for neutrophils, eosinophils, basophils 
and monocytes (Schiffmann et al., 1975; Morita et al., 1989). Although potent, 
the classical chemoattractants are largely non-selective and capable of 
recruiting and activating multiple leukocyte populations. 
1.6.3.2 Chemokines 
Chemokines are a large family of recently discovered secreted proteins 
that stimulate activation and migration of leukocytes. The chemokine family is 
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sub-classified into three sub-families based on the positioning of conserved 
cysteine residues in the N-terminal of the protein (ZIotnik and Yoshie, 2000). 
All chemokines exert their effects by activating G protein-coupled receptors 
(GPCRs) on the cell surface of leukocytes. In contrast to the classical 
chemoattractants discussed above, chemokines are responsible for the highly 
selective recruitment of leukocyte subsets to different tissues and 
microenvironments. This selectivity is achieved by tightly regulated expression 
of both the chemokines and their corresponding receptors on the cell surface 
of different leukocyte populations. Chemokines and their receptors are 
discussed in more detail in the introduction to chapter 3. Table 1.1 displays 
the systematic chemokine nomenclature, familiar names of human ligands 
and homologous murine ligands and the main chemokine receptors to which 
they bind. 
1.6.4 Chemokine receptor signalling 
Chemokines signal through G protein coupled receptors expressed on 
the cell surface of leukocytes. The binding of chemokine to its cell surface 
receptor triggers a series of cytoplasmic events that results in the activation of 
the cells' cytoskeletal machinery. This activation results in the cell acquiring a 
polarized morphology and the cell repeatedly extends and retracts 
cytoplasmic projections called pseudopodia in the direction of the 
chemoattractant gradient. 
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Systematic 
name 
Human 
chromosome Familiar name(s) Chemokine receptor(s) 
CXCL1 4q12-q13 GROa / MGSA-a CXCR2 
CXCL2 4q12-q13 GROP / MGSA-P GXCR2 
CXCL3 4q12-q13 GROy / MGSA-7 CXCR2 
CXCL4 4q12-q13 PF4 GXCR3B 
CXCL5 4q12-q13 ENA-78 GXCR2 
CXCL6 4q12-q13 GCP-2 GXCR1, GXCR2 
CXCL7 4q12-q13 NAP-2 GXCR2 
CXCL8 4q12-q13 IL-8 CXCR1. CXCR2 
CXCL9 4q21.21 Mig GXGR3 
CXCL10 4q21.21 IP-10 GXCR3 
CXCL11 4q21.21 l-TAC CXGR3 
CXCL12 10q11.1 SDF-1a/p GXGR4 
CXCL13 4q21 BLC / BCA-1 GXGR5 
CXCL14 5q31 BRAK / bolekine Unknown 
(CXCL15) 
CXCL16 17p13 SR-PSOX CXCR6 
CXCL17 19q13.2 VCC-1 Unknown 
CCL1 17q11.2 1-309 GCR8 
CCL2 17q11.2 MGP-1 / MCAF GGR2 
CCL3 17q11.2 MIP-1a/LD78a CGR1, GGR5 
CCL4 17q11.2 MIP-1P GGR5 
CCL5 17q11.2 RANTES CCR1. CCR3, CGR5 
(CCL6) 
CCL7 17q11.2 MGP-S CCR1, GCR2, CCR3 
CCL8 17q11.2 MCP-2 GCR1, CCR2, CCR3, 
(CCL9/10) 
CCL11 17q11.2 Eotaxin CCR3, CCR2 
(CCL12) 
CCL13 17q11.2 MCP-4 GCR2, CGR3 
CCL14 17q11.2 HCC-1 CCR1 
CCL15 17q11.2 HCC-2/Lkn-1 / MIP-15 GGR1, GGR3 
CCL16 17q11.2 HCC-4 / LEG CGR1, CGR8 
CCL17 16q13 TARG CCR4 
CCL18 17q11.2 DC-CK1 / PARC / AMAC-1 Unknown 
CCL19 9p13 MIP-3P / ELC / exodus-3 CGR7 
CCL20 2q33-q37 MIP-3a / LARG / exodus-1 CCR6 
CCL21 9p13 6Ckine / SLC / exodus-2 CCR7 
CCL22 16q13 MDC / STCP-1 CCR4 
CCL23 17q11.2 MPIF-1 CCR1 
CCL24 7q11.23 MPIF-2 / Eotaxin-2 CGR3 
CCL25 19p13.2 TECK CCR9 
CCL26 7q11.23 Eotaxin-3 CCR3, GCR2 
CCL27 9p13 CTACK/ILC CGR10 
CCL28 5q11-q12 MEG CCRIO, CCR3 
XCL1 1q23 Lymphotactin / SGM-1a / XGR1 
XCL2 1q23 SGM-1P XCR1 
CX3CL1 16q13 Fractalkine GX3CR1 
Table 1.1 Chemokine families 
Adapted from ZIotnik and Yosliie, 2000. Systematic names given in 
parentheses have been discovered in mice but not in humans. 
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GPCRs are associated with G proteins, heterotrimeric proteins 
composed of three subunits Ga, Gp and Gy. When a chemokine ligand binds 
to its cognate G protein coupled receptor, the receptor undergoes a 
conformational change that promotes the exchange of GTP for the GDP on 
the alpha subunit. This GTP/GDP exchange promotes the dissociation of the 
Ga subunit from Gpy. Both the Ga and GPy subunits can then activate other 
proteins at the inner surface of the cell membrane, initiating the signaling 
cascades required for cell motility. The activated response ceases when the 
Ga subunit, which contains intrinsic GTPase activity, cleaves the GTP to 
GDP, allowing the Ga and Gpy subunits to re-associate (Ross and Wilkie, 
2000). Ga proteins can initiate a number of signaling cascades by activating 
(or inhibiting) adenylyl cyclase, activating G protein-coupled inwardly rectifying 
potassium channels, or activating phospholipase C (PLC). 
In order for immune cells to cease their migration and stop at the points 
of contact with APC or target cells, signaling through GPCRs must turned off. 
This is achieved by a process known as receptor desensitization, which 
involves receptor internalization as well as downstream mechanisms. 
Phosphorylation of GPCRs can lead to a dampening of receptor function and 
this can be mediated by a number of second messengers and kinases, 
including protein kinase A (PKA), protein kinase C (PKC) and a set of G 
protein coupled receptor kinases (GRKs). PKA and PKC can uncouple 
GPCRs from their G proteins or couple them to G proteins with opposing 
effects (Daaka et al., 1997). GRKs phosphorylate the carboxy terminal of 
GPCRs resulting in the recruitment of p-arrestin. The binding of p-arrestin to 
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phosphorylateed GPCRs sterically precludes coupling between the receptor 
and heterotrimeric G proteins, leading to termination of signalling. Receptor-
bound p-arrestin also acts as an adaptor protein, binding to components of 
the clathrin endocytic machinery, promoting the endocytosis of the GPCR into 
clathrin-coated pits (Ahn et a!., 1999). Once internalised, the GPCR can be 
dissociated from its ligand and de-phosphorylated in endosomal 
compartments and subsequently recycled to the plasma membrane. 
Alternatively, the GPCR can be targeted for degradation in lysosomes, 
reducing the number of GPCR molecules on the cell surface (Pierce and 
Lefkowitz, 2001). 
1.6.5 Chemokines in asthma 
A number of chemokines and chemokine receptors have been 
implicated in the pathogenesis of asthma. The chemokine receptor expression 
profile of the leukocytes involved in the pathogenesis of allergic disease is 
shown in figure 1.2. Of particular interest are the chemokine receptors CCR3, 
CCR4 and CCR8, as well as their corresponding chemokines, as one or all of 
these chemokine receptors are present on eosinophils, basophils and Th2 
cells and may play a role in the recruitment of these cell types to the lung. 
CCR3 is expressed by eosinophils (Ponath et al., 1996; Daugherty et 
al., 1996), basophils (Uguccioni et al., 1997), mast cells (Ochi et al., 1999) 
and Th2 lymphocytes (Sallusto et al., 1997). CCR3 is a highly promiscuous 
receptor, capable of binding multiple ligands including CCL5/RANTES, 
CCL13/MCP-4 and the three eotaxin proteins CCL11/Eotaxin-1, 
CCL24/Eotaxin-2 and CCL26/Eotaxin-3. Increased expression of CCR3 and 
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its ligands CCL5/RANTES, CCL11/Eotaxin-1, CCL24/Eotaxin-2, and 
CCL26/Eotaxin-3 have been demonstrated in the allergic lung (Powell et al., 
1996; Berkman et al., 1996; Ying et al., 1997c; Berkman et al., 2001). 
A number of groups have used antibody blockade or gene-deficient 
animals to explore the importance of CCR3 and its ligands in the development 
of allergen-induced allergic airway inflammation. Blockade of CCL11/Eotaxin-
1 results in a decrease in both ain/vay inflammation and AHR (Gonzalo et al., 
1996; Humbles et al., 1997; Gonzalo et al., 1998). In addition, CCL11/Eotaxin-
1 gene-deficient mice exhibit a reduction in allergen-induced lung eosinophilia 
(Rothenberg et al., 1997). Confusingly, another study reported no effect on 
allergen-induced eosinophila in CCL11/Eotaxin-1 gene-deficient mice (Yang 
et al., 1998). These conflicting reports may be due to genetic differences 
between animal strains, as well as compensatory mechanisms and 
redundancy among chemokines in gene-deficient animals. Eosinophil 
recruitment to the lung after allergen challenge in CCR3 knock-out mice was 
reduced while surprisingly, AHR was increased (Humbles et al., 2002). The 
authors proposed that this unexpected result was due to an increased 
accumulation of mast cells in the trachea following allergen challenge. In 
agreement, CCR3 knock-out mice failed to develop allergen-induced AHR 
when a different model system that didn't result in mast cell recruitment to the 
trachea was used (Ma et al., 2002). 
CCR4 is prevalently expressed on Th2 lymphocytes (Bonecchi et al., 
1998). The ligands for CCR4, CCL17/TARC and CCL22/MDC, are 
upregulated in the human lung after allergen challenge (Pilette et al., 2004). 
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Allergen challenge of asthmatic individuals also promotes the recruitment of 
CCR4+ T cells to the lung (Panina-Bordignon et al., 2001; Nouri-Aria et al., 
2002). In addition, bronchoalveolar T cells isolated from asthmatic subjects 
preferentially express CCR4, as well as CCR3 (Morgan et al., 2005a), with a 
significant percentage of T cells demonstrating co-expression of CCR4 and 
CCR8 (Panina-Bordignon et al., 2001). Blockade of CCL17/TARC or 
CCL22/MDC reduced AHR and eosinophilia in vivo (Gonzalo et al., 1999; 
Kawasaki et al., 2001). Anti-CCLI7/TARC antibody also reduced lung 
expression of Th2 cytokines (Kawasaki et al., 2001). CCL22/MDC has been 
shown to be important in the long-term recruitment of Th2 cells to the lung in 
response to repeated allergen exposure (Lloyd et al., 2000). These studies 
suggested that both CCL17/TARC and CCL22/MDC are required for the 
development of allergen-induced airway inflammation. However, in a guinea 
pig model of allergic airways inflammation, blockade of CCL17/TARC had no 
effect on leukocyte recruitment to the lung (Conroy et al., 2003). In addition 
CCR4 deficiency afforded no protection against the development of allergic 
inflammation or AHR (Chvatchko et al., 2000). These discrepancies, like 
those for CCL11/Eotaxin-1 deficient animals above, highlight the need for 
caution when extrapolating results from the rodent to the human and vice 
versa. 
CCR8 is preferentially expressed on Th2 lymphocytes (Zingoni et al., 
1998). CCL1/I-309, the ligand for CCR8, is upregulated in the lung following 
allergen challenge (Bishop and Lloyd, 2003). Blockade of murine CCL1 had 
no effect on allergen-specific Th2 cell recruitment to the lung (Bishop and 
Lloyd, 2003; Chung et al., 2003), although eosinophil numbers were 
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decreased, suggesting that CCR8 may not be critical for Th2 cell trafficking 
but is important for eosinophil recruitment in vivo (Bishop and Lloyd, 2003). 
Moreover, direct instillation of CCL1 into the lungs of allergen-sensitised 
challenged mice induced the recruitment of eosinophils but not Th2 cells. In 
addition, CCR8 deficient animals show no marked effects on allergen-induced 
AHR, inflammation, or Th2 cytokine production (Chung et al., 2003; Goya et 
al., 2003). However, in yet another discrepancy between studies, a third 
report on CCR8 knock-out mice has reported a reduction in Th2 cytokine 
production and eosinophil recruitment in a number of airway inflammation 
models (Chensue et al., 2001). This discrepancy is again likely due to 
differences in genetic background or the model protocols used. 
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Figure 1.2 Chemokine receptor expression of leukocytes implicated in 
the pathogenesis of allergic disease. 
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1.7 Hypothesis and aims 
CD4+CD25+ regulatory T cells have recently become the focus of 
intense interest due to their apparent ability to control a wide variety of 
autoimmune diseases and disorders including allergy and asthma. Despite 
many recent advances in understanding regulatory T cell biology, including 
the recent discovery of the transcription factor specific for this T cell lineage, 
many other aspects of their function remain to be elucidated. The overall 
hypothesis of this thesis is that regulatory T cells play a critical role in 
controlling unwanted allergic and asthmatic reponses in healthy individuals. 
A primary goal of this project was to use comparative microarray 
technology to determine the differential gene expression of CD4+CD25+ 
regulatory T cells compared to their CD4+CD25- T cell counterparts. The aim 
of these experiments was to determine differentially expressed genes that 
may play a role in the mechanism of action of these cells. In addition, a further 
goal was the identification of cell surface molecules specifically expressed by 
CD4+CD25+ regulatory T cells that would be of enormous benefit in the 
isolation and manipulation of these cells. 
This protect further hypothesised that trafficking of CD4+CD25+ 
regulatory T cells plays an important role in their ability to control immune 
responses. We hypothesised that regulatory T cells display a chemokine 
receptor expression profile distinct from their non-regulatory T cell 
counterparts. The aims of this project included determining the chemokine 
receptor expression profile of regulatory and non-regulatory T cells. In 
addition, we hypothesised that regulatory T cells isolated from atopic 
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individuals may display a different chemokine receptor expression profile to 
regulatory T cells isolated from non-atopic individuals, and this may contribute 
to the decreased suppressive function of these cells as previously reported by 
our group. To examine this possibility the chemokine receptor expression 
profile of regulatory and non-regulatory T cells isolated from atopic and non-
atopic individuals were compared. In addition the chemokine-responsiveness 
of these T cell subsets to a number of different chemokines was examined. 
The modulation of chemokine receptor expression on regulatory and non-
regulatory T cells in response in vitro allergen-stimulation was also 
determined. 
, This project also hypothesised that CD4+CD25+ regulatory T cells are 
important in the control of asthmatic responses. This project aimed to 
determine any differences in regulatory T cell number, as well as other 
leukocyte and T cell subsets, in the peripheral blood of asthmatic and non-
asthmatic individuals. In addition, we hypothesised that asthma can be 
characterised by peripheral blood gene expression 'signature'. To investigate 
this hypothesis, microarray analysis of peripheral blood leukocytes isolated 
from asthmatic and non-asthmatic individuals was performed. 
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Chapter 2: Materials and Methods 
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This chapter outlines the general protocols, materials and methods 
used throughout this thesis. 
2.1 Introduction to Methods 
This section will give a brief history and introduction to some of the 
experimental methods used in this thesis. 
2.1.1 Fluorescence Activated Cell Sorter and Flow Cytometry 
The Fluorescence Activated Cell Sorter (FACS) was invented in the 
late 1960s by researchers at Stanford university to do flow cytometry and cell 
sorting of viable cells (Hulett et al., 1969). In collaboration with its inventors, 
Becton Dickinson subsequently introduced the commercial machines in the 
early 1970s. Flow cytometry is a technique for making quantitative 
measurements on single cells or cellular constituents at very high rates of 
speed. Measurements consist of light scatter (particle size and surface 
characteristics) and fluorescence. With the simultaneous development of 
monoclonal antibody technology by Kohler and Milstein (Kohler and Milstein, 
1975), coupled to the work of Albert Coons in linking antibodies with 
fluorescent tags (COONS and KAPLAN, 1950) the FACS has become a very 
valuable research tool in immunology. 
A flow cytometer consists of several different systems that work 
together to generate the final data product (Herzenberg et al., 2002). 
Specifically, there is an optics system to illuminate the cells or particles, a 
fluidics system that brings the cells into the light beam, an electronics system 
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for detecting and processing the signals coming from the cells and a computer 
system for storing and further processing the data. 
The optics system consists of a light source, most often a laser(s). The 
most common lasers used in commercial instruments and their most useful 
wavelengths are Argon ion (365 nm, 488 nm or 514 nm), Krypton (567 nm, 
646 nm) and Helium-Neon (633 nm). Lasers provide a polarised spherical 
light source. A spherical focus provides high beam intensity and fluorescence 
sensitivity but the beam intensity varies greatly across the sample stream 
diameter. Therefore the optics system also contains beam-focusing lenses to 
provide an elliptical-focused beam, thus providing more uniform illumination 
across the diameter of the laser beam. This elliptical-focused beam can also 
provide temporal resolution between cells in the sample stream, illuminating 
only one at a time as they pass one by one into and out of the beam in its 
narrow dimension. 
The goal of the fluidics system on a FACS is to take a suspension of 
single cells and pass the cells in single file through the flow cell, keeping the 
cells in the centre of the fluid stream so that they will be passed through the 
centre of the elliptically-focused light beam and be uniformly illuminated. 
The point in the flow cell at which the light source and the fluid stream 
(containing the cells) intersect is known as the analysis point. It is here that 
the components of the electronics system detect and convert the signals 
coming from the cells. Surrounding the analysis point are lenses that collect 
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light as it emerges after its intersection with the cells in the stream. This light 
(the signal) is focused onto photodetectors (photodiodes or photomultiplier 
tubes) that convert the light signal into an electrical impulse. The intensity of 
the electrical impulse is proportional to the intensity of the light falling on the 
photodetector. 
The photodetectors are situated at various positions relative to the 
illuminating beam depending on the parameter that photodetector is 
measuring (Herzenberg et al., 2002). The photodetector that is situated 
directly in front of the illuminating beam is known as the forward scatter or 
forward-angle light scatter signal (FSC). This photodetector is responsible for 
collecting the light that is bent as it passes through or around the cell. An 
obscuration bar in front of this photodetector blocks illuminating beam that 
passes directly through the flow cell. Any light that is bent as it passes through 
or around the cell will avoid the obscuration bar, strike the photodetector and 
generate a signal. Due to its positioning, the signal detected by the FSC 
photodetector is related to the size and volume of the cell and also to its 
refractive index. 
In addition to the photodetector situated directly in front of the 
illuminating beam others are positioned at right angles to it. As these 
photodetectors are not in the direct line of the illuminating beam any light 
hitting them will be due to light being deflected by a cell in the flow stream or 
due to the cell in the flow stream emitting light itself. As one of these 
photodetectors is fitted with a glass filter of the same colour as the illuminating 
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light, it is responsible for detecting any light that is deflected by the cell 
towards the side of the flow cell. The light registered by this photodetector is 
known as the side scatter light (SSC). The rougher or more irregular or 
granular a cell is, the more it will scatter the illuminating beam to the side. 
Therefore, the signal received by the SSC photodetector is related to the cell's 
surface texture and internal structure (Herzenberg et al., 2002). 
Other photodetectors placed at right angles to the illuminating beam 
are responsible for collecting light of different wavelengths that is emitted by 
the cell. Cells are stained with specific markers conjugated to molecules 
called fluorochromes. As the illuminating beam excites these fluorochromes 
they emit light of a certain wavelength in all directions. Different fluorochromes 
although all excited by the same wavelength of light (the wavelength of the 
illuminating beam), will emit light at different wavelengths. Each photodetector 
will "see" only light of a certain colour due to colour filters placed in front of it 
(Herzenberg et al., 2002). In this way, for example, a photodetector with a 
green colour filter in front of it will detect only light emitted by a cell that has a 
fluorochrome attached that emits green light and none other. For each cell 
that passes through the illuminating beam, each photodetector will receive its 
own unique signal. The photodetectors convert these signals into electrical 
impulses that are then interpreted and stored by the computers software. 
Although some modern flow cytometers are capable of measuring 
FSC, SSC and 12 other fluorescence parameters for each cell, their use is 
limited by the availability of commercial fluorochrome-conjugated monoclonal 
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antibodies. The FACS experiments done in this thesis are all 3-colour or 4-
colour analysis using antibodies conjugated to Fluorescein isothiocyanate 
(FITC), Phycoerythrin (PE), PE:Cyanine-5 (PE-Cy5) or Texas Red (TR) and 
Allophycocyanin (APC). PE-Cy5 is an example of a tandem conjugate of two 
dyes: PE and the cyano dye Cy5. The PE part of this tandem conjugate is 
excited by the standard laser wavelength on flow cytometers, 488 nm, and 
acts as an energy donor. Excitation energy is transferred from PE to the Cy5 
part of the tandem conjugate via resonance transfer, which then emits the 
energy at the longer wavelength of 680 nm. As transfer of energy from PE to 
Cy5 is incomplete, use of this conjugate requires compensation to account for 
the slight emission of energy by the PE part of the tandem upon excitation 
(Lansdorp et al., 1991). 
Flow cytometers also allow for the detection of cells labelled with cell 
tracking dyes (Weston and Parish, 1990; Lyons and Parish, 1994). 
Experiments presented in this thesis make use of the intracellular fluorescein 
dye carboxyfluoroscein succinimidyl ester (CFSE), a fluorochrome that can 
covalently couple with intracellular macromolecules. Cell tracking dyes are 
used to label cells for in vivo migration studies as well as tracking proliferation 
of cells during in vitro cell culture. CFSE is detected by the FL1 channel (FITC 
channel) of the flow cytometer, allowing cells to be simultaneously stained 
with cell surface markers conjugated to fluorochromes detected in the FL2 
(PE), FL3 (Texas Red, PE-Cy5) and FL4 (APC) channels. 
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2.1.2 Real Time Quantitative Polymerase Chain Reaction (RT-QPCR) 
The polymerase chain reaction (PGR) was developed by Kary Mullis in 
the 1980s and won him the Nobel Prize in chemistry in 1993. PGR is an in 
vitro technique for enzymatically replicating DNA (Mullis et al., 1986). The 
discovery of PGR opened the door to a wide variety of genetic and molecular 
research, as well as applications in medicine and forensics. Essentially the 
PGR reaction is a simple technique requiring the presence of template DNA, 
short oligonucleotide primers corresponding to the DNA region of interest, 
deoxynucleotide triphosphates (dNTPS), and crucially, the enzyme Taq 
polymerase to synthesise the new DNA. The primers included in the reaction 
are complimentary to the 5' and 3' ends of the DNA region that is to be 
amplified, resulting in specific and rapid amplification of that DNA sequence. 
Real time Q-PGR is a modification of the original PGR technique. In 0 -
PGR, the amount of amplified product is linked to fluorescence intensity using 
a fluorescent reporter molecule (Valasek and Repa, 2005). Measuring the 
amount of amplified product can be used to quantitatively measure the 
starting amount of target DNA. The point at which the fluorescent signal is 
measured in order to calculate the initial template quantity can either be at the 
end of the reaction (endpoint QPGR) or while the amplification is still 
progressing (real-time QPGR). 
In endpoint PGR, fluorescence data are collected after the amplification 
reaction has been completed (usually after 30-40 cycles) and this final 
fluorescence is used to back-calculate the amount of template present prior to 
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PGR. However, this method can give inconsistent results because the PGR 
reaction efficiency can decrease during later amplification cycles as reagents 
are consumed and inhibitors to the reaction accumulate. These effects may 
result in differences in final fluorescence values that are not related to the 
concentrations of the starting template. 
Measuring the fluorescence after each amplification cycle, as in RT-
PGR gives more sensitive and reproducible results. RT-PGR allows for 
quantification of the template to be based on the fluorescent signal during the 
exponential phase of the amplification, before limiting reagents, accumulation 
of inhibitors, or inactivation of the polymerase have started having an effect on 
the efficiency of amplification. Fluorescent readings at these earlier cycles of 
the reaction will measure the amplified template quantity where the reaction is 
more efficient and more reproducible than at the endpoint. 
A fluorescent reporter molecule is used to monitor the progress of the 
amplification reaction (Valasek and Repa, 2005). The fluorescence intensity 
increases proportionally with each amplification cycle in response to the 
increased amplicon concentration. The first cycle at which the fluorescence 
can be distinguished as being above the background signal is called the "Gt" 
or threshold cycle. This Gt value can be directly correlated to the starting 
target concentration for the sample. The greater the amount of initial DNA 
template in the sample, the earlier the Gt value for that sample. The reporter 
molecule used in real-time PGR reactions can be (1) a non-specific DNA 
binding dye that fluoresces when bound to double-stranded DNA or (2) a 
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sequence-specific probe composed of an oligonucleotide labelled with a 
fluorescent dye plus a quencher. When free in solution, DNA binding dyes 
display relatively low fluorescence, but when bound to double-stranded DNA 
its fluorescence increases. The more double-stranded DNA (the amplified 
target) that is present in the PGR reaction the more binding sites there are for 
the dye, so fluorescence increases proportionately to DNA concentration. This 
property allows it to be used to track the amplification of PGR product. One 
limitation of the use of DNA binding dyes is their non-specificity. Binding to 
any double-stranded DNA present in the reaction will result in an increase in 
fluorescence, and so the specificity of the reaction is determined solely by the 
primers used. 
As compared to the non-specificity of DNA binding dyes, using an 
internal probe with primers to detect the product of interest provides a higher 
level of detection specificity. In addition to the PGR primers, this detection 
method includes a third oligonucleotide in the reaction known as the probe. A 
fluorescent dye (reporter) is attached to the 5' end of the probe and a 
quencher is attached to the 3' end. As long as the reporter and quencher are 
maintained in close proximity, the fluorescence from the reporter is quenched 
and no fluorescence is detected (Valasek and Repa, 2005). The probe is 
designed to anneal to one strand of the target sequence just slightly 
downstream of one of the primers. During the PGR reaction, as the 
polymerase extends that primer, it will encounter the 5' end of the probe. 
Here, this method of detection relies on the 5' to 3' exonuclease activity of 
Taq DNA polymerase to both displace the probe and degrade the probe's 5' 
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end, releasing the reporter dye into solution. Following the separation of 
reporter dye from the probe (and hence from the quencher) fluorescence can 
be detected from the reporter dye. The level of fluorescence detected from 
displaced reporter dye is directly related to the amount of amplified target in 
each PGR cycle. 
All of the primers used in the experiments outlined in this thesis use the 
primer and probe method of detection for RT-QPCR. All of the primers used 
are from Applied Biosystems "assay on demand" service. 
2.1.3 Chemokine-induced actin polymerisation. 
The binding of a chemokine to its cognate G-protein coupled receptor 
on leukocytes results in chemotaxis of the cell towards the chemokine 
gradient. The responsiveness of a certain cell type to a chosen ligand can be 
measured in vitro using a number of different methods including the migration 
of cells across a permeable membrane in a transwell assay, the measurement 
of calcium flux, and the shape change induced by ligand binding as measured 
by flow cytometry. Although shape change is a useful method for measuring 
chemokine responses in granulocytes it cannot be used for CD4+ T cells due 
to their smaller cytoplasm. 
The method used in this chapter to measure the chemokine 
responsiveness of CD4+ T cells relies on the importance of actin 
polymerisation within the cell for chemotaxis to occur. Binding of a chemokine 
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to its receptor triggers the reorganisation of the actin cytoskeieton that is 
required for leukocyte chemotaxis. 
Polymerisation of actin filaments induced by chemotactic stimuli can be 
quantified using conjugated phallotoxins (Wulf et al., 1979). Phallotoxins are 
mushroom toxins with a high affinity for actin, which can be conjugated to 
fluorescent dyes that can serve as convenient probes for labelling, identifying 
and quantitating various types of actin in formaldehyde-fixed and 
permeabilised cells. 
2.1.4 DNA microarrays 
Each cell within an organism contains the same set of genes and each 
cell's function is attributed to what genes are transcribed into mRNA and 
hence translated into protein. Between different cell types there is 
considerable difference in which genes are activated. The activity of a gene 
within a cell is reflected by its production of mRNA, and measuring the 
abundance of mRNA corresponding to a certain gene can give an indication 
of that genes activity. DNA microarrays allow for the global study of gene 
expression within a chosen sample. mRNA transcripts from different cell types 
or from different treatments can be compared to give the relative expression 
of multiple, if not all, genes between different samples. 
DNA microarrays consist of an orderly arrangement of DNA fragments 
spotted onto a solid surface, such as a glass, plastic, or silicon chip (Lockhart 
and Winzeler, 2000). Each DNA fragment Is assigned to a specific location on 
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the chip and highly accurate robotic spotters allow for entire genomes to be 
placed on a single microarray. The DNA fragments spotted onto a microarray 
are single stranded, allowing fluorescently labelled DNA or RNA of interest to 
be hybridised to the array. DNA or RNA corresponding to the gene of interest 
will hybridise to its complimentary DNA fragment attached to the array. The 
fluorescence attributed to each spot on the array can then be measured to 
give an indication of the amount of each gene contained within the sample. 
Two main types of microarrays exist, depending on the method of 
nucleic acid deposition on the chip surface: arrays that are robotically spotted, 
or alternatively, high density oligonucleotide arrays synthesised in situ by 
photolithography, in a similar way to computer chips (Lockhart and Winzeler, 
2000). Historically, robotically spotted arrays were referred to as cDNA 
microarrays, because the nucleic acids being spotted were PGR products 
amplified from cDNA libraries. By contrast, the photolithography-synthesised 
arrays were called oligoarrays because oligonucleotides were placed on the 
arrays, with each gene being represented by multiple oligos. However this 
distinction is no longer accurate, as oligonucleotides can now also be 
robotically spotted onto glass slides. 
Oligonucleotide arrays consist of small -25 base pair gene fragments 
(probes) spotted onto the array (Lockhart and Winzeler, 2000). For each gene 
on the array up to 15 copies of these probes are placed in a spot on the array. 
Although these probes are selected to have little cross-reactivity with other 
genes some non-specific hybridisation can occur. To account for this, a 
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second probe, identical to the first except for a mismatched base at its centre, 
is spotted next to the first. Any background hybridisation seen with the 
mismatched probe is then subtracted from the perfect match probe to negate 
any non-specific hybridisation. Only one sample is hybridised to single 
oligoarrays. The sample consists of cRNA that has been transcribed from 
cDNA while incorporating a label such as biotin. The array is then stained with 
a fluorescent dye, which binds to this incorporated label allowing the amount 
of hybridisation for each gene to be quantified. 
cDNA arrays consist of larger probes complimentary to the genes of 
interest. In contrast to oligoarrays, two samples are normally hybridised to 
each array in a comparative hybridisation experiment: a control sample and 
an experimental sample (Lockhart and Winzeler, 2000) . The preparation of 
the sample for hybridisation also differs from that for oligoarrays. As with 
oligoarrays, mRNA is extracted from the cells of interest and reverse 
transcribed into cDNA. However, during this reverse transcription reaction a 
fluorescent dye is incorporated into the newly formed cDNA. Different dyes, 
usually the green-flourescing dye Cy3 and the red-flourescing dye Cy5, are 
used to label the control and experimental samples. Both samples are then 
hybridised to the array, where they will competitively bind to the probes on the 
array. The amount of fluorescence for each gene on the array is then 
measured and the ratio between the two dyes indicates the relative 
abundance of a gene in the two samples. In light of these differences between 
robotically-spotted arrays and photolithography synthesised arrays they are 
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sometimes distinguished based on their detection systems: dual colour arrays 
and single colour arrays. 
The microarrays used in the experiments outlined in chapter 4 
consisted of oligonucleotides robotically spotted onto glass slides. The 
microarrays were assembled in-house at Lorantis Ltd., Cambridge and 
contained probes for 10,368 human genes and expressed sequence tags 
(ESTs). The genes chosen by Lorantis Ltd to be included on their microarrays 
were those thought to be specifically involved in the immune system with a 
particular emphasis on genes related to Notch signalling in immune cells. A 
searchable list of the genes included on these arrays is presented on the CD 
attached to this thesis, under Appendix 1. 
The DNA microarray experiments described in chapter 5 were 
performed in collaboration with Dr. Damien Chaussabel and Dr. Jacuques 
Banchereau, and were undertaken at their laboratory at the Baylor Institute for 
Immunology Research (BUR), Dallas, Texas. The experiments were 
undertaken in collaboration with these researchers in order to avail of their 
novel approach to analysing microarray gene expression data. These 
researchers employ a technique of analysing microarray data in the context of 
"gene modules" identified by their laboratory, in contrast to analysing the data 
in an individual gene manner. Employing this novel approach of microarray 
data analysis revealed no differences in expression of these "gene modules" 
between the samples studied. As the collaborators of this study wish their 
methods of analysis to remain confidential they will not be expanded upon in 
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this thesis. Alternatively, the microarray experiments performed will be 
analysed and presented here using the standard methods used for microarray 
analysis. 
The microarray platform used in these experiments was lllumina 
BeadArray Technology and the model of microarray chip used was the Sentrix 
Human-6 Expression BeadChip. Each Human-6 BeadChip contains six arrays 
on a single BeadChip, with each array consisting of >48,000 oligonucleotide 
probes corresponding to known human genes, gene candidates and splice 
variants. Therefore, six different samples can be hybridised to each 
BeadChip, reducing cost, experimental error and array-to-array variability. 
The lllumina BeadArray Technology is based on a novel method for 
microarray manufacture - the random self-assembly of microspheres into 
ordered microwells (Gunderson et al., 2004). The silicon microarray chip is 
firstly etched with millions of 3 um wells in a highly ordered and pre-defined 
pattern. The array elements consist of oligonucleotide probes immobilised 
onto microbeads, with each bead containing hundreds of thousands of copies 
of the oligonucleotide probe. These beads are quantitatively pooled and 
introduced to the etched microarray slide where they spontaneously assemble 
into the 1.6 million micro-wells. On average, greater than thirty copies of each 
bead type is present on each individual array and in this way each reading is 
taken multiple times across the array, increasing the accuracy of the 
measurement. In addition to each bead containing multiple copies of a gene-
specific probe, it also contains a short "address sequence" of twenty-nine 
114 
base pairs that is used during the manufacturing process to identify the bead 
and determine which bead type resides in each micro-well. In this way a 
bead-map can be produced of each microarray that is manufactured. 
The decision to use lllumina BeadChip technology in this study was 
based on previous observations and comparisons of different microarray 
platforms performed by the collaborators of the study at the Baylor Institute for 
Immunology Research. This group has tested a number of different 
commercially available microarray platforms including lllumina and Affymetrix 
technology. They had previously demonstrated reproducibility of experiments 
across both of the above microarray platforms. The decreased costs involved 
in using lllumina BeadChip technology, together with the presence of multiple 
copies of each probe on each microarray were key factors in the decision to 
use this microarray platform for this study. All experimental protocols and 
procedures for use with the lllumina BeadChip technology had been optimised 
in the laboratories at the Baylor Institute for Immunology Research prior to the 
start of this study. 
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2.2 Materials and methods 
Unless otherwise stated, all chemicals were purchased from Sigma, 
Poole, Dorset, UK. 
2.2.1 Ethical Statement 
Local ethics committees of the Royal Brompton NHS Trust or St. 
Mary's Hospital London approved the studies described in this thesis and all 
volunteers involved gave written informed consent. There were no adverse 
effects from blood donation by any of the volunteers recruited for the studies 
described herein. 
2.2.2 Study population 
2.2.2.1 Donor recruitment 
Non-atopic volunteers and volunteers with asthma were recruited by 
advertisement from both the general public and from staff of Imperial College. 
Atopic volunteers with seasonal allergic rhinitis to grass pollen (hay fever) or 
allergy to cat were recruited from the allergy clinics of the Royal Brompton 
Hospital and St Mary's Hospital London or by advertisement. 
2.2.2.2 Diagnosis of atopy 
All volunteers completed a standard questionnaire about allergic 
symptoms and history of allergic disease. To establish presence or absence 
of atopy, skin prick tests (SPTs) to common aeroallergens such as cat 
dander, house dust mite, grass pollen and aspergillus (ALK, Horsholm, 
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Denmark) were performed. Serum specific IgE was detected by 
Radioallergosorbent test (RAST) (Pharmacia, Milton Keynes, UK) in the 
hospital haematology laboratory. Atopic donors were defined on the basis of a 
positive IgE (> 0.35 lU/L) or SPT (as defined below), and a history of allergic 
symptoms, whereas non-atopic donors had no history of allergic symptoms, 
negative SPTs, and normal amounts of serum IgE. 
2.2.2.3 Skin prick tests (SPTs) 
A soluble extract of the allergen (ALK) was placed on the skin of the 
forearm and then pricked beneath the epidermis with a needle. The diameter 
of the wheel and flare reaction was measure after 15 minutes. A positive 
(histamine 10 mg/ml) and negative (diluent) were always used and a positive 
reaction was regarded as being 2 mm greater than the negative control. SPTs 
and clinical characterisation of patients was performed by nurse Maxine 
Aizen. 
2.2.2.4 Methacholine challenge (Five Breath Dosimeter Protocol) 
Methacholine challenge was used as a method of measuring Airway 
Hyperresponsiveness (AHR) in order to define the volunteers into the clinical 
groups of asthma and normal and as a measure of clinical asthma severity. 
Volunteers abstained from caffeine products for 12 hours prior to study visits. 
The asthmatic volunteers were only on salbutamol inhalers at the time of the 
study and abstained from usage for at least 8 hours before the study visit. 
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The five breath dosimeter protocol, first standardised by the National 
Institutes of Health (NIH), v\/as used (Chai et al., 1975). Briefly, the patient is 
first rested for 15 minutes. The baseline Forced Expiratory Volume in 1 
second (FEVi) is measured three times and the highest value recorded. All 
dosimeter inhalations and spirometry were carried out with a nose clip worn. 
The dosimeter was set to the setting of inhalation time of 1 second, pause 
time of 6 seconds and a total number of inhalations to 5. Methacholine was 
made up using normal saline diluent to the following concentrations: 0.03, 
0.06, 0.125, 0.25, 0.50, 1 ,2 ,4 ,8 and 16 mg /ml. 
At end exhalation using tidal breathing (i.e at functional residual 
capacity) the patient is instructed to inhale deeply and slowly to maximal 
capacity and then hold their breath for 6 seconds. This is performed for a total 
of 5 breaths. FEVi measurements at 1 minute and 2 minutes after inhalation 
were recorded and the highest value taken. The initial nebulisation was 
performed with normal saline. If FEVi fell less than 10 % from baseline then 
volunteer proceeded with the methacholine challenge procedure. If FEVi fell ^ 
10 % following saline inhalation the physician present decided whether to 
carry on with the procedure, repeat another diluent challenge or to abort the 
challenge. Volunteers inhaled doubling doses of methacholine until a > 20% 
fall in FEVi from the post saline value was achieved. In order to keep the 
cumulative effect of methacholine relatively constant each methacholine dose 
was administered exactly 5 minutes apart. 
The PC20 is calculated using the following formula: 
PC2o= antilog (log Ci+ (log C2-logC-i) (20-Ri) /(R2-R1)) 
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Ci= second to last [methacholine] 
Ri= % fall in FEVi after Ci 
C2= final [methacholine] leading to 20% FEVi drop 
R2=% fall in FEVi after C2 
Patients were characterised as asthmatic if they exhibited a calculated PC20 of 
less than 16, and normal if they exhibited a PC20 greater than 16. All 
methacholine challenges related to the work published in this thesis were 
performed by Dr. Marsha Kariyawasam and Nurse Maxine Aizen. 
2.2.3 Allergen stocks 
Cat dander and grass pollen allergen extracts were a kind gift from 
Gitte Nordskov Hansen (ALK). These extracts were reconstituted in sterile AB 
media (see section 2.2.4.1) and frozen in aliquots at -20 °C until needed. 
2.2.4 Cell Culture 
2.2.4.1 Composition ofAB media 
The AB media in which human peripheral blood mononuclear cells 
(PBMCs) and T cells were cultured consisted of RPMI 1640 medium with 5 % 
human AB serum, 100 |ig/ml penicillin/streptomycin (Invitrogen Life 
Technologies, Carlsbad, California, USA) and 2 mM L-glutamine (Invitrogen 
Life Technologies). 
2.2.4.2. Isolation of peripheral blood mononuclear cells (PBMCs) 
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150 ml (unless otherwise stated) of human peripheral blood was 
obtained into three 50 ml syringes (BD Biosciences, Belgium) each containing 
0.5 ml of heparin (Leo Laboratories, Buckinghamshire, UK) and then diluted in 
an equal volume of phosphate-buffered saline (PBS). 25 ml of diluted blood 
was then layered over 20 ml of Ficoll paque (Amersham, Buckinghamshire, 
UK) in 12 X 50 ml tubes (Corning, New York, USA). PBMC were isolated at 
room temperature by density centrifugation at 1,600 rpm in a Rotina 46R 
centrifuge (Wolf Laboratories, Germany) for 20 minutes with the brake off. On 
completion of PBMC isolation, cells were washed with PBS and centrifuged at 
4 °C for 10 minutes at 1,600 rpm. Cells were then resuspended in AB media 
and a 20 pi aliquot wais removed and stained with 180 pi trypan blue. The 
number of viable cells was calculated using a haemocytometer. 
2.2.4.3 Separation buffer 
The buffer used for the CD4+ and CD25+ cell isolation experiments 
consisted of PBS with 0.5 % bovine serum albumin (BSA) and 2 mM 
ethylenediaminetetraacetic acid (EDTA), at pH 7.2. 
2.2.4.4 Isolation of CD4+CD25+ and CD4+CD25- T cells by immunomagnetic 
beads 
PBMC were washed in degassed separation buffer. CD4+ T cells were 
then isolated using the MACs CD4 negative selection kit, (Miltenyi Biotech, 
Bisley, UK) according to manufacturers' instructions. Briefly, the cell pellet 
was resuspended in separation buffer in a total volume of 40 pi per 10^ total 
cells and incubated with 10 |al hapten-antibody cocktail (containing 
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monoclonal hapten conjugated CDS, CD11b, CD16, CD19 CD36, CD56 and 
giycophorin antibodies) per 10^ cells for 10 minutes at 6-12 °C. A volume of 
separation buffer equivalent to 30 pi per 10^ total cells was then added and 
incubated with 20 pi MACS anti-hapten microbeads per 10^ total cells for 15 
minutes at 6-12 °C. The cells were then washed with separation buffer and 
resuspended in 500 pi separation buffer per 10^ total cells. The sample was 
separated into CD4+ and CD4- fractions using an AutoMACS separator 
(Milltenyi Biotech), using the programme DEPLETE-S. The CD4+ fraction was 
collected via the negl port and the CD4- fraction collected via the posi port. 
The CD4+ enriched population was further divided into CD4+CD25+ 
and CD4+CD25- enriched subsets using MACS anti-CD25 microbeads, 
(Miltenyi Biotech) according to the manufacturer's instructions. Briefly, CD4+ 
cells were counted, resuspended in 90 pi separation buffer per 10^ cells and 
incubated with 10 pi anti-CD25 microbeads per 10^ cells for 15 minutes at 6-
12 °C. The cells were then washed with separation buffer, resuspended in 500 
pi separation buffer per 10^ cells and the sample applied to the AutoMACS 
separator using the programme POSSEL. The CD4+CD25+ fraction was 
collected via the posi port and the CD4+CD25- fraction collected via the negl 
port. The enriched cell populations were then washed in separation buffer and 
counted prior to subsequent use. The purity of separation was assessed by 
flow cytometry with a FACScalibur (BD Biosciences, Belgium). An example of 
one such CD4+CD25- and CD4+CD25+ T cell isolation is shown in Figure 
2.1. 
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Figure 2.1 Separation of CD4+CD25+ CD4+CD25- T cells from human 
peripheral blood. 
FACs plot (a) to show the forward scatter and side scatter properties of 
PBMCs from a representative donor. Dotplot, (b) to show the % CD4+CD25+ 
cells in PBMCs. Dotplots to show the purity of isolated CD4+CD25- (c) and 
CD4+CD25+ (d) T cell subsets after separation using MACs immunomagnetic 
beads. The quadrants have been positioned after determining the expression 
of a matched isotype control antibody. Histogram (e) to show the expression 
of CD25 on isolated CD4+CD25- and CD4+CD25+ T cells. 
122 
2.2.4.5 Isolation of CD4+CD25+ and CD4+CD25- T cells by FACS sorting 
For some experiments CD4+CD25+ and CD4+CD25- T cells were 
isolated using a FACSVantage Cell Sorter (BD Biosciences). Firstly, CD4+ T 
cells were isolated from human peripheral blood PBMCs using MACs 
immuno-magnetic beads as outlined above. Cells were counted using a 
haemocytometer and resuspended in ice-cold PBA (0.2 % BSA, 0.2 % azide 
in PBS) at a concentration of 2 x 10® c/ml. Anti-human CD25-PE and anti-
human CD4-PE-Cy5 were added to the cells at a concentration of 5 [al/IO® 
cells and the cells incubated for 30 minutes on ice. In addition, 1x10® cells 
were stained with each antibody alone. After incubation cells were washed 
twice in ice cold PBA and resuspended at 4 x 10® c/ml. The two control tubes 
of 1 X 10® cells stained with just one antibody were used to set the instrument 
settings on the FACSVantage Cell Sorter. Collection gates were set to collect 
CD4+CD25high and CD4+CD25low cells. Cells were collected in tubes 
containing 1 ml of ice-cold AB media. After collection cells were washed three 
times in ice-cold AB media, counted using a haemocytometer and 
resuspended in AB media at the appropriate concentration for subsequent 
assays. To minimise contamination of cells by the cell sorter, all removable 
tubing and buffer tanks were autoclaved prior to use. 
2.2.4.6 Irradiation of PBMC or CD4- cells 
Irradiated PBMC or irradiated CD4- cells were used as APC in some 
cultures. 8x10® c/ml diluted in AB media were irradiated at 3,000 rads using 
a Gammacell 3000 Elan irradiator (Nordian International Inc., Vancouver, 
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Canada). Cells were then washed in fresh AB media and resuspended at the 
appropriate concentration. 
2.2.5 Proliferation assays 
2.2.5.1 Stimulation of cells with plate-bound anti-CD3 
PBMCs, CD4+CD25+ or CD4+CD25- cells were incubated in triplicate 
with a polyclonal stimulus of anti-CD3 as had previously been described (Ng 
et al., 2001; Baecher-Allan et al., 2001; Levings et al., 2001; Jonuleit et al., 
2001; Taams et al., 2001; Dieckmann et al., 2001; Stephens et al., 2001). 100 
|j| of a 1 pg/ml solution of anti-CD3 (BD Pharmingen, Oxford, UK) diluted in 
sterile PBS was added to each well of a flat-bottomed 96 well plate. The plate 
was incubated for 4 hours at 37 °C and the antibody removed from the plate 
by pipette. CD4+CD25+ or CD4+CD25- cells were cultured either alone at 0.4 
X 10® c/ml or at a 1:2 ratio (0.2:0.4 x 10® c/ml), for 72 hours at 37 °C and 5 % 
CO2 in flat-bottomed 96 well plates (Corning) with plate bound anti-CD3 
antibody at 1 ^g/ml in the presence of 0.4 x 10® irradiated cells/ml. 
2.2.5.2. Stimulation of cells with allergen 
PBMCs, CD4+CD25+ or CD4+CD25- cells were incubated in triplicate 
at 2 X 10® c/ml in AB media in flat-bottomed 96 well plates (Corning) for 6 
days (unless stated otherwise) at 37 °C, 5 % CO2. This cell density and time 
of culture had previously been identified within our research group to be 
optimal for proliferation and cytokine production to allergen. For the mixing 
experiments CD4+CD25- cells were at a final concentration of 2 x 10® c/ml to 
which CD4+CD25+ cells were added at a final concentration of 1 x 10® c/ml 
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(unless stated othen/vlse). A cell number control contained 3 x 10® 
CD4+CD25- c/ml. Each well also contained 2 x 10® c/ml of irradiated 
autologous cells and 100 |ig/ml of cat or grass pollen extract (ALK). The cells 
were incubated at 37 °C and 5 % CO2 for 6 days. 
2.2.5.3 Quantification of cellular proliferation by thymidine incorporation 
The allergen-specific or polyclonal proliferation of the cells was 
measured by thymidine incorporation. 0.0038 MBq of thymidine (ICN 
Pharmaceuticals Ltd, UK) was added to each well for the final 6 hours of 
culture and the plate was then frozen at -20 °C until needed for analysis. After 
defrosting, the cells were then harvested onto filters (Perkin Elmer, UK), air 
dried, sealed in plastic bags (Perkin Elmer) and 2.5 ml scintillation fluid added. 
Thymidine incorporation was measured in counts per minute (CPM) using a 
micro beta liquid scintillation counter (Perkin Elmer). Allergen specific 
proliferation was calculated as proliferation to allergen minus proliferation to 
media alone. 
2.2.5.4 Quantification of cellular proliferation by carboxyfluoroscein 
succinimidyl ester (CFSE) dilution 
The cell tracking dye CFSE (Molecular Probes, Oregon, USA) was 
used in some experiments to stain cells prior to cell culture, thus allowing both 
proliferating cells (those that become CFSE'°^) and non-proliferating cells 
(those that remain CFSE'^ '®'^ ) to be distinguished from one another when run 
through a flow cytometer (Lyons and Parish, 1994). To stain cells with CFSE, 
the cells were first washed in 0.1 % FCS/PBS to help prevent binding of 
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CFSE to proteins present in growth media. Cells were then resuspended in 
0.1 % FSC/PBS at a concentration of 40 x 10® c/ml. An equal volume of cell 
suspension was added to an equal volume of CFSE stain (diluted to 3 |j.M) to 
give a final cell concentration of 20 x 10® c/ml and a final CFSE concentration 
of 1.5 i^M. After incubation for 8 minutes at room temperature an equal 
volume of pre-warmed 100 % FCS (37 °C) was added to stop labelling. The 
cell suspension was then incubated in a 37 °C water bath for 20 minutes to 
allow excess CFSE to be pumped out of the cells. After incubation the cells 
were then centrifuged at 1,300 rpm for 5 minutes and the supernatant 
discarded. Cells were washed 3 times in 2 % FCS/PBS (1 ml/10® cells) and 
resuspended in AB media for cell culture. A day 0 sample was run on the flow 
cytometer to ensure initial uptake of CFSE. CFSE is read in the FL1 (FITC) 
channel of the flow cytometer allowing the CFSE-stained cells to be further 
stained for cell surface markers using antibodies conjugated to fluorochromes 
corresponding to the FL2 (PE), FL3 (PE-Cy5, Texas Red) and FL4 (APC) 
channels. 
After cells were stained with CFSE and washed they were used in 
allergen-stimulated proliferation assays as outlined in section 2.2.5.2. Cells 
were cultured for a period of six days and on days 2, 4 and 6 aliquots of cells 
were removed from culture and a CD4+ T cell isolation was performed (to 
remove any CD4- cells present) prior to using the cells for subsequent flow 
cytometry analysis 
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2.2.5.5 Addition of reagents to blocl< cytokines /cell surface molecules 
In some experiments, blocking antibodies to cytokines or cell surface 
receptors were added to the mixed cultures. In at least three separate 
experiments for each antibody, anti-CCR6 (R&D Systems, Abingdon, UK), 
anti-CCL20 (R&D Systems) or isotype matched control antibodies were added 
at a concentration of 50 ^g/ml (Yang et al., 1999) or 10 pg/ml respectively to 
mixed cultures stimulated with allergen extract as described above. 
2.2.6 Flow cytometric analysis 
2.2.6.1 Cell surface antigens 
Cells were washed once in PBS to remove growth media and 
resuspended in ice-cold PBA (0.2 % BSA, 0.2 % azide in PBS) to a 
concentration of 2 x 10® c/ml. The appropriate antibodies were added to wells 
on a labelled flat-bottomed 96 well plate. 100 pi of the cell suspension (2x10® 
cells) was added to each well and mixed. The plate was incubated in the dark 
on ice for 30 minutes. After incubation 100 pi of ice-cold PBA was added to 
each well and the plate was centrifuged at 1,300 rpm for 5 minutes at 4 °C. 
The cells were resuspended in 200 p l o f i x BD CellFix (BD Pharmingen) after 
another wash using 200 pi of ice-cold PBA. Data was then acquired 
immediately using a FACSCalibur flow cytometer (BD Biosciences) and 
analysed with CellQuest software (BD Biosciences) or in some cases the 
plate was left in the dark overnight at 4 "C and the data acquired the following 
day. A minimum of 10,000 events per sample was acquired and the 
lymphocyte population was identified and gated using forward scatter and 
side scatter chararteristics. The flow cytometry antibodies used in this thesis 
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were CD3-F1TC, CD4-F1TC, CD4-PE-Cy5, CD4-APC, CD14-F1TC, CD19-PE, 
CD25-FITC, CD25-PE, CD27-FITC, CD28-FITC, CD45RA-FITC, CD45RO-
FITC, CD62L-PE, CD69-FITC, HLA-DR-FITC (all from BD Pharmingen), 
CD127-PE, CCR1-PE, CCR2-APC, CCR3-PE, CCR4-F1TC, CCR4-APC, 
CCR5-PE, CCR6-APC, CCR7-PE, CCR8-APC, CXCR1-PE, CXCR2-PE, 
CXCR3-PE, CXCR3-APC. CXCR4-APC, and CXCR6-APC (all purchased 
from R&D Systems, Abingdon, UK), CD3-TR (Caltag, Ca, USA), CD25-PE 
(Immunotech) and F0XP3-FITC (Ebioscience, San Diego, California, USA). 
The matched isotype controls were also purchased from the same company 
as its corresponding antibody. 
CD4+CD25+ and CD4+CD25- cells were tested for purity after every 
immunomagnetic bead separation. CD3-FITC conjugated mouse anti-human 
antibody, CD4-PE-Cy5 or CD4-APC conjugated anti-human antibody and 
CD25-PE conjugated anti-human antibody or their matched isotype controls 
(all from BD Pharmingen) were used to determine the purity of the isolated 
cell populations. An example of one such CD4+CD25- and CD4+CD25+ T cell 
isolation is shown in Figure 2.1. 
2.2.6.2 CCR8 staining 
In addition to using the CCR8 monoclonal antibody from R&D systems 
mentioned above, CCR8 expression was also investigated using a fusion 
protein of the CCR8-specific viral protein MC148 from l\/lolluscum 
contagiosum with Ig heavy chain. This was a kind gift from Dr David Chantry, 
Millenium Pharmaceuticals (Luttichau et al., 2000). A stably transfected CCR8 
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cell line was used as a positive control for staining using the MC148 fusion 
protein. The cells used were stably transfected 4DE4 cells (a murine pre-B 
cell line) that were transfected to express human CCR8 protein (Tiffany et al., 
1997). This cell line was a kind gift from Dr. James Pease and Dr. James Fox 
(Leukocyte Biology, Imperial College). 
CD4+ T cells or CCRB-transfected 4DE4 cells were washed in ice-cold 
staining buffer and incubated with 10 pg/ml of MC148 fusion protein. After 
washing the cells in ice-cold staining buffer they were then incubated in anti-
mouse lgG1 secondary antibody for 10 mins. Cells were then washed and 
resuspended in ice-cold staining buffer and samples acquired on a flow 
cytometer. As controls, aliquots of cells were incubated with the primary 
antibody - MCI48 fusion protein, or the secondary antibody - anti-mouse 
IgGI only, to determine any background staining due to these antibodies. 
2.2.6.3. Intracellular staining of TYR0BP/DAP12 
To detect expression of intracellular TYR0BP/DAP12, cell surface 
staining for CD4-FITC, CD3-TR and CD25-PE was carried out as above and 
then the cells were resuspended in 100 )liI of ice-cold CellFix and stored at 4 
°C overnight in the dark. After the overnight incubation, 100 |il of ice-cold PBA 
was added to each well and mixed. The plate was centrifuged at 1,200 rpm 
for 5 minutes at 4 °C and the supernatant removed by flicking the plate over a 
sink. Each well was resuspended in 100 \x\ of ice-cold PermAA/ash buffer (PW) 
(BD Pharmingen) and incubated in the dark for 20 minutes on ice. After 
incubation, 100 |il of ice-cold PBA was added to each well, the plate 
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centrifuged for 5 minutes at 1,200 rpm at 4 °C and the supernatant removed. 
5 pi of anti-DAP12-APC antibody (a gift from Professor Eric Vivier, Centre 
d'immunologie de Marseille-Luminy, France) or its matched isotype control 
(BD Pharmingen) was mixed with 100 pi ice-cold PW and added to the cells 
with mixing. The plate was incubated in the dark, on ice, for 35 minutes. After 
this incubation, 100 pi of ice-cold PBA was mixed with each well and the plate 
centrifuged again for 5 minutes at 1,200 rpm at 4 °C. The supernatant was 
removed and the cells resuspended in 200 pi of ice-cold PBA and acquired 
immediately using the FACSCalibur. 
2.2.6.4. Intracellular staining of FoxP3 
In experiments outlined in this thesis, intracellular FoxP3 expression 
was assessed using one of two FoxPS antibodies. Due to the absence of a 
commercially available FoxP3 antibody throughout much of the course of this 
thesis, an anti-Foxp3 IgG antibody purified from the antiserum of a rabbit 
immunized with a HIS-tagged recombinant Foxp3 protein purified from 
Escherichia coli was used (Fontenot et al., 2003). This antibody was a gift 
from Dr Mark Gavin (Department of Immunology, University of Washington). 
The second FoxP3 antibody used in this thesis was a commercially available 
anti-human FoxP3 from Ebioscience. This antibody (clone PCH101) is 
purchased as part of a kit containing all necessary fixation and 
permeabilisation buffers. The staining protocol for each antibody is outlined 
below and the antibody used in particular experiments is mentioned in the 
relevant figure. An example of FoxPS staining using each antibody is shown in 
Figure 2.2. 
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Figure 2.2 FoxP3 and CD25 expression on CD4+CD3+ T cells. 
PBMCs were isolated from human peripheral blood and stained with 
antibodies to CDS, CD4 and CD25. In addition the cells were stained with one 
of two different FoxPS antibodies. Shown are representative FACS plots 
showing FoxPS and CD25 expression on CD4+CDS+ gated T cells. Plot (C) 
showing FoxPS staining using an anti-FoxPS IgG antibody (a gift from Mark 
Gavin) and plot (D) showing FoxPS staining using the PCH101 clone antibody 
from Ebiosciences. Also shown are the corresponding %-positive cells in each 
quadrant. Quadrant gates were set for FOXPS expression based on 
CDS+CD4- T cells as outlined in the protocol accompanying the anti-FoxPS 
IgG antibody from Mark Gavin - no isotype control was available so gates 
were set on T cells that do not express FoxPS. An example is shown in plot A. 
To set quadrant gates for the FoxPS antibody from Ebioscience, cells were 
stained with isotype controls for FoxPS and CD25 as shown in plot B. 
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Anti-FoxP3 IgG antibody staining protocol (from Dr. Mark Gavin) 
2x10® cells were aliquoted into 3 wells on a round-bottomed 96 well 
plate. The cells were spun for 5 minutes at 1,200 rpm at 4 °C and the 
supernatant removed by flicking the plate once over a sink. The cells were 
resuspended with 200 )j,I Cytofix/Cytoperm buffer (BD Pharmingen) per well 
and incubated on ice for 30 minutes with occasional mixing. After washing the 
cells in 10 % AB in RPMI they were resuspended in 20 % AB, 10 % DMSO in 
RPMI and the entire plate frozen at -80 ° C, at least overnight. After thawing 
the plate at room temp 100 pil BD Perm/Wash (PW) was added to each well 
and the plate centrifuged at 1,500 rpm for 3 minutes. Cells were washed once 
again in PW prior to refixing the cells by adding 200 pil ice cold 
Cytofix/Cytoperm to each well and incubating on ice for 4 minutes. Cells were 
then washed twice in PBS and resuspended with 100 ^1 DNase (500 |Lig/ml) + 
MgCb (4 mM) in PBS. After incubating the cells at room temp for 8 minutes, 
100 pi of cold PW was added to each well and the plate centrifuged at 1,500 
rpm for 3 minutes. After removing the supernatant each well was 
resuspended with 50 p,l PW500 (1x PW + 350 mM NaCI) containing 5 % 
normal rabbit serum. After 10 minutes incubation at room temp, anti-FoxP3 
rabbit IgG-digoxigenin was added to a final concentration of 10 pg/ml (only to 
2 wells, an equal volume of PBS was added to the third). The plate was then 
incubated for 40 minutes at room temp with occasional mixing. After 
incubation, the cells were washed twice with 200 ^1 PW500, centrifuged, and 
resuspended in 100 jil PW500 and incubated for 15 minutes at room temp 
with agitation. Each well was washed with 100 |j,l PW500 and the cells 
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resuspended in PW containing 5 |j.g/ml biotinylated mouse-anti-Dig and 5 % 
normal mouse serum. Antibodies to other cell targets were also added at this 
point - 5 pi of CD4 FITC and 3 pi of CDS Texas Red was added to each well 
stained with the primary FoxPS antibody, along with 5 pi of CD25 PE or 5 \i\ of 
its matched isotype control lgG1 PE. The plate was then incubated for 30 
minutes at room temp and washed twice using 200 \i\ PW for each well. The 
cells were resuspended in 100 pi of PW and incubated for 15 minutes at room 
temp with agitation. After washing with 100 pi of PW per well, each well was 
resuspended in 100 pi PW containing strepdavidin-APC (BD Pharmingen) 
diluted 1:400. The plate was incubated for 20 mins at room temp, the cells 
washed twice in PW, resuspended in 100 pi PW and incubated for 15 minutes 
with agitation. After incubation the cells were washed once more in PW and 
resuspended in PBS ready for analysis on a flow cytometer. 
Anti-human FoxPS antibody staining protocol (from Ebioscience) 
Anti-human FoxP3 antibody (clone PCH101) was purchased as part of 
a kit containing all reagents and buffers needed. Staining was performed 
according to the manufacturers' instructions. Briefly, CD4+ T cells were 
stained with cell surface antibodies to CD4 and CD25 and washed in cold 
PBS. Cells were resuspended in fixation/permeabilisation buffer and 
incubated for 45 minutes in the dark. Cells were then washed three times in 
permeabilisation buffer prior to incubating with 2 % normal rat serum at 4 °C 
for 15 minutes. Without washing, 10 pi of anti-human FoxPS antibody 
(PCH101) or matched isotype control was added and cells incubated at 4 °C 
for SO minutes in the dark. Finally, cells were washed twice in 
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permeabilisation buffer, resuspended in PBS and analysed on a flow 
cytometer. 
2.2.7 RNA extraction and Real Time Polymerase Chain Reaction (RT-
PCR) 
2.2.7A RNA Extraction 
RNA was extracted from PBMC, CD4+CD25+ and CD4+CD25- T cells 
that had been pelletted, the supernatant removed, and the cells "snap frozen" 
in liquid nitrogen. These cell pellets were then stored at -80 °C until needed 
for future processing. RNA was then extracted using the Absolutely RNA RT-
PCR Miniprep kit from Stratagene (La Jolla, USA) according to the 
manufacturers' instructions. All reagents were provided with the kit. Cells were 
first homogenised using the lysis buffer/(3-mercaptoethanol provided. 
Following cell lysis, the sample was then pre-filtered in a spin cup to remove 
particles and reduce the amount of DNA. The filtrate was then transferred to a 
spin cup with a silica-based fibre matrix to which the RNA bound. Treatment 
with low-salt wash buffer and digestion with DNase removed any remaining 
DNA and a series of washes removed the DNase and other proteins. Pure 
RNA was then eluted from the fibre matrix with a small volume of low-ionic-
strength buffer and captured in a microcentrifuge tube. 
2.2.7.2 Quantitating RNA yield 
To quantitate the RNA, a small sample was removed, diluted in elution 
buffer and mixed well. The spectrophotometer was set to read at an optical 
density (OD) of 260 nm and blanked with elution buffer. The OD of the sample 
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was then measured at 260 nm. To calculate the concentration of RNA in the 
sample the following equation was used: 
Concentration = A260 x dilution factor x 0.04 pig/ml 
The spectrophotometer was then blanked at OD 280 nm with elution 
buffer and the OD of the sample measured at 280 nm. The ratio of the 260 nm 
to the 280 nm measurements indicates the purity of the sample. Ratios of 1.8 
to 2.1 indicate pure samples; lower ratios indicate possible protein 
contamination. 
2.2.7.3 Generation ofcDNA 
cDNA was generated from extracted RNA using the High Capacity 
cDNA Archive Kit from Applied Biosystems (Foster City, CA, USA) according 
to the manufacturers instructions. All reagents were provided with the kit. 
First, a 2x RT master mix was prepared using the table below. Additional 
reactions to the amount needed were included in the calculations to provide 
excess volume for the loss that occurs during reagent transfers. 50 )liI of 2x 
RT master mix was added to 150 |il PCR tubes along with 50 |il of RNA 
sample (125 ng) and mixed with pipetting. Caps were placed on each reaction 
tube and the tubes centrifuged briefly to spin down the contents and to 
eliminate any air bubbles. The tubes were then incubated for 10 minutes at 25 
°C followed by 120 minutes at 37 °C. The resulting cDNA was stored at -20 
°C until needed. Human Thi and Th2 cell cDNA was used as a control in 
each experiment and was a kind gift from Dr. David Cousins (Kings College 
London)(Cousins et al., 2002). 
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Component Volume (nl) / Reaction 
10X Reverse transcription Buffer 10 
25X dNTPs 4 
10X Random Primers 10 
MultiScribe Reverse Transcriptase, 50 U/^l 5 
Nuclease-free H2O 21 
Total per Reaction 50 
2.2.7.4 Taqman PCR reactions 
25 1^1 PCR procedures were carried out in triplicate using Taqman 
universal PCR mastermix (Applied Biosystems) and gene-specific primer and 
probe mixtures (Applied Biosystems) on an ABI Prism 7700 sequence 
detection system (Applied Biosystems). Primer and probe mixtures were 
purchased using an "assay on demand" service from Applied Biosystems. The 
primers used in this study and their corresponding assay IDs are as follows: 
ribosomal RNA component 18s (Assay ID Hs99999901_s1), 
DAP12 (Hs00182426_m1), CCL20 (Hs00171125_m1), 
F0XP3 (Hs00203958_m1), GATA-3 (Hs00231122_m1), 
T-Bet (Hs00203436_m1), CCR8 (Hs00174764_m1), 
p27 (Hs00153277_m1), Cyclin-D3 (Hs00426901_m1), 
ELK4 (Hs00360813_m1), TNFR2 (Hs00153550_m1), 
HPRT (Hs99999909_m1). 
For each well the following mix was prepared; 
Primer and probe mix 1.25^1, Mastermix 12.5 ^1 
Water 8.75 ^1 
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22.5 pi of the appropriate primer mix was added to each well. 2.5 \x\ of 
cDNA was then added in triplicate and the plate sealed. The plate was 
centrifuged at 2000 rpm for 2 minutes to ensure that there were no air 
bubbles, and the plate analysed on the ABI Prism sequence detection system 
using the following cycler conditions: 
50 °C for 2 minutes 
95 °C for 10 minutes 
95 °C for 15 seconds . 
60 °C for 1 minute } 
2.2.7.5 Analysis of data from Taqman PCR 
The read-out from RT-PCR is the "Ct" value; this represents the cycle 
number at which fluorescence generated during each round of amplification 
exceeds an arbitrary threshold value set within the early linear phase of 
amplification. Two methods are commonly employed for quantifying results 
from RT-PCR analysis: the standard curve method and the comparative 
threshold method. In the standard curve method, a standard curve is first 
constructed from RNA of a known concentration. This curve is then used as a 
reference standard for extrapolating quantitative information for mRNA targets 
of unknown concentrations. Although this method allows for absolute copy 
number to be derived, the method is time-consuming, as cDNA plasmids need 
to be constructed, transcribed into RNA and accurately quantitated. In the 
comparative threshold method, the Ct values of the samples of interest are 
compared with a control or calibrator such as a non-treated sample. The Ct 
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values of both the calibrator and the samples of interest are normalized to an 
appropriate endogenous housekeeping gene 
In this thesis, the gene message of interest was quantified using the 
comparative threshold for detection method (2"^^') described in Applied 
Biosystems user bulletin #2 (http://appliedbiosvstems.com). The amount of 
starting material between samples was normalised to that of 18S and the 
levels of mRNA of the gene of interest was then compared relative to the level 
in either unstimulated CD4+CD25+ or CD4+CD25- T cells. An example of one 
calculation demonstrating the 2"^ ^^^ method is outlined below. 
Calibrator Sample Test sample 
CD4+CD25- T cells CD4+CD25+ T cells 
FoxP3 gene Ct = 29.02 FoxP3 gene Ct = 25.43 
Endogenous control 18s Ct = 9.31 Endogenous control 18s Ct = 9.98 
Firstly, normalisation (ACt) accounts for the possibility that more or less cDNA 
is present in one of the samples and is calculated by subtracting the 
endogenous control form the target Ct value. 
Calibrator Sample ACt = 19.71 Test sample ACT = 15.45 
The samples are then calibrated (AACt) to compare the level of target gene 
expression in the test sample to the calibrator sample by subtracting the ACt 
of the calibrator sample from the ACt of the test sample. 
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AACt = -4.26 
Due to the inverse nature of the relationship (more template generates a 
lower Ct value) and that each cycle represents a 2-fold change in template 
amount, the level of gene expression relative to the calibrator sample is 
calculated by 2"^^'. 
2-AACt = 18.98 = 18.98-fold increase in CD4+CD25+ T cells. 
The results of RT-PCR experiments are presented graphically in this thesis as 
fold-expression relative to unstimulated CD4+CD25+ or unstimulated 
CD4+CD25- T cells. The statistical relevance this fold-expression were 
calculated by applying a Wilcoxon matched pairs test to the ACt value of the 
test sample paired to the ACt of the calibrator sample for 6 different 
experiments. 
2.2.8 Actin Polymerisation 
CD4+ T cells purified from PBMCs by magnetic bead separation as 
described (2.2.4.4) were first stained with CD25-PE and CD4-APC and then 
resuspended at 5 x 10® cells/ml in RPMI containing HEPES and incubated for 
10 mins at 37 °C. After this incubation, 600 pi of cell suspension was 
transferred to a clean polypropylene tube. 100 pi of cell suspension was 
removed and added to 400 pi of F-actin staining buffer to give a baseline 
reading prior to incubation of the cells with agonist. F-actin staining buffer 
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constituted PBS containing 4 % paraformaldehyde, 125 ng/ml 1-
lysophosphatidylcholine palmitoyi and 100 nm FITC-phalloidIn to fix, 
permeabiiise and label F-actin respectively. 5 pi of chemokine was added at 
the appropriate concentration (final dilution of 1:100) to the remaining 500 pi 
of cell suspension and after 15, 30, 45 and 60 seconds 100 pi was removed 
and added to 400 pi of F-actin staining buffer. The cells were then incubated 
for 10 minutes at 37 °C, washed twice with 600 pi of PBS and resuspended in 
FACS buffer. The final 100 pi of cell suspension was left for one hour before 
addition to 400 pi of F-actin staining buffer. Sample fluorescence of 
CD4+CD25'''9\ CD4+CD25+, CD4+CD25- and total CD4+ T cells was 
measured by flow cytometry by gating on both CD4 and CD25 expression and 
results are expressed as percentage increase in fluorescence compared to 
unstimulated cells. 
2.2.9 Recombinant human chemokines 
The chemokines used for the actin polymerisation experiments outlined 
above were CCL5/RANTES, CCL11/Eotaxin, CCL17/TARC, CCL20/Mip-3a, 
CCL21/SLC, CCL22/MDC, CXCL12/SDF (all from Peprotech Inc., NJ, USA) 
and CCL1/I-309 (R&D Systems). 
2.2.10 Gene Array Analysis (chapter 4) 
2.2.10.1 RNA extraction 
RNA was extracted from CD4+CD25+ and CD4+CD25- T cells that had 
been pel letted, the supernatant removed, and the cells "snap frozen" in liquid 
nitrogen. These cells were snap frozen immediately after isolation or after 
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incubation with plate-bound anti-CD3 (as described in section 2.2.5.1) and 
then stored at -80 °C until needed for future processing. RNA was then 
extracted using the RiboPure ™ Kit from Ambion (Texas, USA) according to 
the manufacturers' instructions. All reagents were provided with the kit. Cells 
were first homogenised in RNAwiz, which rapidly lyses cells and inactivates 
nucleases. The addition of chloroform results in separation of the homogenate 
into aqueous (upper) and organic (lower) phases. RNA partitions to the 
aqueous phase, while DNA and protein remain in the interphase and organic 
phase. The RNA is isolated from the aqueous phase by binding to a glass-
fiber filter. After two on-filter washes to remove contaminants, the RNA is 
eluted from the filter with a low salt buffer and captured in a microcentrifuge 
tube. DNase treatment removed any trace amounts of genomic DNA from the 
eluted RNA. 
2.2.10.2 RNA amplification 
Purified RNA from the above procedure was subsequently amplified 
using the MessageAmp aRNA kit (Ambion) according to the manufacturer's 
instructions. All reagents were provided with the kit. The amplification 
procedure involved 5 steps, as outlined in figure 2.3 - first strand copy DNA 
(cDNA) synthesis, second strand cDNA synthesis, cDNA purification, in vitro 
transcription, and amplified RNA (aRNA) purification. The incubation time 
used for the in vitro transcription reaction was 14 hours. 
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Figure 2.3 Protocol showing the steps involved in RNA amplification. 
Adapted from MessageAmp aRNA Kit User's Manual (Ambion). 
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2.2.10.3 Labelling aRNA with Cy3 and Cy5 and purification of single stranded 
RNA (ssRNA) 
After the amplification reactions, the aRNA samples were concentrated 
to 13 pi by vacuum centrifugation and the quantity of aRNA in each sample 
was measured using absorbance at 260 nm (method 2.2.7.2). Samples were 
then labelled with either Cy3 or Cy5 by reverse transcription. For each time 
point, the CD4+CD25+ sample was labelled with Cy5 and the CD4+CD25-
sample with Cy3. An equal amount of aRNA from each sample was used in 
the reverse transcription reaction in the presence of the relevant dye. After the 
reverse transcription labelling step, single-stranded RNA (ssRNA) was purified 
from the reaction mixture using the QIAquick Purification Kit (QIAgen), 
following the manufacturers instructions. 
2.2,11 Gene array analysis (chapter 5) 
2.2.11.1 RNA extraction 
Total RNA was extracted from 5 x 10® washed PBMC using the 
RNeasy mini kit from Qiagen, according to the manufacturers' instructions. 
Briefly, washed PBMCs were pelletted and the supernatant removed. The 
cells were resuspended in 600 p.1 of RLT lysis buffer (containing (3-
Mercaptoethanol), and mixed well by pipetting to ensure inactivation of 
RNase. These homogenised cell lysates in RLT buffer were then stored at -80 
°C, prior to transport on dry ice to the BUR, Dallas, Texas where the protocol 
was continued. Samples were applied to RNeasy MinElute Spin Columns, 
where RNA binds to the silica-gel membrane. Contaminating traces of DNA 
within the sample are removed by DNase treatment on the column. Further 
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washes performed with buffers supplied in the kit removed the DNase and any 
other contaminating traces of proteins. Finally purified total RNA is eluted from 
the column using RNase-free water. 
2.2.11.2 RNA precipitation with alcohol 
Total RNA isolated via the method described above resulted in a 200 |al 
sample of total RNA in RNase-free water. These samples were subsequently 
precipitated in order to remove any contaminants and to concentrate the RNA 
sample. 200 |il of RNA sample was mixed with 20 p.! sodium acetate (3M, 
pH5.5, Ambion), 500 p,l 100 % ethanol (at -20 °C) and 2 i^l glycogen (5 |ag/|al, 
Ambion) and allowed to precipitate overnight at -20 °C. Samples were 
centrifuged at 13,000g for 30 mins at 4 °C and the supernatant discarded. The 
pellet was resuspended in 500 p.1 100 % ethanol, centrifuged for 10 mins at 4 
°C and the supernatant discarded. Pellets were dried on the bench top and 
the RNA sample resuspended in 14 pi RNase-free water. 
2.2.11.3 Quantifying RNA 
The concentration and purity of RNA was quantified using the 
NanoDrop ND-1000 Spectrophotometer (NanoDrop Technologies, Delaware, 
USA). This spectrophotometer rapidly measures the absorbance of a sample 
across a range of wavelengths. Just 1 p.1 of sample is needed which is applied 
directly to the top of the reader, without a need for sample diluttion or use of 
cuvettes. The purity of RNA within the samples was quantified by measuring 
the ratio of absorbance of the sample at 260/280 nm. A ratio of 1.8-2.1 is 
considered sufficient purity for microarray experiments. 
144 
2.2.11.4 RNA quality control using Agilent Technologies 2100 Bioanalyser 
RNA integrity has historically been assessed using gel electrophoresis 
of total RNA followed by staining with ethidium bromide. Gel images allow the 
visualisation of the two bands corresponding to the 28s and 18s ribosomal 
RNA (rRNA) species within the sample. The RNA is deemed to be of high 
integrity when the ratio of the 28s: 18s rRNA bands is approximately 2 or 
higher. The integrity of the RNA used in this study was measured using an 
RNA 600 Nano LabChip kit run on an Agilent 2100 Bioanalyser (Agilent 
Technologies, Foster City, California, USA) following the manufacturers 
instructions. Briefly, RNA samples in a gel-dye matrix are loaded into the 
glass chip, placed into the instrument, electrophoretically separated within 
micro-channels, and quantified by laser detection to generate a virtual gel 
image of the samples. The signals obtained for each sample are compared to 
that of a ladder of defined sizes run on the same chip. The 18S and 28S 
ribosomal RNA bands are automatically detected by the software and the ratio 
of the 28s: 18s rRNA bands is automatically generated. 
In order to standardize the process of RNA integrity interpretation, the 
RNA Integrity Number (RIN) was developed by researchers at Agilent 
Technologies to remove user-dependent interpretation of RNA quality 
(Schroeder et al., 2006). The RIN analyses information from both the rRNA 
bands and potential degradation products to provide a more complete picture 
of RNA degradation states. The RIN software algorithm allows for the 
classification of eukaryotic total RNA, based on a numbering system from 1 to 
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10, with 1 being the most degraded profile and 10 being the most intact. In 
addition to automatically generating values for RNA concentration and 
28s: 18s rRNA ratio, the 2100 Bioanalyser software also generates a RIN 
number for the sample. Examples of electropherograms generated by the 
2100 Bioanalyser for intact and degraded RNA is shown in Figure 2.4. An 
example of a gel image generated by the 2100 Agilent Bioanalyser is shown 
in Figure 5.4. 
2.2.11.5 RNA amplification and labelling 
Purified RNA from the above procedure was subsequently amplified using the 
lllumina Total Prep RNA amplification Kit (Ambion) according to the 
manufacturer's instructions. All reagents were provided with the kit. Although 
this is a different RNA amplification kit to that used in Chapter 4, as outlined in 
section 2.2.10.2, both are from the same company and essentially the same 
protocol. The manufacturers claim that the lllumina TotlalPrep RNA 
amplification kit has been developed and optimised to produce labelled cRNA 
for hybridisation with lllumina microarrays. As with the protocol outlined in 
section 2.2.10.2 and Figure 2.3, the amplification procedure using this RNA 
amplification kit involves five steps - first strand copy DNA (cDNA) synthesis, 
second strand cDNA synthesis, cDNA purification, in vitro transcription, and 
cRNA purification. One difference between the lllumina Total Prep RNA 
amplification kit and the MessageAmp aRNA kit outlined in section 2.2.10.2 is 
the inclusion of a biotin-UTP mix in the in vitro transcription reaction to 
generate cRNA. The inclusion of the biotin-UTP mix results in the generation 
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of biotinylated antisense RNA copies of each mRNA in the sample. The 
incubation time used for the in vitro transcription reaction was 14 hours. 
2.2.11.6 RNA Hybridisation 
After quantifying the amount of cRNA within each sample, 1500 ng of 
each sample was used to hybridise to Sentrix Human-6 expression 
BeadChips (lllumina). As each BeadChip contains six individual arrays, two 
BeadChips were used to hybridise the twelve samples in the study. Three 
cRNA samples from both groups were hybridised to each BeadChip. The 
protocol followed was that provided by the manufacturers (Whole-genome 
gene expression for BeadStation, http://www.illumina.com ) and all reagents 
needed were supplied in a kit. Briefly, cRNA samples were hybridised to 
Sentrix Human-6 expression BeadChips for 16-20 hours and the BeadChips 
then underwent a series of washes. Biotin signal was then detected with 
streptavidin-CyS and the BeadChips scanned with the lllumina BeadArray 
Reader. An outline of the steps involved in this hybridisation protocol, along 
with the steps involved in generating the biotin-labelled cRNA samples is 
shown in Figure 2.5. 
2.2.11.7 Microarray data analysis 
The text files created by the lllumina BeadArray software were 
imported into GeneSpring GX 7.3.1 (Agilent Technologies) for further 
visualisation and analysis of the microarray data generated. A step-by-step 
outline of the analysis performed using this software is detailed in the results 
section. 
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A) Intact total RNA, RIN = 9.2 
B) Partially degraded RNA, RIN = 5.8 
Figure 2.4 Examples of 2100 Bioanalyser electropherograms for intact 
and partially degraded RNA. 
Shown are examples of electropherograms (fluorescence Intensity versus 
migration time) generated by the 2100 Bioanalyser for intact (A) and partially 
degraded (B) RNA samples. Also shown is the RIN corresponding to each 
RNA sample. Images taken from the Agilent 2100 Bioanalyser users manual 
(Agilent Technologies, 2004). 
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Figure 2.5 Flow diagram of the steps involved in RNA amplification, 
labelling and hybridisation. 
2.2.12 Statistical analysis 
Proliferation and chemokine receptor expression of CD4+CD25+ and 
CD4+CD25- cells was statistically analysed using a Wilcoxon matched pairs 
test. For comparisons between different experiment groups (for example 
atopic versus non-atopic) a Mann Whitney U test was used. RT-PCR data 
was analysed statistically using a Wilcoxon matched pairs test to compare 
CD4+CD25+ and CD4+CD25- T cells and using a Mann Whitney U test when 
comparisons involving Th1 or Th2 mRNA was performed. All statistical 
analysis of RT-PCR data was performed on the ACt values generated. 
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Microarray gene expression data was analysed using a Mann Whitney U test 
to compare expression levels of each gene between asthmatic and non-
asthmatic samples. In addition, statistical analysis of cell surface marker 
expression on T cell subsets and analysis of blood leukocyte cell number in 
PBMC from asthmatic and non-asthmatic donors was performed using a 
Mann Whitney U test. 
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Chapter 3: Chemokine receptor expression of 
CD4+CD25+ and CD4+CD25- T cells. 
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3.1 Introduction 
3.1.1 Chemokines and chemokine receptors 
Chemokines are a group of structurally related chemotactic cytokines, 
characterised by a critically positioned 4-cysteine amino acid motif, that 
function in the trafficking of leukocytes to specific sites and micro-
environments. Chemokines exert their function by binding to, and signalling 
through, /-transmembrane G-protein-coupled receptors expressed by 
leukocytes. The human chemokine system comprises about 50 distinct 
chemokines and 19 G-protein-coupled chemokine receptors (Murphy, 2002; 
Burns et al., 2006). Chemokines are generally 70-90 amino acids in length 
and approximately 8-10 kDa in molecular weight. The chemokine superfamily 
is divided into four subfamilies based on the position of the four cysteine 
residues near the amino terminus of the protein (ZIotnik and Yoshie, 2000). 
The subfamilies are known as the CC chemokines (|3 chemokines), CXC 
chemokines (a chemokines), C chemokines (y chemokines) and CX3C 
chemokines (5 chemokines). CC chemokines have two adjacent amino 
terminal cysteine residues; while for CXC and CX3C chemokines these two 
cysteine residues are separated by one and three amino acids respectively. 
The C chemokine subfamily lacks one of the cysteines in the four-cysteine 
amino acid motif. So far, twenty-eight CC chemokines, eighteen CXC 
chemokines, one CX3C chemokine and one C chemokine have been 
identified in humans (ZIotnik and Yoshie, 2000). Table 1.1 displays the 
systematic chemokine nomenclature, familiar names of human ligands and 
homologous murine ligands, and the main chemokine receptors to which they 
bind. 
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Chemokines are generally produced as pro-peptides and are cleaved 
during secretion to produce an active mature protein that functions by 
activating G-protein-coupled receptors. The chemokines CXCL16 and 
CX3CLI are unique within the human chemokine family in that they are 
expressed in a membrane-bound form, at the end of a mucin-rich 
transmembrane stalk (Bazan et al., 1997; Matloubian et al., 2000). This 
surface-bound expression allows these two chemokines to also function as 
adhesion molecules for cells that express the receptors. In addition, the 
membrane-bound form of these chemokines can be cleaved from their stalk 
by the actions of metalloproteinases such as ADAM17 and ADAM 10, resulting 
in a soluble chemoattractant form of the chemokine (Carton et al., 2001; Abel 
et al., 2004). 
As mentioned, chemokines exert their biological function via 7-
transmembrane G-protein coupled receptors on the surface of leukocytes. 
Currently, 19 human chemokine receptors have been identified - 10 CCRs, 7 
CXCRs, 1 CX3CR and one XCR1 (Murphy, 2002; Burns et al., 2006). 
Activation of chemokine receptors by chemokines is restricted by class, for 
example, a CXC chemokine will only activate a receptor within the CXCR 
group. Despite this restriction chemokine-chemokine receptor interactions are 
extremely promiscuous with many chemokines acting as ligands to multiple 
receptors and chemokine receptors capable of binding multiple chemokine 
ligands. It has also been reported that chemokines can act as antagonists for 
some chemokine receptors. For example CXC L11 has been described as a 
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natural antagonist for CCR3 (Xanthou et al., 2003) and CCR5 (Petkovic et al., 
2004b) and CCL26 as an antagonist for CCR1, CCR2 and CCR5 (Ogilvie et 
al., 2003; Petkovic et al., 2004a). This interplay between different chemokines 
and chemokine receptors may serve to finely tune inflammatory responses in 
vivo. 
Chemokine receptor expression on leukocytes is tightly regulated 
depending on cell type and on activation and maturation states. Typically, 
leukocytes will express several different chemokine receptors at any one time, 
in differing numbers. Chemokine receptors can be further sub-divided into two 
groups: 'homeostatic' and 'inflammatory' chemokine receptors. Homeostatic 
receptors are generally constitutively expressed and are responsible for 
trafficking to secondary lymphoid organs. Inflammatory chemokine receptors 
are induced under inflammatory conditions and are responsible for recruitment 
of leukocytes to sites of inflammation. 
Given the importance of the chemokine/chemokine receptor system in 
the localisation of immune cells, several viruses have adapted mechanisms to 
disrupt the immune response to infection. Large DNA viruses, such as 
poxviruses and herpes viruses, encode chemokine-receptor-binding proteins 
within their genome to aid their propagation within a human host. These 
viruses encode many different proteins that act as broad-spectrum or specific 
antagonists for human chemokine receptors (Murphy, 2001). 
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One example of a virally encoded chemokine-receptor-blnding protein 
is the MC148 protein encoded by the poxvirus molluscum contagiosum 
(MCV). MCV causes benign tumours in the skin, characterised by an absence 
of inflammatory cell infiltrates (Heng et al., 1989; Viae and Chardonnet, 1990). 
MC148 protein has been shown to be a specific antagonist for human CCR8 
(Luttichau et al., 2000; Luttichau et al., 2001). 
3.1.2 Chemokine receptor expression on CD4+ T cell subsets 
Similar to other leukocytes, chemokine receptor expression on CD4+ T 
cells is flexible and differs on naive, memory, and effector T cells depending 
on their activation status (Sallusto et al., 1998a). The regulation of chemokine 
receptor expression on CD4+ T cells is important in their homing to secondary 
lymphoid organs, different tissues and to sites of inflammation. It is also 
thought to play a major role in their interaction with antigen presenting cell 
types, including dendritic cells and B cells. 
As well as differing in their cytokine production profile, Thi and Th2 T 
cells have been shown to display a different chemokine receptor expression 
profile. This difference in chemokine receptor expression in Thi and Th2 cells 
is logical in order to recruit one or the other cell subset under particular 
inflammatory conditions. Th2 cells were shown to preferentially express CCR3 
(Sallusto et al., 1997; Bonecchi et al., 1998), CCR4 (Bonecchi et al., 1998) 
and CCR8 (Zingoni et al., 1998) when compared to Th1 cells. In contrast, Th1 
cells have been shown to preferentially express CCR2, CCR5 and CXCR3 
(Bonecchi et al., 1998). This differential pattern of chemokine receptor 
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expression seen on in vitro polarised T cells has also been born out in vivo. T 
cells producing IL-4, recovered from bronchoalveolar lavage of both asthmatic 
and normal subjects have been shown to preferentially express CCR3 and 
CCR4 (Morgan et al., 2005a). Expression of CCR4 has also been observed 
by allergen specific CD4+ T cells from the ainA/ay of atopic children (Banwell 
et al., 2003). In studies of CD4+ T cells infiltrating asthmatic airways after 
allergen challenge, again CCR4 and CCR8 expression was observed 
(Panina-Bordignon et al., 2001; Nouri-Aria et al., 2002) together with an up-
regulation of the CCR4 ligands CCL17/TARC and CCL22/MDC (Pilette et al., 
2004). 
Several reports have described expression of chemokine receptors by 
CD4+CD25+ regulatory T cells and their responsiveness to chemokines. 
These regulatory T cells have been described to express a wide variety of 
chemokine receptors with preferential expression of CCR4 (lellem et al., 2001; 
Annunziato et al., 2002; Lee et al., 2005), CCR5 (lellem et al., 2003; Wysocki 
et al., 2005), CCR6 (Kleinewietfeld et al., 2005), and CCR8 (lellem et al., 
2001; Annunziato et al., 2002) compared to CD4+CD25- effector T cells. A 
preferential recruitment of CD4+CD25+ regulatory T cells has also been 
reported for the CCR4 ligands CCL17/TARC and CCL22/MDC (lellem et al., 
2001), the CCR5 ligand CCL4/Mip-1-(3 (Bystry et al., 2001) and the CCR8 
ligand CCL1/I-309 (lellem et al., 2001; Annunziato et al., 2002; Colantonio et 
al., 2002). 
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3.2 Aims of study 
This study hypothesised that human CD4+CD25+ regulatory T cells 
isolated from peripheral blood display a specific chemokine receptor 
expression profile to their CD4+CD25- T cell counterparts and that this profile 
is modulated upon activation. A secondary hypothesis was that CD4+CD25+ 
regulatory T cells isolated from atopic and non-atopic individuals display a 
different chemokine receptor expression profile that may explain the defect 
observed in CD4+CD25+ T cells from atopic individuals, previously reported 
by our group (Ling et al., 2004). 
The aims of this study were: 
1) Determine the chemokine receptor expression of CD4+CD25^'^'^, 
CD4+CD25+ and CD4+CD25- T cells isolated from human 
peripheral blood. 
2) Compare the chemokine receptor expression profile of 
CD4+CD25+ and CD4+CD25- T cells isolated from atopic and non-
atopic individuals. 
3) Compare the chemokine-responsiveness of CD4+CD25+ and 
CD4+CD25- T cells isolated from atopic and non-atopic individuals. 
4) Observe the modulation of chemokine receptor expression by 
CD4+CD25+ and CD4+CD25- T cells in response to activation with 
allergen in vitro. 
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3.3 Experimental design 
CD4+CD25+ and CD4+CD25- T cells were isolated from human 
peripheral blood. Based on reports by Baecher-Allan et al, regulatory T cells 
were gated on CD25 expression (Baecher-Allan et al., 2001) and the 
FOXP3+CD127- phenotype of CD4+CD25^'9^ T cells (Seddiki et al., 2006; Liu 
et al., 2006) was confirmed by flow cytometry staining of GDI27 (BD 
Pharmingen) and F0XP3 (Ebioscience). The chemokine receptor expression 
profile of CD4+CD25+, 004+0025^'^"^ and CD4+CD25- T cells was measured 
by flow cytometry. The expression of the receptors CCR1, CCR2, CCR3, 
CCR4, CCR5, CCR6, CCR7, CCR8, CXCR1, CXCR2, CXCR3, CXCR4, and 
CXCR6 was measured on each T cell subset. 
Secondly, CD4+CD25+ and CD4+CD25- T cells were isolated from 
human peripheral blood of both atopic and non-atopic individuals (for clinical 
details see tables 3.1 and 3.2). Again the chemokine receptor expression 
profile of CD4+CD25+ and CD4+CD25- T cells was measured by flow 
cytometry. 
Based on the results of this flow cytometry study, CD4+ T cells were 
isolated from the peripheral blood of a further group of patients (for clinical 
details see tables 3.3 and 3.4) and the responses of CD4+CD25-, 
CD4+CD25+, and CD4+CD25^'^'^ T cells to the chemokines CCL1/I-309, 
CCL5/RANTES, CCL1 l/Eotaxin, CCL17/TARC, CCL20/Mip-3-alpha, 
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CCL21/SLC, CCL22/MDC, and CXCL12/SDF was measured using an actin 
polymerisation assay. 
The fourth part of the study outlined in this chapter was to determine 
the changes in CD4+CD25+ and CD4+CD25- T cell chemokine receptor 
expression in response to allergen activation. A schematic outlining the 
experimental method used to determine this is shown in Figure 3.1. In this 
protocol the following antibodies were used to stain CD4+ T cells in 
conjunction with CFSE; CCR1-PE, CCR2-APC, CCR3-PE, CCR4-APC, 
CCR5-PE, CCR6-APC, CCR7-PE, CXCR1-PE, CXCR2-PE, CXCR3-APC, 
CXCR4-APC, CXCR6-APC, and their matched isotype controls (all purchased 
from R&D Systems). The staining template used for these experiments is 
shown in table 3.5. 
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Table 3.1 Clinical details of atopic donors for chemokine receptor 
expression experiments. 
Donor Gender Age SPT Atopic 
CD4+ 
cell purity 
(%) 
CD25+ 
cell purity 
(%) 
1 F 27 Grass Y 89.0 61.5 
2 F 24 HDM, Grass, Cat Y 85.0 64.4 
3 F 34 Cat, Horse Y 86.6 88.2 
4 F 24 HDM Y 91.1 83.1 
5 M 28 HDM, Grass Y 82.0 46.5 
6 M 45 Cat Y 92.6 65 
7 F 42 HDM, Grass, Trees Y 83.3 76.7 
8 F 26 HDM, Grass, Trees, Dog Y 85.2 65.7 
9 F 31 Grass Y 84.6 68.5 
10 M 27 Grass, Cat, Alternaria Y 62.8 38.9 
Summary M = 3 F=7 
31 (24-
45) 
HDM = 5 
Grass = 7 
Cat = 4 
Trees = 2 
Horse = 1 
Dog = 1 
Alternaria = 1 
Y= 10 84.2(62.8-926% 
65.8(38.9-
Table 3.2 Clinical details of non-atopic donors for chemokine receptor 
expression experiments. 
Donor Gender Age SPT Atopic CD4+ cell 
purity (%) 
CD25+ 
cell purity 
(%) 
1 F 25 None N 89.0 62.7 
2 F 29 None N 91.6 67.9 
3 F 27 None N 93.8 79.3 
4 M 39 None N 94.0 80.0 
5 F 25 None N 85.0 41.5 
6 M 25 None N 89.1 78.1 
7 M 34 None N 84.7 61.8 
Summary M=3, F=4 29 (25-39) N=7 N=7 
89.6(84.7-
94) 
67.3(41.5-
79.3) 
Legend: F = female, M = male, HDM = house dust mite, Y = yes, N = no. 
Summary = sum of values or median and (range). 
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Table 3.3 Clinical details of atopic donors for actin polymerisation 
experiments. 
Donor Gender Age SPT Atopic CD4+ cell 
purity (%) 
1 M 26 HDM Y 93 
2 M 30 Grass, HDM Y 94 
3 F 36 Cat, 
Horse 
Y 91 
4 M 28 Grass, 
Trees, HDM 
Y 85 
5 M 46 Cat, 
HDM 
Y 89 
6 F 27 Grass, HDM Y 88 
7 M 28 
Grass, 
Trees, Dog, 
HDM 
Y 94 
Summary 
M=5, 
F=2 
31.5 
^26-46; 
HDM=6, 
Grass=4, 
Cat=2, 
Horse=1, 
Trees=2, 
Dog=1 
Y= 7 
90.5 
(85 - 94) 
Table 3.4 Clinical details of non-atopic donors for actin polymerisation 
experiments. 
Donor Gender Age SPT Atopic CD4+ cell 
purity 
1 F 30 None N 80 
2 F 35 None N 92 
3 F 24 None N 91 
4 F 25 None N 83 
5 M 26 None N 80 
6 M 29 None N 78 
Summary 
M=2, 
F=4 
2&7 
(24 = 35) None = 6 N = 6 
84 
(78 -91) 
Legend: F = female, M = male, HDM = house dust mite, Y = yes, N = no 
Summary = sum of values or median and (range). 
161 
150ml blood 
PBMC 
CD4+ negative selection 
by MACS 
Irradiated CD4- CD4+ Irradiated CD4-
CD25+ positive selection 
by MACS 
CD4+CD25- CD4+CD25+ 
CFSE stain 
Culture A Culture B 
Day 2, 4, 6 
CD4+ CD4+ negative selection CD4+ 
by MA CS 
FACS analysis FACS analysis 
Figure 3.1. Schematic showing details of experiments investigating the 
chemokine receptor expression profile of CD4+CD25+ and CD4+CD25- T 
cells during allergen culture. 
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SAMPLE FL1 (FITC) FL2 (PE) FL3 (PE:Cy-5) FL4 (APC) 
1 
2 CFSE 
3 CCR7 
4 CD4 
5 CCR4 
6 CFSE Ms lgG2a Ms lgG1 Ms lgG2b 
7 CFSE Ms lgG2b Ms lgG1 Ms lgG1 
8 CFSE Rat lgG2a Ms lgG1 
9 CFSE CCR1 CD4 CCR2 
10 CFSE CCR5 CD4 CCR4 
11 CFSE CCR7 CD4 CCR6 
12 CFSE CXCR1 CD4 CXCR3 
13 CFSE CXCR2 CD4 CXCR4 
14 CFSE CCR3 CD4 CXCR6 
15 CFSE CD25 CD4 
Table 3.5. FACS staining template 
FACS staining template used for experiments investigating the chemokine 
receptor expression profile of CD4+CD25+ and CD4+CD25- T cells during 
allergen-stimulated culture. 
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3.4 Results - Chemokine receptor expression and 
responsiveness of CD4+CD25-, CD4+CD25+, and 
CD4+CD25'''9'' T ceils 
3.4.1 Isolation of CD4+CD25+ and CD4+CD25- T cells from human 
peripheral blood 
Regulatory T cells have been described to reside in the CD25^'^^ 
expressing CD4+ T cell population (Baecher-Allan et al., 2001). They have 
also been characterised as being FoxP3-positive and CD127-negative 
(Seddiki et al., 2006; Liu et al., 2006). To further define the regulatory T cell 
population in the following experiments, CD4+CD25+ T cells were gated 
further on CD25'^ '^ ^ expression (Figure 3.2). These CD4+CD25'^ '^ '^  T cells were 
FoxP3-positive and CD127-negative in agreement with previous studies 
(Figure 3.2). 
3.4.2 CCR4 expression and responsiveness to CCL17/TARC and 
CCL22/MDC 
In agreement with previous studies, CCR4 expression was increased in 
CD4+CD25+ T cells as compared to CD4+CD25- T cells. Gating on 
CD4+CD25'^ '^ '^  and CD4+CD25'°^ T cells showed an even more dramatic 
difference in expression of CCR4, with > 90 % of CD4+CD25'^ '^ '^  T cells 
expressing the receptor (Figure 3.3 A). The difference in expression of CCR4 
between CD4+CD25+ and CD4+CD25- T cells was true for cells isolated from 
both atopic and non-atopic individuals, with no differences seen in the 
expression of CCR4 between the two groups (Figure 3.3 B). 
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Figure 3.2 CD4+CD25'^ '^ ^ T cells isolated from human peripheral blood 
are FoxP3-positlve and CD127-negative. 
Representative dotplots from one individual donor showing CD4 and CD25 
expression on isolated CD4+CD25- (B) and CD4+CD25+ T cells (C). Dotplot 
A shows the non-specific binding using the matched isotype control. The 
typical gate used in the experiments outlined in this chapter to gate 
CD4+CD25^'^'^ T cells is shown (R2). Dotplots D and E show expression of 
FoxP3 (Ebioscience antibody) and CD127 on CD4+CD25- (D) and 
CD4+CD25^'8h gated T cells (E). 
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Figure 3.3 CCR4 expression on CD4+CD25+, CD4+CD25-, CD4+CD25^'9h 
and CD4+CD25'°^ T cells isolated from human peripheral blood. 
GD4+CD25+ and CD4+CD25- T cells were isolated from human peripheral 
blood and the expression of CCR4 was measured on each T cell subset by 
flow cytometry. Graph (a) shows the % CD4+ T cells expressing CCR4 for 
n=7 individual donors (consisting of a mix of healthy and atopic donors). In 
addition the expression of CCR4 on CD4+CD25^'^'^ and CD4+CD25'°^ gated T 
cells is shown. Graph (b) shows the % CD4+ T cells expressing CCR4 for 
n=10 atopic and n=7 non-atopic individuals. Statistical comparisons of 
CD4+CD25+ and CD4+CD25- T ceils were performed using a Wilcoxon 
matched pairs test. Statistical comparisons between groups were performed 
using a Mann Whitney U test. NS denotes not significant. 
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Figure 3.4 Actin polymerisation induced by addition of CCL17/TARC to 
CD4+ T cells. 
CD4+ T cells were isolated from human peripheral blood and the 
responsiveness of CD4+CD25+, CD4+CD25-, CD4+CD25'^ '^ '^  and total CD4+ 
T cells to CCL17/TARC stimulation was measured using an actin 
polymerisation assay. Results are expressed as percentage increase in F-
actin compared to unstimulated cells. Graph (a) shows the responses of n=7 
atopic donors. Graph (b) shows the responses of n=6 non-atopic donors. The 
responses of each T cell subset at each timepoint were statistically compared 
using a Wilcoxon matched pairs test. * denotes p<0.05 for CD4+CD25+ 
compared to CD4+CD25-, t denotes p<0.05 for CD4+CD25^'^'^ compared to 
CD4+CD25-, $ denotes p<0.05 for CD4+CD25'^ '^ '^  compared to CD4+CD25+. 
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Figure 3.5 Actin polymerisation induced by addition of CCL22/MDC to 
CD4+ T cells. 
CD4+ T cells were isolated from human peripheral blood and the 
responsiveness of CD4+CD25+, CD4+CD25-, CD4+CD25'''9'' and total CD4+ 
T cells to CCL22/MDC stimulation was measured using an actin 
polymerisation assay. Results are expressed as percentage increase in F-
actin compared to unstimulated cells. Graph (a) shows the responses of n=7 
atopic donors. Graph (b) shows the responses of n=6 non-atopic donors. The 
responses of each T cell subset at each timepoint were statistically compared 
using a Wilcoxon matched pairs test, * denotes p<0.05 for CD4+CD25+ 
compared to CD4+CD25-, t denotes p<0.05 for CD4+CD25'^'^^ compared to 
CD4+CD25-, t denotes p<0.05 for CD4+CD25'^ '^ '^  compared to CD4+CD25+. 
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Using an actin polymerisation assay, the functional response of CD4+ 
T cells isolated from both atopic and non-atopic individuals to the ligands of 
CCR4, CCL17/TARC and CCL22/MDC, was then determined. In keeping with 
their higher expression of CCR4, CD4+CD25+ and CD4+CD25'^ '^ '^  T cells 
showed a greater functional response to CCL17/TARC (Figure 3.4 A-B). In 
addition, no difference in the responses of each sub-population was seen 
when comparing cells isolated from atopic and non-atopic individuals. Similar 
results were obtained for the second CCR4 ligand CCL22/MDC (Figure 3.5 A-
B). 
3.4,3 CCR5 expression and responsiveness to CCL5/RANTES 
The expression of CCR5, although low on both CD4+CD25+ and 
CD4+CD25- T cells, was increased on the CD4+CD25+ subset. This increase 
was found to be more pronounced on CD4+CD25^'^^ gated T cells when 
compared to CD4+CD25'°^ gated T cells (Figure 3.6 A). Interestingly, this 
increase in CCR5 expression on CD4+CD25+ T cells was only significantly 
higher for T cells isolated from atopic individuals and not for T cells isolated 
from non-atoplc individuals (Figure 3.6 B), although the expression of CCR5 
on each subset was not significantly different between the two population 
groups. 
In agreement with the low expression of CCR5, the functional response 
to its ligand CCL5/RANTES was also low (Figure 3.7 A-B). ForT cells isolated 
from both atopic and non-atopic individuals, only CD4+CD25+ and 
CD4+CD25'^'^'^ T cells showed a functional response to the ligand, although 
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this was not statistically significant. The response was not consistent for T 
cells isolated from all individuals, with 3/7 atopic donors and 1/6 non-atopic 
donor showing this response to CCL5/RANTES. 
3.4.4 CCR6 expression and responsiveness to Mip-3-alpha/CCL20 
The receptor CCR6 was also differentially expressed on CD4+CD25+ 
and CD4+CD25- T cells, again with increased expression of this receptor on 
CD4+CD25+ T cells. This differential expression was again more pronounced 
on CD4+CD25'^ '^ '^  T cells when compared to CD4+CD25'°^ T cells (Figure 3.8 
A). The differential expression of CCR6 between CD4+CD25+ and 
CD4+CD25- T cells was similar for cells isolated from both atopic and non-
atopic individuals, and no difference in the expression of this receptor on each 
subset was seen when comparing both population groups (Figure 3.8 B). 
The chemokine receptor CCR6 has one identified ligand, CCL20/Mip-3-
alpha, in the human chemokine/chemokine receptor system. The functional 
response to this chemokine was in agreement with the expression observed 
for its receptor CCR6. An increased response to CCL20/Mip-3-alpha was 
seen for CD4+CD25+ and CD4+CD25'^ '^ '^  T cells as compared to CD4+CD25-
and CD4+CD25'°^ T cells. The response observed for CCL20/Mip-3-alpha 
was similar for cells isolated from both atopic and non-atopic individuals 
(Figure 3.9 A-B). 
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high Figure 3.6 CCR5 expression on CD4+CD25+, CD4+CD25-, CD4+CD25 
and CD4+CD25'°^ T cells isolated from human peripheral blood. 
CD4+CD25+ and CD4+CD25- T cells were isolated from human peripheral 
blood and the expression of CCR5 was measured on each T cell subset by 
flow cytometry. Graph (a) shows the % CD4+ T cells expressing CCR5 for 
n=7 individual donors (consisting of a mix of healthy and atopic donors). In 
addition the expression of CCR5 on CD4+CD25'^ '^ '^  and CD4+CD25'°^ gated T 
cells is shown. Graph (b) shows the % CD4+ T cells expressing CCR5 for 
n=10 atopic and n=7 non-atopic individuals. Statistical comparisons of 
CD4+CD25+ and CD4+CD25- T cells were performed using a Wilcoxon 
matched pairs test. Statistical comparisons between groups were performed 
using a Mann Whitney U test. NS denotes not significant. 
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Figure 3.7 Actin polymerisation induced by addition of CCL5/RANTES to 
CD4+ T cells. 
CD4+ T cells were isolated from human peripheral blood and the 
responsiveness of CD4+CD25+, CD4+CD25-, CD4+CD25^'^'^ and total CD4+ 
T cells to CCL5/RANTES stimulation was measured using an actin 
polymerisation assay. Results are expressed as percentage increase in F-
actin compared to unstimulated cells. Graph (a) shows the responses of n=7 
atopic donors. Graph (b) shows the responses of n=6 non-atopic donors. The 
responses of each T cell subset at each timepoint were statistically compared 
using a Wilcoxon matched pairs test. NS denotes not significant. 
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Figure 3.8 CCR6 expression on CD4+CD25+, CD4+CD25-, CD4+CD25^'^^ 
and 004+0025'°"" T cells. 
CD4+CD25+ and CD4+CD25- T cells were isolated from human peripheral 
blood and the expression of CCR6 was measured on each T cell subset by 
flow cytometry. Graph (a) shows the % CD4+ T cells expressing CCR6 for 
n=7 individual donors (consisting of a mix of healthy and atopic donors). In 
addition the expression of CCR6 on CD4+CD25^'^'^ and CD4+CD25'°"" gated T 
cells is shown. Graph (b) shows the % CD4+ T cells expressing CCR6 for 
n=10 atopic and n=7 non-atopic individuals. Statistical comparisons of 
CD4+CD25+ and CD4+CD25- T cells were performed using a Wilcoxon 
matched pairs test. Statistical comparisons between groups were performed 
using a Mann Whitney U test. NS denotes not significant. 
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Figure 3.9 Actin polymerisation induced by addition of CCL20/MIP-3-
Alpha to CD4+ T cells. 
CD4+ T cells were Isolated from human peripheral blood and the 
responsiveness of CD4+CD25+, CD4+CD25-, CD4+CD25'^ '^ '^  and total CD4+ 
T cells to CCL20/Mip-3-alpha stimulation was measured using an actin 
polymerisation assay. Results are expressed as percentage increase in F-
actin compared to unstimulated cells. Graph (a) shows the responses of n=7 
atopic donors. Graph (b) shows the responses of n=G non-atopic donors. The 
responses of each T cell subset at each timepoint were statistically compared 
using a Wilcoxon matched pairs test. * denotes p<0.05 for CD4+CD25+ 
compared to CD4+CD25-, f denotes p<0.05 for CD4+CD25'^'^^ compared to 
CD4+CD25-, t denotes p<0.05 for CD4+CD25'^ '^ '^  compared to CD4+CD25+. 
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3.4.5 CCR7 expression and responsiveness to SLC/CCL21 
In contrast to the expression of CCR4, CCR5, and CCR6, the 
expression of CCR7 was observed to be significantly higher on CD4+CD25- T 
cells as compared to CD4+CD25+ T cells. A similar difference in CCR7 
expression was seen for CD4+CD25'°^ compared to CD4+CD25'^ '^ '^  gated T 
cells (Figure 3.10 A). This increased expression of CCR7 on CD4+CD25- T 
cells was true for cells isolated from both atopic and non-atopic individuals, 
and no difference in expression of CCR7 on each cell subset was seen 
between both population groups (Figure 3.10 B). 
A greater functional response to the chemokine CCL21/SLC, a ligand 
for CCR7, was also observed for CD4+CD25'°^ and CD4+CD25- T cells when 
compared to CD4+CD25'^ '^ '^  and CD4+CD25+ T cells. Interestingly this 
increased functional response of CD4+CD25- T cells to CCL21/SLC 
stimulation was only statistically significant for cells isolated from non-atopic 
individuals at the earliest time-point studied (15 seconds) (Figure 3.11 A). In 
contrast, CD4+CD25- T cells isolated from atopic individuals did not display a 
significantly increased response to CCL21/SLC compared to CD4+CD25+ or 
CD4+CD25'''9h T cells (Figure 3.11 B). 
3.4.6 CCR8 expression and responsiveness to CCL1/I-309 
No CCR8 staining was observed on CD4+CD25+ or CD4+CD25- T 
cells using a commercially available monoclonal antibody from R&D systems 
(Figure 3.12 A). In addition, this monoclonal antibody did not detect CCR8 on 
the surface of a CCR8 transfected cell line (Figure 3.12 A). It was concluded 
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Figure 3.10 CCR7 expression on CD4+CD25+, CD4+CD25-, CD4+CD25'''9^ 
and 004+0025'°"" T cells. 
CD4+CD25+ and CD4+CD25- T cells were Isolated from human peripheral 
blood and the expression of CCR7 was measured on each T cell subset by 
flow cytometry. Graph (a) shows the % CD4+ T cells expressing CCR7 for 
n=7 individual donors (consisting of a mix of healthy and atopic donors). In 
addition the expression of CCR7 on CD4+CD25^'^^ and CD4+CD25'°"*' gated T 
cells is shown. Graph (b) shows the % CD4+ T cells expressing CCR7 for 
n=10 atopic and n=7 non-atopic individuals. Statistical comparisons of 
CD4+CD25+ and CD4+CD25- T cells were performed using a Wilcoxon 
matched pairs test. Statistical comparisons between groups were performed 
using a Mann Whitney U test. NS denotes not significant. 
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Figure 3.11 Actin polymerisation induced by addition of CCL21/SLC to 
CD4+ T cells. 
CD4+ T cells were isolated from human peripheral blood and the 
responsiveness of CD4+CD25+, CD4+CD25-, CD4+CD25'^'^^ and total CD4+ 
T cells to CCL21/SLC stimulation was measured using an actin polymerisation 
assay. Results are expressed as percentage increase in F-actin compared to 
unstimulated cells. Graph (a) shows the responses of n=7 atopic donors. 
Graph (b) shows the responses of n=6 non-atopic donors. The responses of 
each T cell subset at each timepoint (15, 30, 45, 60 seconds) were statistically 
compared using a Wilcoxon matched pairs test. * denotes p<0.05 for 
CD4+CD25+ compared to CD4+CD25-, t denotes p<0.05 for CD4+CD25^'^^ 
compared to CD4+CD25-, t denotes p<0.05 for CD4+CD25'^ '^ '^  compared to 
CD4+CD25+, NS denotes not significant. 
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that this monoclonal antibody was not specific for CCR8. Due to the absence 
of staining using the commercially available CCR8 monoclonal antibody, a 
fusion protein of the CCR8-specific viral protein MC148 from Molluscum 
contagiosum with Ig heavy chain was used to examine CCR8 expression on 
CD4+CD25+ and CD4+CD25- T cells. Initially the specificity of this fusion 
antibody was tested using a stably transfected CCR8 cell line (Figure 3.12 B). 
This confirmed the binding of MC148 to the chemokine receptor CCR8. 
However, subsequent staining of both CD4+CD25- and CD4+CD25+ T cells 
could not detect any CCR8 expression on these cell subsets (Figure 3.12 C). 
To further investigate the expression of CCR8, mRNA was purified 
from CD4+CD25+ and CD4+CD25- T cells either directly after isolation from 
peripheral blood, or after three days of culture in the presence of plate-bound 
anti-CD3 antibody. After transcribing the purified mRNA into cDNA, this was 
used in a quantitative PGR assay to determine the relative amounts of CCR8 
mRNA in each cell type. cDNA from Thi and Th2 polarised cells was included 
as a control in the experiment and the mRNA expression of FoxP3 in each cell 
type was also measured as a positive control. CCR8 mRNA was found to be 
~7 fold higher in freshly isolated CD4+CD25+ T cells as compared to 
CD4+CD25- T cells. Expression of CCR8 mRNA was further increased in 
CD4+CD25+ T cells after activation with anti-CD3. In addition, CCR8 mRNA 
in activated CD4+CD25+ T cells was observed to be significantly higher than 
that of Th2 polarized cells (Figure 3.13 A). The expression of FoxP3 mRNA 
showed a similar expression pattern to CCR8 - higher expression in freshly 
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isolated CD4+CD25+ T cells compared to CD4+CD25- T cells, and an 
increase in its expression in CD4+CD25+ T cells after activation (Figure 3.13). 
The functional response of CD4+CD25+ and CD4+CD25- T cells to 
CCL1/I-309, the ligand for CCR8, was in agreement with the expression of 
CCR8 mRNA seen in both cell types. CD4+CD25+ and CD4+CD25^'3^ T cells 
showed a consistent response to CCL1/1-309. In contrast, CD4+CD25- and 
CD4+CD25'°^ T cells showed no functional response to this chemokine 
(Figure 3.14 A-B). Furthermore, a similar functional response to CCL1/I-309 
was seen in CD4+CD25+ or CD4+CD25'^'^'^ T cells isolated from the 
peripheral blood of both atopic and non-atopic individuals. This functional 
response to CCL1/I-309 in CD4+CD25+ and CD4+CD25'''9h j cells was 
blocked by pre-incubation of the cells with the fusion protein MC148, showing 
that this response was indeed mediated through the receptor CCR8 (Figure 
3.15 A). In contrast, the fusion protein MCI48 had no effect on the functional 
response of CCL22/MDC, which signals through the receptor CCR4 (Figure 
3.15 B). 
3.4.7 CCR3 expression and responsiveness to CCL11/Eotaxin 
Similar expression of CCR3 was observed on CD4+CD25+ and 
CD4+CD25- T cells isolated from human peripheral blood. Expression of 
CCR3, if present, was low and in the range of -5-10 %. Interestingly, 
CD4+CD25'^'^'^ gated T cells had a significantly higher expression of CCR3 
when compared to CD4+CD25'°^ T cells, suggesting increased CCR3 
expression on regulatory T cells (Figure 3.16 A). No difference in CCR3 
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Figure 3.12 CCR8 expression on CD4+CD25+ T cells 
Representative histograms showing CCR8 expression on a CCRB-transfected 
cell line and CD4+CD25+ T cells isolated from human peripheral blood using 
a monoclonal antibody from R&D Systems (A) or an MC148 fusion protein (B 
and C). Histogram (A) shows CCR8 expression on CD4+CD25+ T cells (red 
line) and a CCR8-transfected cell line (green line) using CCR8-APC mAb. 
Purple denotes staining due to a matched isotype control. Histograms (B) and 
(C) show CCR8 expression on a CCR8-transfected cell line (B) and 
CD4+CD25+ T cells (C) using an MC148 fusion protein. Cells were stained 
with MC148 fusion protein prior to secondary staining with anti-mouse lgG1-
PE. Purple denotes staining due to the primary antibody (MC148) only, green 
line denotes staining due to the secondary antibody (anti-mouse lgG1-PE) 
only, red denotes staining due to both primary and secondary antibodies. 
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Figure 3.13 Expression of CCR8 and FoxP3 mRNA by CD4+CD25+, 
CD4+CD25-, Th1, and Th2 cells. 
RNA was extracted from freshly Isolated CD4+CD25+ and CD4+CD25- T 
cells or from CD4+CD25+ and CD4+CD25- T cells stimulated with plate-
bound anti-CD3 for 24 hours (n = 6). RNA was then quantified and reverse 
transcribed. 25 pi PGR reactions were carried out in triplicate with Taqman 
universal PGR mastermix, GGR8 or FoxP3 specific primers and labelled 
Taqman probe. Samples were standardised to 18s and normalised to 
GD4+GD25- expression. Data is presented as fold expression of GGRB (a) 
and FoxPS (b) relative to GD4+GD25- expression (GD4+GD25- expression = 
1). The accompanying tables show the results of statistical analysis. For 
comparisons between GD4+CD25+ and CD4+GD25- T cells, a Wilcoxon 
matched pairs test was used. For comparisons involving Th1 or Th2 mRNA, a 
Mann Whitney U test was used. All statistical analysis was performed on AGt 
values, as outlined in section 2.2.7.5. 
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Figure 3.14 Actin polymerisation induced by addition of CCL1/I-309 to 
CD4+ T ceils. 
CD4+ T cells were isolated from human peripheral blood and the 
responsiveness of CD4+CD25+, CD4+CD25-, CD4+CD25'"9^ and total CD4+ 
T cells to CCL1/I-309 stimulation was measured using an actin polymerisation 
assay. Results are expressed as percentage increase in F-actin compared to 
unstimulated cells. Graph (a) shows the responses of n=7 atopic donors. 
Graph (b) shows the responses of n=6 non-atopic donors. The responses of 
each T cell subset at each timepoint were statistically compared using a 
Wilcoxon matched pairs test. * denotes p<0.05 for CD4+CD25+ compared to 
CD4+CD25-, t denotes p<0.05 for CD4+CD25'^ '^ '^  compared to CD4+CD25-, X 
denotes p<0.05 for CD4+CD25'^ '^ '^  compared to CD4+CD25+. 
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Figure 3.15 Actin polymerisation induced by addition of CCL1/I-309 to 
CD4+ T cells is inhibited by pre incubation with MC148 fusion protein. 
Isolated CD4+ T cells were pre-incubated with 10 ug/ml MC148 fusion protein 
or media (untreated) for 30 minutes prior to addition of the chemokines 
CCL1/I-309 or CCL22/MDC. The percentage increase in F-actin compared to 
unstimulated cells was measured at 15 second intervals. Results (n = 3) are 
shown for CD4+, CD4+CD25-, CD4+CD25+ and CD4+CD25'''9^ gated T cells 
at the 30 second time point for CCL1/I-309 (a), and CCL22/MDC (b). 
Statistical comparisons were performed between MC148-treated and 
untreated cells using a paired T test. 
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expression was observed on CD4+CD25+ and CD4+CD25- T cells isolated 
from atopic and non-atopic individuals (Figure 3.16 B). 
Minimal functional response was observed for CCL11/Eotaxin, a ligand 
for CCR3. In both atopic and non-atopic patient groups, CD4+CD25+ and 
CD4+CD25^'^'^ T cells showed a slight response in 2/6 individuals and hence 
this response was not statistically significant (Figure 3.17 A-B). 
3.4.8 CXCR4 expression and responsiveness to CXCL12/SDF 
Similar expression of the receptor CXCR4 was seen on each T cell 
subset - CD4+CD25+, CD4+CD25-, CD4+CD25^'9h gn j CD4+CD25'°'' (Figure 
3.18 A). The expression of CXCR4 was generally absent and if present was 
below 5 %. In T cells isolated from some individuals CXCR4 expression was 
markedly higher but again no difference in the expression of the receptor was 
seen when comparing different T cell subsets from these individuals. 
Furthermore, this similar level of CXCR4 expression on CD4+CD25+ and 
CD4+CD25- T cells was demonstrated for cells isolated from atopic and non-
atopic individuals (Figure 3.18 B). 
Despite the low expression levels of CXCR4 on each cell subset, the 
responsiveness of each to stimulation by the CXCR4 ligand CXCL12/SDF 
was significant, in general the responsiveness of each cell subset to CXCR4 
stimulation was similar and similar levels were observed for cells from both 
atopic and non-atopic individuals (Figure 3.19). However when statistically 
compared, some differences in responsiveness to CXCR4 was noted. 
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CD4+CD25+ and CD4+CD25'^ '^ '^  T cells Isolated from atopic individuals 
displayed a significantly decreased responsiveness compared to CD4+CD25-
T cells at the 15 second time-point (Figure 3.19 A). No significant differences 
were observed for cells isolated from atopic donors at any other time-point 
studied. In contrast, CD4+CD25+ and CD4+CD25'^'^'^ T cells isolated from 
non-atopic individuals did not display a significantly decreased 
responsiveness compared to CD4+CD25- T cells at any time-point studied 
(Figure 3.19 B). Surprisingly both T cell subsets showed a significantly 
increased responsiveness compared to CD4+CD25- T cells at the 45 second 
time-point. However, it must be noted that the responses of each cell subset 
to stimulation with CXCL12/SDF are not very different and the differences 
outlined above at different time-points of the experiment may not be 
biologically significant, as discussed later. 
3.4.9 CCR1, CCR2, CXCR1, CXCR2, and CXCR6 expression 
No significant expression of CCR1, CCR2, CXCR1, CXCR2, or CXCR6 
was observed on CD4+CD25+ or CD4+CD25- T cells isolated from either 
atopic or non-atopic individuals using flow cytometry (Figure 3.20 A-E). 
Expression of CCR1 and CXCR6 was absent on both cell subsets (Figure 
3.20 A + E). Some CCR2 expression was observed but this expression was 
generally low, typically < 5 % (Figure 3.20 B). Expression of CXCR1 and 
CXCR2 was also typically < 5 % apart from 1 - 2 individuals in each group 
where some more pronounced expression was observed (Figure 3.20 C + D). 
185 
A) 
12.5-
10.0-
w 
o 7.5-
O 5.04 
2.5-
0.0 
NS (p=0.937) 
1 ^ 
• 
• 
MM-
• A 
• 
• 
(p=0.031) 
r 
T 
T 
t t T 
V 
• 
• 
T T 
• • 
• 
— A 
CD25+ CD25- CD25' high CD25' low 
B) 
NS (p=0.962) 
I 
NS (p=0.417) 
12.5' 
10.0-
o 7.5-1 
§ 5.04 
2.5-1 
0.0 
NS (p=0.496) 
1 1 
• m 
NS (p=0.375) 
1 1 
T 
T 
TT 
• 
• 
• 
T 
T 
T T T T 
CD25+ CD25- CD25+ CD25-
Atopic Non-atopic 
Figure 3.16 CCR3 expression on CD4+CD25+, CD4+CD25-, CD4+CD25^'9^ 
and 004+0025'°"" T cells. 
CD4+CD25+ and CD4+CD25- T cells were isolated from human peripheral 
blood and the expression of CCR3 was measured on each T cell subset by 
flow cytometry. Graph (a) shows the % CD4+ T cells expressing CCR3 for 
n=7 individual donors (consisting of a mix of healthy and atopic donors). In 
addition the expression of CCR3 on CD4+CD25'^ '^ '^  and CD4+CD25'°"*' gated T 
cells is shown. Graph (b) shows the % CD4+ T cells expressing CCR3 for 
n=10 atopic and n=7 non-atopic individuals. Statistical comparisons of 
CD4+CD25+ and CD4+CD25- T cells were performed using a Wilcoxon 
matched pairs test. Statistical comparisons between groups were performed 
using a Mann Whitney U test. NS denotes not significant. 
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Figure 3.17 Actin polymerisation induced by addition of CCL11/Eotaxin 
to CD4+ T cells. 
CD4+ T cells were isolated from human peripheral blood and the 
responsiveness of CD4+CD25+, CD4+CD25-, CD4+CD25'^'^^ and total CD4+ 
T cells to CCL11/Eotaxin stimulation was measured using an actin 
polymerisation assay. Results are expressed as percentage increase in F-
actin compared to unstimulated cells. Graph (a) shows the responses of n=7 
atopic donors. Graph (b) shows the responses of n=6 non-atopic donors. The 
responses of each T cell subset at each timepoint were statistically compared 
using a Wilcoxon matched pairs test. NS denotes not significant. 
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Figure 3.18 CXCR4 expression on CD4+CD25+, CD4+CD25-, 
CD4+CD25"'3" and CD4+CD25'°^ T cells. 
CD4+CD25+ and CD4+CD25- T cells were Isolated from human peripheral 
blood and the expression of CXCR4 was measured on each T cell subset by 
flow cytometry. Graph (a) shows the % CD4+ T cells expressing CXCR4 for 
n=7 individual donors (consisting of a mix of healthy and atopic donors). In 
addition the expression of CXCR4 on CD4+CD25^'^^ and CD4+CD25'°^ gated 
T cells is shown. Graph (b) shows the % CD4+ T cells expressing CXCR4 for 
n=10 atopic and n=7 non-atopic individuals. Statistical comparisons of 
CD4+CD25+ and CD4+CD25- T cells were performed using a Wilcoxon 
matched pairs test. Statistical comparisons between groups were performed 
using a Mann Whitney U test. NS denotes not significant. 
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Figure 3.19 Actin polymerisation induced by addition of CXCL12/SDF to 
CD4+ T cells. 
CD4+ T cells were Isolated from human peripheral blood and the 
responsiveness of CD4+CD25+, CD4+CD25-, CD4+CD25^'9'' and total CD4+ 
T cells to CXCL12/SDF stimulation was measured using an actin 
polymerisation assay. Results are expressed as percentage increase in F-
actin compared to unstimulated cells. Graph (a) shows the responses of n=7 
atopic donors. Graph (b) shows the responses of n=6 non-atopic donors. The 
responses of each T cell subset at each timepoint (15, 30, 45, 60 seconds) 
were statistically compared using a Wilcoxon matched pairs test. * denotes 
p<0.05 for CD4+CD25+ compared to CD4+CD25-, f denotes p<0.05 for 
CD4+CD25'^ '^ '^  compared to CD4+CD25-, NS denotes not significant. 
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Figure 3.20 CCR1, CCR2, CXCR1, CXCR2, and CXCR6 expression on 
CD4+CD25+, and CD4+CD25- T cells isolated from peripheral blood. 
CD4+CD25+ and CD4+CD25- T cells were isolated from peripheral blood of 
atopic (n = 10) and non-atopic (n = 7) individuals. Expression of CCR1, CCR2, 
CXCR1, CXCR2 and CXCR6 on each cell subset was measured by flow 
cytometry. Results are expressed as % CD4+ T cells expressing CCR1 (a), 
CCR2 (B), CXCR1 (C), CXCR2 (D) and CXCR6 (E). Statistical comparisons 
of CD4+CD25+ and CD4+CD25- T cells were performed using a Wilcoxon 
matched pairs test. Statistical comparisons between groups were performed 
using a Mann Whitney U test. NS denotes not significant. 
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3.5 Results - Chemokine receptor expression on allergen-
activated CD4+CD25+ and CD4+CD25- T cells 
3.5.1 Gating method used to differentiate CD4+CD25+, proliferating 
CD4+CD25-, and non-proliferating CD4+CD25- T cells 
CFSE-labelled CD4+CD25- T cells were cultured in the presence or 
absence of unlabelled CD4+CD25+ T cells using allergen extract as a 
stimulus and autologous irradiated CD4- cells as APC for a period of 6 days. 
On days 2, 4 and 6, cells were removed from culture and the CD4+ T cells 
present were isolated and their chemokine receptor expression was 
examined. The cell tracking dye CFSE allows for the identification of 
proliferating cells within a cell culture - the amount of CFSE in a cell is divided 
evenly between both daughter cells of a proliferating cell resulting in a halving 
of the intensity of staining in the daughter cells compared to the parent cell 
(Lyons and Parish, 1994). When analysed on a flow cytometer, activated, 
proliferating T cells also show an increase in forward scatter and side scatter 
properties. By combining forward scatter and side scatter measurements with 
CFSE intensity three subpopulations of CD4+ cells within the cell culture can 
be identified and gated. In figure 3.21 (A) and (B) R1 represents the entire 
CD4+ population. This can then be divided into two distinct populations of T 
cell depending on their forward scatter v side scatter properties - dividing cells 
(R3), and non-dividing cells (R2). Two further gates are identified based on 
intensity of CFSE staining - dividing cells and non-stained cells (R4) and non-
dividing cells (R5). Using combinations of these different gates allows for the 
identification of CD4+CD25+, proliferating CD4+CD25- and non-proliferating 
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CD4+CD25- T cells. CD4+CD25+ T cells are not stained with CFSE (R4) and 
do not proliferate (R2) and so are identified as being R4 + R2. Proliferating 
CD4+CD25- T cells have medium to low intensity of CFSE (R4) and have 
increased forward scatter v side scatter (R3) and so are identified as being R4 
+ R3. Non-proliferating CD4+CD25- T cells remain CFSE^'^^ throughout 
culture (R5) and so are identified as being R5 + R1. 
3.5.2 Inhibition of CD4+CD25- T cell proliferation by co-culture with 
CD4+CD25+ T cells using a CFSE-based cell culture system 
CD4+CD25+ regulatory T cells are capable of suppressing the 
proliferation of effector T cells in both in vivo mouse models of disease and in 
vitro cell culture assays. The regulatory activity of the CD4+CD25+ T cells 
used in the cell culture system outlined in this chapter was initially examined. 
Proliferation of CFSE-stained CD4+CD25- T cells was measured on day 2, 4 
and 6 of cell culture. Proliferating T cells decreased their intensity of CFSE-
stain, while up-regulating CD25 expression (CD25 used in this instance as a 
marker of T cell activation). No proliferation was seen by day 2 of culture 
(Figure 3.22 A i). By day 4 of cell culture, substantial proliferation of 
CD4+CD25- T cells was observed (Figure 3.22 A ii), which was even more 
pronounced by day 6 (Figure 3.22 A iii). Cell counts for T cells at different 
rounds of cell division are shown for days 2, 4 and 6 in Figure 3.22 B i, ii and 
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Figure 3.21 Gating method used to identify CD4+CD25+, proliferating 
CD4+CD25-, and non-proliferating CD4+CD25- T cells from mixed CD4+ 
T cells. 
Dotplots (a) and (b): CD4+ cells are gated into total CD4+ population (R1), 
non-proliferating CD4+ population (R2), and proliferating CD4+ population 
(R3) based on their forward scatter v side scatter signal. Histograms (c) and 
(d): Proliferating CD25- and unstained CD25+ cells are gated on CFSE'°^ 
(R4), and non-proliferating CD25- T cells are gated on CFSE '^^ *^  (R5). The 
different sub-populations of cells can then be identified from mixed cultures 
using the following gates: 
CD25+: R2 and R4 
Non-proliferating CD25-: R1 and R5 
Proliferating CD25-: R3 and R4 
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Figure 3.22 Measurement of allergen-stimulated CD4+CD25- T cell 
proliferation by CFSE dilution and inhibition of proliferation by 
CD4+CD25+ T cells. CD4+CD25- T cells were isolated and stained with 
CFSE prior to culture in the absence (culture A) or presence (culture B) of 
CD4+CD25+ T cells at a 2:1 ratio (2 x 106 c/ml:1 x 106 c/ml). Cells were 
cultured in the presence of grass pollen extract (lOOjig/ml) and irradiated 
CD4- cells as APC (1 x 106c/ml). On days 2, 4 and 6, CD4+ cells were 
isolated and stained with CD25-PE and analysed by flow cytometry. Dot plots 
a and c showing CFSE dilution and CD25 expression of CD4+ cells from 
culture condition A and B respectively. Corresponding histograms b and d 
showing CD4+ cells from each cell culture condition. Blue = undivided, 
Orange = 1 division, Turquoise = 4 divisions, yellow = 5 divisions, Clear = 
CD4+CD25+ T cells. Data from one representative experiment of 12. 
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Co-culture of CD4+CD25- T cells in the presence of regulatory T cells 
at a 2:1 ratio resulted in an inhibition of the proliferation seen for CD4+CD25-
T cells. Again no proliferation is seen by day 2 of cell culture (Figure 3.22 C i). 
A small amount of CD4+CD25- T cell proliferation is seen by days 4 and 6 
(Figure 3.22 C ii and iii) but the amount of proliferating cells in the presence of 
regulatory T cells is dramatically reduced. This is illustrated more clearly in 
Figure 3.22 D i, ii and iii where it can be seen that the proportion of dividing 
cells is only a very small fraction of the undivided cell number, in contrast to 
the proportion of divided cells seen when CD4+CD25- T cells were cultured 
alone (Figure 3.22 B I, ii and iii). These observations confirmed the 
suppressive ability of CD4+CD25+ T cells in the allergen-stimulated, CFSE-
based cell culture assay used in these experiments. 
The percentage suppression of CD4+CD25- T cell proliferation by co-
culture with CD4+CD25+ regulatory T cells is shown for all donors in Figure 
3.23. The mean percentage suppression seen for all donors was 91%. Our 
group has previously reported a defect in suppression by CD4+CD25+ T cells 
from atopic individuals (Ling et al., 2004). Separating the eight individuals 
depending on their atopic status revealed a drop in mean suppression to 86% 
for atopics while mean suppression in non-atopics rose to 96%. Unfortunately 
due to the low n number for atopics and non-atopics in this study this 
difference is not significant but the trend seen is in agreement with the 
previously published report by our group. 
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Figure 3.23 Inhibition of CD4+CD25- T cell proliferation by co-culture 
with CD4+CD25+ regulatory T cells. 
CD4+CD25- T cells were cultured in the presence of 100 pg/ml grass pollen 
allergen extract and irradiated CD4- cells as APC (1 x 10® c/ml) in the 
presence or absence of CD4+CD25+ regulatory T cells at a 2:1 ratio (2x10® 
c/ml:1 X 10® c/ml). The proliferation of CD4+CD25- T cells was measured by 
counting the number of CFSE-low cells present within the culture. This 
proliferation was inhibited by co-culture with CD4+CD25+ T cells. The graph 
shows the percentage suppression of CD4+CD25- T cell proliferation by 
CD4+CD25+ T cells for n = 8 donors. The graph also shows the percentage 
suppression for those 8 donors split into two groups - atopic (n = 4) and non-
atopic (n =4). 
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3.5.3 Expression of CCR4 on allergen-activated CD4+CD25+ and 
CD4+CD25- T cells 
As outlined above freshly isolated CD4+CD25+ peripheral blood T cells 
show significantly higher CCR4 expression when compared to CD4+CD25- T 
cells. Expression of CCR4 on allergen-activated CD4+CD25+ T cells 
decreased over the 6-day cell culture period (Figure 3.24 A). CCR4 
expression decreased from -50 % to -20 % by day 6 of cell culture. CCR4 
expression on non-proliferating CD4+CD25- T cells also decreased over the 6 
day cell culture period (Figure 3.24 B). In contrast, proliferating CD4+CD25- T 
cells tended to increase CCR4 expression upon allergen-activation, although 
this was not a significant increase (Figure 3.24 C). Due to the low numbers of 
proliferating CD4+CD25- T cells present on days 2 and 4 of cell culture, only 
the expression of CCR4 on days 0 and 6 is shown in figure 3.24 C. 
3.5.4 Expression of CCR6 on allergen-activated CD4+CD25+ and 
CD4+CD25- T cells 
Freshly isolated peripheral blood CD4+CD25+ T cells have significantly 
higher CCR6 expression compared to CD4+CD25- T cells as outlined above. 
Although no significant increase or decrease in CCR6 expression on 
CD4+CD25+ T cells was observed between day 0 and day 6 after allergen-
activation, a significant down-regulation of CCR6 expression was observed 
between day 2 and day 4 of cell culture (Figure 3.25 A). Curiously those 
CD4+CD25+ T cells that showed low CCR6 expression at baseline (< 30%) 
increased that expression by day 2 of cell culture. Conversely, those 
CD4+CD25+ T cells that had a high CCR6 expression at baseline (>30%) all 
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showed decreased expression by day 2. Following this seemingly differential 
regulation of CCR6 expression during the first two days of cell culture, all 
CD4+CD25+ T cells decreased their expression of the receptor by day 4. 
Non-proliferating CD4+CD25- T cells showed no significant net 
increase or decrease in CCR6 expression over the course of the cell culture 
period (Figure 3.25 B). Between 10-20 % of CD4+CD25- T cells expressed 
CCR6 at the end of the time course. A decrease in CCR6 expression was 
observed between day 2 and day 6 of cell culture but whether this change is 
truly significant must be questioned due to the p value observed (p = 0.0313). 
Proliferating CD4+CD25- T cells also showed no difference in CCR6 
expression between day 0 and day 6 with 10-20% of cells expressing the 
receptor after 6 days of allergen stimulation (Figure 3.25 C). 
3.5.5 Expression of CCR7 on allergen-activated CD4+CD25+ and 
CD4+CD25- T ceils. 
Allergen-activated CD4+CD25+ T cells increased expression of CCR7 
during cell culture. This increase was maximal at day 2 of cell culture and 
remained constant through to day 6 (Figure 3.26 A). CCR7 expression on 
non-proliferating CD4+CD25- T cells remained constant during the cell culture 
period (Figure 3.26 B). In contrast, proliferating CD4+CD25- T cells decreased 
CCR7 expression over the course of the experiment (Figure 3.26 C). 
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Figure 3.24 CCR4 expression on allergen-activated CD4+CD25+ and 
CD4+CD25- T cells. 
CD4+CD25- and CD4+CD25+ T cells were Isolated from human peripheral 
blood and cultured at a ratio of 2:1 (2 x 10® c/ml:1 x 10® c/ml) in the presence 
of grass pollen allergen extract (100jLig/ml) and irradiated CD4- APC (1 x 10® 
c/ml). On days 0, 2, 4, and 6, cells were stained with CCR4 and analysed by 
flow cytometry. Cells were gated into CD4+CD25+, proliferating CD4+CD25-, 
and non-proliferating CD4+CD25- T cells using the gating method shown in 
figure 3.21. Results are shown for CD4+CD25+ T cells (a), non-proliferating 
CD4+CD25- T cells (b), and proliferating CD4+CD25- T cells (c) for n = 8 
individual donors (consisting of a mix of healthy and atopic donors). 
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Figure 3.25 CCR6 expression on allergen-activated CD4+CD25+ and 
CD4+CD25- T cells. 
CD4+CD25- and CD4+CD25+ T cells were isolated from human peripheral 
blood and cultured at a ratio of 2:1 (2x10® c/ml:1 x 10® c/ml) in the presence 
of grass pollen allergen extract (100|j,g/mi) and irradiated CD4- ARC (1 x 10® 
c/ml). On days 0, 2, 4, and 6, cells were stained with CCR6 and analysed by 
flow cytometry. Cells were gated into CD4+CD25+, proliferating CD4+CD25-, 
and non-proliferating CD4+CD25- T cells using the gating method shown in 
figure 3.21. Results are shown for CD4+CD25+ T cells (a), non-proliferating 
CD4+CD25- T cells (b), and proliferating CD4+CD25- T cells (c) for n = 8 
individual donors (consisting of a mix of healthy and atopic donors). 
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Figure 3.26 CCR7 expression on allergen-activated CD4+CD25+ and 
CD4+CD25- T cells. 
CD4+CD25- and CD4+CD25+ T cells were Isolated from human peripheral 
blood and cultured at a ratio of 2:1 (2 x 10® c/ml:1 x 10® c/ml) in the presence 
of grass pollen allergen extract (lOO^ig/ml) and irradiated CD4- APC (1 x 10® 
c/ml). On days 0, 2, 4, and 6, cells were stained with CCR7 and analysed by 
flow cytometry. Cells were gated into CD4+CD25+, proliferating CD4+CD25-, 
and non-proliferating CD4+CD25- T cells using the gating method shown in 
figure 3.21. Results are shown for CD4+CD25+ T cells (a), non-proliferating 
CD4+CD25- T cells (b), and proliferating CD4+CD25- T cells (c) for n = 8 
individual donors (consisting of a mix of healthy and atopic donors). 
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3.5.6 Expression of CXCR4 on allergen-activated CD4+CD25+ and 
CD4+CD25- T cells. 
In the allergen-driven cell culture system used, both CD4+CD25+ and 
non-proliferating CD4+CD25- T cells increased CXCR4 expression over the 
time-course studied. Up-regulation of CXCR4 occurred as early as day 2, 
followed by a gradual decrease on days 4 and 6 (Figure 3.27 A + B). In 
contrast, CXCR4 expression on proliferating CD4+CD25- T cells remained 
low or absent, similar to unstimulated CD4+CD25- T cells (Figure 3.27 C). 
3.5.7 Co-culture of CD4+CD25- T cells with CD4+CD25+ regulatory cells 
does not effect the modulation of chemokine receptor expression on 
CD4+CD25- cells. 
To examine the effect that regulatory T cells may have on the 
chemokine receptor expression of allergen-stimulated CD4+CD25- T cells, 
CD4+CD25- cells were cultured alone in the presence of CD4- APC or in the 
presence of CD4+CD25+ regulatory cells at a 2:1 ratio prior to measuring the 
expression of chemokine receptors on day 2, 4 and 6 of cell culture. Figure 
3.28-3.30 show that the presence of regulatory T cells in the culture do not 
effect the modulation of chemokine receptor expression compared to 
CD4+CD25- T cells cultured alone. This was true for both proliferating and 
non-proliferating CD4+CD25- T cells. As mentioned earlier, CCR4 expression 
decreased on non-proliferating CD4+CD25- T cells cultured in the presence of 
regulatory T cells. Figure 2.28 shows that culture in the absence or presence 
of regulatory T cells resulted in an identical modulation of CCR4 expression 
on CD4+CD25- T cells - decreased expression on non-proliferating cells and 
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no significant changes in expression on proliferating cells. Similarly, figures 
3.29 and 3.30 show culture in the absence or presence of regulatory T cells 
resulted in an identical modulation of CCR7 and CXCR4 expression on 
CD4+CD25- T cells respectively. Under both culture conditions non-
proliferating CD4+CD25- cells showed no modulation of CCR7 expression 
(figure 3.29) and increased CXCR4 expression (figure 3.30), and proliferating 
CD4+CD25- cells decreased CCR7 expression (figure 3.29) and showed no 
significant modulation in CXCR4 expression (figure 3.30). Statistical analysis 
of expression levels of each receptor on non-proliferating and proliferating 
CD4+CD25- cells in the presence and absence of regulatory T cells showed 
no significant differences in expression levels, as shown in figures 3.28-3.30. 
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Figure 3.27 CXCR4 expression on allergen-activated CD4+CD25+ and 
CD4+CD25- T cells. 
CD4+CD25- and CD4+CD25+ T cells were isolated from human peripheral 
blood and cultured at a ratio of 2:1 (2x10® c/ml:1 x 10® c/ml) in the presence 
of grass pollen allergen extract (100|a.g/ml) and irradiated CD4- ARC (1 x 10® 
c/ml). On days 0, 2, 4, and 6, cells were stained with CXCR4 and analysed by 
flow cytometry. Cells were gated into CD4+CD25+, proliferating CD4+CD25-, 
and non-proliferating CD4+CD25- T cells using the gating method shown in 
figure 3.21. Results are shown for CD4+CD25+ T cells (a), non-proliferating 
CD4+CD25- T cells (b), and proliferating CD4+CD25- T cells (c) for n = 8 
individual donors (consisting of a mix of healthy and atopic donors). 
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Figure 3 .28 Co-culture of C D 4 + C D 2 5 - T cells with CD4-hCD25+ regulatory 
cells does not effect the modulation of C C R 4 expression 
CD4+CD25- and CD4+CD25+ T cells were isolated from human peripheral 
blood and cultured at a ratio of 2:1 (2x10® c/ml;1 x 10® c/ml) in the presence 
of grass pollen allergen extract (100pig/ml) and irradiated CD4- APC (1 x 10® 
c/ml). In addition, CD4+CD25- cells were cultured under the same conditions 
in the absence of CD4+CD25+ T cells. On days 0, 2, 4, and 6, cells were 
stained with CCR4 and analysed by flow cytometry. Cells were gated into 
proliferating CD4+CD25- and non-proliferating CD4+CD25- T cells using the 
gating method shown in figure 3.21. Results are shown for non-proliferating 
CD4+CD25- T cells (A), and proliferating CD4+CD25- T cells (B) for n = 8 
individual donors (consisting of a mix of healthy and atopic donors). NS = not 
significant using a Wilcoxon matched pairs test. 
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Figure 3.29 Co-culture of CD4+CD25- T cells with CD4+CD25+ regulatory 
cells does not effect the modulation of CCR7 expression 
CD4+CD25- and CD4+CD25+ T cells were Isolated from human peripheral 
blood and cultured at a ratio of 2:1 (2x10® c/ml:1 x 10® c/ml) in the presence 
of grass pollen allergen extract (100|ig/ml) and irradiated CD4- APC (1 x 10® 
c/ml). In addition, CD4+CD25- cells were cultured under the same conditions 
in the absence of CD4+CD25+ T cells. On days 0, 2, 4, and 6, cells were 
stained with CCR7 and analysed by flow cytometry. Cells were gated into 
proliferating CD4+CD25- and non-proliferating CD4+CD25- T cells using the 
gating method shown in figure 3.21. Results are shown for non-proliferating 
CD4+CD25- T cells (A), and proliferating CD4+CD25- T cells (B) for n = 8 
individual donors (consisting of a mix of healthy and atopic donors). NS = not 
significant using a Wllcoxon matched pairs test. 
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Figure 3.30 Co-culture of CD4+CD25- T cells with CD4+CD25+ regulatory 
cells does not effect the modulation of CXCR4 expression 
CD4+CD25- and CD4+CD25+ T cells were isolated from human peripheral 
blood and cultured at a ratio of 2:1 (2x10® c/ml:1 x 10® c/ml) in the presence 
of grass pollen allergen extract (lOOjug/ml) and irradiated CD4- APC (1 x 10® 
c/ml). In addition, CD4+CD25- cells were cultured under the same conditions 
in the absence of CD4+CD25+ T cells. On days 0, 2, 4, and 6, cells were 
stained with CXCR4 and analysed by flow cytometry. Cells were gated into 
proliferating CD4+CD25- and non-proliferating CD4+CD25- T cells using the 
gating method shown in figure 3.21. Results are shown for non-proliferating 
CD4+CD25- T cells (A), and proliferating CD4+CD25- T cells (B) for n = 8 
individual donors (consisting of a mix of healthy and atopic donors). NS = not 
significant using a Wilcoxon matched pairs test. 
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3.6 Discussion 
The results outlined in this chapter confirm the preferential expression 
of CCR4, CCR6 and CCR8 and responsiveness to their corresponding ligands 
by human peripheral blood CD4+CD25+ T cells. In addition CD4+CD25+ T 
cells were found to exhibit lower CCR7 expression as well as a decreased 
responsiveness to CCL21/SLC when compared to the CD4+CD25- T cell 
subset. In response to allergen stimulation CD4+CD25+ T cells down-
regulated CCR4 expression and increased CCR7 and CXCR4 expression. In 
contrast, CD4+CD25- effector T cells up-regulated CCR4 and down-regulated 
expression of CCR7. These changes in chemokine receptor expression on 
CD4+CD25- cells in response to allergen stimulation was true for CD4+CD25-
cells cultured both in the presence and absence of CD4+CD25+ regulatory T 
cells, indicating that the presence of regulatory T cells does not effect the 
modulation of chemokine receptor expression on CD4+CD25- T cells. It was 
interesting to speculate prior to undertaking this study that the presence of 
CD4+CD25+ regulatory T cells may effect the modulation of chemokine 
receptor expression on allergen-activated CD4+CD25- T cells, either as a 
consequence of or as another mode of action of these cells. However, the 
results presented here do not support this hypothesis. 
In the experiments presented in this chapter it was confirmed that the 
CD4+CD25+ population analysed contained suppressive T cells. However, 
allergen reactive regulatory T cells could not be sub-selected and whether all 
CD4+CD25+ T cells analysed were of a regulatory phenotype was unknown. 
Based on current knowledge, CD4+CD25+ regulatory T cells are proposed to 
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reside within the CD4+CD25^'^^ population and also be both FoxP3+ and 
CD27- (Liu et al., 2006). Therefore, CD4+CD25'^'^^ T cells were initially 
confirmed to have the FoxP3+CD27- phentype and subsequent chemokine 
receptor expression and chemokine responsiveness was analysed on these 
CD4+CD25'^'^'^ T cells. Despite being unable to confirm if all CD4+CD25+ T 
cells analysed were of a regulatory phenotype, the finding of similar 
chemokine receptor profiles for CD4+CD25'^'^^FoxP3+CD27- T cells supports 
the relevance of these findings for regulatory T cell trafficking. 
It is important to highlight the problem encountered in this project using 
directly conjugated monoclonal antibodies. All antibodies used in this study 
were purchased from R&D systems. The CCR8 monclonal antibody used did 
not stain peripheral blood T cells to any significant degree and also did not 
stain a CCR8-transfected cell line. In addition to the chemokine receptors 
outlined in this chapter, CXCR3 expression was also measured on 
CD4+CD25+ and CD4+CD25- T cells. This monoclonal antibody gave varying 
results in the study and after completion of the study we were informed by 
R&D systems of problems with that particular batch of CXCR3 monoclonal 
antibody. Therefor, results using this CXCR3 antibody have been excluded 
from this presentation. In addition it has been reported that different clones of 
directly conjugated monoclonal antibodies may stain different cells to varying 
degrees, highlighting the problem in using them in a flow cytometry study such 
as the one outlined in this chapter (Kivisakk et al., 2003). 
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Another important condideration to note is the implication of not 
separating CD45RA+ versus CD45RO+ T cells when comparing chemokine 
receptor expression on CD4+CD25- and CD4+CD25+ T cells. CD4+CD25+ 
regulatory T cells have previously been hown to be predominantly CD45RO+, 
while the CD4+CD25- T cells used in this study would consist of a similar 
number of CD45RA+ and CD45RO+ cells (Taams et al., 2001). Therefor the 
CD4+CD25+ regulatory T cells used in this study would contain a significantly 
higher proportion of CD45RO+ cells. Naive CD45RA+ and memory CD45RO+ 
T cells have previously been shown to differentially express a number of 
chemokine receptors. While most naive CD45RA+ T cells express CCR7, 
expression of CCR7 divides CD45RO+ T cells into two distinct memory T cell 
populations - central memory T cells (CD45RO+CCR7+) and effector memory 
T cells (CD45RO+CCR7-) (Sallusto et al., 1999). Naive CD45RA+ T cells 
express high levels of CXCR4 (approximately 95%), while central memory 
and effector memory T cells express CXCR4 to a lower degree (22% and 11 % 
respectively) (Sallusto et al., 1999). Central memory and effector memory T 
cells also showed higher expression of CCR4 (18% and 6%), CCR5 (2% and 
52%), CCR6 (40% and 45%) and CXCR3 (34% and 61%) compared to naive 
CD45RA+ T cells (Sallusto et al., 1999). Therefor, due to the lack of 
separating both the CD4+CD25+ and CD4+CD25- T cell populations used in 
this study based on CD45RA/CD45RO expression, may have skewed the 
resulting differences seen in chemokine receptor expression on the two T cell 
subsets. 
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A possible explanation for our group's previous finding of deficient 
regulatory activity of CD4+CD25+ regulatory T cells from atopic donors in 
allergen stimulated cultures when compared to cells from non-atopic donors 
would be a difference in chemokine receptor expression. A different 
chemokine receptor expression profile on regulatory T cells in atopic 
individuals may affect T cell-APC or T cell-T cell interactions and contribute to 
the deficient regulatory activity of CD4+CD25+ T cells isolated from atopic 
individuals. CCR5 was found to be the only chemokine receptor studied that 
was differentially expressed on CD4+CD25+ T cells from these two groups. 
CCR5 expression on CD4+CD25+ T cells was significantly higher when 
compared to CD4+CD25- T cells in atopic patients but not in non-atopic 
patients. This finding may suggest a preferential recruitment of CD+CD25+ T 
cells in atopic individuals by professional APC and B cells acting via CCL4. 
Previously CCR5 has been implicated in chemoattraction of CD4+CD25+ 
regulatory T cells, particularly in their interactions with B cells (Bystry et al., 
2001). 
CD4+ T cell subsets isolated from atopic and non-atopic individuals 
displayed a differential responsiveness to the CCR7 ligand CCL21/SLC. For 
CD4+CD25+ and CD4+CD25'^'^^ T cells isolated from non-atopics a 
significantly decreased responsiveness was observed compared to the 
CD4+CD25- T cell subset (Figure 3.11 B). This observation was in agreement 
with the expression levels of CCR7 seen on each T cell subset - higher 
expression on CD4+CD25- compared to CD4+CD25+ T cells (Figure 3.10 B). 
Curiously, despite a similar CCR7 expression profile for CD4+CD25+ and 
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CD4+CD25- T cells isolated from atopic donors (Figure 3.10 B), no 
significantly decreased responsiveness of CD4+CD25+ and CD4+CD25'^ '^ '^  T 
cells to CCL21/SLC stimulation was observed (Figure 3.11 A). It is unclear if 
this difference is biologically significant. Upon a closer inspection of the 
responsiveness of each cell subset to CCL21/SLC, this discrepancy seems to 
arise due to an increased initial responsiveness to the chemokine by 
CD4+CD25- T cells isolated from non-atopic compared to atopic donors. A 
statistical comparison (Mann Whitney U test) of the responses of each T cell 
subset from atopic and non-atopic volunteers at the 15-second time-point 
reveals no significant difference between the responses of CD4+CD25high, 
CD4+CD25+ or CD4+CD25- T cells. Further experiments to increase the 
number of subjects in each patient group will be needed to conclude if the 
trend of an increased initial responsiveness seen for CD4+CD25- T cells 
isolated from non-atopic donors is statistically significant. 
The profile of chemokine receptor expression detected on human 
CD4+CD25+ T cells is broadly in agreement with previous reports, lellem et al 
showed preferential expression of CCR4 and CCR8 together with 
responsiveness to CCL17/TARC or CCL22/MDC and CCL1/I-309 by human 
CD4+CD25+ regulatory T cells (lellem et al., 2001). In addition, Annuziato et 
al detected CCR8 expression by human CD4+CD25+ thymocytes (Annunziato 
et al., 2002). Cell-surface staining of CCR8 on peripheral blood CD4+CD25+ 
T cells could not be detected using flow cytometry but CD4+CD25+ T cells did 
show increased mRNA expression and in vitro responsiveness to CCL1/I-309, 
which was blocked by the viral CCR8 antagonist MCI48. It is possible that 
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CCR8 expression on tlie cell surface of CD4+CD25+ T cells is too low to be 
detectable by flow cytometry with the MC148 fusion protein used in this study. 
It is also possible that CD4+CD25+ T cells may express CCR8 intracellularly 
and hence is not detectable using the methods used. Further experiments 
staining for intracellular CCR8 expression will be needed to prove or disprove 
this hypothesis; however, results on the responsiveness of CD4+CD25+ T 
cells to CCL1/1-309 suggest that this is not the case. CD4+CD25+ T cells 
isolated from human peripheral blood were capable of eliciting a response to 
CCL1/1-309 stimulation, which was blocked by prior incubation of the cells with 
the fusion protein MC148. For MC148 to have this blocking effect on CCL1/1-
309 responsiveness it must be binding to, and blocking, CCR8 expressed on 
the cell surface of CD4+CD25+ T cells. A recent publication has reported on 
the measurement of CCR8 expression on the surface of peripheral blood 
CD4+ T cells using flow cytometry methods. Using a fluorescent form of the 
CCR8 ligand CCL1, Soler et a/demonstrated preferential expression of CCR8 
on a subset of human memory CD4+ T cells (Soler et al., 2006). In addition, 
approximately 20 % of CD4+ T cells expressing CCR8 expressed the 
transcription factor F0XP3 and indeed, 60 % of CD4+FOXP3+ T cells 
expressed CCR8. In light of this recent publication, unfortunately it must be 
concluded that the method of CCR8 detection by flow cytometry used in this 
thesis is not capable of determining CCR8 expression on peripheral blood 
CD4+ T cells. 
It is of note that relative responsiveness to CCL1/1-309 was less than 
that to CCL17/TARC or CCL22/MDC in our system, in keeping with results 
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from previous reports, and it may be that CCR8 receptor expression is 
markedly less than that for CCR4. At the same time it is also important to note 
that responsiveness to CCL 1/1-309 seems to be the most specific for 
CD4+CD25+ T cells. Although the responsiveness to CCL17/TARC, 
CCL22/MDC and CCL1/1-309 was higher for CD4+CD25+ T cells compared to 
CD4+CD25- T cells, a significant response to the ligands CCL17/TARC and 
CCL22/MDC was still seen for CD4+CD25- T cells. This was not the case for 
CCL1/1-309, which showed a far more specific effect on CD4+CD25+ and 
CD4+CD25'^ '®'^  T cells with minimal responsiveness seen in the CD4+CD25- T 
cell subset. This implies that CCR8 may be the chemokine receptor that is 
most specifically expressed by CD4+CD25+ regulatory T cells compared to 
CD4+CD25- T cells (In addition, Th2 cells also display increased expression 
of CCR8). This hypothesis is further enforced by the results seen for CCR8 
and FoxP3 mRNA expression by freshly isolated and anti-CD3 stimulated 
CD4+CD25+ T cells. Freshly isolated CD4+CD25+ T cells specifically express 
both CCR8 and FoxP3 and expression of both mRNAs is increased further 
after activation. In addition both CCR8 and FoxP3 mRNA are significantly 
increased in CD4+CD25- T cells after activation, however this fold-increase is 
greater for FoxP3 suggesting that CCR8 is at least as specific, if not more 
specific, for human CD4+CD25+ regulatory T cells. 
Increased expression of CCR6 has previously been reported on 
CD4+CD25+ regulatory T cells isolated from mice (Kleinewietfeld et al., 2005), 
where it was suggested to define regulatory effector/memory-like cells within 
the CD4+CD25+ T cell subset. The results presented here extend the finding 
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of CCR6 expression on CD4+CD25+ T cells to cells isolated from human 
peripheral blood. In addition to the increased CCR6 expression seen for 
CD4+CD25+ T cells compared to CD4+CD25- T cells, the CD4+CD25+ T 
cells subset also show an increased responsiveness to its ligand CCL20/Mip-
3a. Interestingly it has previously been reported that human (S-defensin can 
act as a chemoattractant for T cells expressing CCR6 (Yang et al., 1999). 
Human (3-defensin is a cationic antimicrobial peptide primarily expressed by 
skin and mucosal surfaces, released upon microbial invasion (Stolzenberg et 
al., 1997). This observation, coupled to the observation of increased CCR6 
expression on CD4+CD25+ T cells, suggests that human (3-defensin may 
recruit regulatory T cells to cutaneous or mucosal sites of microbial invasion. 
By this method the immune system may attract regulatory T cells to prevent 
an over-zealous immune response. 
CD4+ T cell subsets isolated from atopic and non-atopic donors also 
displayed a differential responsiveness to CXCL12/SDF, a ligand for CXCR4. 
In the actin polymerisation assay used, CD4+CD25+ and CD4+CD25'^ '^ '^  T 
cells isolated from atopic donors displayed a decreased initial responsiveness 
to this chemokine. In contrast this decreased responsiveness was not 
observed for cells isolated from non-atopic individuals, which actually 
displayed an increased responsiveness at later time-points of the assay 
compared to CD4+CD25- T cells (Figure 3.19 A-B). This data suggests that 
CD4+CD25+ and CD4+CD25- T cells isolated from atopic and non-atopic 
donors may display a different response to stimulation via CXCL12/SDF. 
However, it is possible that this difference in response may be due to very 
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slight variations in CXCR4 expression on T cells isolated from different donors 
and may not be biologically significant. It is clear that even though CXCR4 
expression is typically very low (<5%) on T cells isolated from peripheral 
blood, CXCL12/SDF can still elicit a very robust response in these cells. 
Therefore one might assume that slight differences in the expression of 
CXCR4 may give rise to significant differences in responses to its ligands. 
Indeed, expression of CXCR4 was observed to vary considerably in some 
individuals from atopic and non-atopic groups (Figure 3.18 B). Unfortunately, 
due to the design of the experiment, the expression of CXCR4 on those cells 
used to measure chemokine responsiveness in the actin polymerisation assay 
is not known. It is possible that the differences in responsiveness to 
CXCL12/SDF observed for T cells isolated from atopic and non-atopic 
individuals may be accounted for by slight differences in CXCR4 expression 
by the different T cell subpopulations. As the design of the study did not 
include measuring the expression of chemokine receptors and chemokine-
responsiveness on the same cells (different donors were used in each part of 
the study) it would have been of value to perform blocking studies as part of 
the actin polymerisation assay. Blocking studies would also have confirmed 
that the response seen was specific for the chemokine and chemokine 
receptor(s) being studied. The effect of blocking the chemokine receptor on 
the cells prior to the actin polymerisation assay was investigated for CCR8 
using the fusion protein MC148 (figure 3.15). This experiment confirmed that 
the chemokine 1-309 was acting through CCR8 and suggested that the actin 
polymerisation assay used did reveal the specific responses of the chemokine 
being tested. 
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No expression of CCR1, CCR2, CXCR1, CXCR2 or CXCR6 was 
observed on either CD4+CD25+ or CD4+CD25- T cells isolated from both 
atopic and non-atopic donors. Therefore, subsequent analysis of the 
functional response of these cell sub-populations to chemokines 
corresponding to these receptors was not considered. Although the 
assumption that no functional response to these chemokines would be 
observed due to the absence of expression of these receptors is likely to be 
true, it must be noted that this cannot be ruled out conclusively. Indeed, as 
seen for CXCR4 and its ligand CCL12/SDF, despite low level of expression of 
the receptor on CD4+CD25+ and CD4+CD25- T cells, CXCL12/SDF is still 
capable of eliciting a very robust response in these cells. 
Increased expression of CCR4 by allergen-reactive T cells derived from 
the adenoids of atopic and non-atopic children has previously been described 
by members of our group (Banwell et al., 2003). Here these findings are 
extended to allergen-reactive CD4+CD25- T cells from peripheral blood of 
adults showing increased expression of CCR4 in dividing cells together with 
down-regulation of CCR7 as expected for effector T cells (Rivino et al., 2004). 
In addition, co-culture of CD4+CD25- T cells with regulatory CD4+CD25+ 
cells did not alter the modulation of chemokine receptor expression on the 
CD4+CD25- T cell population compared to CD4+CD25- T cells cultured alone. 
It can therefore be concluded that the mode of action of regulatory T cells 
does not involve altering the expression of chemokine receptors on effector T 
cells in response to allergen activation. Interestingly the CD4+CD25+ T cells 
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in allergen-stimulated cultures down-regulated CCR4 and increased 
expression of CCR7 and CXCR4. It cannot be certain what proportion of the 
CD4+CD25+ T cell population at 6 days remains from the cells added at day 
0, although previous data from the group suggests that there is relatively little 
apoptosis or cell division in this population in a 6 day MLR culture (Clare 
Notely PhD thesis, University of London). Trafficking of CXCR4+ regulatory T 
cells to bone marrow has previously been described (Zou et al., 2004): 
whether up-regulation of CXCR4 in culture reflects aging cells destined for 
apoptosis in the bone marrow or whether these cells have a regulatory 
function in the marrow remains to be established. It is possible that allergen 
reactive CD4+CD25+ regulatory T cells down regulate CCR4 and up regulate 
CCR7 in order to allow egress from the site of allergic inflammation and 
trafficking to lymphoid organs where they might suppress activation of 
allergen-responsive naive T cells. Tracking experiments in animal model 
systems will be required to further elucidate this process. 
In conclusion the experiments outlined in this chapter confirm the 
potential importance of CCR4, CCR6 and CCR8 and their ligands in trafficking 
of human CD4+CD25+ T cells and show that these may be involved in both 
recruitment and recirculation of allergen stimulated T cells. CD4+CD25+ T 
cells isolated from human peripheral blood show a different chemokine 
receptor expression profile to their CD4+CD25- T cell counterparts and both 
subsets of T cell regulate their expression of these receptors differently in 
response to allergen stimulation (Figure 3.30). 
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Figure 3.31 Chemokine receptor expression on CD4+CD25+ regulatory 
and CD4+CD25- effector T cells. 
Cartoon showing the expression of chemokine receptors on CD4+CD25+ and 
CD4+CD25- T cells freshly isolated from human peripheral blood and after 
allergen activation in vitro. Chemokine receptors in blue = high expression, 
chemokine receptors in black = low expression. 
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Chapter 4: Gene array analysis of CD4+CD25+ 
and CD4+CD25- T cells. 
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4.1 Introduction 
The publication by Sakaguchi et al of a regulatory subset of T cell 
residing in the CD4+CD25+ T cell population saw the re-emergence of 
regulatory T cells as an intense area of research (Sakaguchi et al., 1995). 
Since then much focus has concentrated on identifying better and more 
specific markers of this regulatory T cell population. The use of CD25 as a cell 
surface marker specific for regulatory T cells is impossible as this molecule is 
up-regulated on all recently activated CD4+ T cells. Indeed the lack of more 
specific markers for regulatory T cells may have hampered the 
characterisation and manipulation of this population of cells. 
The method by which CD4+CD25+ T cells exert their suppression of 
effector T cell activation and proliferation is still largely unknown, with several 
different mechanisms suggested. In addition, the pathways responsible for the 
phenotype seen for CD4+CD25+ regulatory T cells, including their lack of a 
proliferative response to TCR stimulation, remain to be described. 
Many groups have addressed these outstanding questions regarding 
CD4+CD25+ regulatory T cell biology using microarray technology, with some 
degree of success. Gavin et al published the first work on the different gene 
expression profiles of CD4+CD25+ regulatory and CD4+CD25- effector T 
cells in 2002 (Gavin et al., 2002). They analysed the gene expression profiles 
of cells isolated from normal B6 mice and reported multiple differentially 
expressed genes involved in T cell signalling, blocking of TCR and cytokine 
signalling, and inhibition of apoptosis. Some of the genes described in this 
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study that were more abundantly expressed by CD4+CD25+ T cells included 
integrin ae, OX40 (Tnfrsf4), 4-1BB (Tnfrsf9), GITR (TnfrsfS), TNFR2 
(Tnfrsfib), TGF-(3R2 and Socs2. Genes expressed more abundantly in non-
regulatory T cells included FasL, PDE3 and Lef1. 
Almost simultaneously another study using gene array analysis was 
published describing the over-expression of GITR by CD4+CD25+ T cells and 
its role in regulatory T cell function (McHugh et al., 2002). This study 
examined the differential gene expression of resting CD4+CD25+ and 
CD4+CD25- T cells and the differential gene expression, after activation. The 
study found 29 genes differentially expressed in resting cells and 77 
differentially expressed following activation, including a number of genes over-
expressed by CD4+CD25+ T cells that overlapped with the Gavin et al study 
outlined above - GITR, OX40, 4-1 BB, SOCS2 and LEF-1. In addition they 
reported increased expression of CTLA-4, GDI 03 and Galectin-1 on resting 
CD4+CD25+ cells, and decreased expression of TCR-a. Genes differentially 
expressed on activated cells included mip-1-a, mip-1-[3 and IL-10, which were 
increased in CD4+CD25+ T cells. The cell surface receptors reported in this 
study that were increased on resting CD4+CD25+ T cells were all found to be 
up regulated on both cell populations after activation and so were not found to 
be specific for regulatory T cells. However, blocking signalling through GITR 
using a polyclonal antibody to the extracellular domain of the protein was 
found to reverse suppression induced by freshly isolated CD4+CD25+ T cells. 
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The first study to report on the differential gene expression of human 
CD4+CD25+ and CD4+CD25- T cells described increased expression of 
CD150, FK506 binding protein 5, CN0T2, Leukocyte membrane antigen, 
Ubiquitinol-cytc reductase, STAT4, Fyn, Ras homologue gene, TXK tyrosine 
kinase, and MAP kinase 9 by CD4+CD25+ T cells. In contrast, decreased 
expression of the following genes was found for CD4+CD25+ T cells; cell 
division cycle 25B, signal transducing adaptor molecule, D0X1, and vJun 
(Rati et al., 2003). In a follow-up study it was reported that cell surface 
expression of CD150 was similar for CD4+CD25+ and CD4+CD25- T cells 
and increased expression was observed on both cell subpopulations after 
activation. However, when activated CD4+CD25+ T cells were sorted based 
on expression of CD150, suppressive activity was contained primarily in the 
CD 150+ fraction (Browning et al., 2004). The authors suggested that CD 150 
could be used as a marker for the identification of alloantigen-activated 
CD4+CD25+ regulatory T cells. 
In yet another comparative gene expression study it was discovered 
that LAG-3 is selectively expressed by human CD4+CD25+ T cells, although 
no cell surface protein expression could be detected (Huang et al., 2004). This 
lack of cell surface expression of LAG-3 excludes it as a cell surface marker 
for regulatory T cells. In addition, LAG-3 gene expression was up-regulated in 
activated CD4+CD25- T cells in a dose-dependent manner. 
Neuropilin 1 (NRP1) is a co-receptor to a tyrosine kinase receptor for 
both vascular endothelial growth factor (VEGF) semaphorin family members 
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and plays versatile roles in angiogenesis, axon guidance, cell survival, 
migration, and invasion. Using comparative gene array experiments, Bruder et 
al discovered that NRP1 gene expression is increased in CD4+CD25+ T cells 
(Bruder et a!., 2004). Interestingly, NRP1 is constitutively expressed on the 
cell surface of CD4+CD25+ T cells, while in contrast; expression is down-
regulated on activated CD4+CD25- T cells. The authors also report that 
CD4+NRP1'^ '^ '^  T cells express high levels of FoxP3 and are potent 
suppressers of CD4+CD25- T cell proliferation. 
Comparative gene expression studies using microarrays have also 
been used previously to investigate the mechanisms by which CD4+CD25+ 
regulatory T cells respond to IL-2 signals. It had been shown that despite the 
expression of the high-affinity IL-2 receptor on CD4+CD25+ T cells, they failed 
to proliferate upon IL-2 stimulation in contrast to their CD4+CD25- T cell 
counterparts (Thornton and Shevach, 1998). IL-2 signalling in activated T cells 
results in the activation of multiple signalling pathways downstream of the IL-2 
receptor but the activation of these pathways in CD4+CD25+ T cells in 
response to IL-2 signalling was unknown. Bensinger et al addressed this 
question using techniques including cDNA microarray analysis (Bensinger et 
al., 2004) and found that CD4+CD25+ regulatory T cells displayed a distinct 
IL-2 receptor signalling pattern. They reported that IL-2 receptor signalling 
altered transcription of fewer genes in CD4+CD25+ T cells when compared 
with primed CD4+ T cells. Specifically they found that CD4+CD25+ T cells 
regulated 71 genes in response to IL-2 stimulation in contrast to 120 genes 
regulated in primed CD4+ T cells. The authors went on to conclude that the 
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JAK/STAT5 signalling pathway was intact in CD4+CD25+ T cells and was 
sufficient to promote cellular survival in response to IL-2 stimulation. In 
contrast, they demonstrated the inability of IL-2 to stimulate signalling 
pathways downstream of PI3K and that this coincided with high expression of 
the lipid phosphatase PTEN in CD4+CD25+ T cells. 
The published experiments outlined above show that comparative gene 
expression studies using DNA microarrays have proved to be a useful tool in 
determining regulatory T cell biology. However, many more aspects of 
regulatory T cell function still need to be addressed, including the identification 
of specific cell surface markers to enable the isolation and manipulation of this 
subset of T cell. 
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4.2 Aims of study 
The aims of this study were to use comparative gene array technology 
to identify genes differentially expressed by CD4+CD25+ regulatory T cells 
and their CD4+CD25- non-regulatory T cell counterparts. It was hoped that 
this might lead to the discovery of cell surface markers specific for 
CD4+CD25+ regulatory T cells. In addition, it was the goal of these 
experiments to Identify genes expressed by CD4+CD25+ regulatory T cells 
that may play a role In the function and phenotype of this Important T cell 
population. 
The experimental method employed In the experiments described in 
this chapter involved the initial identification of differentially expressed genes 
between CD4+CD25+ and CD4+CD25- T cells Isolated from human 
peripheral blood. Identified gene targets were subsequently confirmed or 
dismissed using Taqman RT-PCR analysis and flow cytometry. 
4.3 Experimental design 
CD4+CD25+ and CD4+CD25- T cells were isolated from human 
peripheral blood of three different donors and the suppressive activity of 
CD4+CD25+ T cells was confirmed using a cell proliferation assay. 
CD4+CD25+ and CD4+CD25- T cells were also Incubated with plate-bound 
anti-CD3 for 4 hours or 24 hours prior to mRNA extraction. Extracted mRNA 
was then used to create probes to hybridise to DNA microarrays to compare 
gene expression between these two T cell subpopulations, resulting in a list of 
differentially expressed genes. This experiment was repeated using mRNA 
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isolated from three further donors resulting in a second list of differentially 
expressed genes. Genes appearing in both generated lists were then 
considered for confirmation experiments using Taqman PGR. Six genes were 
chosen for this validation step and their expression in mRNA isolated from a 
further six individuals was investigated. The microarray study was performed 
as collaboration with researchers at Lorantis Ltd to avail of their custom 
microarrays and experience in conducting microarray investigations. The 
experiment including RNA isolations, microarray hybridisations and microarray 
scanning was performed by myself at Lorantis Ltd. However the analysis of 
the microarrays and the generation of lists of differentially expressed genes 
was performed by researchers at Lorantis Ltd. 
The results of this experiment are presented and discussed below in 
two parts. Firstly, the results of the duplicate microarray experiments are 
presented and the resulting lists of differentially expressed genes are 
discussed. Secondly, the results of RT-PCR experiments on six differentially 
expressed genes as seen in the microarray experiments are presented and 
discussed. 
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4.4 Results: DNA microarray analysis of CD4+CD25+ and 
CD4+CD25- T cells. 
4.4.1 Isolation of CD4+CD25+ and CD4+CD25- T cells from human 
peripheral blood by magnetic beads and FACS cell sorting. 
CD4+CD25+ and CD4+CD25- T cells were isolated from human 
peripheral blood using two methods - immuno-magnetic bead separation and 
FACS cell sorting. For both methods, PBMCs were first isolated from human 
peripheral blood by density gradient centrifugation. CD4+ T cells were then 
isolated by negative selection using immuno-magnetic beads. CD4+CD25+ 
and CD4+CD25- T cells were isolated from CD4+ T cells by a further immuno-
magnetic bead isolation step or by FACS cell sorting. While the purity of 
CD4+CD25+ T cells isolated using immuno-magnetic beads is generally 
within the range of 75-85 %, cells isolated using FACS cell sorting are 
consistently higher purity, no less than 98 %. 
To optomize the purity of the cells used for the subsequent microarray 
study it was decided to use FACS cell sorting to isolate CD4+CD25+ and 
CD4+CD25- T cells. However, CD4+CD25+ T cells isolated by this method 
lost their ability to suppress the proliferation of CD4+CD25- T cells and also 
lost their 'anergic' phenotype, proliferating to the same extent as their 
CD4+CD25- T cell counterparts (figure 4.1 A). To discount that this effect may 
have been dependant on the CD25 antibody used (BD Biosciences, clone M-
A251), further T cell isolations were performed using a different monoclonal 
antibody to CD25 (Immunotech, clone 7D4). Again, the CD4+CD25+ T cells 
isolated failed to suppress the proliferation of CD4+CD25- T cells when co-
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cultured, and proliferated to the same extent as their CD4+CD25- T cell 
counterparts when cultured alone (figure 4.1 B). 
This effect was consistently seen despite precautions to limit 
contamination of the cells during sorting including autoclaving all removable 
tubing and buffer tanks prior to the procedure. Isolated cells were also washed 
extensively after isolation. To determine if the effect was due to contamination 
of the cells as they passed through the cell sorter, a number of parallel 
isolations using MACS immuno-magnetic beads and cell sorting were 
performed (figure 4.2). CD4+ T cells were split into two fractions. CD4+CD25+ 
and CD4+CD25- T cells were isolated from one fraction using cell sorting and 
from the other using CD25 immuno-magnetic beads. As a further control 
some cells isolated by immuno-magnetic beads were then passed through the 
cell sorter and collected without any further staining or manipulation. 
CD4+CD25+ T cells isolated by immuno-magnetic beads were capable of 
suppressing the proliferation of their CD4+CD25- T cell counterparts when co-
cultured (figure 4.2: black bars), while as before CD4+CD25+ T cells isolated 
by FACS cell sorting lost this ability (figure 4.2: green bars). CD4+CD25+ T 
cells that had been isolated by immuno-magnetic beads and then passed 
through the cell sorter also lost their ability to suppress their CD4+CD25- T 
cell counterparts (red bars). Mixing experiments of the populations isolated in 
different ways showed that CD4+CD25+ T cells that had been separated by 
MACS immuno-magnetic beads retained their suppressive ability on 
CD4+CD25- T cells isolated by cell sorting (blue bars). Conversley, 
CD4+CD25+ T cells isolated by MACS immuno-magnetic beads and then 
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passed through the cell sorter lost their suppressive ability on CD4+CD25- T 
cells isolated by cell sorting (yellow bars). These experiments confirmed that 
contamination or activation of the CD4+CD25+ T cells as they passed through 
the cell sorter subsequently abrogated their suppressive ability in co-culture 
with CD4+CD25- T cells. As this resulting alteration in CD4+CD25+ T cell 
phenotype was highly likely to be coupled to changes in gene expression in 
these cells it was decided to continue the microarray study using cells isolated 
by MACS immuno-magnetic beads. 
4.4.2 Isolation of CD4+CD25+ and CD4+CD25- T cells from human 
peripheral blood by magnetic beads for use in DNA microarray analysis. 
CD4+CD25+ and CD4+CD25- T cells were isolated from human 
peripheral blood by magnetic bead separation and the purity of each isolated 
cell subset (in relation to CD25 expression) was examined using FACS 
analysis. The clinical details of the donors used in this study and the purity of 
the isolated cells are outlined in Table 4.1. The purity of CD4+CD25+ T cells 
was in the range 12.8 - 78 % with a median value of 52.9 % and of 
CD4+CP25- T cells in the range 0.9 - 16.2 % with a median value of 6.6 %. 
Of note, for two donors (donors 1 and 6) the purity of isolated CD4+CD25+ T 
cells was substantially lower than that of the remaining donors (<25 %). This 
is likely due to performance issues with the flow cytometer on the particular 
days of these experiments. However, the contamination of CD25-expressing 
cells within the CD4+CD25- T cell populations of these donors is also 
substantially lower than the remaining individuals implying that a massive 
enrichment of CD4+CD25+ T cells was achieved during these two 
experiments. The suppressive ability of the isolated CD4+CD25+ T cell 
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population was confirmed using a cell proliferation assay. Triplicate wells of 
PBMC, CD4+CD25+ and CD4+CD25- T cells were cultured for 72 hours using 
plate-bound anti-CD3 as a stimulus. Irradiated PBMC were added to each well 
to act as ARC. In addition, CD4+CD25- cells were co-cultured with 
CD4+CD25+ T cells. Proliferation of CD4+CD25+ T cells alone was 
significantly less than that seen for CD4+CD25- T cells alone, confirming the 
anergic phenotype of isolated CD4+CD25+ T cells to TCR stimulation. In co-
culture experiments, CD4+CD25+ T cells inhibited the proliferation of 
CD4+CD25- T cells, confirming the suppressive ability of CD4+CD25+ T cells 
isolated in these experiments (Figure 4.3). 
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Donor Gender Age 
CD25+ 
Purity 
{%CD25+) 
CD25-
Purity 
(%CD25+) 
CD25+ 
Tcell 
number 
(xlO®) 
CD25-
Tcell 
number 
{x10®) 
RNA 
pooled 
4 
hours 
RNA 
pooled 
24 
hours 
Microarray experiment 1 
1 F 27 12.8 0.9 2.9 94.6 Yes -
2 F 25 43.9 8.2 2.6 95.4 Yes -
3 M 26 73.9 12.0 3.4 64.4 Yes -
4 F 31 77.0 16.2 5.0 145 - Yes 
5 F 32 66.4 9.2 6.5 117 - Yes 
6 M 32 25.0 1.8 3.4 64.4 - Yes 
Microarray experiment 2 
7 F 24 55.1 3.6 2.9 44.0 Yes Yes 
8 F 29 44.3 1.9 1.7 61.9 Yes Yes 
9 M 42 78.0 6.4 1.9 38.7 Yes Yes 
Summary 
6 = F 
3 = M 
30 
(25-
42) 
52.9 
(12.8-78) 
6.6 
(0.9-16.2) 
3.3 
(1.7-
6.5) 
80.6 
(38.7-
145) 
- -
Table 4.1 Clinical details of donors and purity of isolated cells used for 
DNA microarray analysis. 
CD4+CD25+ and CD4+CD25- T cells were Isolated from 150 ml of human 
peripheral blood by immuno-magnetic bead separation. The purity of the 
isolated T cell populations was analysed by flow cytometry. CD4+CD25+ and 
CD4+CD25- T cells were cultured at 0.4 x 10 c/ml in the presence of 
autologous irradiated PBMC as APC at a concentration of 0.4 x 10® c/ml. Cells 
were stimulated with plate-bound anti-CD3 at 10 p,g/ml for either 4 or 24 
hours. After culture RNA was isolated from the cells and RNA from three 
individual donors was pooled, as outlined, to create the probes for subsequent 
microarray analysis. Two individual microarray experiments were performed. 
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A) Cell sorting using BD monoclonal anti-CD25 antibody 
1500001 
100000-
Q. 
o 
50000-
X 
B) Cell sorting using Immunotech monoclonal anti-CD25 antibody 
1 5 0 0 0 0 1 
100000-
Q. 
o 
50000-
Figure 4.1 CD4+CD25+ T cells isolated by cell sorting lose their 
suppressive effects on the proliferation of CD4+CD25- T cells. 
Proliferation, measured by tritiated thymidine incorporation, of PBMCs, 
CD4+CD25+ and CD4+CD25- cells after polyclonal stimulation with plate-
bound anti-CD3 (10 i-ig/ml). Addition of CD4+CD25+ cells to CD4+CD25-
cells was at a ratio of 1:2 (labelled CD25+/-). A cell number control of 
CD4+CD25- cells only was included (labelled CD25-/-). Cells were cultured at 
0.4 X 10^ c/ml (0.6 x 10® c/ml in CD25+/- and CD25-/- wells) for 3 days. All 
wells contained irradiated autologous PBMCs. Data from one representative 
experiment of six for each monoclonal antibody. 
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Figure 4.2 Loss of CD4+CD25+ T cell suppressive function after cell 
sorting is due to contamination or activation during isolation. 
Proliferation, measured by tritiated thymidine incorporation, of PBMCs, 
CD4+CD25+ and CD4+CD25- cells after polyclonal stimulation with plate-
bound anti-CD3 (10 |ig/ml). Addition of CD4+CD25+ cells to CD4+CD25-
cells was at a ratio of 1:2 (labelled CD25+/-). A cell number control of 
CD4+CD25- cells only was included (labelled CD25-/-). Cells were cultured at 
0.4 X 10® c/ml (0.6 x 10® c/ml in CD25+/- and CD25-/- wells) for 3 days. All 
wells contained irradiated autologous PBMCs. CD4+CD25+ and CD4+CD25-
T cells were isolated using MACS immuno-magnetic beads (black bars) or 
FACS cell sorting (green bars). Some cells isolated by irnmuno-rTiagnetic 
beads were subsequently passed through the cell sorter prior to the assay 
(red bars). Mixing experiments were also performed using CD4+CD25+ T 
cells isolated by immuno-magnetic beads and subsequently passed through 
the cell sorter and CD4+CD25- cells isolated by cell sorting (yellow bars). In 
addition mixing experiments were performed using CD4+CD25+ T cells 
isolated by immuno-magnetic beads and CD4+CD25- cells isolated by cell 
sorting. Data from one representative experiment of three. 
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Figure 4.3 Suppression of proliferation of anti-CD3 activated CD4+CD25-
T cells by human CD4+CD25+ regulatory T cells. 
Proliferation, measured by tritiated tliymidine incorporation, of PBIVICs, 
CD4+CD25+ and CD4+CD25- cells after polyclonal stimulation with plate-
bound anti-CD3 (10 ^g/ml). Addition of CD4+CD25+ cells to CD4+CD25-
cells was at a ratio of 1:2 (labelled CD25+/-). A cell number control of 
CD4+CD25- cells only was included (labelled CD25-/-). Cells were cultured at 
0.4 X 10® c/ml (0.6 x 10® c/ml in CD25+/- and CD25-/- wells) for 3 days. All 
wells contained irradiated autologous PBIVICs. Means + SE of triplicate values 
are shown for all donors used in the gene array study (n = 9). ** denotes p = 
0.0039. 
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4.4.3 Genes differentially expressed between CD4+CD25+ and 
CD4+CD25- T cells. 
In addition to culturing CD4+CD25+ and CD4+CD25- T cells to 
measure cell proliferation, both subsets of T cell were also cultured under the 
same conditions for four and twenty-four hours. After this cell culture period, 
the cells were removed from culture and the mRNA was isolated from both T 
cell subsets. Due to the small quantities of mRNA isolated from each cell 
sample from individual donors, it was decided to pool the mRNA from three 
different donors prior to amplification. Therefore, CD4+CD25+ and 
CD4+CD25- mRNA from donors 1, 2, and 3 was pooled to create the four 
hour timepoint samples. Similarly, mRNA isolated from donors 4, 5, and 6 was 
pooled to create the twenty-four hour timepoint samples (Table 4.1). The 
pooled mRNA samples were created using equal amounts of mRNA from 
each individual donor. These pooled mRNA samples were then used to create 
probes for the first microarray experiment. Subsequently, for the second, 
duplicate experiment, it was decided to again pool mRNA from three different 
donors prior to amplification - donors 7, 8 and 9. In the only difference from 
the first microarray experiment, mRNA from the same donors was used to 
create the probes for both the four and twenty-four hour timepoints. 
Results of the first microarray experiment performed revealed the up-
regulation of nineteen genes in CD4+CD25+ T cells compared to CD4+CD25-
T cells and the down-regulation of eighty-two genes at the four-hour activation 
timepoint. The comparison between CD4+CD25+ and CD4+CD25- T cells at 
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the twenty-four hour activation timepoint revealed twenty-three genes up-
regulated in CD4+CD25+ T cells and twenty-four genes down-regulated. 
In the second, duplicate array, a total of eleven genes were identified 
as being up-regulated in CD4+CD25+ T cells compared to CD4+CD25- T 
cells at the four-hour activation timepoint (Table 4.2). In addition, eleven 
genes were identified as being down-regulated in CD4+CD25+ T cells at this 
timepoint (Table 4.3). The comparison between CD4+CD25+ and 
CD4+CD25- T cells at the twenty-four hour timepoint revealed twenty-two 
genes upregulated in the CD4+CD25+ T cell subset (Table 4.4) and a total of 
thirty-nine genes down-regulated (Table 4.5). The normalised ratio (NR) for 
each differentially expressed gene in the second array is shown in tables 4.2-
4.5. 
Comparing the lists of differentially expressed genes from the duplicate 
arrays revealed a number of genes up-regulated or down-regulated in both 
microarray experiments. These genes are boxed and highlighted in bold, italic 
font in tables 4.2-4.5. At the four-hour timepoint, one gene, CCL20, was up-
regulated in CD4+CD25+ T cells in both microarrays. The genes TYRO and 
Tetraspan 5, and the ESTs N39053 and AA493249 were found to be down-
regulated in CD4+CD25+ T cells in both arrays. At the twenty-four hour 
timepoint, four genes (CD25, TNFRSFIb, ELK4 and Transcription Factor 3), 
and one hypothetical protein (MGC27165) were found to be up-regulated in 
CD4+CD25+ T cells. The gene CyclinD3 was the only one identified as being 
2 3 7 
down-regulated in CD4+CD25+ T cells in the duplicate arrays at the twenty-
four hour timepoint. 
Code Array ID Name 
NR 
array 2 
IFIT1 42 Interferon-induced protein with tetratricopeptide repeats 1 2.66 
CUGBP1 7450 CUG triplet repeat, RNA binding protein 1 2.60 
CCL20 10125 Chemokine (C-C motif) ligand 20 2.35 
VIL2 9751 Viliin 2 (ezrin) 2.03 
IFI16 6611 Interferon, gamma-inducible protein 16 2.16 
IL2RA 10135 Interleukin 2 receptor, alpha 2.34 
SAR1 2769 SAR1 protein 2.07 
PABPC1 2525 Poly(A) binding protein, cytoplasmic 1 2.13 
ADH7 8833 
Alcohol dehydrogenase 7 (class IV), mu or sigma 
polypeptide 
2.20 
N/A 6466 Homo sapiens cDNA clone IMAGE: 113019 2.66 
N/A 9793 Homo sapiens cDNA clone IMAGE: 1677030 2.01 
Table 4.2 Genes up-regulated in CD4+CD25+ T cells at 4 hour timepoint. 
Code Array ID Name 
NR 
array 2 
ZNF265 5019 Zinc finger protein 265 0.38 
TYROBP 4782 TYRO protein tyrosine kinase binding protein 0.41 
IFI30 9849 Interferon, gamma-inducible protein 30 0.49 
IGKC 9455 Immunoglobulin kappa constant 0.43 
IGKC 6782 Immunoglobulin kappa constant 0.38 
LLGL1 5012 Lethal giant larvae homolog 1 (Drosophila) 0.47 
HBB 6654 Hemeglobin, beta 0.28 
TM4SF9 7659 Tetraspan 5 0.42 
N/A 4604 EST (ilVIAGE: 243507) 0.244 
N/A 4643 Homo sapiens cDNA clone IMAGE: 1651906 0.46 
N/A 6579 EST (IlVIAGE: 956217) 0.45 
Table 4.3 Genes down-regulated in CD4+CD25+ T cells at the 4-hour 
timepoint. 
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Code 
Array 
ID 
Name 
NR 
Array 
2 
SNRP70 5323 
small nuclear ribonucleoprotein 70kDa polypeptide (RNP 
antigen) 0.76 
1GLL1 2742 immunoglobulin lambda-like polypeptide 1 3.18 
TCF3 3765 
transcription factor 3 (E2A immunoglobulin enhancer 
binding factors E12JE47) 4.04 
IGHM 8729 immunoglobulin heavy constant mu 2.49 
QSCN6 3532 quiescin Q6 2.00 
MMP7 1779 matrix metalloproteinase 7 (matrilysin, uterine) 2.14 
FCER1G 5710 
Fc fragment of IgE, high affinity 1, receptor for; gamma 
polypeptide 
2.37 
IGHG3 7595 immunoglobulin heavy constant gamma 3 (G3m marker) 6.55 
CXCL3 6898 chemokine (C-X-C motif) ligand 3 3.58 
CXCL1 2119 
chemokine (C-X-C motif) ligand 1 (melanoma growth 
stimulating activity, alpha) 4.20 
ANXA5 2011 annexin A5 2.55 
CSTB 3879 cystatin B (stefin B) 2.18 
HLA-DRB1 5707 major histocompatibility complex, class II, DR beta 1 2.36 
IGL@ 8022 immunoglobulin lambda locus 8.97 
IL2RA 10135 interleukin 2 receptor, alpha 2.32 
TNFRSF1B 4524 
tumor necrosis factor receptor superfamily, member 
1B 
2.52 
PRDX1 8023 peroxiredoxin 1 3.68 
IGKC 9455 immunoglobulin kappa constant 5.60 
IGKC 6782 immunoglobulin kappa constant 6.2 
ELK4 8308 ELK4, ETS-domain protein (SRF accessory protein 1) 5.99 
N/A 9309 hypothetical protein MGC27165 6.63 
N/A 9012 Homo sapiens, clone IMAGE: 4711494 2.11 
Table 4.4 Genes up-regulated in CD4+CD25+ T cells at the 24-hour 
timepoint. 
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Code 
Array 
ID 
Name 
NR 
Array 
2 
RPA1 4177 replication protein A1, 70kDa 0.46 
CACNB2 4105 calcium channel, voltage-dependent, beta 2 subunit 0.49 
LILRB5 4178 
leukocyte immunoglobulin-like receptor, subfamily B (with 
TM and ITIM domains), member 5 0.47 
RNF11 4195 ring finger protein 11 0.46 
PIGPC1 4142 p53-induced protein PIGPC1 0.43 
SIAH1 5347 seven in absentia homoiog 1 (Drosophila) 0.49 
RFNG 9447 radical fringe homoiog (Drosophila) 0.47 
BVES 3963 blood vessel epicardial substance 0.44 
SMARCA3 2813 
SWI/SNF related, matrix associated, actin dependent 
regulator of chromatin, subfamily a, member 3 
0.48 
GJB5 5293 gap junction protein, beta 5 (connexin 31.1) 0.48 
EHD3 4143 EH-domain containing 3 0.49 
ELF3 4123 
E74-like factor 3 (ets domain transcription factor, epithelial-
specific) 0.44 
TENC1 4089 tensin like C1 domain-containing phosphatase 0.38 
CCND3 3999 cyclin D3 0.36 
ARHGEF16 9535 Rho guanine exchange factor (GEF) 16 0.44 
HIST1H3H 3981 histone 1, H3h 0.37 
TRO 4160 trophinin 0.41 
KLKB1 4071 kallikrein B, plasma (Fletcher factor) 1 0.35 
EIF2B1 4053 
eukaryotic translation initiation factor 2B, subunit 1 alpha, 
26kDa 
0.36 
DSPG3 5275 dermatan sulfate proteoglycan 3 0.46 
MAGEC 1 5257 melanoma antigen, family C, 1 0.49 
BLMH 4196 bleomycin hydrolase 0.45 
GAD1 9907 glutamate decarboxylase 1 (brain, 67kDa) 0.29 
HF1 4035 H factor 1 (complement) 0.35 
DRIM 4125 down-regulated in metastasis 0.36 
NRP1 4017 neuropilin 1 0.39 
MAP2K4 9746 mitogen-activated protein kinase kinase 4 0.36 
HSPC189 9696 HSPC189 protein 0.47 
Table 4.5 Genes down-regulated in CD4+CD25+ T cells at the 24-hour 
timepoint. 
Continued on next page. 
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Code 
Array 
ID 
Name 
NR 
Array 
2 
P0LA2 9906 polymerase (DNA-directed), alpha (70kD) 0.06 
NRXN2 8002 neurexin 2 0.27 
RPLP2 9575 ribosomal protein, large P2 0.47 
EEF1A1 9621 eukaryotic translation elongation factor 1 alpha 1 0.45 
RPLP1 9980 ribosomal protein, large, PI 0.49 
N/A 4088 Homo sapiens, clone IMAGE:5754260, mRNA 0.49 
N/A 4107 hypothetical protein BC013576 0.39 
N/A 9713 
Homo sapiens cDNA clone IMAGE:109161 3'similar to 
SP:JU0188 JU0188 BAND 4.1 SUPERFAMILY MEMBER 
PROTEIN 
0.48 
N/A 9608 
ESTs, Highly similar to S44454 transcription factor BTF2 chain 
p44 - human [H.sapiens] 0.33 
N/A 6549 hypothetical protein MGC11257 0.49 
N/A 9793. Homo sapiens cDNA clone IMAGE:1677030 0.42 
Table 4.5 (continued) Genes down-regulated in CD4+CD25+ T cells at the 
24-hour timepoint. 
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4.5 Discussion of results from cDNA microarray analysis of 
CD4+CD25+ and CD4+CD25- T cells. 
A number of genes were identified as being up-regulated or down-
regulated in the duplicate array experiments outlined above. Specifically six 
genes were found to be up-regulated and five genes were found to be down-
regulated, at one of the two timepoints, in CD4+CD25+ T cells from both 
microarray experiments. These genes will first be discussed in this section 
prior to the presentation of further results from RT-PCR confirmation 
experiments on a set of genes identified in the microarray study. 
4.5.1 Genes up-regulated in CD4+CD25+ T cells at 4 or 24 hours. 
4.5. r j CCL20 (Mip-3-a) 
The (3 chemokine CCL20 was the first to be identified using the 
approach of bioinformatics-based searches of DNA databases using amino-
acid sequences of known chemokines. Three groups working independently 
each identified and cloned the receptor from different tissue sources and 
hence the receptor was originally given three different names: liver and 
activation-regulated chemokine (LARC), macrophage inflammatory protein-3a 
(MIP-3a), and Exodus-1 (Hieshima et al., 1997; Rossi et al., 1997; Hromas et 
al., 1997). CCL20 is the only chemokine that binds to the receptor CCR6. 
CCL20 binds CCR6 only and does not elicit a response through any other 
chemokine receptor, this selectivity being an exception to the general rule of 
promiscuity of chemokines and their receptors. Again, the discovery that 
CCR6 was the receptor for CCL20 was reported by a number of independent 
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groups due to the multiple names for both the chemokine and the receptor 
(Baba et a!., 1997; Power et al., 1997; Liao et al., 1997; Greaves et al., 1997). 
Expression of CCR6 and hence responsiveness to CCL20 has been 
observed on a variety of leukocytes. Its expression has been reported on 
immature dendritic cells (DCs), which may recruit these cells to sites of 
antigen entry. CCR6 expression and CCL20 responsiveness has also been 
reported by CD45RO+ effector/memory T cells in contrast to CD45RA+ naive 
T cells (Liao et al., 1999), particularly mucosa-homing and skin-homing 
effector/memory T cells and by memory B cells (Krzysiek et al., 2000). The 
CCL20-CCR6 axis seems to play an important role in the recruitment of 
immature DCs, effector/memory T cells and B cells to sites of continuous 
allergen challenge. As the only chemokine identified as being differentially 
regulated between CD4+CD25+ and CD4+CD25- T cells, coupled with the 
observation of increased CCR6 expression on CD4+CD25+ T cells outlined in 
chapter 3, CCL20 expression was chosen for further analysis using RT-PCR. 
4.5.1.2 Transcription Factor 3 (TCF3) 
The transcription factor 3 (also known as E2A) gene encodes two 
different proteins, called E l2 and E47, that arise through differential splicing 
(Mellentin et al., 1989). E l2 and E47 are two helix-loop-helix (HLH) proteins 
that are required for the generation of functional B cells. E2A-deficient mice 
fail to generate mature B cells and this arrest in B cell development occurs at 
an early stage, prior to immunoglobulin gene rearrangement (Bain et al., 
1994; Zhuang et al., 1994). Homozygous E2A-deficient mice contain no B 
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cells, with no defect observed in other cell lineages. Interestingly, 
heterozygous E2A-deficient mice have approximately 50 % of the number of B 
cells seen in wild-type mice. 
4.5.1.3 Interleukin 2 receptor alpha (IL2RA/CD25) 
The interleukin 2 receptor is composed of three subunits, IL2Ra 
(CD25), IL2R(3 (CD122) and the common Yc chain (Cosman et a!., 1984; 
Leonard et a!., 1984; Nikaido et al., 1984; Sharon et al., 1986; Takeshita et al., 
1992a). While both the (3 and y chains are shared by other interleukin 
receptors, the a subunit is specific for the IL-2 receptor. The |3 and y chains 
form a receptor of intermediate affinity which can be converted to a high 
affinity IL-2 receptor by co-expression of the a chain (Arima et al., 1991; 
Takeshita et al., 1992b). The different subunits of the IL-2 receptor are 
differentially expressed on peripheral blood mononuclear cells (Ohashi et al., 
1989). The majority of resting CD4+ T cells do not express the alpha subunit 
of the receptor but its expression is induced by activation of the T cell 
receptor. The demonstration by Sakaguchi et al of the contribution of 
CD4+CD25+ T cells in maintaining self-tolerance has led to a recent increase 
in research into regulatory T cells (Sakaguchi et al., 1996). Approximately 10 
% of resting peripheral blood CD4+ T cells express CD25. 
4.5.1.4 Tumor necrosis factor receptor superfamily member IB 
(TNFRSF1b/TNFR2) 
TNFR2 is the larger of the two TNF-a receptors and is expressed on 
many different cell types, particularly activated T and B lymphocytes. In 
addition, TNFR2 has been shown to be the predominant TNFR on activated T 
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cells (Ware et al., 1991). Studies on TNFR2 have suggested a co-stimulatory 
role for this receptor in T cell activation and proliferation. TNF-a added 
exogenously can enhance the proliferative response of T cells activated 
through the TCR, and the proliferative response of T cells to stimulation 
through the TCR complex is inhibited in the presence of a neutralizing 
antibody to TNF-a (Pimentel-Muinos et al., 1994). In addition, agonist 
antbodies to TNFR2, but not TNFR1, can mimic this effect, implying that 
TNFR2 is the receptor responsible (Tartaglia et al., 1993). Kim et al showed 
that the proliferative response of T cells to TCR cross-linking was significantly 
reduced in T cells isolated from TNFR2-deficient mice, while T cells from 
TNFR1-deficient mice did not show this proliferative defect (Kim and Teh, 
2001). In addition, the authors showed that T cells deficient in TNFR2 required 
a five-fold greater TCR stimulation to elicite a similar proliferative response as 
seen in wild type T cells, and concluded that stimulation through TNFR2 
decreases the threshold of T cell activation. This function of TNFR2 as a 
costimulator for T cell activation was confirmed in a separate study by 
Aspalter et al using agonist antibodies specific to TNFR2 or TNFR1 (Aspalter 
etal., 2003). 
The differential gene expression of TNFR2 seen in the duplicate 
microarray experiments outlined in this chapter, coupled with the published 
role of TNFR2 as a costimulator of T cell activation, suggest that TNFR2 may 
play a role in decreasing the threshold of T cell receptor activation needed to 
activate CD4+CD25+ T cells. A recent study has also reported that addition of 
exogenous TNFa or agonistic antibody to TNFR2 can reverse the suppressive 
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activity of human CD4+CD25+ T cells in vitro by downmodulating the 
expression of F0XP3 (Valencia et al., 2006). 
4.5.1.5 ELK4, ETS domain protein (SRF accessory protein 1) 
The transcription factor ELK4 (also known as SAP-1) is a member of 
the ternary complex factor (TCP) subfamily of Ets domain proteins. The TCP 
subfamily members are recruited to their target promoters through interaction 
with a partner transcription factor, serum response factor (SRP) (Treisman, 
1994). Each TCP contains three conserved domains: an N-terminal Ets 
domain which binds DNA, a domain known as the B-box region which 
interacts with the SRP DNA binding domain, and a C-terminal domain that 
contains multiple sites for MARK phosphorylation (Hassler and Richmond, 
2001). Transcriptional activation of the TCPs is regulated by the Erk pathway, 
which has been demonstrated to be involved in thymocyte positive selection. 
Hence, Costello et al used gene targeting and T cell receptor transgenic 
approaches to characterise the function of ELK4 in thymocyte development 
(Costello et al., 2004). This study reported that ELK4-deficient mice displayed 
reduced numbers of single-positive thymocytes and peripheral T-cells. T cell 
receptor induced transcription of ELK-4 target genes, including Egr1, was 
defective in ELK-4 deficient thymocytes. The authors also reported that 
positive selection was dramatically reduced in ELK-4 deficient mice, while 
negative selection was unimpaired. This report on the requirement of ELK-4 
for thymocyte positive selection made ELK4 an interesting gene to examine 
further in CD4+CD25+ T cells. CD4+CD25+ regulatory T cells are reported to 
be positively selected in the thymus through a high-affinity recognition of self-
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peptides (Jordan et al., 2001). These data suggested that expression of ELK4 
by CD4+CD25+ T cells may contribute to their positive selection in the thymus 
and so it was decided to include ELK4 gene expression in subsequent 
confirmation experiments. 
4.5.1.6 Hypothetical protein MGC27165 
A hypothetical protein is a protein whose sequence has been predicted 
by the discovery of an open reading frame during genome analysis. However, 
no experimental evidence exists for its expression in vivo. Therefore, the 
hypothetical protein MGC27165 was not considered for inclusion in further 
experiments using RT-PCR. 
4.5.2 Genes down-regulated in CD4+CD25+ T cells at 4 or 24 hours. 
4.5.2.1 TYRO protein tyrosine l<inase binding protein (TYR0BP/DAP12) 
DNAX-activation protein 12 (DAP12) is also sometimes referred to as 
protein tyrosine kinase binding protein (TYROBP) or killer cell activating 
receptor-associated protein (KARAP). DAP12 is an immunoreceptor tyrosine-
based activation motif (ITAM)-bearing membrane adapter molecule that is 
associated with multiple cell-surface activating receptors expressed in both 
lymphoid and myeloid cells (Tomasello et al., 1998). DAP 12 expression was 
originally described for NK cells where it mediates signalling for numerous 
cell-surface receptors expressed by these cells, playing a role in NK cell 
activation (Lanier et al., 1998; Smith et al., 1998). Subsequently, DAP12 has 
been shown to associate with many other cell surface receptors, including the 
triggering-receptors expressed on myeloid cells (TREMs), expressed on 
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granulocytes, monocytes, macrophages and DCs. Recently however, a 
number of studies have highlighted an inhibitory role for DAP 12 in cellular 
activation (Hamerman et al., 2005; Hamerman et al., 2006; Turnbull et al., 
2006). 
To date, DAP 12 has been shown to associate with up to 20 different 
cell surface receptors including the activating isoforms of the killer-cell 
immunoglobulin-like receptor (KIR) family, the activating members of the 
mouse Ly49 family, the receptor complex CD94-NKG2C and TREM1, 2 and 3. 
The over-expression of DAP12 in CD4+CD25- non-regulatory T cells may 
result in its association with either activating or inhibitory receptors where it 
may potentiate or attenuate signalling. Clearly, any role that DAP 12 may play 
in CD4+ T cell activation would be dependent on what cell surface receptor 
this signalling adaptor molecule is associated with in these cells. It is 
interesting to speculate that DAP 12 may play an activating role in CD4+CD25-
non-regulatory T cell activation, and its absence in CD4+CD25+ regulatory T 
cells may result in the hypoproliferative and anergic pehenotype of this T cell 
population. 
4.5.2.2 Tetraspan 5 (TM4SF9) 
Tetraspan 5 is a member of a large family of abundantly expressed 
transmembrane proteins that consist of four transmembrane domains and 
several conserved amino acids. Their function is not known but it is thought 
that they play a role in organisation of multimolecular membrane complexes. 
To date, thirty-two tetraspanins have been identified in mammals and several 
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are present on nearly all animal cell and tissue types (Hemler, 2005). 
Reagents to label cell surface tetraspanins are ineffective due to the 
inaccessibility to the molecule, which extends only 4-5 nm above the 
membrane surface. In addition, the lack of anti-human mouse antibodies to 
many tetraspanins may result from the failure of the mouse immune system to 
recognise tetraspanins on the surface of human cells. Due to the lack of 
available reagents to further study tetraspan 5 expression, it was not included 
in subsequent RT-PCR experiments. 
4.5.2.3 Cyclin D3 (CCND3) 
The D cyclin proteins play a role in the regulation of cell cycle 
progression at the Gi/S checkpoint - the point in the cell cycle at which a cell 
commits to cell division. Three D cyclins have been described in mammalian 
cells which are all encoded for by separate genes (Inaba et al., 1992). The 
expression of the D cyclins are regulated by the extracellular environment and 
so link extracellular mitogenic signals with control of cell cycle. Upon 
induction, D cyclins associate with and activate cyclin dependent kinases 
(CDKs). The D cyclin-CDK complexes initiate a phosphorylation cascade 
resulating in the induction of transcription factors that are required to drive the 
cell into the next phase of the cell cycle, the S phase, and cell division. 
The observation from the duplicate microarrays of a decreased 
expression of Cyclin D3 by activated CD4+CD25+ T cells may indicate why 
CD4+CD25+ T cells display a hypo-proliferative response to stimulation via 
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the TCR. It suggests a differential induction of Cyclin D3 in CD4+CD25+ and 
CD4+CD25- T cells in response to TCR stimulation. 
4.5.2.4 EST IMAGE 243507 and EST IMAGE956217 
Expressed Sequence Tags (ESTs) are short strands of DNA sequence 
that have been transcribed from cDNA isolated from a particular cell, tissue or 
organ. As they come directly from cDNA they correspond to an expressed 
gene, and can be used for further mapping and isolation of that gene. For 
many thousands of ESTs that have been identified, there is no experimental 
validation of the existence of the corresponding gene. For similar reasons to 
exclude hypothetical protein MGC27165, the differentially expressed ESTs 
were not considered for inclusion in subsequent RT-PCR experiments. 
Inclusion was restricted to genes for which experimental validation of their 
existence had previously been demonstrated. 
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4.6 Results: Confirmation of differential gene expression 
using RT-PCR. 
Based on literature searches of the genes found to be differentially 
expressed between CD4+CD25+ and CD4+CD25- T cells, the following 
genes were included in the follow-up confirmation RT-PCR experiments: 
CCL20 (Mip-3-a), TNFR2, ELK4, TYROBP and CyclinDS. The expression of 
these genes was measured in both freshly isolated CD4+CD25+ and 
CD4+CD25- T cells (subsequently reffered to as non-activated cells) and in 
both T cell subsets after twenty-four hours stimulation with plate-bound anti-
CD3 (subsequently reffered to as activated cells). The expression of the 
chosen genes was also measured in mRNA from Th1 and Th2 polarised cells 
as a comparison. In addition, expression of FoxPS, T-bet and Gata-3 was 
measured to act as a control for regulatory, Th1 and Th2 cells respectively. 
4.6.1 Expression of the transcription factors FoxPS, T-bet and Gata-3 
Expression of the regulatory T cell transcription factor FoxP3 confirmed 
the presence of regulatory T cells within the isolated CD4+CD25+ T cell 
subset. FoxP3 mRNA expression was increased approximately twenty-fold in 
non-activated CD4+CD25+ T cells compared to CD4+CD25- T cells (Figure 
4.4). After activation this differential expression of FoxP3 between 
CD4+CD25+ and CD4+CD25- T cells was even more striking. Activated 
CD4+CD25+ T cells displayed an approximately 2.5-fold increase in FoxP3 
mRNA expression compared to non-activated CD4+CD25+ T cells. In 
addition, activated CD4+CD25- T cells displayed a small but significant 
increase in FoxPS mRNA expression after activation. 
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Figure 4.4 Expression of FoxP3 mRNA by CD4+CD25+, CD4+CD25-, Th1, 
and Th2 cells. 
RNA was extracted from freshly isolated CD4+CD25+ and CD4+CD25- T 
cells or from CD4+CD25+ and CD4+CD25- T cells stimulated with plate-
bound anti-CD3 for 24 hours (n = 6). RNA was then quantified and reverse 
transcribed. 25 pi PGR reactions were carried out in triplicate with Taqman 
universal PGR mastermix, FoxP3 specific primers and labelled Taqman 
probe. Samples were standardised to 18s and normalised to GD4+GD25-
expression. Data is presented as fold expression of FoxP3 relative to 
GD4+GD25- expression (CD4+GD25- expression = 1). The accompanying 
tables show the results of statistical analysis and the fold expression for each 
individual donor. For comparisons between CD4+CD25+ and CD4+CD25- T 
cells, a Wilcoxon matched pairs test was used. For comparisons involving Th1 
or Th2 mRNA, a Mann Whitney U test was used. All statistical analysis was 
performed on AGt values, as outlined in section 2.2.7.5. 
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Figure 4.5 Expression of T-bet mRNA by CD4+CD25+, CD4+CD25-, Th1, 
and Th2 cells. 
RNA was extracted from freshly isolated CD4+CD25+ and CD4+CD25- T 
cells or from CD4+CD25+ and CD4+CD25- T cells stimulated with plate-
bound anti-CD3 for 24 hours (n = 6). RNA was then quantified and reverse 
transcribed. 25 pi PGR reactions were carried out in triplicate with Taqman 
universal PGR mastermix, T-bet specific primers and labelled Taqman probe. 
Samples were standardised to 18s and normalised to GD4+GD25-
expression. Data is presented as fold expression of T-bet relative to 
CD4+GD25- expression (GD4+GD25- expression = 1). The accompanying 
tables show the results of statistical analysis and the fold expression for each 
individual donor. For comparisons between GD4+GD25+ and GD4+GD25- T 
cells, a Wilcoxon matched pairs test was used. For comparisons involving Th1 
or Th2 mRNA, a Mann Whitney U test was used. All statistical analysis was 
performed on ACt values, as outlined in section 2.2.7.5. 
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Figure 4.6 Expression of GATA-3 mRNA by CD4+CD25+, CD4+CD25-, 
Thi, and Th2 cells. 
RNA was extracted from freshly isolated CD4+CD25+ and CD4+CD25- T 
cells or from CD4+CD25+ and CD4+CD25- T cells stimulated with plate-
bound anti-CD3 for 24 hours (n = 6). RNA was then quantified and reverse 
transcribed. 25 pi PGR reactions were carried out in triplicate with Taqman 
universal PGR mastermix, GATA-3 specific primers and labelled Taqman 
probe. Samples were standardised to 18s and normalised to CD4+GD25-
expression. Data is presented as fold expression of GATA-3 relative to 
GD4+GD25- expression (GD4+GD25- expression = 1). The accompanying 
tables show the results of statistical analysis and the fold expression for each 
individual donor. For comparisons between GD4+GD25+ and GD4+GD25- T 
cells, a Wilcoxon matched pairs test was used. For comparisons involving Th1 
or Th2 mRNA, a Mann Whitney U test was used. All statistical analysis was 
performed on AGt values, as outlined in section 2.2.7.5. 
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Expression of the Th1-specific transcription factor, T-bet, was 
significantly increased in mRNA from Th1 polarised T cells, with almost no 
expression detectable in mRNA from Th2 cells (Figure 4.5). Conversely, 
expression of the Th2-specific transcription factor, Gata-3, was significantly 
increased in Th2 mRNA, with almost no expression detectable in mRNA from 
Th1 cells (Figure 4.6). Interestingly non-activated CD4+CD25+ T cells 
displayed a significantly increased expression of T-bet mRNA compared to 
non-activated CD4+CD25- T cells although this difference varied between 
each individual with a mean fold-increase of 3 (Figure 4.5). Both activated 
CD4+CD25+ and activated CD4+CD25- T cells displayed an increase in 
expression of T-bet mRNA compared to their non-activated T cell 
counterparts. However no significant difference in T-bet mRNA expression 
was observed between the two activated T cell subsets. No significant 
difference in Gata-3 mRNA expression was observed between non-activated 
CD4+CD25+ and CD4+CD25- T cells (Figure 4.6). However both activated 
CD4+CD25+ and CD4+CD25- T cells displayed a significant decrease in 
Gata-3 mRNA expression compared to non-activated cells. 
4.6.2 Expression of CCL20 
CCL20 was identified as being up-regulated in CD4+CD25+ T cells in 
duplicate arrays at the four hour activation time-point. Results from RT-PCR 
analysis revealed that expression of CCL20 mRNA was significantly increased 
in non-activated CD4+CD25+ T cells compared to CD4+CD25- T cells in all 
six donors (Figure 4.7). The fold-increase seen for CD4+CD25+ T cells 
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ranged from 1.8 - 9.2. Both CD4+CD25+ and CD4+CD25- T cells significantly 
increased their expression of CCL20 after activation compared to non-
activated CD4+CD25- T cells. This increase was greater than 100-fold for 
each donor. However, no significant difference in expression of CCL20 mRNA 
was seen between activated CD4+CD25+ and CD4+CD25- T cells, in contrast 
to the differential expression seen in non-activated T cell subsets, t h e results 
of this RT-PCR analysis confirmed the differential expression of CCL20 in 
CD4+CD25+ and CD4+CD25- T cell subsets seen in the duplicate microarray 
experiments, although this difference in expression was only statistically 
significant in non-activated T cells. 
To further examine any potential role of the CCL20-CCR6 axis in the 
function of CD4+CD25+ regulatory T cells, blocking antibodies to both the 
chemokine and the receptor were tested for their ability to block the 
suppressive function of the regulatory T cell subset. Blocking signalling 
through CCR6 had no effect on the suppression of CD4+CD25- T cell 
proliferation by CD4+CD25+ T cells in response to anti-CD3 stimulation 
(Figure 4.8 A). In addition, blocking antibody to CCL20/Mip-3-alpha also had 
no effect on the suppression of CD4+CD25- T cell proliferation by 
CD4+CD25+ T cells (Figure 4.8 B). 
4.6.3 Expression of TNFR2 
TNFR2 was identified as being up-regulated in CD4+CD25+ T cells in 
duplicate arrays at the 24 hour activation time-point. Results from RT-PCR 
analysis revealed that expression of TNFR2 mRNA was significantly 
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Figure 4.7 Expression of CCL20 mRNA by CD4+CD25+, CD4+CD25-, Th1, 
and Th2 cells. 
RNA was extracted from freshly isolated CD4+CD25+ and CD4+CD25- T 
cells or from CD4+CD25+ and CD4+CD25- T cells stimulated with plate-
bound anti-CD3 for 24 hours (n = 6). RNA was then quantified and reverse 
transcribed. 25 pi PGR reactions were carried out in triplicate with Taqman 
universal PGR mastermix, GGL20 specific primers and labelled Taqman 
probe. Samples were standardised to 18s and normalised to GD4+GD25-
expression. Data is presented as fold expression of GGL20 relative to 
GD4+GD25- expression (GD4+GD25- expression = 1). The accompanying 
tables show the results of statistical analysis and the fold expression for each 
individual donor. For comparisons between GD4+GD25+ and GD4+GD25- T 
cells, a Wilcoxon matched pairs test was used. For comparisons involving Th1 
or Th2 mRNA, a Mann Whitney U test was used. All statistical analysis was 
performed on ACt values, as outlined in section 2.2.7.5. 
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Figure 4.8 Neutralising antibodies to CCR6 or CCL20/Mip-3-alpha have 
no effect on CD4+CD25+ T cell mediated suppression. 
CD4+CD25+ and CD4+CD25- T cells were isolated from human peripheral 
blood and cultured with plate-bound anti-CD3 in the presence of irradiated 
PBMC for 72 hours. Proliferation was measured by thymidine incorporation for 
the final 6 hours of cell culture. Neutralising antibodies to CCR6 (A) or 
CCL20/Mip-3-a (B) or matched isotype controls were included in the cell 
culture at concentrations of 50 pg/ml and 10 pg/ml respectively. Results 
shown are the CPM values obtained for cell cultures containing isotype control 
antibody (C - white bars) and neutralising antibody (T - black bars) for CCR6 
(n=4 individual donors) and CCL20/Mip-3-a (n=3 individual donors). 
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increased in non-activated CD4+CD25+ T cells compared to CD4+CD25- T 
ceils (Figure 4.9). Expression of TNFR2 mRNA was not significantly increased 
in activated CD4+CD25+ T cells compared to non-activated CD4+CD25+ T 
cells, but a significant increase was observed between activated and non-
activated CD4+CD25- T cells. However, expression of TNFR2 mRNA was still 
significantly higher in CD4+CD25+ T cells compared to CD4+CD25- T cells 
after activation. In addition, a significant increase in TNFR2 mRNA expression 
was observed in Th1 compared to Th2 cells. The differential expression of 
TNFR2 mRNA in CD4+CD25+ and CD4+CD25- T cells was in agreement with 
that seen in the duplicate microarray experiments. 
4.6.4 Expression of ELK4 
ELK4 was identified as being up-regulated in CD4+CD25+ T cells in 
duplicate arrays at the 24 hour activation time-point. In subsequent RT-PCR 
analysis no significant difference in expression of ELK4 mRNA was observed 
between non-activated CD4+CD25+ and CD4+CD25- T cells (Figure 4.10). In 
addition no significant increase or decrease was observed in either T cell 
subset after activation and hence no significant difference in ELK4 mRNA 
expression was observed between activated CD4+CD25+ and CD4+CD25- T 
cells. No difference in ELK4 mRNA expression was observed between Th1 
and Th2 polarised T cells. Therefore, results from RT-PCR analysis of ELK4 
mRNA expression in CD4+CD25+ and CD4+CD25- T cells was not in 
agreement with that seen in the duplicate microarray experiments. 
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Figure 4.9 Expression of TNFR2 mRNA by CD4+CD25+, CD4+CD25-, Th1, 
and Th2 cells. 
RNA was extracted from freshly isolated CD4+CD25+ and CD4+CD25- T 
cells or from CD4+CD25+ and CD4+CD25- T cells stimulated with plate-
bound anti-CD3 for 24 hours (n = 6). RNA was then quantified and reverse 
transcribed. 25 pi PGR reactions were carried out in triplicate with Taqman 
universal PGR mastermix, TNFR2 specific primers and labelled Taqman 
probe. Samples were standardised to 18s and normalised to CD4+CD25-
expression. Data is presented as fold expression of TNFR2 relative to 
GD4+GD25- expression (GD4+GD25- expression = 1). The accompanying 
tables show the results of statistical analysis and the fold expression for each 
individual donor. For comparisons between GD4+CD25+ and GD4+GD25- T 
cells, a Wilcoxon matched pairs test was used. For comparisons involving Th1 
or Th2 mRNA, a Mann Whitney U test was used. All statistical analysis was 
performed on AGt values, as outlined in section 2.2.7.5. 
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Figure 4.10 Expression of ELK4 mRNA by CD4+CD25+, CD4+CD25-, Th1, 
and Th2 cells. 
RNA was extracted from freshly isolated CD4+CD25+ and CD4+CD25- T 
cells or from CD4+CD25+ and CD4+CD25- T cells stimulated with plate-
bound anti-CD3 for 24 hours (n = 6). RNA was then quantified and reverse 
transcribed. 25 pi PGR reactions were carried out in triplicate with Taqman 
universal PGR mastermix, ELK4 specific primers and labelled Taqman probe. 
Samples were standardised to 18s and normalised to GD4+GD25-
expression. Data is presented as fold expression of ELK4 relative to 
GD4+GD25- expression (GD4+GD25- expression = 1). The accompanying 
tables show the results of statistical analysis and the fold expression for each 
individual donor. For comparisons between GD4+GD25+ and GD4+GD25- T 
cells, a Wilcoxon matched pairs test was used. For comparisons involving Th1 
or Th2 mRNA, a Mann Whitney U test was used. All statistical analysis was 
performed on ACt values, as outlined in section 2.2.7.5. 
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4.6.5 Expression of TYR0BP/DAP12 
TYROBP was identified as being down-regulated in CD4+CD25+ T 
cells in duplicate arrays at the 4 hour activation time-point. Using RT-PCR 
analysis no significant difference was observed in expression of TYROBP 
mRNA between non-activated CD4+CD25+ and CD4+CD25- T cells, although 
an increase in expression by CD4+CD25+ T cells was observed in 5/6 donors 
(Figure 4.11). Activated CD4+CD25+ T cells displayed a significant decrease 
in TYROBP expression compared to non-activated CD4+CD25+ T cells. No 
significant difference in expression was observed between activated and non-
activated CD4+CD25- T cells although a trend for increased expression was 
displayed in 4/6 individuals. Again no significant difference in expression was 
observed between activated CD4+CD25+ and CD4+CD25- T cells. 
Expression of TYROBP mRNA was absent from both Th1 and Th2 polarised 
T cells. Therefore, the results from RT-PCR analysis of TYROBP mRNA 
expression in CD4+CD25+ and CD4+CD25- T cells was not in agreement 
with that seen in the duplicate microarray experiments. 
Expression of TYROBP was examined further using intraceulluar 
staining and flow cytometry. Expression of TYROBP was similar for 
CD4+CD25+ and CD4+CD25- T cells with approximately 60 % of cells in each 
subset expressing TYROBP (Figure 4.12). Therefore, flow cytometry analysis 
confirmed the similar expression of TYROBP seen with the RT-PCR analysis 
outlined above. 
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4.6.6 Expression of CyclinDS 
CyclinDS was identified as being down-regulated in CD4+CD25+ T 
cells in duplicate arrays at the 24 hour activation time-point. Using RT-PCR 
analysis, non-activated CD4+CD25+ T cells displayed an increased 
expression of CyclinDS mRNA compared to non-activated CD4+CD25- T cells 
(Figure 4.13). Expression of CyclinDS was significantly increased by activated 
CD4+CD25- T cells compared to non-activated CD4+CD25- T cells. No such 
increase or decrease was observed when expression between activated and 
non-activated CD4+CD25+ T cells was compared. Despite the significant 
increase in expression of CyclinDS mRNA by activated CD4+CD25- T cells, 
no significant difference in expression was observed between activated 
CD4+CD25+ and CD4+CD25- T cells. Therefore, results from RT-PCR 
analysis of CyclinDS mRNA expression in CD4+CD25+ and CD4+CD25- T 
cells was not in agreement with that seen in the duplicate microarray 
experiments which identified CyclinDS as being decreased in activated 
CD4+CD25+ T cells. Indeed, in non-activated T cells CyclinDS mRNA 
expression was increased in CD4+CD25+ compared to CD4+CD25- T cells. 
Interestingly, a significant increase in CyclinDS mRNA expression was 
observed in Th1 cells compared to Th2 cells. 
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Figure 4.11 Expression of DAP12 mRNA by CD4+CD25+, CD4+CD25-, 
Th1, and Th2 cells. 
RNA was extracted from freshly isolated CD4+CD25+ and CD4+CD25- T 
cells or from CD4+CD25+ and CD4+CD25- T cells stimulated with plate-
bound anti-CD3 for 24 hours (n = 6). RNA was then quantified and reverse 
transcribed. 25 pi PGR reactions were carried out in triplicate with Taqman 
universal PGR mastermix, DAP12 specific primers and labelled Taqman 
probe. Samples were standardised to 18s and normalised to GD4+GD25-
expression. Data is presented as fold expression of DAP12 relative to 
GD4+GD25- expression (GD4+GD25- expression = 1). The accompanying 
tables show the results of statistical analysis and the fold expression for each 
individual donor. For comparisons between GD4+GD25+ and GD4+GD25- T 
cells, a Wilcoxon matched pairs test was used. For comparisons involving Th1 
or Th2 mRNA, a Mann Whitney U test was used. All statistical analysis was 
performed on AGt values, as outlined in section 2.2.7.5. 
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Figure 4.12 TYROBP/DAP12 expression on CD4+CD25+ and CD4+CD25-
T cells 
Representative FACSplots showing TYR0BP/DAP12 expression on 
CD4+CD25+ and CD4+CD25- T cells. PBMCs were isolated from human 
peripheral blood and stained with antibodies to CD4-F1TC, CD25-PE and 
CD3-TR prior to intracellular staining with anti-TYR0BP/DAP12-APC. PBMCs 
were gated (R1) on CD3+CD4+ T cells as shown in dotplot (A). CD4+CD25+ 
(R2) and CD4+CD25- (R3) T cell subsets were subsequently gated on 
CD3+CD4+ cells based on expression of CD25 as shown dotplot (B). 
Expression of TYRO BP/DAP 12 on gated CD4+CD25+ and CD4+CD25- T 
cells are shown in dotplots (C) and (D) respectively. Quadrant marker 
positions are based on staining from matched isotype controls. Results are 
representative of three individual experiments. 
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Figure 4.13 Expression of CyiinDS mRNA by CD4+CD25+, CD4+CD25-, 
Th1, and Th2 cells. 
RNA was extracted from freshly isolated CD4+CD25+ and CD4+CD25- T 
cells or from CD4+CD25+ and CD4+CD25- T cells stimulated with plate-
bound anti-CD3 for 24 hours (n = 6). RNA was then quantified and reverse 
transcribed. 25 pi PGR reactions were carried out in triplicate with Taqman 
universal PGR mastermix, GyclinDS specific primers and labelled Taqman 
probe. Samples were standardised to 18s and normalised to GD4+GD25-
expression. Data is presented as fold expression of CyclinD3 relative to 
GD4+GD25+ expression (GD4+GD25+ expression = 1). The accompanying 
tables show the results of statistical analysis and the fold expression for each 
individual donor. For comparisons between GD4+GD25+ and GD4+GD25- T 
cells, a Wilcoxon matched pairs test was used. For comparisons involving Thi 
or Th2 mRNA, a Mann Whitney U test was used. All statistical analysis was 
performed on AGt values, as outlined in section 2.2.7.5. 
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4.7 Discussion 
The aim of the experiments outlined in this chapter was to identify 
genes differentially expressed between CD4+CD25+ and CD4+CD25- T cell 
subsets. The approach used was to identify candidate genes using 
comparative microarray technology and to subsequently confirm this 
differential gene expression using RT-PCR analysis. Results from the 
duplicate microarrays identified six genes as being up-regulated in 
CD4+CD25+ T cells - one at the four hour activation time-point and five at the 
twenty-four hour activation timepoint. In addition, five genes were identified as 
being down-regulated in CD4+CD25+ T cells - four at the four hour activation 
timepoint and one at the twenty-four hour activation timepoint. From this list of 
eleven differentially expressed genes, five were subsequently chosen for 
confirmation experiments using RT-PCR. This analysis confirmed the 
increased expression of CCL20 and TNFR2 by CD4+CD25+ regulatory T 
cells. The results did not support the differential expression of ELK4, TYROBP 
and CyclinDS. In light of these results it is important to review all aspects of 
the experimental design of the microarray experiments and comment on the 
success of the experiment. 
In order to isolate highly purified cells for the subsequent microarray 
study, initial experiments using FACS cell sorting were employed. Although 
this technique resulted in highly pure populations of CD4+CD25+ and 
CD4+CD25- T cells (>98 %), it consistently resulted in altered CD4+CD25+ T 
cell phenotype. CD4+CD25+ T cells isolated by FACS cell sorting lost their 
ability to suppress to the proliferation of CD4+CD25- T cells when co-cultured, 
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as well as proliferating to the same degree as their CD4+CD25- T cell 
counterparts when cultured alone. CD4+CD25+ T cells isolated in parallel 
isolations using FACS cell sorting and MACS immuno-magnetic beads 
showed that this phenomenon was specific for CD4+CD25+ T cells that had 
passed through the cell sorter. It was concluded that the CD4+CD25+ T cell 
subset was becoming either contaminated or activated as it passed through 
the cell sorter resulting in an altered phenotype and hence and altered gene 
expression. Therefor it was decided to continue the microarray study using 
cells isolated by MACS immuno-magnetic beads. 
As outlined in table 1 and figure 4.3, some isolations of CD4+CD25+ T 
cells diplayed a relatively poor purity and weak suppression of CD4+CD25- T 
cell proliferation when co-cultured. Contamination of the CD4+CD25+ T cell 
fraction with CD4+CD25- T cells may have affected the results of the 
subsequent microarray study. Differentially expressed genes between 
regulatory and non-regulatory T cells may have been diluted by this 
contamination of the CD4+CD25+ T cell fraction with CD4+CD25- T cells. 
This may have resulted in a differentially expressed genes not being identified 
in the microarray analysis. However, all of the MACS immuno-magnetic bead 
isolations separated the CD4+CD25high T cells into the CD4+CD25+ T cell 
fraction, with no contamination of CD4+CD25high T cells in the CD4+CD25-
fractions. As regulatory T cells are reported to reside within the 
CD4+CD25high population (Baecher-Allan et al., 2001) it can therefore be 
assumed that all regulatory T cells were separated into the CD4+CD25+ T cell 
fraction using immuno-magnetic beads and the CD4+CD25- T cell fraction did 
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not contain regulatory T cells. However this does not discount the fact that 
RNA from contaminating CD4+CD25- T cells in the CD4+CD25+ T cell 
fraction may have diluted any differences in gene expression that could have 
been present. 
Both microarray experiments identified a very low number of genes as 
being differentially expressed between the two cell types studied. Although 
one would expect the vast majority of genes present on the microarray to be 
expressed similarly in both cell types, one would equally expect more targets 
to be identified as differentially expressed than was the case with either 
microarray. Combining the results of both arrays identified only six targets as 
up-regulated and five targets as down regulated in the duplicate microarrays. 
Clearly this extremely low number of identified genes suggests problems with 
one or both microarray experiments. The subsequent RT-PCR analysis, 
where only two out of the five identified genes supported the microarray 
findings, unfortunately reinforces the conclusion of problems with the 
experiment. 
Microarray experiments are an expensive undertaking and the 
experiments outlined in this chapter were designed with this fact in mind. 
These experiments were designed and executed four years ago when the 
cost and difficulty of performing comparative microarray experiments were 
much higher than today. Indeed, as outlined in the next chapter, microarray 
technology has quickly become more cost effective and easier to use, even in 
the four-year period since these experiments were performed. The choices 
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available at the time these experiments were undertaken were to make use of 
a collaborator's in-house custom microarrays or to employ the expertise of a 
commercial hybridisation service. Due to the extremely complex and costly 
nature of microarray experiments, the choice of going with the cheaper option 
of using a collaborator's in-house custom microarrays is justified. This also 
allowed for the experimental design to include the provision of doing the entire 
experiment in duplicate: an undertaking that would have been impossible with 
a commercial hybridisation service due to the cost. The inclusion of duplicate 
microarrays in the experimental design was deemed important and in keeping 
with best practise guidelines such as MIAME - Minimum Information About A 
Microarray Experiment (Brazma et al., 2001). In addition, the technology and 
experimental protocols needed to conduct the microarray experiments were 
already optimised and in use by our collaborators at Lorantis Limited and 
making use of their expertise rather than "going it alone" was a sensible 
option. 
A feature of the microarray experiment design was that the RNA used 
for each microarray had been amplified from a pool of RNA derived from three 
individual donors. The question arises as to what were the advantages and 
disadvantages of pooling samples in this fashion? The motivation for pooling 
samples was that there was insufficient RNA from each individual donor to 
perform the assay, due to the small CD4+CD25+ T cell numbers isolated from 
human peripheral blood. In addition, performing a microarray experiment on 
pooled RNA from a number of different donors was deemed more robust than 
performing the same experiment on just one individual. It was reasoned that 
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the concentration of an mRNA molecule in the pooled sample was likely to be 
closer to the average concentration than the concentration in a sample from a 
single individual. However, this reasoning is dependant on there being 
precisely equal amounts of all contributory RNAs, and that their mixing was 
completely efficient. 
Another question regarding the RNA is as to whether the use of 
amplified RNA in the microarray experiments may have been a source of error 
and contributed to its unsatisfactory conclusion. A number of studies have 
investigated whether cDNA ratios are preserved in amplified RNA samples, 
and all have reported correlation coefficients of greater than 0.8 (Feldman et 
al., 2002; Hu et al., 2002; ScheidI et al., 2002; Zhao et al., 2002). Therefore in 
general, a consensus has emerged that RNA amplification produces reliable 
data in microarray experiments. 
An obvious question to address is the absence of known regulatory T 
cell gene transcripts in the differentially expressed gene lists generated by the 
microarray experiments. Unfortunately the main candidate gene, FoxP3, was 
not included in the custom microarrays used in these experiments and indeed 
highlights a problem of their use. The microarrays used in this study were 
designed prior to the discovery of FoxP3 as the transcriptional regulator of 
CD4+CD25+ regulatory T cells. For custom microarrays, where the genes 
present on the array are specifically picked for inclusion, continuing research 
in the field may render them redundant, with the discovery of new molecules 
and pathways relevant to the area being studied. For custom microarrays of 
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this kind to remain relevant, the genes they include must continually be 
reviewed and updated, often at great expense. An additional drawback of the 
custom microarrays used in this study, highlighted by the absence of FoxP3 
on the array, is the exclusion of a many number of genes from the experiment 
from the outset. The custom microarrays used by Lorantis Limited included 
10,368 targets. The current estimates from the International Human Genome 
Sequencing Consortium (IHGSC) put the number of genes encoded by 
human DNA at somewhere between 20,000 - 25,000 protein-coding genes 
(The Human Genome Sequencing Project, 2004). Clearly, the exclusion of 
such a high number of gene targets from the experiment minimises the 
possible findings of the experiment. A searchable list of the genes present on 
the microarrays used in this study is presented on the CD attached to this 
thesis, under the title Appendix 1. In hindsight, the absence of FoxPS on the 
microarrays used in this study was a major drawback, as its presence would 
have served as the perfect positive control for these experiments. If FoxPS 
was present on the microarrays used, it would have given an immediate 
indicator to the success of the experiment. 
Despite the absence of FoxPS on the microarrays used, certain genes 
present on the differentially expressed gene lists generated do hint towards 
the relative success of the experiment. In the absence of FoxPS, the next 
clearly relevant indicator is the expression of CD25 itself. CD25 was one of 
the genes identified as up-regulated in CD4+CD25+ T cells in both microarray 
experiments at the twenty-four hour activation timepoint. At the four-hour 
activation timepoint, CD25 was also identified as up-regulated in CD4+CD25+ 
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T cells In the second microarray experiment but not in the first. The 
identification of CD25 is reassuring that the microarray experiments were 
somewhat successful. In addition CTLA4, another published marker for 
regulatory T cells, was also identified as being up-regulated in CD4+CD25+ T 
cells. However, it was only identified in the first microarray experiment at both 
the four and twenty-four hour activation timepoints. Taken together, these 
observations suggest the microarray experiments were partly successful but 
the failure to identify both these genes in both microarray experiments at both 
activation timepoints equally suggests failure in one or both microarray 
experiments. With this in mind the genes identified and subsequently 
analysed by RT-PCR will be discussed below. 
The chemokine CCL20 was identified as being up-regulated by 
CD4+CD25+ T cells in the duplicate arrays at the four hour activation 
timepoint. This differential expression was confirmed by RT-PCR in non-
activated T cells, with an approximate 5-fold increase seen in CD4+CD25+ T 
cells. RT-PCR analysis also revealed a massive up-regulation of CCL20 
mRNA upon activation of CD4+CD25+ T cells, similar to that seen upon 
activation of CD4+CD25- T cells. In light of this result and the observation of 
increased expression of CCR6, the receptor for CCL20, by CD4+CD25+ T 
cells outlined in the previous chapter, it was decided to examine the effect of 
blocking this ligand-receptor axis in proliferation and function of CD4+CD25+ 
T cells. However, in response to activation by anti-CD3, blocking CCR6 or 
CCL20 with neutralising antibodies had no effect on the proliferation of 
CD4+CD25+ or CD4+CD25- T cells. In addition, neutralising antibodies had 
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no effect on CD4+CD25+ T cell-mediated suppression of CD4+CD25- T cell 
proliferation in co-culture experiments. Subsequent analysis of blocking CCR6 
and CCL20 in an allergen-driven cell culture system also revealed no effect on 
the proliferative responses of either CD4+CD25+ or CD4+CD25- T cells (Dao 
Nguyen, Leukocyte Biology - personal communication). These results 
suggest that CCL20 does not play a role in the mechanism of suppression by 
CD4+CD25+ T cells at least in in vitro cell culture systems. However, it must 
be noted that the proliferation assay used as readout to test the functional role 
of CCL20 is limited. The culture of cells at relatively high densities and in 
close proximity in this in vitro assay may override any functional role for 
CCL20 in the mode of action of CD4+CD25+ regulatory T cells. In addition, 
blocking chemokines and chemokine receptors in this in vitro assay using 
monoclonal antibodies may not completely inhibit their function. To definitivly 
rule out a role for CCL20 in regulatory T cell function would require studies 
using CD4+CD25+ regulatory T cells from CGL20-deficient mice. Failure of 
CCL20-deficient regulatory T cells to control autoimmunity in adoptive transfer 
animal models would point toward a role for the chemokine in the function of 
regulatory T cells, possibly through recruitment and subsequent interaction 
with APC. 
The question remains as to the reason why CD4+CD25+ T cells would 
have an increased expression of CCL20 in comparison to their CD4+CD25- T 
cell counterparts. The answer may be that even though non-activated 
CD4+CD25+ T cells do show an increased expression of CCL20, this 
expression is in fact minimal. The amplification of CCL20 from CD4+CD25+ T 
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cells during the RT-PCR reactions gave an average Ct value of 35, 
approaching the limits of detection for RT-PCR. In conclusion, the differential 
expression of CCL20 seen for non-activated CD4+CD25+ and CD4+CD25- T 
cells may be irrelevant, although RT-PCR analysis does suggest that 
CD4+CD25+ regulatory T cells are capable of up-regulating CCL20 
expression upon activation to a similar degree as their CD4+CD25- T cell 
counterparts. This is in contrast to published findings for cytokine expression 
in these T cell subsets. CD4+CD25+ regulatory T cells have been reported to 
be "anergic" to TCR stimulation, failing to upregulate expression of cytokines 
such as IL-2 and IFN-y in contrast to their CD4+CD25- T cell counterparts 
(Levings et al., 2001). The massive up-regulation of CCL20 mRNA in both 
CD4+CD25+ and CD4+CD25- T cells upon activation suggests that the 
production of chemokines by activated CD4+CD25+ T cells may not differ 
from CD4+CD25- T cells in contrast to the production of cytokines. Proof of 
this concept will require further analysis of in vitro cell cultures to measure the 
secretion of various chemokines by activated CD4+CD25+ and CD4+CD25- T 
cells. 
Expression of TNFR2, a receptor for TNF-a, was identified as up-
regulated in CD4+CD25+ T cells in duplicate microarrays at the twenty-four 
hour activation timepoint. Subsequent RT-PCR analysis confirmed this 
differential expression of TNFR2 in both activated and non-activated 
CD4+CD25+ and CD4+CD25- T cells. Expression of TNFR2 on CD4+CD25+ 
regulatory T cells has been reported previously (Annunziato et al., 2002). It is 
likely that expression of this receptor may be another marker of the 
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"previously activated-memory" phenotype of this T cell subset. Its use as a 
specific marker for regulatory T cells is impossible as it is up-regulated on all T 
cells upon activation and is not specific for this T cell subset. 
The possibility remains that the constitutive expression of TNFR2 by 
CD4+CD25+ regulatory T cells may play a role in the phenotype or function of 
these cells. It has been reported that signalling through TNFR2 can decrease 
the threshold of activation of T cells (Kim and Teh, 2001). Therefore, it is 
possible that increased expression of TNFR2 on circulating non-activated 
CD4+CD25+ T cells compared to CD4+CD25- T cells may result in a 
decreased threshold of activation needed for these cells. In this way TNFR2 
expression on non-activated regulatory T cells may result in their activation 
prior to their CD4+CD25- T cell counterparts, to dampen down any unwanted 
immune response. Unfortunately time constraints did not allow for this 
hypothesis to be investigated during this project. The use of agonists and 
antagonists specific to either TNFR1 or TNFR2 would allow this hypothesis to 
be tested using in vitro cell culture systems. 
A recent study has reported that TNF-a, acting through TNFR2, can 
abrogate the suppressve function of CD4+CD25+ T cells (Valencia et a!., 
2006). This loss of suppressive function was associated with a 
downmodulation of F0XP3 expression by the CD4+CD25+ T cells. This 
observation suggests that production of TNF-a in response to microbial 
invasion may limit the suppressive activity of regulatory T cells and hence 
allow an immune response to proceed. A subsequent decrease in TNF-a 
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once the insult had been resolved may result in enhanced regulatory T cell 
function that would prevent any unwanted immune response to autologous 
tissue antigens revealed during inflammation. 
Expression of ELK4 mRNA was identified as being up-regulated by 
CD4+C.D25+ T cells in duplicate microarrays at the twenty-four activation 
timepoint. However, RT-PCR analysis did not support these findings. 
Expression of ELK4 mRNA was found to be identical in non-activated 
CD4+CD25+ and CD4+CD25- T cells along with no induction or reduction in 
levels after TCR stimulation. Two obvious reasons for this observation using 
RT-PCR analysis are that either ELK4 mRNA is not expressed by either T cell 
subset or that the primers used for the RT-PCR reaction did not amplify the 
intended target. Both of these conclusions can be ruled out by the 
amplification curves generated by the RT-PCR reaction for ELK4. Typical 
amplification curves were seen for ELK4 for all T cell subsets studied and the 
Ct values observed were well within the detection limits for RT-PCR. In fact, 
as a comparison, the Ct values observed for ELK4 from each T cell subset 
were similar to the Ct values seen for FoxP3 for CD4+CD25+ T cells. 
Therefore it must be concluded that ELK4 mRNA is expressed to some 
degree in both CD4+CD25+ and CD4+CD25- T cells and this expression is 
similar in both T cell subsets. The identification of increased ELK4 expression 
in CD4+CD25+ T cells by microarray analysis must therefore be regarded as 
a spurious result. 
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Expression of TYROBP was identified by duplicate microarray 
experiments as down-regulated in CD4+CD25+ T cells at the four hour 
activation timepoint. Subsequent RT-PCR analysis did not confirm this finding 
and indeed the trend was for an increased expression of TYROBP in non-
activated CD4+CD25+ T cells. Analysis of TYROBP protein expression by 
flow cytometry was in agreement with the result seen in the RT-PCR analysis 
with similar expression levels in both CD4+GD25+ and CD4+CD25- T cells. 
Approximately 60 % of both T cell subsets expressed TYROBP. Therefore, 
the identification of decreased expression of TYROBP by CD4+CD25+ T cells 
in the microarray experiments must be regarded as another spurious result. 
Expression of CyclinDS was identified as decreased in CD4+CD25+ T 
cells at the twenty-four hour activation timepoint in duplicate microarrays. RT-
PCR analysis did not support this finding with increased expression observed 
in non-activated CD4+CD25+ T cells compared to CD4+CD25- T cells. No 
statistically significant difference in expression was observed in activated T 
cells using RT-PCR. However, expression was increased in activated 
CD4+CD25- T cells compared to CD4+CD25+ T cells in 5/6 donors. The fold 
difference in these individuals was approximately two suggesting that this was 
the reason behind its identification by microarray analysis as being 
differentially expressed. 
This chapter presents the results of microarray analysis of CD4+CD25+ 
and CD4+CD25- T cells with the aim of identifying gene targets specific for 
regulatory T cells. Unfortunately as detailed above, these experiments were 
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unsuccessful. Microarray technology, in the right hands and used correctly, 
can be an extremely efficient tool for gaining insight into the genes 
responsible for a cell's phenotype: clearly demonstrated by its previous 
successful use in exploring the gene expression profile of regulatory T cells. 
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Chapter 5: Comparison of regulatory T cell 
subsets and gene expression in PBMC from 
asthmatic and non-asthmatic individuals. 
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5.1 Introduction 
Microarray technology has the ability to measure genome-wide 
transcriptional activity of a given tissue source. Microarrays are particularly 
useful in identifying genes differentially expressed between disease and non-
disease states. A number of studies have utilised this technology to identify 
potential genes and pathways involved in diseases such as cancer. 
Peripheral blood acts as a reservoir for immune cells and can be easily 
collected in sufficient quantities from patients throughout the course of a 
disease. Blood is potentially a very valuable and accessible source of clinically 
relevant material for diseases that possess a strong immune component. A 
recent review has discussed the potential of microarray profiling of peripheral 
blood leukocytes for research, diagnostic and treatment purposes in internal 
diseases (Gladkevich et al., 2005). The authors of this review argued that 
gene expression profiling of peripheral white blood cells using microarray 
technology could be a valuable tool for the investigation of pathophysiology of 
diseases in which inflammation is a major component, such as asthma, 
rheumatoid arthritis and systemic lupus erythematosis (SLE). They proposed 
that each disease might have specific a "disease gene signature" in addition 
to having a common "inflammation gene signature". 
Recent studies have demonstrated experimental evidence for the 
proposal put forward by the authors of this review. Ramilo et al have shown 
that changes in peripheral blood leukocyte gene expression patterns can be 
used to distinguish patients with acute infections caused by four different 
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pathogens, namely influenza A virus, Escherichia coli, Staphylococcus aureus 
and Streptococcus pneumoniae (Ramilo et al., 2007). Further experimental 
evidence for the existence of disease-specific peripheral blood gene 
signatures comes from the work of Chaussabel et al who studied the gene 
expression profile of peripheral blood leukocytes isolated from patients 
suffering from SLE, bacterial infections [Escherichia coll, Staphylococcus 
aureus and Streptococcus pneumoniae) and acute influenza A infection 
(Chaussabel et al., 2005). In addition, they also analysed the peripheral blood 
leukocyte gene expression profile of liver transplant recipients who had 
accepted the allograft under pharmacological immunosuppressive therapy, as 
well as bone marrow recipients with graft versus host disease. The authors 
demonstrated that peripheral blood leukocyte gene expression signatures 
specific for each disease could be identified, as well as identifying a common 
gene expression profile, which they suggested constituted a "sickness gene 
signature". 
A number of studies have been published that use microarray 
technology to determine the gene expression profile in animal models of 
asthma. In a monkey model of allergic asthma, Zou et al identified 149 genes 
differentially expressed in the lungs of allergen-challenged monkeys 
compared to non-challenged monkeys (Zou et al., 2002). The genes found to 
be differentially expressed included both novel genes and genes previously 
implicated in asthma pathogenesis, such as chemokines, matrix proteins and 
metalloproteases. Zimmermann et al analysed lung gene expression in two 
well-established murine models of allergic asthma (Zimmermann et al., 2003). 
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Analysis of genes expressed in the lungs of mice challenged with either 
ovalbumin or with Aspergillus extract identified 291 genes expressed in both 
mouse models of disease. Indeed this analysis revealed the expression of a 
number of genes (arginase 1, arginase II and CAT2) involved in the 
metabolism of L-arginine that the authors subsequently showed were 
expressed higher in lung macrophages and epithelial cells from human 
asthmatic but not non-asthmatic individuals. 
Surprisingly, the published literature includes only one study comparing 
the gene expression profile of bronchial tissue from human asthmatic and 
non-asthmatic patients (Laprise et al., 2004). The study identified 79 genes 
that were differentially expressed between the control and asthmatic groups. 
In addition, inhaled corticosteroid therapy normalised partly or completely the 
expression of 26 of the 79 identified differentially expressed genes. The lack 
of similar studies as the one performed by Laprise et al highlights both the 
problem obtaining high quality RNA for microarray studies from bronchial 
tissue and also the advantage of performing similar experiments on peripheral 
blood leukocytes. Peripheral blood can be easily and repeatedly collected in 
sufficient quantities to enable microarray analysis to be done on individual 
donors. 
However, the question remains as to whether changes in gene 
expression that are relevant to asthma can be identified in peripheral blood 
leukocytes. Certainly the data from the studies mentioned above suggest that 
specific disease signatures can be identified from peripheral blood for a 
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number of different diseases (Chaussabel et a!., 2005; Ramilo et al., 2007). In 
addition, as the review by Gladkevich et al proposes, asthma should prove to 
be a disease where a specific blood leukocyte gene signature can be 
identified, as the involvement of both T and B cells, in particular Th2 cells is 
well recognised (Larche et al., 2003). 
Studies by two groups profiling the gene expression of peripheral blood 
leukocytes in asthma patients using microarray technology support the 
hypothesis that a gene signature for asthma can be identified from peripheral 
blood. Hansel et al analysed the gene expression of CD4+ T cells isolated 
from patients with severe or mild asthma (Hansel et al., 2005). This study 
identified 40 genes as differentially expressed between the two patient 
groups, including TGF-(3 and genes involved in T cell activation, proliferation 
and cytoskeletal changes. Hakonarson et al demonstrated that glucocorticoid-
responsive asthma patients could be separated from giucocorticoid-resistant 
asthma patients by using the expression levels of only a few genes in 
peripheral blood leukocytes (Hakonarson et al., 2005). 
The identification of a reliable and reproducible peripheral blood gene 
signature for asthma would be of enormous benefit for diagnostic purposes 
and monitoring treatment efficacy, as well as identifying potential pathways 
and molecules involved in the disease for further research. Recent advances 
in microarray technology make it possible to perform gene expression 
analysis on peripheral blood leukocytes isolated from individual donors. The 
continuing decline in the cost of performing microarray analysis increases the 
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potential for the technology to be used as a diagnostic tool. Over the course of 
a disease and its treatment, changes in gene expression profiles can be 
monitored using microarray analysis and could potentially be used as an 
indicator of successful treatment. 
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5.2 Aims of study 
This study hypothesises that asthma can be characterised by changes 
in blood leukocyte number, specifically changes in T cell subsets, and by a 
specific gene signature associated with peripheral blood leukocytes. This 
hypothesis was tested experimentally by two methods: 
1. Differences in peripheral blood T cell subsets were analysed using flow 
cytometry. A number of T cell markers corresponding to different 
populations of T cells, including memory and regulatory T cells, were 
measured on peripheral blood T cells isolated from both asthma and 
matched healthy control subjects. 
2. Microarray analysis of peripheral blood leukocytes isolated from both 
asthma and matched healthy control subjects was used to identify the 
presence of a blood leukocyte gene signature for asthma. If a specific 
blood leukocyte gene signature for asthma failed to be identified, this 
microarray analysis was to be used to identify genes that may play a 
role in asthma pathogenesis. 
5.3 Experimental design 
PBMCs were isolated from the peripheral blood of six donors with mild 
asthma and six healthy controls. Differential cell counts and flow cytometry 
was used to determine differences in numbers of leukocyte populations and T 
cell subsets within the PBMC population. 
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Microarray analysis was used to investigate differential gene 
expression in PBMC isolated from asthmatic and non-asthmatic donors. 
Microarray experiments were performed in collaboration with researchers at 
Baylor Institute for Immunology Research, Dallas. For these experiments, Dr. 
Casey Glaser performed hybridisation of the probes to the microarray chips. 
Prior isolation and preparation of the RNA samples and all subsequent data 
analysis was performed by myself. 
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5.4 Results 
5.4.1 Patient selection and characterisation 
Twelve patients were selected for inclusion in this study - six with mild 
asthma and six healthy controls, see Tables 5.1 and 5.2 for clinical details. 
Mild asthmatics were chosen for inclusion in the study as the aim was to 
include only symptomatic asthmatics not taking inhaled steroids, to avoid the 
effects of treatment. Therefor mild asthmatics not on steroid treatment were 
included, as opposed to more severe asthmatics that would have been 
receiving steroid treatment to control their asthma symptoms. The reason for 
wanting to avoid the inclusion of asthmatics taking inhaled corticosteroids is 
due to the published findings of significant changes in gene expression as a 
result of inhaled steroid treatment. The mild asthmatic and healthy control 
patient groups were matched with regard to gender and age of the subjects. 
All healthy control subjects had negative skin prick tests, while all mild asthma 
subjects had at least one positive skin prick test. Mild asthma subjects had 
demonstrated a PC20 of less than 16 in a previous laboratory study and were 
hence chosen for inclusion in this study. However, two subjects displayed a 
PC20 of greater than 16 when their PC20 was measured a second time for this 
particular study. Patient 4 had previously displayed a PC20 of < 4, while 
patient 5 had displayed a previous PC20 of < 8. All subjects within the healthy 
control group displayed a PC20 of greater than 16. 
5.4.2 Differential blood leukocyte cell counts 
A differential cell count was performed on a sample of blood taken from 
each donor. The two study groups showed no significant difference in the 
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Table 5.1 Clinical details of asthmatic donors 
Donor Gender Age FEV1 % Pred PC20 
Total 
IgE SPT RAST Asthma 
1 F 30 96.6 <0.125 73 HDM 16.6 Y 
2 M 29 107.6 < 1 28 HDM 8.53 Y 
3 M 32 99.78 <0.5 354 HDM 100 Y 
4 M 28 115.8 > 16 25 Cat dander 6.34 Y 
5 F 40 122 > 16 387 Cat dander 22.5 Y 
6 M 30 79 <0.03 194 Grass pollen 13.7 Y 
Summary 4 = M 2 = F 
31.5 
(28-
40) 
103.4 
(79-
115.8) 
4 <16 
2 >16 
176.8 
(25-
387; 
3 = 
HDM 
2 = Cat 
1 = 
Grass 
27.9 
r&34-
100) 
6=Y 
Table 5.2 Clinical details of non-asthmatic donors 
Donor Gender Age FEV1 % Pred P C 2 0 
Total 
IgE SPT RAST Asthma 
7 M 33 121 > 16 N/A Negative N/A N 
8 M 29 113.6 > 16 N/A Negative N/A N 
9 M 30 132 > 16 N/A Negative N/A N 
10 F 47 105 > 16 N/A Negative N/A N 
11 F 26 100 > 16 N/A Negative N/A N 
12 M 28 109 > 16 N/A Negative N/A N 
Summary 4 = M 2 = F 
32 
(26-
47) 
113.4 
(100-
f32; 
> 16 N/A 6 = Negative N/A 6 = A/ 
Gender: F = female, M = male. IgE levels measured by RAST test in lU/ml. 
Asthma: Y = yes, N = no. Summary is median and range where appropriate or 
summary of values. N/A = unavailable data. Skin prick tests (SPT): performed 
with house dust mite (HDM), cat dander, and grass pollen extract. Summary = 
sum of values or median and range. 
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numbers of lymphocytes, neutrophils, monocytes or basophils (Table 5.3). 
However, eosinophil cell number was significantly higher in the mild asthma 
group compared to the healthy control group. 
Flow cytometry was used to further investigate any potential 
differences in different populations of lymphocyte between the two groups. 
However, no significant difference in the percentage of CD3+ (T cell), CD4+ 
(T cell), CD14+ (monocytes/macrophages) or CD19+ (B cell) cells contributing 
to the PBMC population was observed between the two study groups. 
5.4.3 Characterisation of T cell subsets 
Flow cytometry was used to characterise T cell subsets present in the 
isolated PBMCs of each subject. Isolated PBMC were stained as per the 
staining template outlined in table 5.4. A representative analysis is shown in 
Figure 5.1, corresponding to patient 2. For analysis, CD3+CD4+ T cells were 
first gated based on CDS and CD4 expression (Figure 5.1 A), and expression 
of the T cell markers CD25, CD45RA, CD45RO, CCR7, CCR4, CXCR3, 
CD62L, CD27, CD69, HLA-DR and CD28 in this population of cells was 
measured. No significant difference in percent expression on CD3+CD4+ T 
cells was found for any of these T cell markers between the two study groups 
(Table 5.5). 
In addition, the co-expression of these T cell markers on the surface of 
CD3+CD4+ cells was analysed but again no significant difference in the 
290 
percentage of cells co-expressing these markers was found between the two 
study groups (Table 5.6). 
5.4.4 RNA quality control for microarray expression study 
The quality and integrity of the RNA isolated from peripheral blood 
PBMCs was initially checked using both a NanoDrop Spectrophotometer and 
an Agilent Bioanalyser. The digital gel image created on the Bioanalyser for 
each sample in the study revealed a clear resolution of the bands 
corresponding to the 18s and 28s ribosomal RNAs. In addition, no detectable 
degradation products were revealed for any of the RNA samples (Figure 5.2). 
Likewise, the electropherograms generated for each sample revealed that 
each sample consisted of intact RNA with no degradation products present 
(Figures 5.3-5.5). 
The ratio of the 18s:28s ribosomal RNA bands reveals the integrity of 
the RNA within a sample. An RNA sample is deemed to be of high integrity 
when this ratio is approximately 2 or higher. The 18s:28s ratios for the twelve 
samples in this study were in the range 1.6 - 2.2, with an average value of 
1.87. An even better indication of the integrity of an RNA sample is the RIN 
generated by the Bioanalyser, with a RIN of 10.0 indicating a perfect RNA 
sample. The RIN for the twelve samples in the study were in the range 9.0 -
10.0, with an average value of 9.65 (Figures 5.3-5.6). These results indicate 
that the RNA isolated for use in this study was of a sufficiently high quality and 
integrity for the subsequent microarray experiment. A summary of the quality 
control for each patient sample is shown in figure 5.6. 
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Donor To ta l W B C (x10®)/Litre L y m p h Neut Mon Baso E o s * * 
% CD4 o f 
PBMC 
% CDS of 
PBMC 
% CD4 of 
CDS 
% C D 1 4 o f 
P B M C 
% CD19 of 
PBMC 
1 N/D N/D N/D N/D N/D N/D 29.7 54.1 54.2 N/D N/D 
2 5.6 1.6 3.0 0.7 0.1 0.3 25.8 46.6 54.4 25.0 4.5 
3 5.4 1.6 3.1 0.4 0.1 0.2 27.4 55.6 48.2 19.0 1.4 
4 N/D N/D N/D N/D N/D N/D 29.2 66.4 43.5 18.2 8.5 
5 6.3 1.6 3.8 0.5 0.0 0.3 33.5 58.2 56.3 19.5 4.1 
6 4.3 1.6 1.9 0.4 0.0 0.3 36.9 57.9 61.8 17.3 5.5 
Summary 5.4 
^ 4 . 3 - 6 . 3 ; 
1.6 
(1.6-
1.6) 
3.0 
(1.9-
3.8; 
0.5 
(0.4-
0.7) 
0.05 
(0-
0.1) 
0.3 
(0.2-
0.3; 
30.4 (25.8-
36.9) 
56.4 (46.6 — 
66.4) 
53.0 (43.5 
-61.8) 
19.8(17.3-
25; 
4.8 
(1.4-8.5) 
7 5.6 1.7 3.0 0.4 0.1 0.2 13.4 28.0 39.0 N/D N/D 
8 6.4 2.5 3.3 0.3 0.1 0.1 36.8 61.8 57.8 N/D N/D 
9 6.5 2.2 3.6 0.4 0.0 0.1 19.3 56.6 32.0 N/D N/D 
10 6.2 1.7 4.0 0.3 0.0 0.1 32.4 71.0 44.3 N/D N/D 
11 3.9 1.3 2.1 0.2 0.0 0.0 27.0 43.0 61.4 17.2 5.9 
12 7.4 2.7 3.8 0.7 0.1 0.1 19.0 46.0 40.5 21.7 2.9 
Summary 6.0 
^ 3 . 9 - 7.4; 
2.0 
(1.3-
2.7) 
3.3 
(2.1-
4.0) 
0.4 
(0.2-
0.7) 
0.05 
(0 -
0.1) 
0.1 
(0 -
0.2) 
24.6(19.0-
3GU% 
51.0 
(28-71) 
45.8 
(32-61.4) 
19.5(17.2-
21.7) 
4.4 
(2.9-5.9) 
Table 5.3 Differential cell counts from asthmatic and non-asthmatic patients 
Differential cell counts were performed on a sample of peripheral blood taken from asthmatic (1-6) and non-asthmatic (7-12) donors 
involved in this study, to determine numbers of total white blood cells (WBC), lymphocytes (Lymph), neutrophils (Neut), monocytes 
(Mon), basophils (Bas), and eosinophils (Eos). Flow cytometry was used to determine the % CD4+, % CD3+, % CD14+, and % 
CD19+ cells contributing to the isolated PBMC population. Summary is median and range. N/D = Not done. Statistical comparisons 
were performed between the two population groups using a Mann Whitney U test. ** denotes 0.0095 
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TUBE FL1 (FITC) FL2 (PE) FL3 (TR) FL4 (APC) 
1 
2 CD45RA 
3 CCR4 
4 CD4 
5 CD62L 
6 CDS 
7 CD4 
8 Ms lgG2b Ms lgG2a CDS CD4 
9 Ms lgG2a Ms IgGI CDS CD4 
10 Ms IgGI Ms IgGI CDS CD4 
11 Ms IgGI Ms lgG2a CDS CD4 
12 Ms lgG2a Ms lgG2a CDS CD4 
13 Ms lgG2b Ms IgGI CDS CD4 
14 CD45RA CCR7 CDS CD4 
15 CD45RO CCR7 CDS CD4 
16 CD45RA CD25 CDS CD4 
17 CD45RO CD25 CDS CD4 
18 CD28 CD25 CDS CD4 
19 CD27 CCR7 CDS CD4 
20 CD27 CD25 CDS CD4 
21 CD25 CCR7 CDS CD4 
22 CD45RA CD62L CDS CD4 
23 CD45RO CD62L CDS CD4 
24 HLA-DR CD25 CDS CD4 
25 CD69 CD25 CDS CD4 
26 CCR4 CXCR3 CDS CD4 
27 CD14 CD19 CDS CD4 
Table 5.1 FACS staining template used to phenotype PBMC from 
asthmatic and non-asthmatic donors. 
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Figure 5.1 Representative FACS analysis of PBMC from an asthmatic 
donor 
PBMC were isolated from peripheral blood and stained according to the 
template in table 5.1. CD3+CD4+ T cells were gated as in (a) and co-
expression of various cell surface markers on CD3+CD4+ T cells is shown in 
(b-n). Expression of CD14 and CD19 from ungated PBMC is shown in (o). 
Shown here are the results from donor 2. 
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Donor % CD25+ % CD25- % CD25hi 
% 
CD45RA 
% 
CD45RO 
% CCR7 % CCR4 % CXCR3 
% CD62L % CD27 % CD69 % HLA-DR 
% CD28 % FoxP3 
1 3.2 96.7 1.4 70.1 51 16.1 49.4 0.7 93.5 91.5 0.5 2.7 92.7 ND 
2 9.7 90.3 3.1 42.4 62 3 8.8 69 1.3 85.4 86.6 1.6 3.9 95 2.62 
3 5.9 94 2.2 52.7 48 11.2 44.2 0.7 87.9 92.9 0.7 4.7 98.8 2.57 
4 4.0 96 1.2 45.5 58.3 9.3 49.1 0.9 87.9 88.7 0.9 1.9 97.3 5.54 
5 4.7 95.3 1.4 51.3 49.7 11.9 58.1 0.9 90.7 90.9 0.6 1.7 97 1.47 
6 8.2 91.8 2.9 32.8 71.6 3.8 47.4 0.5 84.5 87.7 0.8 2.3 97.7 1.57 
Median 
5.9 
f a 2 -
9.7) 
94.0 
96.;^ 
2.0 
(1.2-
3.1) 
49.1 
(32.8-
T D j ; 
56.8 
(48-
623% 
10.2 
(8.8-
16.1) 
52.8 
(44.2-
69; 
0.8 
(0.5-
1.3) 
8&3 
(85.5-
93.5; 
8&7 
(86.6-
92.9j 
0.8 
(0.5-
1.6) 
2.9 
(1.7-
4.7) 
9&4 
f92.7 
9&(% 
2.75 
(1.47-
5.54) 
7 10 90 2.5 3&5 58.2 3.8 59.4 1.5 74.7 88.2 2.1 5.6 94.8 3.01 
8 2.8 97.2 0.5 71.9 35.4 11.2 69.5 0.3 92.3 92.4 0.5 2.1 98.1 2.56 
9 7 93 2.4 54.9 56 6.3 58.6 1.6 83.1 67.8 0.7 2.7 72.9 3.73 
10 4.5 95.5 1.4 52 47.6 10.2 42.8 0.1 89.1 92.8 0.3 2.4 96.3 ND 
11 6.8 93.1 2.2 48.2 54 12.1 45.2 0.3 89.5 94.5 0.6 2.6 97.7 3.69 
12 8.9 91 2.7 38.1 66.1 8.1 39.9 0.5 83.2 77.1 1.2 2.5 95.5 2.14 
Median 
6.7 
(4.5-
10) 
93.3 
(91-
97.2; 
2.0 
(0.5-
2.7) 
50.6 
f3&7-
52.8 
(35.4-
6&7; 
8.6 
(3.8-
12.1) 
52.5 
^39.9-
69.5) 
0.7 
(0.1-
1.6) 
85.3 
(74.7-
923; 
85.4 
r67.8-
94.5) 
0.9 
(0.3-
2.1) 
3.0 
(2.1-
5.6; 
92.5 
f729 
98. 
ao2 
f274-
3.74j 
Table 5.5 Expression of cell surface markers, intracellular FoxP3 and CTLA-4 on CD3+CD4+ T cells from asthmatic and 
non-asthmatic donors. 
PBMC were purified from peripheral blood of asthmatic (1-6) and non-asthmatic (7-12) patients and stained according to the 
template in table 5.1. Cells were then analysed by flow cytometry. Results shown are % expression on gated CD3+CD4+ T cells for 
each donor. Summary is median and range for both population groups, asthmatic and non-asthmatic. Statistical comparisons were 
performed between the two population groups using a Mann Whitney U test. 
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Donor CD45RA+ CCR7+ 
CD45RO+ 
CCR7+ 
CD45RA+ 
CD25+ 
CD45RO+ 
CD25+ 
CD28+ 
CD25+ 
CD27+ 
CCR7+ 
CD27+ 
CD25+ 
CD25+ 
CCR7+ 
CD45RA+ 
CD62L+ 
CD45RO+ 
CD62L+ 
HLADR+ 
CD25+ 
CD69+ 
CD25+ 
CCR4+ 
CXCR3+ 
1 5.06 5.45 1.34 2.42 4.15 2.95 2.95 0.94 67.7 45.6 0.97 0.08 0.75 
2 2..96 2J8 1.07 9.52 10.3 3.77 7.38 1.21 42.8 46.8 1.26 0.38 1.18 
3 3.19 2.49 0.33 5.32 6.31 3.17 5.07 0.43 53.6 35 1.39 0 0.51 
4 2.06 2.71 0.48 4.63 5.3 1.33 3.06 0.75 44.8 45.3 0.76 0.2 0.84 
5 2.72 2.93 0.48 4.07 5.13 2.2 3.31 0.52 51.6 39.7 0.43 0.23 0.79 
6 2.34 1.47 0.59 4.65 5.19 2.36 5.46 0.61 29.5 55.1 0.61 0.06 0.44 
Median 
3.05 
( 2 0 6 -
5.06) 
2.97 
(1.47-
5.45) 
0.71 
f&33-
7.34 
5.10 
^ . 4 2 -
9.52) 
&06 
(4.15-
VO.3; 
2.63 
(1.33-
37% 
4.53 
(2.95-
7.38; 
0.74 
(0.43-
7.27; 
4&3 
(29.5-
67.7) 
44.5 
(35-
55.1) 
0.9 
(0.43-
1.39) 
0.15 
(0-
0.38) 
0.75 
(0.44 -
^ 7 ^ 
7 2.84 1.69 0.82 5.07 8.68 2.19 6.69 1.01 41 35.9 1.17 1 1.58 
8 3.41 3.6 0.81 3.01 3.39 2.61 1.68 0.53 72.4 27.7 0.66 0.16 0.39 
9 2.51 233 0.91 6.63 6.36 2.81 6.06 0.72 46.7 42.2 1.48 0.16 1.46 
10 3.14 2.2 0.68 3.55 4.26 3.31 4.22 0.58 52.6 36.7 0.78 0.03 0.07 
11 3.87 2.45 0.74 6.51 6.97 3.74 5.47 0.76 46.2 42.6 0.91 0 0.29 
12 1^8 1.86 1.62 6.31 7.36 3.18 5.92 0.78 35.1 46.5 0.8 0.14 0.4 
Median 
2.94 
f ^ 8 8 -
28% 
2.35 
(7.69-
3.6; 
0.93 
(0.68-
7.6^ 
5.14 
(3.01 -
6.63; 
6.17 
(3.39-
&6g 
2.97 
(2.19-
3.74; 
5.0 
(1.68-
6.6^ 
0.73 
(0.58-
7.07; 
49 
(35.1-
72.4; 
3&6 
(27.7-
46.5) 
&96 
(0.66-
^ 4 ^ 
0.24 
(0-
0.16) 
&69 
(0.29 -
1 5 ^ 
Table 5.6. Co-expression of cell surface markers on CD3+CD4+ T cells from asthmatic and non-asthmatic donors. 
Results shown are the % co-expression of the surface markers from table 5.4 on gated CD3+CD4+ T cells from the same 
asthmatic (1-6) and non-asthmatic (7-12) donors. Summary is median and range for both population groups, asthmatic and non-
asthmatic. Statistical comparisons were performed between the two population groups using a Mann Whitney U test. 
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Figure 5.2 Gel Image created by 2100 Agilent Bioanalyser. 
Aliquots of isolated total RNA were run on an RNA 600 Nano LabChip on the 
2100 Agilent Bioanalyser. Shown is the gel image created after samples had 
been electrophoretically separated and quantified using laser detection. This 
gel image is one of three performed and contains patient samples 1, 2,5, 6, 7, 
9, 10, 11 and 12, as well as three mock samples designated M. Patient 
samples 3, 4 and 8 were run on additional LabChips and are not shown here. 
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1 I I I I I 1 r 
20 25 30 35 40 45 50 55 60 [s] 
Patient sample: 1 
RNA concentration: 23ng/|.i[ 
rRNA ratio (28s: 18s): 1.6 
RNA Integrity Number (RIN): 9.0 
1 0 0 -
I I I I I I I I I r 
20 25 30 35 40 45 50 55 60 [s] 
Patient sample: 2 
RNA concentration: 225ng/)il 
rRNA ratio (28s: 18s): 2.0 
RNA Integrity Number (RIN): 9.7 
1 0 0 -
1 — I 1 — I r — I — n — I — I r 
20 25 30 35 40 45 50 55 60 65 [s] 
Patient sample: 3 
RNA concentration: 430ng/|.il 
rRNA ratio (28s: 18s): 1.9 
RNA Integrity Number (RIN): 9.6 
1 I I I I I r 
20 25 30 35 40 45 50 55 60 65 [s] 
Patient sample: 4 
RNA concentration: 200ng/|.il 
rRNA ratio (28s: 18s): 1.9 
RNA Integrity Number (RIN): 9.7 
Figure 5.3 RNA quantity and quality control using 2100 Agilent 
Bioanalyzer, samples 1-4. 
RNA electrpherogram profiles (fluorescence intensity versus migration time) 
generated from the 2100 Agilent Bioanalyser for patient samples 1-4. Also 
shown is the RNA concentration, rRNA ratio (28s: 18s) and RNA Integrity 
Number (RIN) for each sample, generated by the analysis of the 
electropherogram profiles by the Bioanalyser's software. 
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1 I r 
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Patient sample: 5 
RNA concentration: 192 ng/pl 
rRNA ratio (28s: 18s): 1.8 
RNA Integrity Number (RIN): 9.9 
Patient sample: 6 
RNA concentration: 256 ng/jul 
rRNA ratio (28s:IBs): 1.9 
RNA Integrity Number (RIN): 9.8 
Patient sample: 7 
RNA concentrat ion: 54 ng/|Lil 
rRNA ratio (28s: 18s): 1.9 
RNA Integrity Number (RIN): 10 
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Figure 5.4 RNA quantity and quality control using 2100 Agilent 
Bioanalyzer, samples 5-8. 
RNA electrpherogram profiles (fluorescence intensity versus migration time) 
generated from the 2100 Agilent Bioanalyser for patient samples 5-8. Also 
shown is the RNA concentration, rRNA ratio (28s: 18s) and RNA Integrity 
Number (RIN) for each sample, generated by the analysis of the 
electropherogram profiles by the Bioanalyser's software. 
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RNA concentrat ion: 326 ng/|Lil 
rRNA ratio (28s: 18s): 1.7 
RNA Integrity Number (RIN): 9.4 
Figure 5.5 RNA quantity and quality control using 2100 Agilent 
Bioanalyzer, samples 9-12. 
RNA electrpherogram profiles (fluorescence intensity versus migration time) 
generated from the 2100 Agilent Bioanalyser for patient samples 9-12. Also 
shown is the RNA concentration, rRNA ratio (28s: 18s) and RNA Integrity 
Number (RIN) for each sample, generated by the analysis of the 
electropherogram profiles by the Bioanalyser's software. 
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Figure 5.6 Summary of quality and quantity of RNA isolated from patient 
samples. 
Total RNA was isolated from 5x10® PBMC from 6 asthmatic (1-6) and 6 non-
asthmatic (7-12) patients. The quality of the isolated mRNA was then 
determined by measuring the ratio of the ribosomal bands 28s/18s and the 
RNA integrity (RIN) using an Agilent Bioanalyzer. The quantity of isolated 
RNA was quantified using the NanoDrop ND-1000 Spectrophotometer. The 
ratios of 28s/18s should be 1 .9 -2 .1 and a perfect RNA integrity from Agilent 
is a 10.0. 
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5.4.5 Microarray analysis and visualisation using GeneSpring 
As outlined in the methods section, two Sentrix Human-6 expression 
BeadChips, each containing six individual microarrays, were used to compare 
the blood leukocyte gene expression profile between six normal and six 
asthmatic samples. Three samples from each patient group were hybridised 
to each BeadChip - the first included the samples 2, 5, 6 (asthma samples), 
7, 11 and 12 (normal samples) and the second BeadChip included samples 1, 
3, 4 (asthma samples), 8, 9 and 10 (normal samples). The text files created by 
the lllumina BeadArray Reader and software were imported into GeneSpring 
GX 7.3.1 for further analysis and visualisation of the microarray experiment. 
Normalisation of samples 
The first step in the analysis involved the normalisa tion of the data. 
GeneSpring allows for a number of different normalisations to be performed. 
For this analysis the normalisation used was to normalise each gene in 
reference to specific samples, in this case the six control samples. This is 
achieved by dividing each gene in each of the asthma samples by the 
average intensity for that gene obtained for the control samples. 
Gene Filtering 
A number of gene filters can be used to sort through the masses of 
expression data generated by a microarray experiment. Genes can be filtered 
on any data associated with the genes and any genes that pass a filter can be 
made into a list. Filtering is typically a multi-step process in which the result of 
the first filter becomes input for subsequent filters. For the analysis of this 
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experiment genes were first filtered based on the detection of a signal in a 
given number of the samples in the experiment. The list of genes created was 
further filtered on fold change to generate a list of genes differentially 
expressed between the two sample groups. Finally, the list of genes passing 
the fold change filter was filtered based on statistical analysis to filter for 
significantly differential gene expression between the two sample groups. 
Filtering on Data File 
The first step following normalisation of the data involved the filtering of 
genes within each sample group to generate a "quality control" gene-list. 
Essentially this is filtering the genes to generate a list of those that pass the 
detection limits of the experiment. The detection limit is set at greater than 
0.99 and the user can specify in how many samples the gene must be 
detected for it to be included in this quality control gene list. For the purposes 
of this experiment four different quality control gene lists were created. 
Firstly, a list of genes that passes the detection limit of greater than 
0.99 in at least 3 out of the 6 asthma samples was created. The list created in 
this way contained 11,990 genes. Similarly, a list of genes that passed the 
same detection limit in at least 3 out of the 6 control samples was created. 
This gene-list contained 12,188 genes. Finally, to create the quality-control 
gene list for genes appearing in at least 3 out of 6 samples for each group, a 
combined gene list was created from those that passed the detection limit for 
either sample group. The venn diagram shown in Figure 5.7 A outlines the 
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number of genes contained in each gene list and those common to both. The 
final quality control gene list created contained 12,578 genes. 
To create more stringent quality-control gene lists, the above filtering 
was repeated sequentially to include only those genes present in at least 4 out 
of the 6 samples in either group, then 5 out of the 6 samples, then all of the 
samples in each group. The Venn diagrams for these filters are shown in 
Figure 5.7 B-D. The quality control gene lists generated in this way contained 
11,918 genes (at least 4 out 6 samples), 11,329 genes (at least 5 out of 6 
samples) and 10,651 genes (6 out of 6 samples). The quality control gene list 
present in at least 4 out of 6 samples (11,918 genes) was chosen as the basis 
for further analysis and was subsequently used as input for the next gene filter 
based on fold change. 
Filter on Fold Change 
Filtering on Fold Change filters genes based on a comparison of two 
samples or conditions. By applying this filter to this experiment genes 
differentially expressed between the asthma and control groups can be 
identified. Using one of the four quality control gene lists outlined above as the 
starting list and setting the fold change at 2 creates a list of genes that are 
over-expressed or under-expressed by at least 2-fold between the two study 
groups. Applying this filter to the quality control gene list present in at least 4 
out of 6 samples outlined above (11,918 genes) generated a list of 104 genes 
differentially expressed between the asthma and control samples. Of these 
104 differentially expressed genes, 24 were over-expressed in asthma 
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samples compared to control, while 80 were under-expressed. A line graph of 
these differentially expressed genes is shown in Figure 5.8 (A). Additionally, a 
gene tree, created by clustering these genes based on similar expression 
profiles is shown in Figure 5.8 (B). 
Filter on statistical significance 
The gene list created by filtering on fold change (104 genes) was used 
as input for the final gene filter, filtering on statistical significance between the 
two sample groups. A Mann Whitney test was performed on this gene list to 
statistically compare mean expression levels of each gene between the two 
groups of samples. The test identifies the set of genes that show statistical 
differences between the two sample groups with a cut-off of p < 0.05. The 
gene list identified by this statistical analysis contained 65 genes with 11 over-
expressed and 54 under-expressed in asthma compared to control samples. 
A line graph of these statistically significant differentially expressed genes is 
shown in Figure 5.9 (A). Additionally, a gene tree, created by clustering these 
genes based on similar expression profiles is shown in Figure 5.9 (B). 
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a) At least 3/6 samples 
12,578 genes 
b) At least 4/6 samples 
11,918 genes 
QC asthma 3out6 (11,990) OC normal 3out6 (12, 
11600 
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all genes 
35374 
aH genes 
c) At least 5/6 samples 
11,329 genes 
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QC asthma 5out6 (10,825) QC normal 5out6 (11,043) QC asthma ALL (10,087) QC normal ALL (10,358) 
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al genes 
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all genes 
Figure 5.7 Venn Diagrams showing the quality control gene lists created 
by filtering on data file. 
Shown is the venn diagram corresponding to genes present in (a) at least 3/6 
samples in each group, (b) at least 4/6 samples in each group, (c) at least 5/6 
samples in each group and (d) all of the samples in each group. The number 
of genes specific for asthma (red), normal controls (green) and common to 
both (yellow) is shown. 
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Figure 5.8 Genes differentially expressed between asthma and control 
samples, filtered on fold change. 
Genes present in the quality control gene list, present in at least 4/6 samples 
for each group (11,918 genes), were filtered on 2x fold change. Shown is the 
line graph (a) and gene tree (b) for the resulting gene list passing the fold 
change filter. The line graph (a) shows each individual gene's normalised 
expression (y-axis) for each sample (x-axis). The gene tree (b) shows the 
identified genes, clustered based on similar expression profiles. A total of 104 
genes passed this filter; 24 over-expressed and 80 under-expressed in 
asthma samples compared to control samples. 
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Figure 5.9 Genes differentially expressed between asthma and control 
samples, filtered on statistical significance. 
Genes present In the filtered on fold change gene list (104 genes), were 
filtered based on statistical significance using a Mann Whiltney test. Shown is 
the line graph (a) and gene tree (b) for the resulting gene list passing the 
statistical significance filter. The line graph (a) shows each individual gene's 
normalised expression (y-axis) for each sample (x-axis). The gene tree (b) 
shows the identified genes, clustered based on similar expression profiles. A 
total of 65 genes passed this filter: 11 over-expressed and 54 under-
expressed in asthma samples compared to control samples. 
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5.3.5 Differentially expressed genes between asthma and healthy 
controls 
Microarray analysis of peripheral blood leukocytes from asthmatic and 
non-asthmatic individuals identified 65 gene targets as being differentially 
expressed between the two sample groups. Of these differentially expressed 
gene targets, 11 were over-expressed and 54 under-expressed in asthma 
compared to control samples. The identified over-expressed and under-
expressed gene targets are listed in Table 5.7 and Table 5.8 respectively. 
Literature and public gene database searches revealed that 6 of the 11 
identified over-expressed gene targets corresponded to known genes -
ABLIM3, SLC24A3, ZNF576, GPRC5B, PI3 and PVRL2. The normalised 
expression of these genes in each sample is shown in Figure 5.10. Similarly, 
13 of the 54 identified under-expressed gene targets corresponded to known 
genes - PARP15, PDGFD, MYBL1, CTRC, UBE21, ATF4, SNF1LK, TAGLN, 
CMIP, RASD1, NR4A2, BCR and RASSF5. The normalised expression of 
these genes in each sample is shown in Figure 5.11. The remaining 
differentially expressed gene targets identified corresponded to UniGene 
clusters (sequences that represent a unique gene that have been deposited in 
the GenBank database), putative gene transcripts predicted by Gnomon, open 
reading frames identified in the human genome and hypothetical proteins for 
which no experimental evidence exists as yet for its expression in vivo 
(Wheeler et al., 2007; Benson et al., 2007). 
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Gene target ID. Common name Normalised mean 
expression Asthma 
Normalised mean 
expression Healthy 
Poliovirus receptor-related 2 PVRL2 2.460 1.00 
Hypothetical protein FLJ20481 FLJ20481 2.603 1.00 
Protease inhibitor 3 (SKALP) PI3 3.611 1.00 
Chromosome 14 open reading 
frame 132 C14orf132 2.441 1.00 
G protein-coupled receptor 
family C group 5 member B GPRC5B 2.186 1.00 
Homo sapiens KIAA1463 
protein N/A 3.630 1.00 
Similar to transmembrane helix 
receptor (LOC401428) mRNA N/A 2.005 1.00 
Zinc finger protein 576 ZNF576 2.378 1.00 
Solute carrier family 24 
member 3 SLC24A3 2.316 1.00 
Hypothetical protein FLJ13262 N/A 2.313 1.00 
Actin binding LIM protein 
family member 3 ABLIM3 2.030 1.00 
Table 5.7 Gene targets over-expressed in asthma samples compared to healthy controls. 
Shown is the list of gene targets identified as statistically significant over-expressed in asthma samples compared to control 
samples. Columns show gene target ID, common gene name (if known, N/A = not applicable), normalised mean expression for the 
6 asthma samples and normalised mean expression for the 6 healthy control samples. Gene targets corresponding to known genes 
are highlighted in italics. 
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Gene target ID Common 
name 
Normalised mean 
expression Asthma 
Normalised mean 
expression Healthy 
UniGene Cluster 306733 N/A 0.430 1.00 
RefSeq Gnomon gene hmm7706 N/A 0.463 1.00 
UniGene Cluster 522502 N/A 0.539 1.00 
Homo sapiens LOC221931 mRNA N/A 0.365 1.00 
UniGene Cluster 378430 N/A 0.486 1.00 
UniGene Cluster 517064 N/A 0.535 1.00 
Hypothetical protein MGC16384 mRNA N/A 0.454 1.00 
RefSeq Gnomon gene hmm1412 N/A 0.448 1.00 
UniGene cluster 356457 N/A 0.466 1.00 
Ras association (RalGDS/AF-6) donnain family 5 
transcript variant 2 RASSF5 0.408 1.00 
UniGene Cluster 459430 N/A 0.440 1.00 
UniGene Cluster 469811 N/A 0.486 1.00 
Homo sapiens similar to PI-3-kinase-related 
kinase SMG-1 isoform 2 N/A 0.451 1.00 
UniGene Cluster 510289 N/A 0.474 1.00 
UniGene Cluster 469811 N/A 0.512 1.00 
UniGene Cluster 469875 N/A 0.461 1.00 
UniGene Cluster 382708 N/A 0.487 1.00 
Breakpoint cluster region transcript variant 1 BCR 0.374 1.00 
Nuclear receptor subfamily 4 group A member 2 
transcript variant 4 NR4A2 0.431 1.00 
Table 5.8 Gene targets under-expressed in asthma samples compared to healthy controls. 
Continued on next page. 
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Gene target ID Common 
name 
Normalised mean 
expression Asthma 
Normalised mean 
expression Healthy 
RAS dexamethasone-induced 1 RASD1 0.305 1.00 
Ataxia telangiectasia mutated transcript variant 3 N/A 0.418 1.00 
UniGene Cluster 468267 N/A 0.406 1.00 
UniGene Cluster 483413 N/A 0.454 1.00 
Homo sapiens FLJ20202 protein mRNA FAM46C 0.424 1.00 
c-Maf-inducing protein transcript variant C-mip 
mRNA CMIP 0.438 1.00 
UniGene Cluster 507163 N/A 0.466 1.00 
UniGene Cluster 462969 N/A 0.441 1.00 
UniGene Cluster 485761 N/A 0.438 1.00 
Transgelin TAGLN 0.474 1.00 
UniGene Cluster 443417 N/A 0.443 1.00 
UniGene Cluster 406820 N/A 0.453 1.00 
UniGene Cluster 506784 N/A 0.405 1.00 
UniGene Cluster 9333 N/A 0.460 1.00 
UniGene Cluster 503979 N/A 0.469 1.00 
SNF1-iike kinase SNF1LK 0.496 1.00 
Homo sapiens LOC282956 N/A 0.431 1.00 
Activating transcription factor 4 (tax-responsive 
enhancer element b67) ATF4 0.392 1.00 
UniGene Cluster 475082 N/A 0.449 1.00 
Chromosome 6 open reading frame 59 C6orf59 0.429 1.00 
UniGene Cluster 407647 N/A 0.440 1.00 
Table 5.8 (continued) Gene targets under-expressed in asthma samples compared to healthy controls. 
Continued on next page. 
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Gene target ID Common 
name 
Normalised mean expression 
Asthma 
Normalised mean expression 
Healthy 
UniGene Cluster 487323 N/A 0.433 1.00 
UniGene Cluster 475430 N/A 0.420 1.00 
Ubiquitin-conjugating enzyme E2I transcript 
variant 2 UBE2I 0.414 1.00 
Chymotrypsin C (caldecrin) CTRC 0.467 1.00 
UniGene Cluster 452714 N/A 0.473 1.00 
v-myb myeloblastosis viral oncogene homolog 
(avian)-like 1 MYBL1 0.454 1.00 
Platelet derived growth factor D transcript 
variant 2 PDGFD 0.477 1.00 
Homo sapiens LOC388301 mRNA N/A 0.491 1.00 
Poly (ADP-ribose) polymerase family, member 
15 PARP15 0.428 1.00 
UniGene Cluster 493679 N/A 0.470 1.00 
UniGene Cluster 475611 N/A 0.356 1.00 
UniGene Cluster 509544 N/A 0.448 1.00 
UniGene Cluster 189409 N/A 0.473 1.00 
UniGene Cluster 514879 N/A 0.440 1.00 
Table 5.8 (continued) Gene targets under-expressed in asthma samples compared to healthy controls. Shown is the list of 
gene targets identified as statistically significant under-expressed in asthma samples compared to control samples. Columns show 
gene target ID, common gene name (if known, N/A = not applicable), normalised mean expression for the 6 asthma samples and 
normalised mean expression for the 6 healthy control samples. Gene targets corresponding to known genes are highlighted in 
italics. 
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Figure 5.10 Genes over-expressed in asthma compared to control 
samples. 
Graphs a-f showing the normalised expression for genes identified as being 
over-expressed in asthma samples compared to healthy controls. Of the final 
list of over-expressed genes, 6 of the 11 identified gene targets corresponded 
to known genes in public databases and these 6 genes are shown here, 
namely (a) ABLIM3, (b) SLC24A3, (c) ZNF576, (d) GPRC5B, (e) PIS and (f) 
PVRL2. Also shown is the p value generated by statistical comparison of the 
two sample groups using a Mann Whitney U test. In addition, the data-points 
corresponding to asthma samples 4 and 5 are indicated on each graph. 
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Figure 5.11 (continued) Genes under-expressed in asthma compared to 
control samples. 
Graphs a-m showing the normalised expression for genes identified as being 
under-expressed in asthma samples compared to healthy controls. Of the final 
list of under-expressed genes, 13 of the 54 identified gene targets 
corresponded to known genes in public databases and these 13 genes are 
shown here, namely (a) PARP15, (b) PDGFD, (c) MYBL1, (d) CTRC, (e) 
UBE21, (f) ATF4, (g) SNF1LK, (h) TAGLN, (i) CMIP, (j) RASD1, (k) NR4A2, (I) 
BCR and (m) RASSF5. Also shown is the p value generated by statistical 
comparison of the two sample groups using a Mann Whitney U test. In 
addition, the data-points corresponding to asthma samples 4 and 5 are 
indicated on each graph. 
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5.4 Discussion 
The results outlined in this chapter describe the identification of a 
peripheral blood leukocyte gene signature in asthma. Using microarray 
technology, statistically significant genes differentially expressed in peripheral 
blood leukocytes isolated from asthmatic and healthy control individuals were 
identified. Analysis of gene expression from six mild symptomatic asthmatic 
and six healthy control samples revealed the over-expression of 11 gene 
targets and under-expression of 54 gene targets in asthmatic individuals. Of 
the identified gene targets, 6 of the over-expressed group and 13 of the 
under-expressed group represent known genes. These known genes and 
their relevance or potential relevance to asthma pathology are discussed in 
more detail below. However, with regard to regulatory T cells, no apparent link 
between any differentially expressed gene and regulatory T cell function can 
be identified in the published literature. Further experiments examining the 
expression of these genes in regulatory T cells purified from the peripheral 
blood of asthmatic and non-asthmatic individuals will be required to determine 
if the genes identified are differentially expressed within the regulatory T cell 
subset in asthmatic individuals. 
To complement the microarray experiment, flow cytometry was used to 
quantify the cell populations present in the PBMC population isolated from the 
peripheral blood of the same 12 patient samples. It was the hypothesis of the 
project that differences in peripheral blood leukocyte number, specifically 
differences in T cell subsets, may be reflective of asthma pathology. However, 
this hypothesis was not substantiated by the results presented here. No 
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significant differences in tlie numbers of lympliocytes, neutrophils, monocytes, 
basophils, T cells or B cells was noted in the PBMC population isolated from 
both patient groups. However, a significant increase in the number of 
eosinophils present in asthmatic peripheral blood was revealed, in agreement 
with previous studies (Bousquet et al., 1990; Schwartz and Weiss, 1993). 
In addition, the contribution of a number of different T cell subsets to 
the PBMC population was investigated. Again, no significant difference in 
these T cell subsets was observed in the peripheral blood of the two study 
groups. Similar numbers of activated CD4+CD25+ (Uchiyama et al., 1981) or 
CD4+CD69+ T cells (Cebrian et al., 1988), CD4+CD25high regulatory T cells 
(Baecher-Allan et al., 2001), naive CD4+CD45RA+ T cells (Michie et al., 
1992), memory CD4+CD45RO+ T cells (Michie et al., 1992), central memory 
CD4+CD45RO+CCR7+ T cells (Sallusto et al., 1999), effector memory 
CD4+CD45RO+CCR7- T cells (Sallusto et al., 1999), activated CD4+CXCR3+ 
Thi cells (Bonecchi et al., 1998), and activated CD4+CCR4+ Th2 cells 
(Bonecchi et al., 1998) were found in peripheral blood of asthmatic and non-
asthmatic individuals. In light of these results it must be concluded that 
although peripheral blood eosinophil number is a marker for asthma 
pathology, mild asthma is not characterised by changes in any other 
peripheral blood leukocyte number. This is in agreement with previous studies 
that have demonstrated normal numbers of T cells in the peripheral blood of 
mild non-symptomatic asthmatics, while increases in activated T cells were 
noted in the peripheral blood of more severe asthmatics with current 
symptoms (Robinson et al., 1993b). 
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The number of regulatory T cells in the peripheral blood of asthmatic 
individuals and healthy controls was compared using two methods to identify 
regulatory T cells. Regulatory T cells were identified based on their high 
expression of CD25 (CD4+CD25high) or on their expression of F0XP3 
(CD4+FOXP3+). No differences in regulatory T cell numbers in the peripheral 
blood of asthmatic individuals and healthy controls was observed using either 
of these methods. This is in agreement with a number of previous studies that 
could not identify increased or decreased numbers of regulatory T cells in the 
peripheral blood of asthmatic individuals. It can therefore be concluded that 
the defective function of regulatory T cells isolated from the peripheral blood 
of atopic individuals, previously reported by our group (Ling et al., 2004), is 
not coupled to changes in number of regulatory T cells present in the 
peripheral blood of these individuals. 
Although disproving one part of the hypothesis of these experiments, 
the finding of no differences in peripheral blood leukocyte number between 
the two study groups strengthened the findings of the subsequent microarray 
study. The differentially expressed genes identified cannot be explained by 
increases in specific cell numbers and so are likely to represent true 
differential expression by peripheral blood leukocytes. 
One aspect of the study that must be noted is the inclusion of two 
asthma patients who demonstrated a PC20 value of greater than 16. Both 
patients had demonstrated a PC20 of less than 16 in a previous study and 
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were therefore chosen for inclusion in this study. It cannot be ruled out that 
one or both of these patients is not asthmatic but it is likely that both are, 
based on previous methacholine challenge tests and on clinical history. The 
discrepancy between the methacholine challenge test results on these two 
patients for this study and the previous study is likely explained by the fact 
that mild non-symptomatic asthmatics were chosen for inclusion in this study. 
The main hypothesis of this study was that comparing gene expression 
in mild asthmatics to healthy controls could identify a peripheral blood 
leukocyte gene signature for asthma. The identification of 65 differentially 
expressed gene targets between these two sample groups supports this 
hypothesis. However, further experiments are required to confirm this gene 
signature in a separate cohort of subjects. Until confirmed in a separate group 
of asthmatic and healthy control subjects, the gene signature identified is only 
potentially characteristic of asthma. However, the number of subjects included 
in each sample group and the stringent subsequent analysis strengthens the 
gene signature identified. 
To confirm this gene signature in further experiments would require 
microarray analysis of peripheral blood leukocytes from 6 mild asthmatic and 
6 healthy control subjects. In addition, a comparison of these two sample 
groups with 6 severe asthmatic individuals would indicate if this gene 
signature is also present in asthma patients with a severe form of the disease. 
The gene expression of peripheral blood leukocytes could be measured from 
these patients before and after allergen challenge, to further define any 
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changes in the identified gene signature during active disease. An experiment 
of this type would fine-tune the identified gene signature to include genes that 
are differentially expressed in all severities of asthma. It would also 
demonstrate if the gene signature is modulated by active disease and could 
be of use as a diagnostic marker for asthma. In addition, the modulation of the 
identified peripheral blood gene signature by glucocorticoid therapy could be 
investigated by taking blood from severe asthmatics after a period of 
abstaining from glucocorticoids and again after glucocorticoid therapy has 
been resumed. 
Recent advances in microarray technology make an experiment of this 
type both possible and affordable. Current cost estimates on performing a 
microarray analysis identical to those done in this study suggest that it can 
cost as little as £100 per sample. In addition, the new Tempus Blood RNA 
Tubes from Applied Biosystems allow the purification of RNA of sufficient 
quality for microarray studies from just 3 ml of whole blood. This again 
highlights the value of peripheral blood as a potential source of clinically 
relevant material that can be easily and repeatedly collected. 
Of the 11 gene targets identified as being over-expressed in asthma 
samples compared to healthy controls, 6 were found to correspond to known 
genes -SLC24A3, PVRL2, PIS, ABLIM3, GPRC5B, and ZNF576. As outlined 
below, a potential link to asthma pathology or the immune cells involved can 
be demonstrated for a number of these genes including SLC24A3, PVRL2 
and PI3. Too little is known about the function of the remaining three genes -
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ABLIM3, GPRC5B and ZNF576 - to demonstrate any potential link to asthma 
pathology. 
Solute Carrier Family 24 member 3 (SLC24A3), also known as 
sodium/potassium/calcium exchanger 3 (NCKX3) encodes a plasma 
membrane K+-dependent Na+/Ca2+ ion exchanger (Kraev et al., 2001). Two 
types of Na+Ca2+ ion exchangers have been described in mammals, K+-
independent and K+-dependent. As yet, three K+-independent and four K+-
dependent ion exchangers have been identified. Aneiros et al examined the 
expression of both types of Na+Ca2+ ion exchangers in rat basophilic 
leukemia mast cells and murine bone marrow-derived mast cells using RT-
PCR and northern blot analysis and demonstrated a predominant expression 
of SLC24A3 (Aneiros et al., 2005). Furthermore the authors demonstrated a 
role for SLC24A3 in the Ca+ homeostasis of mast cells. Calcium plays an 
important role in transmitting signals from the mast cell surface that result in 
mast cell degranulation and release of histamine and other pro-inflammatory 
mediators. Stimulation of cell surface receptors induce the release of Ca+ 
from the endoplasmic reticulum, which in turn trigger the opening of calcium 
channels in the plasma membrane, further increasing and sustaining the 
signal. 
The increased expression of SLC24A3 seen in peripheral blood 
leukocytes isolated from asthmatic individuals may reflect an increase in mast 
cell numbers (or mast cell progenitor cells) in peripheral blood of asthmatics. 
However this is unlikely as mast cells are specifically tissue-resident cells. It 
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may also reflect an increased expression of Na+Ca+ ion exchangers on the 
plasma membrane of mast cells (or other leukocytes) in asthmatic individuals. 
It could be speculated that increased expression of Na+Ca+ ion exchangers 
on mast cells in asthmatic individuals may result in a decreased threshold of 
activation needed for degranulation and release of pro-inflammatory 
mediators. Further experiments on the expression of Na+Ca+ ion exchangers 
on human mast cells, in particular SLC24A3, will be required to investigate 
this possibility. 
Poliovirus receptor-like 2 (PVRL2) was originally identified in mice 
based on its homology to human poliovirus receptor (PVR) (Morrison and 
Racaniello, 1992). Subsequently, the human counterpart was identified 
(Eberle et al., 1995) and has now been designated GD112. PVRL2 and PVR 
have been demonstrated to be ligands for CD226 (Bottino et al., 2003; 
Tahara-Hanaoka et al., 2004). Mast cells and eosinophils both express high 
levels of PVRL2 and mast cells also express high levels of CD226. In addition, 
CD226 has a co-stimulatory function on mast cells; engagement of CD226 
augmented FcsRI-induced mast cell activation (Bachelet et al., 2006). Mast 
cell FcsR1-mediated activation was also augmented in the presence of 
eosinophils and blocking PVRL2 on eosinophils neutralised this effect. These 
results suggest that CD226 and PVRL2 may have a role in modulating the 
allergic response. PVRL2 expression has also been demonstrated on mature 
dendritic cells (Pende et al., 2006). 
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Proteinase Inhibitor 3 (PIS), also known as skin-derived anti-
leukoproteinase (SKALP) or elafin, encodes a neutrophil elastase inhibitor 
originally isolated from psoriatic skin (Schalkwijk et al., 1991) and lung 
secretions (Sallenave et a!., 1992). Elafin protein has been shown to be 
present in the BAL fluid of normal subjects and to be increased significantly in 
the BAL fluid of patients suffering from active farmers lung disease, a form of 
hypersensitivity pneumonitis caused by a hypersensitisation to repeated 
inhalations of certain bacterial or fungal spores (Tremblay et al., 1996). In 
addition to its role as a neutrophil elastase inhibitor, direct anti-microbial 
activities against gram-positive and gram-negative respiratory pathogens have 
also been demonstrated for elafin (Simpson et al., 1999). 
Actin binding LIM protein 3 (ABLIM3) is a member of the large family of 
LIM domain proteins that have been demonstrated to play key roles in various 
biological processes such as embryonic development, cell lineage 
determination and cancer differentiation. ABLIM3 was identified using 
computational biology and comparative genetics, based on its homology to 
two other LIM domain proteins, ABLIM1 and ABLIM2 (Krupp et al., 2006). 
ABLIM1 and ABLIM 2 are suggested to be a possible bridging molecules 
between the actin-based cytoskeleton and signalling pathways (Roof et al., 
1997). In support of this hypothesis, ABLIM3 has been demonstrated to 
directly bind F-actin (Barrientos et al., 2006). No link between ABLIM3 and 
asthma or allergic disease exists in the published scientific literature. 
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G protein-coupled receptor family C group5 member B (GPRC5B), also 
known as retinoic acid-inducible gene 2 (RAIG2) is a member of the 7 
transmembrane G protein-coupled receptor superfamily, the largest known 
protein family in humans (Robbins et al., 2000; Brauner-Osborne and 
Krogsgaard-Larsen, 2000). GPCRs have been grouped into four classes 
based on structural homology and functional similarity, Class A, B, C and D. 
Class C GPCRs regulate a number of important physiological functions and 
consist of the metabotropic glutamate receptor family, the GABA receptor, the 
calcium-sensing receptor and five orphan receptors of which GPRC5B is one. 
Although there is no information about GPRC5B in the published literature, 
the class C subfamily of GPCRs is being intensively pursued as drug targets 
(Brauner-Osborne et al., 2007). 
Zinc finger protein 576 (ZNF576) as its name suggests, is a member of 
the large family of zinc finger proteins that can interact with DNA and RNA via 
a zinc finger motif (Brown, 2005). There is, however, no information on 
ZNF576 in the published literature, and its relevance to asthma pathology is 
unknown. 
Of the 54 gene targets identified as being under-expressed in asthma 
samples compared to healthy controls, 13 were found to correspond to known 
genes - PARP15, PDGFD, MYBL1, CTRC, UBE21, ATF4, SNF1LK, TAGLN, 
CMIP, RASD1, NR4A2, BCR and RASSF5. While a role for many of these 
genes in the function of immune cells has not been identified, as outlined 
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below, some including NR4A2 and TAGLN, may play a role in the immune 
cells responsible for asthma pathology. 
The TAGLN gene encodes a protein designated transgelin or SM22-
alpha that is expressed at high levels in smooth muscle cells (Solway et al., 
1995). Transgelin has been demonstrated to bind to actin filaments and may 
therefore play a role in smooth muscle contraction (Fu et al., 2000). No 
expression of transgelin has been reported in immune cells and so it is 
unclear what peripheral blood leukocyte could account for the under-
expression of transgelin in asthma reported in this study. A role for transgelin 
in repressing matrix metalloproteinase 9 (MMP-9) expression, that is 
independent of its actin-binding, has recently been demonstrated (Nair et al., 
2006). 
MMP-9 is present in normal lung but is elevated in a number of lung 
diseases, including asthma. MMP-9 levels in BAL fluid increase upon allergen 
challenge (Kelly et al., 2000). This increase in MMP-9 has prompted 
speculation that it may play a role in the inflammatory or tissue remodelling 
processes in asthma (Atkinson and Senior, 2003). Many lung resident cells, 
as well as inflammatory cells infiltrating the lung, can produce MMP-9. MMP-9 
expression has been demonstrated for macrophages (Welgus et al., 1990), 
eosinophils (Ohno et al., 1997), mast cells (Kanbe et al., 1999), T cells 
(Weeks et al., 1993), NK cells (Albertsson et al., 2000) and dendritic cells 
(Bartholome et al., 2001). If indeed MMP-9 does play a role in the pathology 
of asthma, the under-expression of transgelin in asthmatic peripheral blood 
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leukocytes may reveal a mechanism by which decreased repression of MMP-
9 expression by transgelin results in increased MMP-9 expression by 
peripheral blood leukocytes in asthma. 
Interestingly, in the gene array study by Zou et al describing 
differentially expressed genes in the lungs of allergen-challenged monkeys, 
mentioned in the introduction to this chapter, transgelin gene expression was 
reported to be one of those over-expressed in allergen-challenged lung (Zou 
et al., 2002). In this study, transgelin mRNA expression was up-regulated in 
allergen-challenged lung four hours after allergen-challenge. Expression was 
still elevated at 18 hours and returned to similar levels as control at 24 hours 
after allergen challenge. 
Nuclear receptor subfamily 4, group A, member 2 (NR4A2 or NURR1) 
encodes a member of the nuclear receptor superfamily. Unlike other nuclear 
receptors whose ligands have been identified, the ligand for NR4A2 has yet to 
be discovered and it is referred to as an orphan receptor. Furthermore, recent 
evidence suggests that NR4A2 does not possess a domain suitable for ligand 
binding and may be activated in a ligand-independent manner, possibly via 
control of protein expression or post-translational modification (Wang et al., 
2003). NR4A2 has been shown to play a role in the differentiation of 
dopaminergic neurons (Zetterstrom et al., 1997) and mutations in NR4A2 can 
cause dopaminergic dysfunction that has been associated with Parkinson's 
Disease (Le et al., 2003). In addition, a number of studies have implicated a 
role for NR4A2 in inflammation and immune cell function. McEvoy et al 
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demonstrated increased expression of NR4A2 in synovial tissue of 
rheumatoid arthritis patients compared to healthy controls. Expression was 
increased in synoviocytes upon in vitro stimulation with the proinflammatory 
cytokines IL-1(3, TNF-a or PGE2 (McEvoy et al., 2002). Expression of NR4A2 
is also induced in macrophages by inflammatory stimuli such as cytokines 
(TNF-a) and the TLR ligand LPS (Pei et al., 2005). 
A number of studies have demonstrated an expression profile for 
NR4A2 that supports the finding presented here of lower expression in 
peripheral blood leukocytes from asthmatic individuals. In a microarray study 
comparing gene expression profiles of CD4+ T cells from atopic dermatitis 
(AD) patients and healthy controls, under-expression of NR4A2 was observed 
in the AD group. This under-expression of NR4A2 was subsequently 
confirmed by RT-PCR (Hijnen et al., 2005). It should also be noted that this 
study also investigated the expression of NR4A2 in asthma patients by RT-
PCR as a comparison to the AD sample group. The authors reported no 
difference between asthma and healthy individuals in expression of NR4A2 in 
CD4+ T cells. One difference between the study by Hinjen et al and the study 
outlined in this chapter is the use of corticosteroids by asthmatic individuals 
prior to obtaining a blood sample. While patients included in this study 
abstained from corticosteroids (but not Salbutamol - a short acting P2-
adrenergic receptor agonist), those in the Hinjen et al study did not abstain. 
Potentially, NR4A2 could be differentially expressed in CD4+ T cells from 
asthmatic individuals and this expression may be normalised by glucocorticoid 
therapy. 
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In a similar microarray study, this time focusing on eosinophils isolated 
from peripheral blood of AD patients and healthy controls, expression of 
NR4A2 as well as two other members of this nuclear receptor family was 
found to be over-expressed in eosinophils from AD patients (Kagaya et al., 
2005). However, when peripheral blood leukocytes from healthy patients were 
fractionated, NR4A2 expression was not eosinophil-specific, while NR4A3 
expression was highest in eosinohils. This suggests that NR4A2 may play a 
role in eosinophil function and may be over-expressed in eosinophils from 
patients with AD. It is also possible that NR4A2 is over-expressed in 
eosinophils in asthmatic patients, however, as it is expressed in other 
peripheral blood leukocytes this differential expression might be masked in the 
study presented in this chapter by its marked decrease in other peripheral 
blood leukocyte subsets. Further experiments on purified populations of 
peripheral blood leukocytes will be required to deduce in what cell types 
NR4A2 is expressed in both asthmatic and non-asthmatic individuals. 
Platelet-derived growth factor D (PDGFD) was the fourth member of 
the PDGF family identified and was originally cloned independently by two 
groups (Bergsten et al., 2001; LaRochelle et al., 2001). PDGF family 
members are secreted proteins that bind to two cell surface receptors 
PDGFR-alpha and PDGFR-beta, although PDGFD has been demonstrated to 
bind PDGF-beta specifically (Bergsten et al., 2001). Although no data exists 
investigating PDGFD and asthma, two members of the family, PDGFA and 
PDGFB, and both receptors have been studied. Similar levels of PDGFA and 
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PDGFB were found in BAL fluid from asthmatics and controls. In addition, no 
significant difference in expression of PDGFA and PDGFB or the receptors 
PDGFR-aipha or PDGFR-beta was seen in bronchial biopsies from asthmatic 
and control subjects (Chanez et al., 1995). 
MYBL1 encodes a protein homologue of the avian v-myb transcription 
factor. In vertebrates 3 members of the myb family have been identified: A-
myb, B-myb and C-myb. MYBL1 corresponds to A-myb (Nomura et al., 1988). 
All three myb proteins have DNA binding domains that are almost identical 
and all three proteins bind the same DNA sequence in vitro. In addition, some 
overlap in expression of the three myb proteins has been noted. However, 
studies in knockout mice have revealed that all three proteins have distinct 
biological functions. Rushton et al further demonstrated this by ectopically 
expressing each protein individually in human tissue culture cells. Each myb 
protein activated a distinct set of endogenous genes (Rushton et al., 2003). It 
is thought that post-translational modifications and interaction with co-factors 
in specific cell types may regulate the transcriptional activity of each myb 
protein. 
Expression of the three myb proteins differs in peripheral blood 
leukocytes. B-myb and C-myb expression is undetectable in resting T and B 
cells and is induced upon stimulation. In contrast, A-myb protein is expressed 
in resting T lymphocytes and gradually decreases after mitogenic stimulation 
(Golay et al., 1991). No expression of myb protein was observed in resting or 
activated monocytes or granulocytes. However, experiments by Ying et al 
330 
suggest that A-myb is functionally active in human B cells but not T cells and 
plays a role in B cell proliferation and/or differentiation (Ying et al., 1997a). 
This finding is supported by mice ectopically over-expressing A-myb that 
developed hyperplasia of spleen and lymph nodes, which was mostly due to 
an expanded B ceil population (DeRocco et al., 1997). No published link 
exists between A-myb and asthma but it is possible that the under-expression 
of A-myb in asthma identified in this microarray study may reflect a down-
regulation of this protein in peripheral blood B cells. In turn, this down-
regulation of A-myb may have consequences for B cell proliferation or 
differentiation. 
C-Maf-inducing protein (CMIP) was originally cloned from cDNA 
libraries isolated from human brain (Nagase et al., 2000). Subsequently, 
Grimbert et al isolated a splice variant of CMIP when screening a cDNA library 
derived from T cells from a patient with Minimal Change Nephrotic Syndrome 
(MCNS) (Grimbert et al., 2003). The splice variant encoded a truncated 
protein that the authors named Tc-MIP. Using RT-PCR analysis of PBMC 
subsets, CMIP expression was demonstrated in resting monocytes, CD8^, 
CD4^T cells, and B lymphocytes, whereas the Tc-mip transcript was detected 
at lower levels only in CD4'" and CD8^ T cells. The expression of both 
transcripts was down regulated upon activation. In addition, in vitro polarised 
Th2 cells expressed Tc-MIP while Th1 cells did not. In the microarray study 
presented here, CMIP was identified as under-expressed in asthma samples 
compared to controls. Upon a re-analysis of the microarray data, the 
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expression of the truncated transcript Tc-IVllP showed no difference between 
asthma and control samples, with a normalised ratio of 0.93. 
The BCR (Breakpoint Cluster Region) gene derived its name from a 
reciprocal chromosome translocation, the breakpoint for which is located 
within the BCR gene. A reciprocal translocation occurring between 
chromosomes 22 and 9 produces the Philadelphia chromosome, which is 
often found in patients with chronic myeloid leukemia (Groffen et al., 1984). 
The translocation produces a fusion protein, which is encoded by sequence 
from both BCR and ABL, the gene at the chromosome 9 breakpoint. Although 
the BCR-ABL fusion protein has been extensively studied, the function of the 
normal BCR gene product is not clear (Laurent et al., 2001). The protein has 
been demonstrated to have serine/threonine kinase activity (Maru and Witte, 
1991). Two transcript variants encoding different isoforms have been found for 
the BCR gene (Dhut et al., 1988). The transcript identified in this study as 
under-expressed in asthma corresponds to the longer transcript, transcript 
variant 1. 
The human RASSF5 (RAS association domain family protein 5) gene 
encodes three proteins by alternative splicing. Two differentially spliced 
transcripts have been designated NOREIA-alpha and NOREIA-beta (Hesson 
et al., 2003), while a third transcript arising from alternative splicing and 
differential promoter usage has been designated N0RE1B or more commonly 
RARL (Katagiri et al., 2003). The transcript identified as under-expressed in 
asthma corresponds to the NOREIA-beta variant. Little has been published 
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on N0RE1A-beta but it appears to be a tumour suppressor gene that is 
inactivated in a number of human cancers (Hesson et a!., 2003). In contrast, 
the N0RE1B (RAPL) transcript is predominantly expressed in lymphoid 
tissues and is critical for lymphocyte and dendrite cell trafficking (Price and 
Bos, 2004; Katagiri et al., 2004). A re-analysis of the microaray data revealed 
that the transcript N0RE1B was slightly, but not significantly, under-expressed 
in asthma peripheral blood leukocytes, with a normalised ratio of 0.74. 
Ubiquitin-conjugating enzyme E2I (UBE2I) is the human homolog of the 
much-studied yeast ubiquitin-conjugating enzyme UBC9. Ubiquitin-
conjugating enzymes are involved in the ubiquitin-dependent protein 
degradation system (Ciechanover, 1998). Proteins are targeted for 
degradation in the proteasome by the covalent attachment of ubiquitin 
molecules via multi-step enzymatic reactions. Firstly, ubiquitin is activated by 
binding to ubiquitin-activating enzyme (El). Activated ubiquitin in an E1-
ubiquitin complex is then transferred to ubiquitin-conjugating enzyme (E2). 
Finally, ubiquitin is covalently attached to the target protein on an internal 
lysine residue, catalyzed by ubiquitin ligase (E3). Through multiple runs of 
reactions, ubiquitin is covalently attached to substrates resulting in 
polyubiquitinated conjugates that are rapidly recognized and degraded by the 
26S proteasome (Ciechanover, 1998). Recently it has been demonstrated that 
mono-ubiquitination can lead to altered protein activity and subcellular 
localization, rather than degradation. UBE2I is one of a number of E2 
enzymes identified in humans. Currently, no information exists on the specific 
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protein substrates of UBE2I and it exhibits a ubiquitous expression in human 
tissue (Watanabe et a!., 1996). 
Poly (ADP-ribose) polymerase family, member 15 (PARP15) is one of 
18 proteins that constitute the large family of known poly (ADP-ribose) 
polymerases in eukaryotes. It has only recently been identified and was 
previously known as hypothetical protein FLJ40597 (Aguiar et al., 2005). Due 
to its very recent discovery, the published scientific literature contains no data 
on PARP15. 
Chymotrypsin C (CTRC), or caldecrin, is a chymotrypsin-type serine 
protease which belongs to the elastase family (Tomomura et al., 1996). The 
protein was originally isolated from porcine pancreas and expression has 
subsequently been demonstrated in rat brain (Tomomura et al., 2002). No 
expression of caldecrin has been reported in cells of the immune system and 
any potential role in these cells is unknown. 
Activating Trancription factor 4 (ATF4) is a transcription factor that has 
been demonstrated to be essential for the later stages of eye lens fibre cell 
differentiation as ATF4-deficient mice exhibit severe microphthalmia (Tanaka 
et al., 1998). No expression or role for ATF4 has previously been reported for 
any immune cell subset. 
SNFI-like kinase (SNF1LK) was originally cloned in a screen for 
kinases expressed during the early cardiogenesis in the mouse (Ruiz et al., 
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1994). Subsequently, the same group cloned the human ortholog and 
demonstrated that SNF1LK may a play a role in cell cycle regulation 
(Stephenson et al., 2004). 
RAS protein dexamethasone-induced 1 (RASD1 or DEXRAS1) is a 
novel Ras-like G protein that modulates multiple signalling cascades 
(Cismowski et al., 2000). A number of studies, including studies with RAS01 
knockout mice, have indicated a role for RASD1 in determining the 
responsiveness of the circadian clock, the body's internal timekeeper, to 
external timing cues (Cheng and Obrietan, 2006). No information exists on a 
potential role for RASD1 in inflammation or of expression in any PBMC 
subset. 
As mentioned earlier the differentially expressed genes identified in this 
study require further confirmation in a new cohort of subjects. Equally, the 
specific peripheral blood leukocyte responsible for the differential expression 
of each gene requires identification. This could be achieved by expanding the 
follow-up microarray experiment mentioned earlier to include RT-PCR 
analysis of these genes in specific isolated populations of peripheral blood 
leukocytes. This experiment could then simultaneously confirm the gene 
signature identified in a new cohort of subjects and identify the type of 
peripheral blood leukocyte where each gene is differentially expressed. 
Additionally, RT-PCR analysis of the genes identified in this study in 
regulatory T cells isolated from peripheral blood would determine if the 
differential expression of these genes is present in the regulatory T cell 
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population - possibly contributing to the defective function of regulatory T cells 
isolated from atopic individuals. In addition, it may be of value to investigate 
the expression of these genes in bronchial tissue from normal and asthmatic 
lung to determine if differences in peripheral blood gene expression are also 
evident in tissue. Our group has recently shown that bronchial tissue can be 
safely obtained from the same asthmatic patient at a number of timepoints 
after allergen challenge (Kariyawasam et al, in press). Using this method the 
expression of the genes identified in this study could be investigated in 
bronchial tissue of normal and asthmatic patients before and at a number of 
intervals after allergen challenge to additionally give an insight to the 
expression of these genes in tissue during active disease. 
In summary this chapter describes a microarray study that for the first 
time has potentially identified a peripheral blood gene signature for asthma. In 
addition, the study has highlighted a number of differentially expressed genes 
in peripheral blood leukocytes that may play a role in asthma pathology. The 
study has also demonstrated that asthma is not associated with changes in 
peripheral blood leukocyte number, including numbers of regulatory T cells. 
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Chapter 6: Concluding comments and future 
direction 
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In recent years populations of regulatory T cells have become the focus 
of intense research due to their therapeutic potential in a number of human 
diseases. In particular, the naturally occurring CD4+CD25+ regulatory T cell 
population has been studied intensively in both humans and rodents. This 
research has led to the description of a number of important aspects of 
CD4+CD25+ regulatory T cells. They consitute approximately 10 % of 
peripheral blood CD4+ T cells and are capable of suppressing the proliferation 
and cytokine production by CD4+ effector T cells. In order to exert this 
suppressive function on effector T cells, CD4+CD25+ regulatory T cells 
require activation through their TCR. The mechanism by which CD4+CD25+ 
regulatory T cells suppress effector T cell proliferation has been demonstrated 
to be cell-contact dependent in vitro, while some importance for cytokines 
such as IL-10 and TGF-|3 has also been demonstrated in vivo. The 
transcription factor responsible for Treg phenotype and function, F0XP3, has 
also recently been described. 
Despite the recent advances in CD4+CD25+ regulatory T cell biology, 
a number of outstanding questions remain. It was the purpose of this thesis to 
address a number of these questions. Chapter 3 describes the chemokine 
receptor expression and responsiveness of CD4+CD25+ regulatory T cells, as 
well the modulation of chemokine receptor expression in response to allergen 
stimulation. Chapter 4 describes the results of a comparative DNA microarray 
study of CD4+CD25+ regulatory T cells and CD4+CD25- non-regulatory T 
cells, which attempted to identify molecules that may play a role in regulatory 
T cell function. 
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Asthma is a chronic inflammatory disorder of the airways in which 
many cells and cellular elements play a role, in particular mast cells, 
eosinophils, T lymphocytes, neutrophils and epithelial cells (Lemanske, Jr. 
and Busse, 2003). The incidence of asthma, atopy and allergic disease has 
been steadily increasing over recent decades, particularly in the western world 
(Holgate, 2004). Chapter 5 describes the results of microarray studies profiling 
the gene expression of peripheral blood leukocytes isolated from asthmatic 
and non-asthmatic individuals. The aim of these experiments was to identify a 
peripheral blood leukocyte gene signature associated with asthma pathology 
with a potential for use as a diagnostic tool. 
6.1 Trafficking of CD4+CD25+ regulatory T cells. 
Chemokines and chemokine receptors play an essential role in the 
human immune system by directing the recruitment of specific leukocyte 
subsets to sites of inflammtion and tissue micronvironments. Chapter 3 
describes the chemokine receptor expression profile of CD4+CD25+ 
regulatory T cells. In comparison to their non-regulatory T cell counterparts, 
CD4+CD25+ regulatory T cells express higher levels of CCR4, CCR5, CCR6 
and CCR8 and exhibit increased responsiveness to most of the chemokine 
ligands of these receptors. In addition, CD4+CD25+ regulatory T cells express 
lower levels of CCR7. These experiments confirmed that CD4+CD25+ 
regulatory T cells exhibit a different chemokine receptor profile to their non-
regulatory T cell counterparts and is in agreement with a number of previous 
studies (Bystry et al., 2001; lellem et al., 2001; Annunziato et al., 2002; 
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Colantonio et al., 2002; Wysocki et al., 2005; Lee et al., 2005; Kleinewietfeld 
et al., 2005). This differential chemokine receptor expression profile on 
CD4+CD25+ regulatory T cells is logical in order for these cells to perform 
their suppressive function in a number of different tissues. The results suggest 
that CD4+CD25+ regulatory T cells are more responsive than their non-
regulatory T cell counterparts to a number of different chemokine-chemokine 
receptor pathways and this may result in the preferential recruitment of these 
cells initially, in response to infection and inflammation. In addition, the 
preferential expression of chemokine receptors involved in both Th1 (CCR5) 
and Th2 (CCR4, CCR8) trafficking suggests that CD4+CD25+ regulatory T 
cells express a chemokine receptor repertoire capable of directing them to 
sites of both Th1 and Th2 immune responses. Indeed previous reports have 
outlined an increased responsiveness of CD4+CD25+ regulatory T cells to the 
Th1-recruiting chemokine CCL4 (Bystry et al., 2001) and the Th2-recruiting 
chemokine CCL1/I-309 (Colantonio et al., 2002). This thesis extends those 
findings and demonstrates an increased responsiveness of CD4+CD25+ 
regulatory T cells to the chemokines CCL17/TARC, CCL22/MDC and 
CCL20/MIP-3-alpha, the ligands for CCR4 and CCR6. 
Experiments were also undertaken to determine if the chemokine 
receptor expression profile of CD4+CD25+ regulatory T cells differed between 
cells isolated from the peripheral blood of atopic and non-atopic individuals. It 
was hypothesised that the defect in CD4+CD25+ regulatory T cell mediated 
suppression of effector T cell proliferation and cytokine production in atopic 
individuals, previously demonstrated by our laboratory (Ling et al., 2004), 
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could be explained by differing chemokine receptor expression profiles. CCR5 
proved to be the only chemokine receptor that showed significantly different 
expression levels between atopic and non-atopic individuals, with increased 
expression on CD4+CD25+ T cells in atopics compared to CD4+CD25- T 
cells. However, CCR5 expression on the CD4+CD25+ regulatory T cell subset 
did not differ significantly between the two groups suggesting that this 
receptor is not responsible for the defect seen regulatory T cells isolated from 
atopic individuals. To conclusively rule out a role for CCR5 in this defect 
associated with CD4+CD25+ regulatory T cells from atopic individuals would 
require further experiments. Blocking antibodies to CCR5 in in vitro co-culture 
experiments of CD4+CD25+ regulatory T cells and CD4+CD25- T cells would 
reveal if this receptor were responsible for the defect noted in CD4+CD25+ 
regulatory T cell mediated suppression in cells isolated from atopic 
individuals. 
Chapter 3 also describes the modulation of chemokine receptor 
expression by CD4+CD25+ regulatory T cells in response to allergen 
activation, which may be important in regulating allergic and asthmatic 
responses. CD4+CD25+ regulatory T cells increase their expression of CCR7 
and CXCR4 while decreasing expression of CCR4. In contrast, non-regulatory 
T cells increased expression of CCR4 while decreasing expression of CCR7 
and CXCR4. These observations confirmed a differential modulation of 
chemokine receptor expression by regulatory and non-regulatory T cell 
subsets in response to allergen stimulation. Taken together, the results 
suggest that by displaying a broad repertoire of chemokine receptors, 
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CD4+CD25+ regulatory T cells are capable of responding to a number of 
different chemokines and therefore are capable of populating numerous 
tissues. In response to activation, CD4+CD25+ regulatory T cells then 
modulate their chemokine expression profile which may allow the cell to 
egress from sites of inflammation and traffick to lymph nodes via increased 
CCR7 expression, where they can regulate the activation of naTve T cells. 
The results of the experiments outlined in chapter 3 raise a number of 
important questions regarding the suppression mediated by CD4+CD25+ 
regulatory T cells. If these cells modulate their chemokine receptor profile 
upon activation, allowing their egress from sites of inflammation, what 
timescale of interaction with effector T cells is required for them to exert their 
regulatory function? Do they require a transient interaction with effector T cells 
or a more sustained interaction? This question could be addressed using the 
CFSE-based cell culture system described in chapter 3. Instead of labelling 
the CD4+CD25- T cells subset with CFSE, the CD4+CD25+ regulatory T cell 
subset could be labelled prior to co-culturing both T cell subsets. FACS 
sorting could then be employed to deplete the CFSE-labelled CD4+CD25+ 
regulatory T cells at different timepoints of cell culture prior to measuring the 
proliferation of the CD4+CD25- T cell subset using thymidine incorporation 
after the cell culture period. This type of experiment would reveal if a transient 
or sustained interaction between regulatory and effector T cells is required for 
regulatory cells to exert their suppressive function. 
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6.2 Differential gene expression by CD4+CD25+ regulatory T 
cells. 
Chapter 4 describes the results of a comparative gene array study of 
CD4+CD25+ regulatory and CD4+CD25- non-regulatory T cell subsets. 
Comparative gene array studies have previously been used successfully in 
identifying molecules specific for regulatory T cells, including the identification 
of GITR (McHugh et al., 2002), LAG-3 (Huang et al., 2004) and Neuropilin-1 
(Bruder et al., 2004). It was the goal of this study to identify cell surface 
markers specific for regulatory T cells that would be of use in the isolation and 
manipulation of this T cell population. In addition it was the aim to identify 
molecules that may play a role in the phenotype associated with these cells. 
Unfortunately, as discussed at the end of chapter 4, these experiments must 
be regarded as limited in outcome. The intention was to identify differentially 
expressed genes in both unstimulated and stimulated cells by microarray 
analysis and subsequently confirm this differential expression using RT-PCR 
techniques. The identification of just 11 genes as being differentially 
expressed in the duplicate microarrays points to errors in one or both 
microarray experiments. This conclusion is supported by the results of 
confirmatory RT-PCR analysis on 5 of these genes where the differential 
expression of just 2 was found to be complimentary to the microarray 
analysis. However the two genes identified, TNFR2 and CCL20, may be 
potentially of interest for further study. TNFR2 expression was increased in 
CD4+CD25+ regulatory T cells in both the microarray and RT-PCR 
experiments. A co-stimulatory role for TNFR2 in T cell activation has 
previously been demonstrated (Tartaglia et al., 1993; Pimentel-Muinos et al., 
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1994; Kim and Teh, 2001; Aspalter et al., 2003). Increased expression of 
TNFR2 on CD4+CD25+ regulatory T cells may result in decreasing the 
threshold of activation for these cells. Therefore during an immune response 
in \Nh\dr\ TNF-a is produced, CD4+CD25+ regulatory T cells may be activated 
more efficiently than their CD4+CD25- non-regulatory T cell counterparts 
providing a mechanism by which these cells can control the magnitude of the 
immune response. In vitro proliferation experiments utilising agonistic and 
antagonistic antibodies to both TNFR1 and TNFR2 could provide an answer 
to this question. In addition, the suppressive ability of CD4+CD25+ regulatory 
T cells isolated from TNFR2-deficient mice could be compared to their wild-
type counterparts to determine if a defect in suppression of proliferation is 
exhibited by regulatory T cells in the absence of TNFR2. 
Expression of the chemoklne CCL20/MlP-3-alpha was also increased 
in CD4+CD25+ regulatory T cells in both the microarray and RT-PCR studies. 
As expression of CCR6, the only chemokine receptor capable of binding 
CCL20/I\/llP-3-alpha, was identified as increased on CD4+CD25+ regulatory T 
cells, blocking antibodies were used to assess the contribution of this 
chemokine-chemokine receptor pathway in regulatory T cell mediated 
suppression in vitro. However, blocking neither CCL20/MlP-3-alpha nor CCR6 
showed any effect on CD4+CD25+ regulatory T cell mediated suppression. 
6.3 Identification of a gene signature associated with asthma. 
Chapter 5 describes experiments characterising the PBMC phenotype 
and gene expression associated with asthma pathology. While peripheral 
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blood eosinophil number was significantly increased in asthmatic patients, no 
differences in any other leukocyte or T cell subset number was identified. 
Peripheral blood leukocyte gene expression has recently been suggested to 
have potential for research, diagnostic and treatment purposes in internal 
diseases such as asthma (Gladkevich et al., 2005). Furthermore, peripheral 
blood leukocyte gene signatures have recently been identified for a number of 
immune responses including bacterial infections and SLE (Chaussabel et al., 
2005; Ramilo et al., 2007). The ability of these gene signatures to discriminate 
between different types of infections has also been demonstrated, indicating 
their potential use as a diagnostic tool (Ramilo et al., 2007). The results 
presented here in chapter 5 detail the results of experiments attempting to 
identify a peripheral blood leukocyte gene signature for asthma. These 
experiments revealed the differential expression of 65 gene targets in 
peripheral blood leukocytes isolated from asthmatic and normal individuals. 
Unfortunately time constraints of the project prevented the confirmation of this 
differential expression in a new cohort of patients. Without confirmation, either 
by further microarray studies or RT-PCR, the study presented here must be 
regarded as a pilot study demonstrating the feasibility of identifying a 
peripheral blood leukocyte gene signature for asthma. Further microarray 
experiments using a new cohort of patients are needed to demonstrate the 
validity of the gene signature identified and its potential as a diagnostic for 
asthma. However, the inclusion of 6 individual microarray analysis in each 
group of patients, as well as the stringent subsequent analysis of the data, 
strengthen the gene signature proposed in this study. 
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In addition to the description of a potential peripheral blood leukocyte 
gene signature, the results presented in chapter 5 also highlight a number of 
genes that may be of interest for further research. Of the 65 differential gene 
targets identified, 19 correspond to known genes. A number of these genes 
have a previously published role in the immune cells that contribute to asthma 
pathology and may represent valuable new targets for further research. Future 
experiments will first require the confirmation of the differential expression of 
these genes in peripheral blood leukoctes isolated from asthmatic and non-
asthmatic individuals by RT-PCR. Subsequently, performing RT-PCR analysis 
on particular FACS-sorted cell subsets could elucidate the leukocyte type 
responsible for this differential expression. Subsequent analysis of bronchial 
tissue could determine if these genes are expressed by leukocytes infiltrating 
the lungs and airways in asthmatic individuals. 
6.4 Final statement 
The experiments outlined in this thesis have attempted to further our 
knowledge of naturally occurring CD4+CD25+ regulatory T cells, a subset of 
immunoregulatory cells that may be of considerable therapeutic value in 
allergic disease and asthma. This thesis describes the specific chemokine 
receptor expression profile and chemokine responsiveness of these cells, as 
well as the modulation of this chemokine receptor repertoire in response to 
allergen stimulation. In addition, the specific gene expression profile of this 
cell population was addressed using comparative microarray techniques. This 
thesis also describes the identification of a potential peripheral blood gene 
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signature for asthma that may be of value as a diagnostic tool, as well as 
identifying a number of novel genes that may be interest for further research. 
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